Disease on EC 2.7.10.2 - non-specific protein-tyrosine kinase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Aberrant Crypt Foci
Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon.
Aberrant Crypt Foci
Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon.
Abscess
Expression of transforming growth factor-beta1, 2, 3 isoforms and type I and II receptors in acute focal cerebral ischemia: an immunohistochemical study in rat after transient and permanent occlusion of middle cerebral artery.
Acantholysis
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Acantholysis
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
Acantholysis
Pemphigus vulgaris autoimmune globulin induces Src-dependent tyrosine-phosphorylation of plakophilin 3 and its detachment from desmoglein 3.
Acidosis
A central role for Pyk2-Src interaction in coupling diverse stimuli to increased epithelial NBC activity.
Acidosis
Dominant negative c-Src inhibits angiotensin II induced activation of NHE3 in OKP cells.
Acne Vulgaris
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Acquired Hyperostosis Syndrome
Exosomal proteome from the serum, bone marrow, and palm and toe pustular skin tissues of a single patient with SAPHO syndrome.
Acquired Immunodeficiency Syndrome
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Acquired Immunodeficiency Syndrome
Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms.
Acquired Immunodeficiency Syndrome
HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation.
Acquired Immunodeficiency Syndrome
HIV-1 Nef perturbs the function, structure, and signaling of the golgi through the Src kinase Hck.
Acquired Immunodeficiency Syndrome
Identification of an allosteric signaling network within Tec family kinases.
Acquired Immunodeficiency Syndrome
Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor.
Acquired Immunodeficiency Syndrome
Methodological comparison of two anti-ZAP-70 antibodies.
Acquired Immunodeficiency Syndrome
Role of the F-BAR Family Member PSTPIP2 in Autoinflammatory Diseases.
Acquired Immunodeficiency Syndrome
The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling.
Acquired Immunodeficiency Syndrome
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
Acromegaly
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
Activated Protein C Resistance
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Acute Coronary Syndrome
Insufficient deactivation of the protein tyrosine kinase lck amplifies T-cell responsiveness in acute coronary syndrome.
Acute Coronary Syndrome
The Role of FAK in the Secretion of MMP9 after CD147 Stimulation in Macrophages.
Acute Kidney Injury
Amelioration of sepsis-induced acute kidney injury through inhibition of inflammatory cytokines and oxidative stress in dendritic cells and neutrophils respectively in mice: Role of spleen tyrosine kinase signaling.
Acute Kidney Injury
Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
Acute Kidney Injury
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Acute Kidney Injury
Focal adhesion kinase signaling mediates acute renal injury induced by ischemia/reperfusion.
Acute Kidney Injury
Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer.
Acute Kidney Injury
M1 macrophage triggered by Mincle leads to a deterioration of acute kidney injury.
Acute Kidney Injury
Negative Regulation of Tec Kinase Alleviates LPS-Induced Acute Kidney Injury in Mice via theTLR4/NF-?B Signaling Pathway.
Acute Kidney Injury
Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.
Acute Kidney Injury
The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Acute Kidney Injury
WITHDRAWN: Spleen tyrosine kinase (SYK) protects renal tubular epithelial cell against hypoxia injury in children with acute kidney injury.
Acute Kidney Injury
[Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors.]
Acute Lung Injury
Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase.
Acute Lung Injury
Induced Pluripotent Stem Cells Attenuate Endothelial Leakage in Acute Lung Injury via Tissue Inhibitor of Metalloproteinases-1 to Reduce Focal Adhesion Kinase Activity.
Acute Lung Injury
Inhibiting Bruton's Tyrosine Kinase Rescues Mice from Lethal Influenza Induced Acute Lung Injury.
Acute Lung Injury
Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and ?? T cells respectively in mice.
Acute Lung Injury
JAK2/STAT1-mediated HMGB1 translocation increases inflammation and cell death in a ventilator-induced lung injury model.
Acute Lung Injury
Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Coninfections: Insights Into 1918 H1N1 Pandemic?
Acute Lung Injury
Retrograde perfusion in isolated perfused mouse lungs-Feasibility and effects on cytokine levels and pulmonary oedema formation.
Acute Lung Injury
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
Acute Lung Injury
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Acute Lung Injury
Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury.
Acute Lung Injury
The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy.
Acute Lung Injury
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
Adenocarcinoma
3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Adenocarcinoma
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Adenocarcinoma
A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Adenocarcinoma
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
Adenocarcinoma
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Adenocarcinoma
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Adenocarcinoma
An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors.
Adenocarcinoma
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Adenocarcinoma
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Adenocarcinoma
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Adenocarcinoma
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Adenocarcinoma
Association of polymorphisms in transforming growth factor-? receptors with susceptibility to gastric cardia adenocarcinoma.
Adenocarcinoma
CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells.
Adenocarcinoma
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Adenocarcinoma
Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line.
Adenocarcinoma
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Adenocarcinoma
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Adenocarcinoma
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Adenocarcinoma
Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Adenocarcinoma
Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Adenocarcinoma
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
Adenocarcinoma
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.
Adenocarcinoma
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Adenocarcinoma
ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.
Adenocarcinoma
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Adenocarcinoma
Evaluation of the Clinical Significance of Focal Adhesion Kinase and Src Expression in Human Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.
Adenocarcinoma
Expression of cortactin and focal adhesion kinase in colorectal adenocarcinoma: correlation with clinicopathologic parameters and their prognostic implication.
Adenocarcinoma
Expression of FAK and PTEN in Bronchioloalveolar carcinoma and lung adenocarcinoma.
Adenocarcinoma
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Adenocarcinoma
Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth.
Adenocarcinoma
Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.
Adenocarcinoma
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Adenocarcinoma
Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis.
Adenocarcinoma
Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.
Adenocarcinoma
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Adenocarcinoma
HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Adenocarcinoma
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Adenocarcinoma
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Adenocarcinoma
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Immunohistochemical expression of TGF beta (TGF-?), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
Adenocarcinoma
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Adenocarcinoma
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Adenocarcinoma
M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin ?3, Focal Adhesion Kinase, and Cofilin.
Adenocarcinoma
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Adenocarcinoma
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Adenocarcinoma
Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.
Adenocarcinoma
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Adenocarcinoma
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
Adenocarcinoma
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Adenocarcinoma
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Adenocarcinoma
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Adenocarcinoma
Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Adenocarcinoma
Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.
Adenocarcinoma
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Adenocarcinoma
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
Adenocarcinoma
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Adenocarcinoma
Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study.
Adenocarcinoma
Src activation in malignant and premalignant epithelia of Barrett's esophagus.
Adenocarcinoma
Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
Adenocarcinoma
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion.
Adenocarcinoma
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Adenocarcinoma
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Adenocarcinoma
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
Adenocarcinoma
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Adenocarcinoma
The human splice variant ?16HER2 induces rapid tumor onset in a reporter transgenic mouse.
Adenocarcinoma
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Adenocarcinoma
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Adenocarcinoma
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Adenocarcinoma
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Adenocarcinoma
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Adenocarcinoma
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Adenocarcinoma
Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer.
Adenocarcinoma
v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
Adenocarcinoma of Lung
ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Adenocarcinoma of Lung
ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
Adenocarcinoma of Lung
Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts.
Adenocarcinoma of Lung
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Adenocarcinoma of Lung
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.
Adenocarcinoma of Lung
Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNF?-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.
Adenocarcinoma of Lung
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Adenocarcinoma of Lung
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.
Adenocarcinoma of Lung
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Adenocarcinoma of Lung
High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.
Adenocarcinoma of Lung
Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells.
Adenocarcinoma of Lung
IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line.
Adenocarcinoma of Lung
Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.
Adenocarcinoma of Lung
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Adenocarcinoma of Lung
MicroRNA-204 deregulation in lung adenocarcinoma controls the biological behaviors of endothelial cells potentially by modulating Janus kinase 2-signal transducer and activator of transcription 3 pathway.
Adenocarcinoma of Lung
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
Adenocarcinoma of Lung
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Adenocarcinoma of Lung
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Adenocarcinoma of Lung
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Adenocarcinoma of Lung
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
Adenocarcinoma of Lung
The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.
Adenocarcinoma of Lung
Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis.
Adenocarcinoma of Lung
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Adenocarcinoma of Lung
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Adenocarcinoma of Lung
[The possible mechanisms of simvastatin on apoptosis of lung adenocarcinoma cells].
Adenocarcinoma, Follicular
Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase.
Adenocarcinoma, Follicular
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Adenocarcinoma, Mucinous
Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors.
Adenoma
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Adenoma
An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
Adenoma
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Adenoma
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Adenoma
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Adenoma
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Adenoma
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Adenoma
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Adenoma
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Adenoma
Genetic alterations are frequent in APC but rare in the TGF-beta type II receptor gene in cancer in adenomas of the colon.
Adenoma
Genome-wide association studies and meta-analysis reveal novel quantitative trait loci and pleiotropic loci for swine head-related traits.
Adenoma
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Adenoma
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Adenoma
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Adenoma
Protein western array analysis in human pituitary tumours: insights and limitations.
Adenoma
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Adenoma
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Adenoma
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Adenoma
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Adenoma, Liver Cell
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Adenoma, Liver Cell
Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
Adenomatous Polyposis Coli
An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
Adenomatous Polyposis Coli
Chibby drives ? catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Adenomatous Polyposis Coli
Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Adenomatous Polyposis Coli
Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing.
Adenomatous Polyposis Coli
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Adenomatous Polyposis Coli
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Adenomatous Polyposis Coli
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Adenomatous Polyposis Coli
Tanshinone IIA promotes cardiac differentiation and improves cell motility by modulating the Wnt/??catenin signaling pathway.
Adenomatous Polyposis Coli
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Adenomatous Polyposis Coli
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Adenomyosis
Expression of focal adhesion kinase in the eutopic endometrium of women with adenomyosis varies with dysmenorrhea and pelvic pain.
Adenomyosis
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.
adenosine deaminase deficiency
Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency.
Adenovirus Infections, Human
Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase.
Adrenocortical Carcinoma
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Agammaglobulinemia
A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion.
Agammaglobulinemia
A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia.
Agammaglobulinemia
A mutation in the pleckstrin homology (PH) domain of the FGD1 gene in an Italian family with faciogenital dysplasia (Aarskog-Scott syndrome).
Agammaglobulinemia
A novel Bruton tyrosine kinase gene variation was found in an adult with X-linked agammaglobulinemia during blood cross-matching prior to surgical operation.
Agammaglobulinemia
A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia.
Agammaglobulinemia
A novel Bruton's tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia.
Agammaglobulinemia
A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.
Agammaglobulinemia
A novel deletion mutation and structural abnormality in the Bruton's tyrosine kinase gene identified in a Chinese patient with X-linked agammaglobulinemia.
Agammaglobulinemia
A novel mutation (Cys145-->Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male.
Agammaglobulinemia
A novel mutation leading to a deletion in the SH3 domain of Bruton's tyrosine kinase.
Agammaglobulinemia
A novel single basepair insertion in exon 6 of the Bruton's tyrosine kinase (Btk) gene from a Japanese X-linked agammaglobulinemia patient with growth hormone insufficiency.
Agammaglobulinemia
A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.
Agammaglobulinemia
A postmeningitic cochlear implant patient who was postoperatively diagnosed as having X-linked agammaglobulinemia.
Agammaglobulinemia
A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.
Agammaglobulinemia
Absence of memory B cells in patients with common variable immunodeficiency.
Agammaglobulinemia
An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.
Agammaglobulinemia
Analysis of clinical presentations of bruton disease: a review of 20 years of accumulated data from pediatric patients at severance hospital.
Agammaglobulinemia
Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites.
Agammaglobulinemia
Analysis of the genetic alterations in a case of juvenile multiple colon carcinoma with hypogammaglobulinemia.
Agammaglobulinemia
B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.
Agammaglobulinemia
B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.
Agammaglobulinemia
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.
Agammaglobulinemia
Bruton tyrosine kinase gene mutations in Turkish patients with presumed X-linked agammaglobulinemia.
Agammaglobulinemia
Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells.
Agammaglobulinemia
Bruton's agammaglobulinemia in an adult male due to a novel mutation: a case report.
Agammaglobulinemia
Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein.
Agammaglobulinemia
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Agammaglobulinemia
Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
Agammaglobulinemia
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
Agammaglobulinemia
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
Agammaglobulinemia
Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
Agammaglobulinemia
Bruton's Tyrosine Kinase Is Required for TLR2 and TLR4-Induced TNF, but Not IL-6, Production.
Agammaglobulinemia
Bruton's tyrosine kinase mutations in 8 Chinese families with X-linked agammaglobulinemia.
Agammaglobulinemia
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Agammaglobulinemia
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Agammaglobulinemia
BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector.
Agammaglobulinemia
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Agammaglobulinemia
BTK mediated apoptosis, a possible mechanism for failure to generate high titer retroviral producer clones.
Agammaglobulinemia
Btk29A-mediated tyrosine phosphorylation of armadillo/?-catenin promotes ring canal growth in Drosophila oogenesis.
Agammaglobulinemia
Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Characterization of germline mutations of the gene encoding Bruton's tyrosine kinase in families with X-linked agammaglobulinemia.
Agammaglobulinemia
Characterization of mutations, including a novel regulatory defect in the first intron, in Bruton's tyrosine kinase gene from seven Korean X-linked agammaglobulinemia families.
Agammaglobulinemia
Characterization of novel Bruton's tyrosine kinase gene mutations in Central European patients with agammaglobulinemia.
Agammaglobulinemia
Characterization of the pleckstrin homology domain of Btk as an inositol polyphosphate and phosphoinositide binding domain.
Agammaglobulinemia
Clinical and Genetic Study of X-linked Agammaglobulinemia Patients (The Benefit of Early Diagnosis).
Agammaglobulinemia
Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis.
Agammaglobulinemia
Clinical characteristics and molecular analysis of 21 chinese children with congenital agammaglobulinemia.
Agammaglobulinemia
Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton's tyrosine kinase (BTK) gene mutations.
Agammaglobulinemia
Clinical findings leading to the diagnosis of X-linked agammaglobulinemia.
Agammaglobulinemia
Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients.
Agammaglobulinemia
Concomitant diagnosis of immune deficiency and Pseudomonas sepsis in a 19 month old with ecthyma gangrenosum by host whole-genome sequencing.
Agammaglobulinemia
Conservation and covariance in PH domain sequences: physicochemical profile and information theoretical analysis of XLA-causing mutations in the Btk PH domain.
Agammaglobulinemia
Constitutive membrane association potentiates activation of Bruton tyrosine kinase.
Agammaglobulinemia
Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.
Agammaglobulinemia
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.
Agammaglobulinemia
Cutting edge: lack of peripheral B cells and severe agammaglobulinemia in mice simultaneously lacking Bruton's tyrosine kinase and the B cell-specific transcriptional coactivator OBF-1.
Agammaglobulinemia
De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma.
Agammaglobulinemia
Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection.
Agammaglobulinemia
Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Dendritic and T Cell Response to Influenza is Normal in the Patients with X-Linked Agammaglobulinemia.
Agammaglobulinemia
Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia.
Agammaglobulinemia
Distinct Clinical Features and Novel Mutations in Taiwanese Patients With X-Linked Agammaglobulinemia.
Agammaglobulinemia
Disturbed Transcription of TLRs' Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients.
Agammaglobulinemia
Dynamic Allostery Mediated by a Conserved Tryptophan in the Tec Family Kinases.
Agammaglobulinemia
Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region.
Agammaglobulinemia
Ecthyma gangrenosum due to Pseudomonas aeruginosa sepsis as initial manifestation of X-linked agammaglobulinemia: a case report.
Agammaglobulinemia
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
Agammaglobulinemia
Expression of Bruton's tyrosine kinase protein within the B cell lineage.
Agammaglobulinemia
Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
Agammaglobulinemia
Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.
Agammaglobulinemia
G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase.
Agammaglobulinemia
Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway.
Agammaglobulinemia
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Agammaglobulinemia
Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia.
Agammaglobulinemia
HIV-mediated expression of Btk in hematopoietic stem cells is not sufficient to restore B cell function in X-linked immunodeficient mice.
Agammaglobulinemia
Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials.
Agammaglobulinemia
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Agammaglobulinemia
Identification and characterization of a molecule, BAM11, that associates with the pleckstrin homology domain of mouse Btk.
Agammaglobulinemia
Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK).
Agammaglobulinemia
Identification of a new Bruton's tyrosine kinase (BTK) mutation associated with a mild phenotype in a child with X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.
Agammaglobulinemia
Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients.
Agammaglobulinemia
Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients.
Agammaglobulinemia
Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 Australian families with X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Impact of amino acid substitution in the kinase domain of Bruton tyrosine kinase and its association with X-linked agammaglobulinemia.
Agammaglobulinemia
Impaired polysaccharide responsiveness without agammaglobulinemia in three patients with hypomorphic mutations in Bruton Tyrosine Kinase - no detection by newborn screening for primary immunodeficiences.
Agammaglobulinemia
Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia.
Agammaglobulinemia
In vitro Correction of a Novel Splicing Alteration in the BTK Gene by Using Antisense Morpholino Oligonucleotides.
Agammaglobulinemia
Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Agammaglobulinemia
Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.
Agammaglobulinemia
Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia.
Agammaglobulinemia
Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report.
Agammaglobulinemia
Missense mutations affecting a conserved cysteine pair in the TH domain of Btk.
Agammaglobulinemia
Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia.
Agammaglobulinemia
Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Molecular characterization of Bruton's tyrosine kinase deficiency in 12 Iranian patients with presumed X-linked agammaglobulinemia.
Agammaglobulinemia
Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.
Agammaglobulinemia
Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers.
Agammaglobulinemia
Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China.
Agammaglobulinemia
Mutation pattern in the Bruton's tyrosine kinase gene in 26 unrelated patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.
Agammaglobulinemia
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan.
Agammaglobulinemia
Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.
Agammaglobulinemia
Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia.
Agammaglobulinemia
Novel BTK mutation in X-linked agammaglobulinemia: Report of a 17-year-old male.
Agammaglobulinemia
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis.
Agammaglobulinemia
Novel deletion mutation in Bruton's tyrosine kinase results in X-linked agammaglobulinemia: A case report.
Agammaglobulinemia
Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia.
Agammaglobulinemia
Novel insertions of Bruton tyrosine kinase in patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia.
Agammaglobulinemia
PBMC-derived integration-free iPSCs line SDQLCHi039-A from a patient with X-linked agammaglobulinemia carrying a novel 9-bp in-frame deletion in BTK gene.
Agammaglobulinemia
Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells.
Agammaglobulinemia
Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Agammaglobulinemia
Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.
Agammaglobulinemia
Phylogenetic Profiles Reveal Structural and Functional Determinants of Lipid-binding.
Agammaglobulinemia
PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.
Agammaglobulinemia
Point mutation in intron 11 of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.
Agammaglobulinemia
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
Agammaglobulinemia
Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells.
Agammaglobulinemia
Preimplantation genetic diagnosis for X-linked agammaglobulinemia: a case report.
Agammaglobulinemia
Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.
Agammaglobulinemia
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Agammaglobulinemia
Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus.
Agammaglobulinemia
Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.
Agammaglobulinemia
Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity.
Agammaglobulinemia
Recent progress in the diagnosis and treatment of patients with defects in early B-cell development.
Agammaglobulinemia
Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.
Agammaglobulinemia
Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults.
Agammaglobulinemia
Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI.
Agammaglobulinemia
Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase.
Agammaglobulinemia
Relapsing Campylobacter jejuni Systemic Infections in a Child with X-Linked Agammaglobulinemia.
Agammaglobulinemia
Role of the PHTH module in protein substrate recognition by Bruton's agammaglobulinemia tyrosine kinase.
Agammaglobulinemia
Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase.
Agammaglobulinemia
Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia.
Agammaglobulinemia
SH3 domain of Bruton's tyrosine kinase can bind to proline-rich peptides of TH domain of the kinase and p120cbl.
Agammaglobulinemia
Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis.
Agammaglobulinemia
Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.
Agammaglobulinemia
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.
Agammaglobulinemia
Splice-correction strategies for treatment of x-linked agammaglobulinemia.
Agammaglobulinemia
Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.
Agammaglobulinemia
Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.
Agammaglobulinemia
Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain.
Agammaglobulinemia
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
Agammaglobulinemia
The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia.
Agammaglobulinemia
The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C.
Agammaglobulinemia
The protein defective in X-linked agammaglobulinemia, Bruton's tyrosine kinase, shows increased autophosphorylation activity in vitro when isolated from cells in which the B cell receptor has been cross-linked.
Agammaglobulinemia
The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase.
Agammaglobulinemia
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.
Agammaglobulinemia
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Agammaglobulinemia
The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species.
Agammaglobulinemia
The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation.
Agammaglobulinemia
The X-linked immunodeficiency defect in the mouse is corrected by expression of human Bruton's tyrosine kinase from a yeast artificial chromosome transgene.
Agammaglobulinemia
Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase.
Agammaglobulinemia
Transcriptional regulatory elements within the first intron of Bruton's tyrosine kinase.
Agammaglobulinemia
Transient myelodysplastic syndrome in X-linked agammaglobulinemia with a novel Btk mutation.
Agammaglobulinemia
Treosulfan-based reduced toxicity hematopoietic stem cell transplantation in X-linked agammaglobulinemia: A cost-effective alternative to long-term immunoglobulin replacement in developing countries.
Agammaglobulinemia
Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus.
Agammaglobulinemia
Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families.
Agammaglobulinemia
Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions.
Agammaglobulinemia
Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site.
Agammaglobulinemia
Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency.
Agammaglobulinemia
von Recklinghausen disease in a patient with X-linked agammaglobulinemia.
Agammaglobulinemia
WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Agammaglobulinemia
X-chromosome inactivation and mutation pattern in the Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinemia. Italian XLA Collaborative Group.
Agammaglobulinemia
X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.
Agammaglobulinemia
X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
Agammaglobulinemia
X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia.
Agammaglobulinemia
X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase.
Agammaglobulinemia
X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis.
Agammaglobulinemia
X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.
Agammaglobulinemia
X-Linked Agammaglobulinemia Presenting as Neutropenia: Case Report and an Overview of Literature.
Agammaglobulinemia
X-Linked Agammaglobulinemia With Chronic Meningoencephalitis: A Diagnostic Challenge.
Agammaglobulinemia
X-linked agammaglobulinemia: report on a United States registry of 201 patients.
Agammaglobulinemia
xid mice reveal the interplay of homeostasis and Bruton's tyrosine kinase-mediated selection at multiple stages of B cell development.
Agammaglobulinemia
[Detection of Bruton's tyrosine kinase gene mutations and clinical analysis of 6 patients with X-linked agammaglobulinemia].
Albuminuria
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Alopecia
A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
Alopecia
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Alopecia
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Alopecia
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors.
Alopecia
Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?
Alopecia
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Alopecia
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Alopecia Areata
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia Areata
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Alopecia Areata
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors.
Alopecia Areata
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Alopecia Areata
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
Alopecia Areata
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Alopecia Areata
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Alopecia Areata
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Alopecia Areata
Janus kinase inhibitors against other biological treatments in alopecia areata.
Alopecia Areata
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Alopecia Areata
Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future.
Alopecia Areata
Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata.
Alopecia Areata
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Alopecia Areata
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Alopecia Areata
The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.
Alopecia Areata
The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked?
Alopecia Areata
The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Alopecia Areata
Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Alopecia Areata
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Alopecia Areata
Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases.
Alopecia Areata
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Alopecia Areata
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.
Alopecia Areata
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase deficiency
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Alveolar Bone Loss
Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Alzheimer Disease
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Alzheimer Disease
Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides.
Alzheimer Disease
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Alzheimer Disease
Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Alzheimer Disease
Alzheimer's disease risk factor lymphocyte-specific protein tyrosine kinase regulates long-term synaptic strengthening, spatial learning and memory.
Alzheimer Disease
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Alzheimer Disease
Amyloid-ß induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Alzheimer Disease
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer's disease.
Alzheimer Disease
Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population.
Alzheimer Disease
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.
Alzheimer Disease
c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.
Alzheimer Disease
c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.
Alzheimer Disease
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Alzheimer Disease
Canonical JAK-STAT signaling is pivotal for long-term depression at adult hippocampal temporoammonic-CA1 synapses.
Alzheimer Disease
Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses.
Alzheimer Disease
Corrigendum to "Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses" [Neurosci. Lett. 621 (2016) 83-87].
Alzheimer Disease
Defining functional variants associated with Alzheimer's disease in the induced immune response.
Alzheimer Disease
Differential expression of transforming growth factor-beta isoforms in human prion diseases.
Alzheimer Disease
Exploring the mechanistic insights of Cas scaffolding protein family member 4 with protein tyrosine kinase 2 in Alzheimer's disease by evaluating protein interactions through molecular docking and dynamic simulations.
Alzheimer Disease
Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines.
Alzheimer Disease
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Alzheimer Disease
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease.
Alzheimer Disease
Fyn Tyrosine Kinase Elicits Amyloid Precursor Protein Tyr682 Phosphorylation in Neurons from Alzheimer's Disease Patients.
Alzheimer Disease
Gene-based aggregate SNP associations between candidate AD genes and cognitive decline.
Alzheimer Disease
Genetic Association of FERMT2, HLA-DRB1, CD2AP, and PTK2B Polymorphisms With Alzheimer's Disease Risk in the Southern Chinese Population.
Alzheimer Disease
Glucosylpolyphenols as inhibitors of A?-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.
Alzheimer Disease
Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
Alzheimer Disease
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
Alzheimer Disease
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Alzheimer Disease
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.
Alzheimer Disease
Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias.
Alzheimer Disease
Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease.
Alzheimer Disease
Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer disease.
Alzheimer Disease
Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease.
Alzheimer Disease
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Alzheimer Disease
Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.
Alzheimer Disease
No genetic association between Fyn kinase gene polymorphisms (-93A/G, IVS10+37T/C and Ex12+894T/G) and Japanese sporadic Alzheimer's disease.
Alzheimer Disease
Oligomers of Amyloid ? Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.
Alzheimer Disease
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
Alzheimer Disease
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease.
Alzheimer Disease
Polymorphism rs11867353 of Tyrosine Kinase Non-Receptor 1 (TNK1) Gene Is a Novel Genetic Marker for Alzheimer's Disease.
Alzheimer Disease
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Alzheimer Disease
Pyk2 overexpression in postsynaptic neurons blocks amyloid ?1-42-induced synaptotoxicity in microfluidic co-cultures.
Alzheimer Disease
Reduction of Blood Amyloid-? Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.
Alzheimer Disease
Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes.
Alzheimer Disease
STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits.
Alzheimer Disease
The prion protein constitutively controls neuronal store-operated Ca(2+) entry through Fyn kinase.
Alzheimer Disease
The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.
Alzheimer Disease
Transforming growth factor-beta protects human hNT cells from degeneration induced by beta-amyloid peptide: involvement of the TGF-beta type II receptor.
Alzheimer Disease
Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI.
Alzheimer Disease
Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.
Alzheimer Disease
[Analysis of the fyn kinase gene in Alzheimer's disease and schizophrenia]
Ameloblastoma
Focal Adhesion Kinase Expression in Ameloblastoma: A Preliminary Observational Study.
Ameloblastoma
Invadopodia proteins, cortactin, N-WASP and WIP differentially promote local invasiveness in ameloblastoma.
Amyloidosis
Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature.
Amyotrophic Lateral Sclerosis
c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Anaphylaxis
4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice.
Anaphylaxis
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Anaphylaxis
Antiallergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA).
Anaphylaxis
Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.
Anaphylaxis
Bruton's tyrosine kinase-mediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal kinase activation pathway.
Anaphylaxis
Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Anaphylaxis
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Anaphylaxis
Targeting the Fc?RI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.
Anaphylaxis
The Fab fragment of anti-IgE C?2 domain prevents allergic reactions through interacting with IgE-Fc?RI? complex on rat mast cells.
Anaphylaxis
The Src Family Kinase Fgr Is Critical for Activation of Mast Cells and IgE-Mediated Anaphylaxis in Mice.
Anaphylaxis
The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions.
Anemia
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Anemia
Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
Anemia
Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
Anemia
Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
Anemia
Expression of v-src induces a myeloproliferative disease in bone-marrow-reconstituted mice.
Anemia
Identification of e6a2 bcr-abl fusion in a Philadelphia-positive cml with marked basophilia: implications for treatment strategy.
Anemia
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
Anemia
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Anemia
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Anemia
[Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia]
Anemia, Aplastic
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
Anemia, Diamond-Blackfan
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Anemia, Hemolytic, Autoimmune
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Anemia, Refractory
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Anemia, Refractory, with Excess of Blasts
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Anemia, Sickle Cell
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Anemia, Sickle Cell
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Anemia, Sickle Cell
NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
Anemia, Sickle Cell
The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase.
Aneurysm
Evolution of the face in Loeys-Dietz syndrome type II: longitudinal observations from infancy in seven cases.
Aneurysm
First genetic analysis of aneurysm genes in familial and sporadic abdominal aortic aneurysm.
Aneurysm
hiPSC Modeling of Lineage-Specific Smooth Muscle Cell Defects Caused by TGFBR1A230T Variant, and its Therapeutic Implications for Loeys-Dietz Syndrome.
Aneurysm
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome in a boy with Loeys-Dietz syndrome.
Aneurysm, Dissecting
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Aneurysm, Dissecting
Role of c-Abl in Ang II-induced aortic dissection formation: Potential regulatory efficacy on phenotypic transformation and apoptosis of VSMCs.
Angiofibroma
Hypoxia-Inducible Factor-1? (HIF-1?) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis.
Anorectal Malformations
Involvement of the WNT and FGF signaling pathways in non-isolated anorectal malformations: Sequencing analysis of WNT3A, WNT5A, WNT11, DACT1, FGF10, FGFR2 and the T gene.
Anorectal Malformations
The expression analysis of Bmpr1a and Bmp2 during hindgut development in rat embryos with anorectal malformations.
Anti-Glomerular Basement Membrane Disease
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Antiphospholipid Syndrome
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Aortic Aneurysm
Activation of TGF-? signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1.
Aortic Aneurysm
An X-linked Myh11-CreER(T2) mouse line resulting from Y to X chromosome-translocation of the Cre allele.
Aortic Aneurysm
Cyclophilin A contributes to aortopathy induced by postnatal loss of smooth muscle TGFBR1.
Aortic Aneurysm
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Aortic Aneurysm
Focal Adhesion Kinase Promotes the Progression of Aortic Aneurysm by Modulating Macrophage Behavior.
Aortic Aneurysm
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
Aortic Aneurysm
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Aortic Aneurysm
Pregnancy after aortic root replacement in Loeys-Dietz syndrome: High risk of aortic dissection.
Aortic Aneurysm
Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.
Aortic Aneurysm
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
Aortic Aneurysm, Abdominal
ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Aortic Aneurysm, Thoracic
Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations.
Aortic Aneurysm, Thoracic
Association of the TGF-beta receptor genes with abdominal aortic aneurysm.
Aortic Aneurysm, Thoracic
Identification and surgical repair of familial thoracic aortic aneurysm and dissection caused by TGFBR1 mutation.
Aortic Aneurysm, Thoracic
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Aortic Aneurysm, Thoracic
Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.
Aortic Aneurysm, Thoracic
Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center.
Aortic Aneurysm, Thoracic
TGFBR1 Rare Variant Associated With Thoracic Aortic Aneurysm, Double Chamber Left Ventricle, Coronary Anomaly, and Inducible Ventricular Tachycardia.
Aortic Aneurysm, Thoracic
TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections.
Aortic Aneurysm, Thoracic
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Aortic Aneurysm, Thoracic
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Aortic Diseases
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Arachnodactyly
FBN2, FBN1, TGFBR1, and TGFBR2 analyses in congenital contractural arachnodactyly.
Arrhythmias, Cardiac
Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats.
Arrhythmias, Cardiac
c-Src Kinase Inhibition Reduces Arrhythmia Inducibility and Connexin43 Dysregulation After Myocardial Infarction.
Arteriosclerosis
Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor.
Arteriovenous Malformations
EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.
Arteriovenous Malformations
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Arteriovenous Malformations
Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants.
Arthralgia
Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Arthritis
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Arthritis
A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy.
Arthritis
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.
Arthritis
An allosteric hot spot in the tandem-SH2 domain of ZAP-70 regulates T-cell signaling.
Arthritis
Anti- and non-tumor necrosis factor-?-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Arthritis
Anti-rheumatoid arthritis effects in adjuvant-induced arthritis in rats and molecular docking studies of Polygonum orientale L. extracts.
Arthritis
B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status.
Arthritis
Bruton's tyrosine kinase deficiency inhibits autoimmune arthritis but fails to block immune complex-mediated inflammatory arthritis.
Arthritis
Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.
Arthritis
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Arthritis
EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance.
Arthritis
Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis.
Arthritis
Formation of invadopodia-like structures by synovial cells promotes cartilage breakdown in arthritis. Involvement of the protein tyrosine kinase src.
Arthritis
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Arthritis
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers.
Arthritis
Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis.
Arthritis
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Arthritis
Resveratrol inhibits Src tyrosine kinase, STAT3, and Wnt signaling pathway in collagen induced arthritis model.
Arthritis
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Arthritis
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Arthritis
Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-?B signaling pathways.
Arthritis
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Arthritis
Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1.
Arthritis
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.
Arthritis
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Arthritis
The inhibition of Src kinase suppresses the production of matrix metalloproteinases in from synovial fibroblasts and inhibits MAPK and STATs pathways
Arthritis
The SKG mutation in ZAP-70 also confers arthritis susceptibility in C57 Black mouse strains.
Arthritis
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis
ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis.
Arthritis
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Arthritis
[Total saponins of Clematis inhibits JAK2/STAT3 signal pathway of adjuvant-induced arthritis rats].
Arthritis, Experimental
5,7,3'-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway.
Arthritis, Experimental
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Arthritis, Experimental
Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice.
Arthritis, Experimental
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Arthritis, Experimental
Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis.
Arthritis, Experimental
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Arthritis, Experimental
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Arthritis, Experimental
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Arthritis, Experimental
SOCS3 participates in cholinergic pathway regulation of synovitis in rheumatoid arthritis.
Arthritis, Experimental
Tetrandrine attenuates the bone erosion in collagen-induced arthritis rats by inhibiting osteoclastogenesis via spleen tyrosine kinase.
Arthritis, Experimental
The adaptor molecule SAP is essential in mechanisms involving the Fyn tyrosine kinase for induction and progression of collagen-induced arthritis.
Arthritis, Experimental
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Arthritis, Juvenile
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Arthritis, Juvenile
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Psoriatic
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Arthritis, Psoriatic
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Arthritis, Psoriatic
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Arthritis, Psoriatic
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Arthritis, Psoriatic
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Arthritis, Psoriatic
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Arthritis, Psoriatic
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Arthritis, Psoriatic
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Arthritis, Psoriatic
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Arthritis, Psoriatic
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
Arthritis, Psoriatic
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Arthritis, Psoriatic
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Arthritis, Psoriatic
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Arthritis, Psoriatic
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Arthritis, Psoriatic
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Arthritis, Psoriatic
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Arthritis, Psoriatic
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Arthritis, Psoriatic
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Arthritis, Psoriatic
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Arthritis, Psoriatic
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Arthritis, Psoriatic
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis?.
Arthritis, Psoriatic
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Arthritis, Psoriatic
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Arthritis, Psoriatic
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Arthritis, Psoriatic
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
Arthritis, Psoriatic
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility.
Arthritis, Psoriatic
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Arthritis, Psoriatic
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Arthritis, Psoriatic
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.
Arthritis, Psoriatic
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Arthritis, Psoriatic
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Psoriatic
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Arthritis, Psoriatic
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Arthritis, Psoriatic
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Arthritis, Psoriatic
Upadacitinib Pharmacokinetics and Exposure-Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients - Analyses of Phase 3 Clinical Trials.
Arthritis, Rheumatoid
'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'
Arthritis, Rheumatoid
4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
Arthritis, Rheumatoid
A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
Arthritis, Rheumatoid
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Arthritis, Rheumatoid
A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.
Arthritis, Rheumatoid
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Arthritis, Rheumatoid
A Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats.
Arthritis, Rheumatoid
A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-? and IL-17 production by human CD4(+) T cells.
Arthritis, Rheumatoid
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
Arthritis, Rheumatoid
A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
Arthritis, Rheumatoid
A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate.
Arthritis, Rheumatoid
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.
Arthritis, Rheumatoid
A Peptide-Based Biosensor Assay To Detect Intracellular Syk Kinase Activation and Inhibition.
Arthritis, Rheumatoid
A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy.
Arthritis, Rheumatoid
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Arthritis, Rheumatoid
A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease.
Arthritis, Rheumatoid
A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis.
Arthritis, Rheumatoid
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.
Arthritis, Rheumatoid
Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.
Arthritis, Rheumatoid
Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor ? induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Arthritis, Rheumatoid
ADAM15 in apoptosis resistance of synovial fibroblasts: converting Fas/CD95 death signals into the activation of pro-survival pathways by calmodulin recruitment.
Arthritis, Rheumatoid
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Arthritis, Rheumatoid
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Arthritis, Rheumatoid
An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents.
Arthritis, Rheumatoid
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Arthritis, Rheumatoid
An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Arthritis, Rheumatoid
Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Arthritis, Rheumatoid
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Arthritis, Rheumatoid
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Arthritis, Rheumatoid
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Arthritis, Rheumatoid
Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.
Arthritis, Rheumatoid
Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Arthritis, Rheumatoid
Arthritis-associated osteoclastogenic macrophages (AtoMs) participate in pathological bone erosion in rheumatoid arthritis.
Arthritis, Rheumatoid
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis.
Arthritis, Rheumatoid
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Arthritis, Rheumatoid
Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Arthritis, Rheumatoid
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Arthritis, Rheumatoid
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Arthritis, Rheumatoid
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Arthritis, Rheumatoid
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Arthritis, Rheumatoid
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Arthritis, Rheumatoid
Caring for patients in a new pandemic: the necessity and challenges of observational research.
Arthritis, Rheumatoid
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Arthritis, Rheumatoid
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Arthritis, Rheumatoid
Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
Arthritis, Rheumatoid
Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis.
Arthritis, Rheumatoid
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Arthritis, Rheumatoid
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Arthritis, Rheumatoid
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Arthritis, Rheumatoid
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Arthritis, Rheumatoid
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
Arthritis, Rheumatoid
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Arthritis, Rheumatoid
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.
Arthritis, Rheumatoid
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Arthritis, Rheumatoid
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Arthritis, Rheumatoid
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Arthritis, Rheumatoid
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Arthritis, Rheumatoid
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Arthritis, Rheumatoid
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
Arthritis, Rheumatoid
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Arthritis, Rheumatoid
Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Arthritis, Rheumatoid
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.
Arthritis, Rheumatoid
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis.
Arthritis, Rheumatoid
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.
Arthritis, Rheumatoid
Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS.
Arthritis, Rheumatoid
Development and Characterization of a JAK-2-specific Antibody Suitable for Immunohistochemical Investigative Studies.
Arthritis, Rheumatoid
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.
Arthritis, Rheumatoid
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Development of Bruton's tyrosine kinase Inhibitors for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
Arthritis, Rheumatoid
Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Arthritis, Rheumatoid
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Arthritis, Rheumatoid
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
Arthritis, Rheumatoid
Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Arthritis, Rheumatoid
Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues.
Arthritis, Rheumatoid
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Arthritis, Rheumatoid
Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
Arthritis, Rheumatoid
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Arthritis, Rheumatoid
Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Arthritis, Rheumatoid
Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.
Arthritis, Rheumatoid
Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats.
Arthritis, Rheumatoid
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
Arthritis, Rheumatoid
Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Arthritis, Rheumatoid
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Arthritis, Rheumatoid
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial.
Arthritis, Rheumatoid
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Arthritis, Rheumatoid
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis, Rheumatoid
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Arthritis, Rheumatoid
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Arthritis, Rheumatoid
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Arthritis, Rheumatoid
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Arthritis, Rheumatoid
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
Arthritis, Rheumatoid
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
Arthritis, Rheumatoid
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Arthritis, Rheumatoid
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Arthritis, Rheumatoid
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Arthritis, Rheumatoid
Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Arthritis, Rheumatoid
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Arthritis, Rheumatoid
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.
Arthritis, Rheumatoid
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.
Arthritis, Rheumatoid
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Arthritis, Rheumatoid
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Arthritis, Rheumatoid
Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Arthritis, Rheumatoid
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Arthritis, Rheumatoid
Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Arthritis, Rheumatoid
Extended-release Once-daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-release Tofacitinib and Impact of Food.
Arthritis, Rheumatoid
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Arthritis, Rheumatoid
Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.
Arthritis, Rheumatoid
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Arthritis, Rheumatoid
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Arthritis, Rheumatoid
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.
Arthritis, Rheumatoid
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Arthritis, Rheumatoid
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Arthritis, Rheumatoid
Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US.
Arthritis, Rheumatoid
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Arthritis, Rheumatoid
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Arthritis, Rheumatoid
High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: central to rheumatoid arthritis pathogenesis?
Arthritis, Rheumatoid
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis, Rheumatoid
Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Arthritis, Rheumatoid
Identification of distinct disease activity trajectories in methotrexate-naïve patients with rheumatoid arthritis receiving tofacitinib over 24 months.
Arthritis, Rheumatoid
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses.
Arthritis, Rheumatoid
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
Arthritis, Rheumatoid
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Arthritis, Rheumatoid
Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Arthritis, Rheumatoid
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Arthritis, Rheumatoid
Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus kinase (JAK)inhibitor: results from a randomized, double-blind, placebo-controlled trial.
Arthritis, Rheumatoid
In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Arthritis, Rheumatoid
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Arthritis, Rheumatoid
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Arthritis, Rheumatoid
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Arthritis, Rheumatoid
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Arthritis, Rheumatoid
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Arthritis, Rheumatoid
Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium.
Arthritis, Rheumatoid
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Arthritis, Rheumatoid
Inhibition of JAK/STAT signaling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Arthritis, Rheumatoid
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
Arthritis, Rheumatoid
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity.
Arthritis, Rheumatoid
Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs.
Arthritis, Rheumatoid
Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
Arthritis, Rheumatoid
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
Arthritis, Rheumatoid
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.
Arthritis, Rheumatoid
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Arthritis, Rheumatoid
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Arthritis, Rheumatoid
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Arthritis, Rheumatoid
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Arthritis, Rheumatoid
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
Arthritis, Rheumatoid
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Arthritis, Rheumatoid
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Arthritis, Rheumatoid
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis Fibroblast-like Synoviocytes.
Arthritis, Rheumatoid
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
Arthritis, Rheumatoid
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5?years: integrated analysis of data from the global clinical trials.
Arthritis, Rheumatoid
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Arthritis, Rheumatoid
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.
Arthritis, Rheumatoid
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Arthritis, Rheumatoid
Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, Osteoblastogenesis, Cardiovascular disease, Malignancies.
Arthritis, Rheumatoid
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis.
Arthritis, Rheumatoid
Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients.
Arthritis, Rheumatoid
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
Arthritis, Rheumatoid
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.
Arthritis, Rheumatoid
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Arthritis, Rheumatoid
Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.
Arthritis, Rheumatoid
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
Arthritis, Rheumatoid
New insights into IFN-? in rheumatoid arthritis: role in the era of JAK inhibitors.
Arthritis, Rheumatoid
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Novel concepts and treatments for autoimmune disease: ten focal points.
Arthritis, Rheumatoid
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Arthritis, Rheumatoid
Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib.
Arthritis, Rheumatoid
Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways.
Arthritis, Rheumatoid
Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis.
Arthritis, Rheumatoid
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Arthritis, Rheumatoid
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.
Arthritis, Rheumatoid
Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.
Arthritis, Rheumatoid
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Arthritis, Rheumatoid
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Arthritis, Rheumatoid
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Arthritis, Rheumatoid
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Arthritis, Rheumatoid
Pharmacokinetics of Fostamatinib, a SYK Inhibitor, in Healthy Human Subjects Following Single and Multiple Oral Dosing In Three Phase I Studies.
Arthritis, Rheumatoid
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Arthritis, Rheumatoid
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Arthritis, Rheumatoid
Placebo and nocebo responses in randomized controlled trials of Janus kinase inhibitor monotherapy for rheumatoid arthritis : A meta-analysis.
Arthritis, Rheumatoid
Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
Arthritis, Rheumatoid
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Arthritis, Rheumatoid
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Arthritis, Rheumatoid
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Arthritis, Rheumatoid
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Arthritis, Rheumatoid
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis [corrected].
Arthritis, Rheumatoid
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
Arthritis, Rheumatoid
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.
Arthritis, Rheumatoid
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Arthritis, Rheumatoid
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Arthritis, Rheumatoid
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Arthritis, Rheumatoid
Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.
Arthritis, Rheumatoid
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis.
Arthritis, Rheumatoid
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
Arthritis, Rheumatoid
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
Arthritis, Rheumatoid
Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Arthritis, Rheumatoid
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Arthritis, Rheumatoid
Rational design of highly selective spleen tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib.
Arthritis, Rheumatoid
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Real-world experience with tofacitinib for treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Arthritis, Rheumatoid
Regulation of inflammatory responses in tumor necrosis factor - activated and rheumatoid arthritis synovial macrophages by Janus kinase inhibitors.
Arthritis, Rheumatoid
Remission of anti-tumor necrosis factor-? antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis.
Arthritis, Rheumatoid
Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice.
Arthritis, Rheumatoid
Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.
Arthritis, Rheumatoid
Response to: 'Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials' by Lee and Song.
Arthritis, Rheumatoid
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Arthritis, Rheumatoid
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Arthritis, Rheumatoid
Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Arthritis, Rheumatoid
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis, Rheumatoid
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study.
Arthritis, Rheumatoid
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies.
Arthritis, Rheumatoid
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Arthritis, Rheumatoid
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Arthritis, Rheumatoid
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
Arthritis, Rheumatoid
Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil).
Arthritis, Rheumatoid
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Arthritis, Rheumatoid
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Arthritis, Rheumatoid
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Arthritis, Rheumatoid
Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis.
Arthritis, Rheumatoid
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Arthritis, Rheumatoid
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Arthritis, Rheumatoid
Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor.
Arthritis, Rheumatoid
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Arthritis, Rheumatoid
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Arthritis, Rheumatoid
Spectrophotometric method to quantify tofacitinib in lyotropic liquid crystalline nanoparticles and skin layers: Application in ex vivo dermal distribution studies.
Arthritis, Rheumatoid
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Arthritis, Rheumatoid
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Arthritis, Rheumatoid
Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis.
Arthritis, Rheumatoid
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
Arthritis, Rheumatoid
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
Arthritis, Rheumatoid
Structure Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Arthritis, Rheumatoid
Super-enhancers delineate disease-associated regulatory nodes in T cells.
Arthritis, Rheumatoid
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Arthritis, Rheumatoid
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype.
Arthritis, Rheumatoid
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.
Arthritis, Rheumatoid
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Arthritis, Rheumatoid
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Arthritis, Rheumatoid
Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib.
Arthritis, Rheumatoid
Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?
Arthritis, Rheumatoid
The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development.
Arthritis, Rheumatoid
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Arthritis, Rheumatoid
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Arthritis, Rheumatoid
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Arthritis, Rheumatoid
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Arthritis, Rheumatoid
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Arthritis, Rheumatoid
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
Arthritis, Rheumatoid
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Arthritis, Rheumatoid
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Arthritis, Rheumatoid
The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
Arthritis, Rheumatoid
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Arthritis, Rheumatoid
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Arthritis, Rheumatoid
The Pharmacokinetics, Pharmacodynamics and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers.
Arthritis, Rheumatoid
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Arthritis, Rheumatoid
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Arthritis, Rheumatoid
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Arthritis, Rheumatoid
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Arthritis, Rheumatoid
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Arthritis, Rheumatoid
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Arthritis, Rheumatoid
Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
Arthritis, Rheumatoid
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial.
Arthritis, Rheumatoid
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study.
Arthritis, Rheumatoid
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Arthritis, Rheumatoid
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Arthritis, Rheumatoid
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
Arthritis, Rheumatoid
Tofacitinib prevents radiographic progression in rheumatoid arthritis.
Arthritis, Rheumatoid
Tofacitinib restores the balance of ??Treg/??T17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome.
Arthritis, Rheumatoid
Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
Arthritis, Rheumatoid
Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice.
Arthritis, Rheumatoid
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Rheumatoid
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis.
Arthritis, Rheumatoid
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Arthritis, Rheumatoid
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Arthritis, Rheumatoid
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Arthritis, Rheumatoid
Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis.
Arthritis, Rheumatoid
Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.
Arthritis, Rheumatoid
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Arthritis, Rheumatoid
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Arthritis, Rheumatoid
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Arthritis, Rheumatoid
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Arthritis, Rheumatoid
Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis.
Arthritis, Rheumatoid
Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan.
Arthritis, Rheumatoid
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Arthritis, Rheumatoid
Upadacitinib Pharmacokinetics and Exposure-Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients - Analyses of Phase 3 Clinical Trials.
Arthritis, Rheumatoid
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Arthritis, Rheumatoid
Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity.
Arthritis, Rheumatoid
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Arthritis, Rheumatoid
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study.
Arthritis, Rheumatoid
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Arthritis, Rheumatoid
VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Arthritis, Rheumatoid
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.
Arthritis, Rheumatoid
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Arthritis, Rheumatoid
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Aspergillosis
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Aspergillosis
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Asthenozoospermia
Correlative study on the JAK-STAT/PSM?3 signal transduction pathway in asthenozoospermia.
Asthma
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Asthma
Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK.
Asthma
Banhahubak-Tang Tablet, a Standardized Medicine Attenuates Allergic Asthma via Inhibition of Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 6 (STAT6) Signal Pathway.
Asthma
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Asthma
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Asthma
Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Asthma
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Asthma
Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma.
Asthma
Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis.
Asthma
Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors.
Asthma
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Asthma
Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Asthma
Inhibition of spleen tyrosine kinase (SYK) attenuates allergen-mediated airway constriction.
Asthma
JAK-1 rs2780895 C-Related Genotype and Allele but not JAK-1 rs10789166, rs4916008, rs2780885, rs17127114, and rs3806277 Are Associated with Higher Susceptibility to Asthma.
Asthma
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma.
Asthma
Lyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma.
Asthma
Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity.
Asthma
MicroRNA-203 negatively regulates c-Abl, ERK1/2 phosphorylation, and proliferation in smooth muscle cells.
Asthma
Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.
Asthma
Status of serine tyrosine kinase at germline and expressional levels in asthma patients.
Asthma
Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
Asthma
The effect of siRNA-mediated lymphocyte-specific protein tyrosine kinase (Lck) inhibition on pulmonary inflammation in a mouse model of asthma.
Asthma
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Asthma
Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).
Asthma
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Asthma
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Asthma
[The Involvement of Src in Airway Inflammation Induced by Repeated Exposure to Lipopolysaccharide in Mice].
Asthma
[The transcription levels of linker for activation of T cell and its upstream regulatory factors in T cells of asthmatic patients]
Astrocytoma
Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression.
Astrocytoma
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Astrocytoma
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Astrocytoma
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.
Astrocytoma
Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells.
Astrocytoma
Increased expression in human astrocytomas of a 100 kDa protein with sequence homology to the ros tyrosine kinase domain.
Astrocytoma
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.
Astrocytoma
No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
Astrocytoma
p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo.
Astrocytoma
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Astrocytoma
Tumour induction in fetal brain transplants exposed to the viral oncogenes polyoma middle T and v-src.
Astrocytoma
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
Ataxia
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Ataxia Telangiectasia
Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation.
Ataxia Telangiectasia
c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP.
Ataxia Telangiectasia
c-Abl tyrosine kinase is not essential for ataxia telangiectasia mutated functions in chromosomal maintenance.
Ataxia Telangiectasia
Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals.
Ataxia Telangiectasia
Determination of cell fate by c-Abl activation in the response to DNA damage.
Ataxia Telangiectasia
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Ataxia Telangiectasia
Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy.
Atherosclerosis
A Disintegrin and Metalloproteinase 15 Contributes to Atherosclerosis by Mediating Endothelial Barrier Dysfunction via Src Family Kinase Activity.
Atherosclerosis
A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells.
Atherosclerosis
CircRNA?0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR?107.
Atherosclerosis
Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis.
Atherosclerosis
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Atherosclerosis
Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
Atherosclerosis
Mulberry water extracts inhibit atherosclerosis through suppression of the integrin-??/focal adhesion kinase complex and downregulation of nuclear factor ?B signaling in vivo and in vitro.
Atherosclerosis
Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells.
Atherosclerosis
The critical role of IL-1 receptor-associated kinase 4-mediated NF-kappaB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis.
Atherosclerosis
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Atherosclerosis
Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.
Atherosclerosis
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Atherosclerosis
Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
Atrial Fibrillation
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Atrial Fibrillation
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Atrial Fibrillation
Focal adhesion kinase mediates atrial fibrosis via the AKT/S6K signaling pathway in chronic atrial fibrillation patients with rheumatic mitral valve disease.
Atrial Fibrillation
Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy.
Atrial Fibrillation
Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
Atrial Fibrillation
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Atrial Fibrillation
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Atrial Fibrillation
Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation.
Atrial Fibrillation
[Involvement of Src kinase in the down-regulation of ultra-rapid delayed rectifier K(+)current induced by tumor necrosis factor-? in cardiomyocytes].
Autoimmune Diseases
A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmune reactivity.
Autoimmune Diseases
A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.
Autoimmune Diseases
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Autoimmune Diseases
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Autoimmune Diseases
A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants.
Autoimmune Diseases
Bayesian Machine Learning to Discover Bruton's Tyrosine Kinase (BTK) Inhibitors.
Autoimmune Diseases
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Autoimmune Diseases
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.
Autoimmune Diseases
Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
Autoimmune Diseases
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Autoimmune Diseases
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Autoimmune Diseases
Curcumin modulation of the activation of PYK2 in peripheral blood mononuclear cells from patients with lupus nephritis.
Autoimmune Diseases
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.
Autoimmune Diseases
Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Autoimmune Diseases
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
Autoimmune Diseases
Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Autoimmune Diseases
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Autoimmune Diseases
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
Autoimmune Diseases
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Autoimmune Diseases
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Autoimmune Diseases
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Autoimmune Diseases
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
Autoimmune Diseases
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Autoimmune Diseases
Discovery of Novel Bruton's Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking.
Autoimmune Diseases
Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Autoimmune Diseases
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Autoimmune Diseases
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Autoimmune Diseases
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
Autoimmune Diseases
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Autoimmune Diseases
Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes of autoimmune disease patients.
Autoimmune Diseases
Essential Kinases and Transcriptional Regulators and Their Roles in Autoimmunity.
Autoimmune Diseases
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Autoimmune Diseases
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Autoimmune Diseases
Genetic interdependence of lyn and negative regulators of B cell receptor signaling in autoimmune disease development.
Autoimmune Diseases
GLIS3 and TYK2 Single Nucleotide Polymorphisms Are Not Associated with Dermatomyositis/Polymyositis in Chinese Han Population.
Autoimmune Diseases
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Autoimmune Diseases
Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays.
Autoimmune Diseases
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Autoimmune Diseases
Identification of Inhibitors of the Association of ZAP-70 with the T Cell Receptor by High-Throughput Screen.
Autoimmune Diseases
Identification of metabolites of evobrutinib in rat and human hepatocytes by using ultra-high performance liquid chromatography coupled with diode array detector and Q Exactive Orbitrap tandem mass spectrometry.
Autoimmune Diseases
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Autoimmune Diseases
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Autoimmune Diseases
Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.
Autoimmune Diseases
Interleukin-6 Trans-Signaling Exacerbates Inflammation and Renal Pathology in Lupus-Prone Mice.
Autoimmune Diseases
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Autoimmune Diseases
JAK1, but not JAK2 and STAT3, confers susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Han Chinese population.
Autoimmune Diseases
JAK2 and STAT3 polymorphisms in a Han Chinese population with Behçet's disease.
Autoimmune Diseases
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Autoimmune Diseases
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
Autoimmune Diseases
Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Autoimmune Diseases
Measuring atropisomers of BMS-986142 using 2DLC as an enabling technology.
Autoimmune Diseases
Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding.
Autoimmune Diseases
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Autoimmune Diseases
Novel concepts and treatments for autoimmune disease: ten focal points.
Autoimmune Diseases
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Autoimmune Diseases
Pancreatic Effects of a Bruton's Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent.
Autoimmune Diseases
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Autoimmune Diseases
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Autoimmune Diseases
Pharmacophore modeling of JAK1: A target infested with activity-cliffs.
Autoimmune Diseases
Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients.
Autoimmune Diseases
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Autoimmune Diseases
PTPN22 phosphorylation acts as a molecular rheostat for the inhibition of TCR signaling.
Autoimmune Diseases
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
Autoimmune Diseases
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Autoimmune Diseases
Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Autoimmune Diseases
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.
Autoimmune Diseases
Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Autoimmune Diseases
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
Autoimmune Diseases
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Autoimmune Diseases
Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
Autoimmune Diseases
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
Autoimmune Diseases
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Autoimmune Diseases
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
Autoimmune Diseases
Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
Autoimmune Diseases
Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Autoimmune Diseases
Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6.
Autoimmune Diseases
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Autoimmune Diseases
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Autoimmune Diseases
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Autoimmune Diseases
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Autoimmune Diseases
The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
Autoimmune Diseases
The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice.
Autoimmune Diseases
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Autoimmune Diseases
Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Autoimmune Diseases
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.
Autoimmune Diseases
Tyrosine Kinase Inhibitor Tyrphostin AG490 Retards Chronic Joint Inflammation in Mice.
Autoimmune Diseases
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Autoimmune Diseases
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Autoimmune Diseases
VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease.
Autoimmune Lymphoproliferative Syndrome
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Avian Leukosis
Identification of Avian leukosis virus subgroup J associated acutely transforming viruses carrying the v-src oncogene in layer chickens.
Avian Leukosis
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene.
Avian Leukosis
Rescue of avian leukosis subgroup-J-associated acutely transforming viruses carrying different lengths of the v-fps oncogene and analysis of their tumorigenicity.
Axial Spondyloarthritis
Beyond the TNF-? Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.
Axial Spondyloarthritis
Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.
Axial Spondyloarthritis
Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.
Azoospermia
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Bacteremia
MyD88- and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses.
Bacterial Infections
A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
Bacterial Infections
Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells.
Bacterial Infections
Chlamydial Infection of Monocytes Stimulates IL-1beta Secretion Through Activation of the NLRP3 Inflammasome.
Bacterial Infections
Functional analysis of the porcine USP18 and its role during porcine arterivirus replication.
Bacterial Infections
Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia.
Bacterial Infections
Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.
Bacterial Infections
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Bacterial Infections
Neutrophil specific deletion of Syk kinase results in reduced host defense to bacterial infection.
Bacterial Infections
Novel Mutation of ZAP-70-related Combined Immunodeficiency: First Case from the National Iranian Registry and Review of the Literature.
Bacterial Infections
Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response.
Bacterial Infections
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Bacterial Infections
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
Bacterial Infections
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase.
Bacterial Infections
Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells.
Barrett Esophagus
Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Barrett Esophagus
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Behcet Syndrome
Janus kinase 2 V617F mutation and thrombotic events in Behcet's disease: The Alexandria experience.
Bicuspid Aortic Valve Disease
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Bicuspid Aortic Valve Disease
Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve.
Biliary Tract Neoplasms
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line.
Blast Crisis
A case of biphenotypic blast crisis of unclassified myeloproliferative disorder.
Blast Crisis
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
Blast Crisis
A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.
Blast Crisis
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Blast Crisis
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Blast Crisis
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Blast Crisis
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Blast Crisis
ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
Blast Crisis
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Blast Crisis
Acquired homozygosity of the rearranged bcr allele during the acute leukemic phase of a patient with Ph-negative chronic myeloid leukemia.
Blast Crisis
Activation of EVI1 transcription by the LEF1/?-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Blast Crisis
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Blast Crisis
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Blast Crisis
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Blast Crisis
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Blast Crisis
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Blast Crisis
Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
Blast Crisis
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Blast Crisis
Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Blast Crisis
An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
Blast Crisis
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Blast Crisis
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Blast Crisis
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/?-catenin signaling.
Blast Crisis
Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Blast Crisis
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Blast Crisis
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Blast Crisis
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Blast Crisis
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Blast Crisis
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Blast Crisis
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Blast Crisis
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
Blast Crisis
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
Blast Crisis
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Blast Crisis
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Blast Crisis
Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adults.
Blast Crisis
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Blast Crisis
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Blast Crisis
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.
Blast Crisis
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Blast Crisis
Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Blast Crisis
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Blast Crisis
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Blast Crisis
Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Blast Crisis
Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report.
Blast Crisis
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Blast Crisis
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Blast Crisis
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Blast Crisis
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Blast Crisis
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Blast Crisis
Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia.
Blast Crisis
Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.
Blast Crisis
Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
Blast Crisis
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Blast Crisis
Description of a new BCR-ABL point mutation in a CML patient with evolution to lymphoid blast crisis.
Blast Crisis
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Blast Crisis
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Blast Crisis
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Blast Crisis
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Blast Crisis
Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Blast Crisis
Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
Blast Crisis
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Blast Crisis
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Blast Crisis
Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype.
Blast Crisis
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Blast Crisis
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Blast Crisis
Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.
Blast Crisis
Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Blast Crisis
Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.
Blast Crisis
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Blast Crisis
Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Blast Crisis
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Blast Crisis
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Blast Crisis
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice.
Blast Crisis
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Blast Crisis
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Blast Crisis
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Blast Crisis
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Blast Crisis
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Blast Crisis
Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
Blast Crisis
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Blast Crisis
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Blast Crisis
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.
Blast Crisis
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Blast Crisis
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Blast Crisis
Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Blast Crisis
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Blast Crisis
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Blast Crisis
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
Blast Crisis
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
Blast Crisis
Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Blast Crisis
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Blast Crisis
Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML.
Blast Crisis
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Blast Crisis
Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.
Blast Crisis
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Blast Crisis
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Blast Crisis
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blast Crisis
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
Blast Crisis
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.
Blast Crisis
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Blast Crisis
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Blast Crisis
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Blast Crisis
Regulation and Targeting of Eg5, a Mitotic Motor Protein in Blast Crisis CML: Overcoming Imatinib Resistance.
Blast Crisis
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Blast Crisis
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Blast Crisis
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Blast Crisis
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Blast Crisis
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib.
Blast Crisis
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Blast Crisis
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
Blast Crisis
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Blast Crisis
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
Blast Crisis
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
Blast Crisis
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
Blast Crisis
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
Blast Crisis
The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Blast Crisis
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Blast Crisis
Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.
Blast Crisis
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Blast Crisis
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
Blast Crisis
[Molecular analysis of bcr-abl mRNA during long-term follow-up of cases of chronic myelogenous leukemia]
Blast Crisis
[Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]
Blast Crisis
[The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia]
Blindness
An Anti-inflammatory Role of VEGFR2/Src Kinase Inhibitor in HSV-1 Induced Immunopathology.
Blister
Caspase-mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell apoptosis.
Blister
Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.
Blister
GnRH Induces ERK-Dependent Bleb Formation in Gonadotrope Cells, Involving Recruitment of Members of a GnRH Receptor-Associated Signalosome to the Blebs.
Blister
LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505.
Blister
Localization of TGF-beta type II receptor and ED-A fibronectin in normal conjunctiva and failed filtering blebs.
Blister
SH4-domain-induced plasma membrane dynamization promotes bleb-associated cell motility.
Blister
Zyxin and vinculin distribution at the cell-extracellular matrix attachment complex (CMAX) in corneal epithelial tissue are actin dependent.
Bone Diseases
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Bone Diseases
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Bone Diseases
Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
Bone Diseases
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bone Diseases
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Bone Diseases
Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Bone Diseases
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Bone Diseases, Metabolic
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Bone Marrow Diseases
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Bone Marrow Failure Disorders
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
Bone Marrow Failure Disorders
Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Bone Marrow Failure Disorders
The thrombopoietin receptor: revisiting the master regulator of platelet production.
Bone Neoplasms
Blockade of spinal dopamine D1/D2 receptor suppresses activation of NMDA receptor through G?q and Src kinase to attenuate chronic bone cancer pain.
Bone Neoplasms
Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model.
Bone Neoplasms
JAK1/STAT3 regulatory effect of ?-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation.
Bone Neoplasms
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Bone Neoplasms
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Bone Resorption
A novel Bruton's tyrosine kinase inhibitor acalabrutinib suppresses osteoclast differentiation and P. gingivalis lipopolysaccharide-induced alveolar bone resorption.
Bone Resorption
A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
Bone Resorption
ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.
Bone Resorption
Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.
Bone Resorption
Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis.
Bone Resorption
Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis.
Bone Resorption
BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells.
Bone Resorption
Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases.
Bone Resorption
Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling.
Bone Resorption
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.
Bone Resorption
c-Src control of chloride channel support for osteoclast HCl transport and bone resorption.
Bone Resorption
Cbp Recruitment of Csk Into Lipid Rafts is Critical to c-Src Kinase Activity and Bone Resorption in Osteoclasts.
Bone Resorption
Compressive force regulates ephrinB2 and EphB4 in osteoblasts and osteoclasts contributing to alveolar bone resorption during experimental tooth movement.
Bone Resorption
Critical role of cortactin in actin ring formation and osteoclastic bone resorption.
Bone Resorption
Development and characterization of a porcine model to study osteoclast differentiation and activity.
Bone Resorption
Effects of Porphyromonas gingivalis lipopolysaccharide on osteoblast-osteoclast bidirectional EphB4-EphrinB2 signaling.
Bone Resorption
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Bone Resorption
Effects of the Src Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Trial.
Bone Resorption
EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair.
Bone Resorption
Fyn positively regulates the activation of DAP12 and FcR?-mediated costimulatory signals by RANKL during osteoclastogenesis.
Bone Resorption
Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression.
Bone Resorption
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
Bone Resorption
In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene.
Bone Resorption
Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
Bone Resorption
Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity.
Bone Resorption
Inhibitory Effect of Adenovirus-Mediated siRNA-Targeting BMPR-IB on UHMWPE-Induced Bone Destruction in the Murine Air Pouch Model.
Bone Resorption
Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis.
Bone Resorption
Lipoic acid increases the expression of genes involved in bone formation in mice fed a high-fat diet.
Bone Resorption
Loss of BMP signaling mediated by BMPR1A in osteoblasts leads to differential bone phenotypes in mice depending on anatomical location of the bones.
Bone Resorption
Macrophage-stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast-like cells.
Bone Resorption
Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1- I?B-NF-?B Pathway.
Bone Resorption
Plectin stabilizes microtubules during osteoclastic bone resorption by acting as a scaffold for Src and Pyk2.
Bone Resorption
Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption.
Bone Resorption
Prognostic significance of ACP5 expression in patients with lung adenocarcinoma.
Bone Resorption
Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation.
Bone Resorption
Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice.
Bone Resorption
Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
Bone Resorption
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Bone Resorption
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Bone Resorption
The potential effect of Bruton's tyrosine kinase in refractory periapical periodontitis.
Bone Resorption
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.
Boutonneuse Fever
Endothelial Cell Proteomic Response to Rickettsia conorii Infection Reveals Activation of the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT)-Inferferon Stimulated Gene (ISG)15 Pathway and Reprogramming Plasma Membrane Integrin/Cadherin Signaling.
Brain Diseases
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Brain Diseases
EphB4 Regulates Self-Renewal, Proliferation and Neuronal Differentiation of Human Embryonic Neural Stem Cells in Vitro.
Brain Diseases
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Brain Edema
Hydrogen Inhalation Ameliorated Mast Cell-Mediated Brain Injury After Intracerebral Hemorrhage in Mice.
Brain Edema
Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.
Brain Edema
PGE2 receptor agonist misoprostol protects brain against intracerebral hemorrhage in mice.
Brain Edema
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Brain Infarction
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Injuries
Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.
Brain Injuries
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Brain Injuries
Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.
Brain Injuries
Dexmedetomidine Exerts Brain-Protective Effects Under Cardiopulmonary Bypass Through Inhibiting the Janus Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway.
Brain Injuries
Distribution of bone morphogenetic protein and bone morphogenetic protein receptor transcripts in the rodent nervous system and up-regulation of bone morphogenetic protein receptor type II in hippocampal dentate gyrus in a rat model of global cerebral ischemia.
Brain Injuries
Experimental treatment for focal hyperglycemic ischemic brain injury in the rat.
Brain Injuries
Inhibition of Src tyrosine kinase and effect on outcomes in a new in vivo model of surgically induced brain injury.
Brain Injuries
Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.
Brain Injuries
Neuroprotection of GluR5-containing Kainate Receptor Activation against Ischemic Brain Injury through Decreasing Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors Mediated by Src Kinase.
Brain Injuries
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke.
Brain Injuries
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Brain Injuries, Traumatic
Downregulation of Src-kinase and glutamate-receptor phosphorylation after traumatic brain injury.
Brain Injuries, Traumatic
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Ischemia
A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury.
Brain Ischemia
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Brain Ischemia
Delayed phosphorylation of p38 mitogen-activated protein kinase in the AT1a knock-out mouse striatal neurons during middle cerebral artery occlusion and reperfusion.
Brain Ischemia
Distribution of bone morphogenetic protein and bone morphogenetic protein receptor transcripts in the rodent nervous system and up-regulation of bone morphogenetic protein receptor type II in hippocampal dentate gyrus in a rat model of global cerebral ischemia.
Brain Ischemia
Electroacupuncture effect on neurological behavior and tyrosine kinase-JAK 2 in rats with focal cerebral ischemia.
Brain Ischemia
Electroacupuncture effects on cortical neurons, as well as Janus kinase 2-signal transducer and activator of transcription 3 signal transduction pathway, in a rat model of cerebral ischemia.
Brain Ischemia
Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.
Brain Ischemia
N-methyl-D-aspartate receptor and L-type voltage-gated Ca2+ channel activation mediate proline-rich tyrosine kinase 2 phosphorylation during cerebral ischemia in rats.
Brain Ischemia
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Ischemia
Non-receptor tyrosine kinase Src is required for ischemia-stimulated neuronal cell proliferation via Raf/ERK/CREB activation in the dentate gyrus.
Brain Ischemia
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Brain Ischemia
S-Nitrosylation of proline-rich tyrosine kinase 2 involves its activation induced by oxygen-glucose deprivation.
Brain Ischemia
Spry2-mediated inhibition of the Ras/ERK pathway through interaction with Src kinase following cerebral ischemia.
Brain Ischemia
Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia.
Brain Ischemia
Study on the mechanism of JAK2/STAT3 signaling pathway-mediated inflammatory reaction after cerebral ischemia.
Brain Ischemia
The role of non-receptor protein tyrosine kinases in the excitotoxicity induced by the overactivation of NMDA receptors.
Brain Ischemia
Two types of calcium channels regulating activation of proline-rich tyrosine kinase 2 induced by transient brain ischemia in rat hippocampus.
Brain Neoplasms
Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors.
Brain Neoplasms
Kinome profiling in pediatric brain tumors as a new approach for target discovery.
Brain Neoplasms
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Brain Neoplasms
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Brain Neoplasms
SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
Brain Neoplasms
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Breast Neoplasms
(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Breast Neoplasms
4-Aryl-4H-naphthopyrans derivatives: one-pot synthesis, evaluation of Src kinase inhibitory and anti-proliferative activities.
Breast Neoplasms
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Breast Neoplasms
A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells.
Breast Neoplasms
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
Breast Neoplasms
A molecular mechanism for stress-induced alterations in susceptibility to disease.
Breast Neoplasms
A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK.
Breast Neoplasms
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
Breast Neoplasms
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Breast Neoplasms
A rapid and sensitive method for EphB4 identification as a diagnostic and therapeutic biomarker in invasive breast cancer.
Breast Neoplasms
A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
Breast Neoplasms
A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation.
Breast Neoplasms
A silent mutation made possible efficient production of active human Frk tyrosine kinase in Escherichia coli.
Breast Neoplasms
Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Breast Neoplasms
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Breast Neoplasms
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Breast Neoplasms
Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.
Breast Neoplasms
Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.
Breast Neoplasms
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Breast Neoplasms
Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Breast Neoplasms
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Breast Neoplasms
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
Breast Neoplasms
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Breast Neoplasms
Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
Breast Neoplasms
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.
Breast Neoplasms
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Breast Neoplasms
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.
Breast Neoplasms
An aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer.
Breast Neoplasms
An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer.
Breast Neoplasms
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Breast Neoplasms
An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway.
Breast Neoplasms
An evaluation of focal adhesion kinase in breast cancer by tissue microarrays.
Breast Neoplasms
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Breast Neoplasms
Analysis of multiple physical parameters for mechanical phenotyping of living cells.
Breast Neoplasms
Anti-metastatic effect of jolkinolide B and the mechanism of activity in breast cancer MDA-MB-231 cells.
Breast Neoplasms
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
Breast Neoplasms
Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.
Breast Neoplasms
Anticancer Activity of Tubulosine through Suppression of Interleukin-6-Induced Janus Kinase 2/Signal Transducer and Activation of Transcription 3 Signaling.
Breast Neoplasms
Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.
Breast Neoplasms
Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells.
Breast Neoplasms
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
Breast Neoplasms
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Breast Neoplasms
Atomic force microscopy and graph analysis to study the P-cadherin/SFK mechanotransduction signalling in breast cancer cells.
Breast Neoplasms
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
Breast Neoplasms
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.
Breast Neoplasms
Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Binding of MMP-9-degraded fibronectin to ?6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
Breast Neoplasms
Bioinformatics analysis of microarray profiling identifies the mechanism of focal adhesion kinase signalling pathway in proliferation and apoptosis of breast cancer cells modulated by green tea polyphenol epigallocatechin 3-gallate.
Breast Neoplasms
Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia.
Breast Neoplasms
Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase.
Breast Neoplasms
Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.
Breast Neoplasms
Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.
Breast Neoplasms
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Breast Neoplasms
Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition.
Breast Neoplasms
Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression.
Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Breast Neoplasms
Breast tumor kinase (Brk/PTK6) plays a role in the differentiation of primary keratinocytes.
Breast Neoplasms
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Breast Neoplasms
Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Breast Neoplasms
Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration.
Breast Neoplasms
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Breast Neoplasms
Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Breast Neoplasms
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.
Breast Neoplasms
BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest.
Breast Neoplasms
BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Breast Neoplasms
BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Breast Neoplasms
Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Breast Neoplasms
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Breast Neoplasms
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Breast Neoplasms
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Breast Neoplasms
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Breast Neoplasms
c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation.
Breast Neoplasms
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
Breast Neoplasms
cAMP Elevation Down-Regulates ?3 Integrin and Focal Adhesion Kinase and Inhibits Leptin-Induced Migration of MDA-MB-231 Breast Cancer Cells.
Breast Neoplasms
Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration.
Breast Neoplasms
CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.
Breast Neoplasms
CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
Breast Neoplasms
Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
Breast Neoplasms
Circulating extracellular vesicles from patients with breast cancer enhance migration and invasion via a Src?dependent pathway in MDA?MB?231 breast cancer cells.
Breast Neoplasms
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Breast Neoplasms
Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer.
Breast Neoplasms
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours.
Breast Neoplasms
Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
Breast Neoplasms
Co-crystal structures of PTK6: With Dasatinib at 2.24 ?, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 ? resolution.
Breast Neoplasms
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Breast Neoplasms
Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition.
Breast Neoplasms
Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
Breast Neoplasms
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Breast Neoplasms
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Breast Neoplasms
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Breast Neoplasms
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Neoplasms
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Breast Neoplasms
Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer.
Breast Neoplasms
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Breast Neoplasms
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Breast Neoplasms
Correction: Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and Invasion.
Breast Neoplasms
Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Breast Neoplasms
Coupling of RAFTK/Pyk2 kinase with c-Abl and their role in the migration of breast cancer cells.
Breast Neoplasms
Crystal structure of the kinase domain of human protein tyrosine kinase 6 (PTK6) at 2.33 ? resolution.
Breast Neoplasms
Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer.
Breast Neoplasms
Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration.
Breast Neoplasms
Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation.
Breast Neoplasms
Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Breast Neoplasms
Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells.
Breast Neoplasms
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.
Breast Neoplasms
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Breast Neoplasms
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004.
Breast Neoplasms
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
Breast Neoplasms
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
Breast Neoplasms
Decreased tyrosine phosphorylation of focal adhesion kinase after estradiol treatment of MCF-7 human breast carcinoma cells.
Breast Neoplasms
Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase.
Breast Neoplasms
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Breast Neoplasms
Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Breast Neoplasms
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand.
Breast Neoplasms
Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance.
Breast Neoplasms
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Breast Neoplasms
Discordant ERBB2 Status and Genome Wide DNA Copy Number Alterations in Breast Cancer and Synchronous Lymph Node Metastasis: A Case Report and Literature Review.
Breast Neoplasms
Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
Breast Neoplasms
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Breast Neoplasms
Doxorubicin induces atypical NF-?B activation through c-Abl kinase activity in breast cancer cells.
Breast Neoplasms
Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.
Breast Neoplasms
Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.
Breast Neoplasms
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Breast Neoplasms
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Breast Neoplasms
Effect of RAD51C expression on the chemosensitivity of E?-Myc p19Arf-/- cells and its clinical significance in breast cancer.
Breast Neoplasms
Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells.
Breast Neoplasms
Effects of hyperactive Janus kinase 2 signaling in mammary epithelial cells.
Breast Neoplasms
Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Breast Neoplasms
EGFR-c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells.
Breast Neoplasms
Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells: Potential Mechanisms Contributing to Progression of HER2-Positive Breast Cancers.
Breast Neoplasms
Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.
Breast Neoplasms
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Breast Neoplasms
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Breast Neoplasms
Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens.
Breast Neoplasms
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Breast Neoplasms
EphB4 tyrosine kinase stimulation inhibits growth of MDA-MB-231 breast cancer cells in a dose and time dependent manner.
Breast Neoplasms
Ephrin?B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis?free survival in breast cancer.
Breast Neoplasms
Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion.
Breast Neoplasms
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Breast Neoplasms
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells.
Breast Neoplasms
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Breast Neoplasms
Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Breast Neoplasms
Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
Breast Neoplasms
Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.
Breast Neoplasms
Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Breast Neoplasms
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Breast Neoplasms
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Breast Neoplasms
Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.
Breast Neoplasms
Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.
Breast Neoplasms
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
Breast Neoplasms
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Breast Neoplasms
Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.
Breast Neoplasms
Expression of GST-fused kinase domain of human Csk homologous kinase from Pichia pastoris facilitates easy purification.
Breast Neoplasms
Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase.
Breast Neoplasms
Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness.
Breast Neoplasms
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Breast Neoplasms
Extracellular AGR3 regulates breast cancer cells migration via Src signaling.
Breast Neoplasms
Extracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach.
Breast Neoplasms
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Breast Neoplasms
FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Breast Neoplasms
FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion.
Breast Neoplasms
FAK overexpression and p53 mutations are highly correlated in human breast cancer.
Breast Neoplasms
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication.
Breast Neoplasms
FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer.
Breast Neoplasms
Fascin Activates ?-Catenin Signaling and Promotes Breast Cancer Stem Cell Function Mainly Through Focal Adhesion Kinase (FAK): Relation With Disease Progression.
Breast Neoplasms
Focal adhesion kinase (FAK) deficiency in mononuclear phagocytes alters murine breast tumor progression.
Breast Neoplasms
Focal adhesion kinase and protein kinase B cooperate to suppress Doxorubicin-induced apoptosis of breast tumor cells.
Breast Neoplasms
Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
Breast Neoplasms
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Breast Neoplasms
Focal adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment and apoptosis.
Breast Neoplasms
Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-? at Tyr789 in breast cancer cells.
Breast Neoplasms
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Breast Neoplasms
Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasis.
Breast Neoplasms
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
Breast Neoplasms
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Breast Neoplasms
Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo.
Breast Neoplasms
Functional interaction between the epidermal growth factor receptor and c-Src kinase activity.
Breast Neoplasms
Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.
Breast Neoplasms
Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Breast Neoplasms
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
Breast Neoplasms
Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Breast Neoplasms
Genetic Variability in the microRNA Binding Sites of BMPR1B, TGFBR1, IQGAP1, KRAS, SETD8 and RYR3 and Risk of Breast Cancer in Colombian Women.
Breast Neoplasms
Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.
Breast Neoplasms
Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
Breast Neoplasms
Heat shock protein 90? stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells.
Breast Neoplasms
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.
Breast Neoplasms
HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Breast Neoplasms
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Breast Neoplasms
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
Breast Neoplasms
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
Breast Neoplasms
High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.
Breast Neoplasms
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Breast Neoplasms
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Breast Neoplasms
Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Breast Neoplasms
Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, MicroRNA-10b expression and RhoA/RhoC upregulation leading to Rho-kinase-associated Cytoskeleton Activation and Breast Tumor Cell Invasion.
Breast Neoplasms
Hyperphosphorylated cortactin in cancer cells plays an inhibitory role in cell motility.
Breast Neoplasms
Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells.
Breast Neoplasms
Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.
Breast Neoplasms
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Breast Neoplasms
Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR.
Breast Neoplasms
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Breast Neoplasms
Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.
Breast Neoplasms
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Breast Neoplasms
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Breast Neoplasms
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Breast Neoplasms
Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Breast Neoplasms
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
Breast Neoplasms
In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.
Breast Neoplasms
In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.
Breast Neoplasms
Increased expression of miR-551a by c-Fos reduces Focal Adhesion Kinase (FAK) levels and blocks tumorigenesis.
Breast Neoplasms
Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Breast Neoplasms
Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase.
Breast Neoplasms
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Breast Neoplasms
Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.
Breast Neoplasms
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Breast Neoplasms
Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells.
Breast Neoplasms
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Breast Neoplasms
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.
Breast Neoplasms
Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2.
Breast Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Breast Neoplasms
Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
Breast Neoplasms
Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer.
Breast Neoplasms
Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Breast Neoplasms
Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.
Breast Neoplasms
Interleukin-1? activates focal adhesion kinase and Src to induce matrix metalloproteinase-9 production and invasion of MCF-7 breast cancer cells.
Breast Neoplasms
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Breast Neoplasms
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Breast Neoplasms
Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Breast Neoplasms
Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells.
Breast Neoplasms
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Breast Neoplasms
Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate.
Breast Neoplasms
Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway.
Breast Neoplasms
Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Breast Neoplasms
Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells.
Breast Neoplasms
Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Breast Neoplasms
Is telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer?
Breast Neoplasms
Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival.
Breast Neoplasms
JAK2, STAT3 and SOCS3 gene expression in women with and without breast cancer.
Breast Neoplasms
Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Breast Neoplasms
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Breast Neoplasms
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor ? positive breast cancer.
Breast Neoplasms
Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Breast Neoplasms
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.
Breast Neoplasms
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Breast Neoplasms
Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells.
Breast Neoplasms
Logic-based analysis of gene expression data predicts association between TNF, TGFB1 and EGF pathways in basal-like breast cancer.
Breast Neoplasms
Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF? and focal adhesion kinase (FAK) signaling.
Breast Neoplasms
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Breast Neoplasms
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
Breast Neoplasms
Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma.
Breast Neoplasms
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.
Breast Neoplasms
Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.
Breast Neoplasms
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Breast Neoplasms
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Breast Neoplasms
Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Breast Neoplasms
Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
Breast Neoplasms
Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.
Breast Neoplasms
Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells.
Breast Neoplasms
Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells.
Breast Neoplasms
MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway.
Breast Neoplasms
MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2?16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Breast Neoplasms
miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2.
Breast Neoplasms
miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells.
Breast Neoplasms
Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity.
Breast Neoplasms
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Breast Neoplasms
Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
Breast Neoplasms
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Breast Neoplasms
Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.
Breast Neoplasms
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Breast Neoplasms
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Breast Neoplasms
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Breast Neoplasms
Myoferlin Depletion Elevates Focal Adhesion Kinase and Paxillin Phosphorylation and Enhances Cell-Matrix Adhesion in Breast Cancer Cells.
Breast Neoplasms
N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
Breast Neoplasms
N-cadherin mediates the migration of bone marrow-derived mesenchymal stem cells toward breast tumor cells.
Breast Neoplasms
Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis.
Breast Neoplasms
Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
Breast Neoplasms
Nuclear p120-catenin contributes to anoikis resistance of Lobular Breast Cancer through Kaiso-dependent Wnt11 expression.
Breast Neoplasms
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Breast Neoplasms
Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells.
Breast Neoplasms
Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway.
Breast Neoplasms
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone.
Breast Neoplasms
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.
Breast Neoplasms
Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Breast Neoplasms
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.
Breast Neoplasms
Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Breast Neoplasms
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Breast Neoplasms
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Breast Neoplasms
Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.
Breast Neoplasms
Overcoming resistance to fulvestrant (ICI182,780) by Downregulating the c-ABL Proto-Oncogene in breast cancer.
Breast Neoplasms
Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification.
Breast Neoplasms
Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells.
Breast Neoplasms
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells.
Breast Neoplasms
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.
Breast Neoplasms
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
Breast Neoplasms
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
Breast Neoplasms
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Breast Neoplasms
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
Breast Neoplasms
Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells.
Breast Neoplasms
Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple?negative breast cancer cell lines.
Breast Neoplasms
PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells.
Breast Neoplasms
PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGF? Responses in Breast Cancer.
Breast Neoplasms
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
Breast Neoplasms
Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules.
Breast Neoplasms
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Breast Neoplasms
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Breast Neoplasms
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Breast Neoplasms
Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Breast Neoplasms
Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Breast Neoplasms
Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells.
Breast Neoplasms
Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation.
Breast Neoplasms
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Breast Neoplasms
Polymorphisms associated with oral clefts as potential susceptibility markers for oral and breast cancer.
Breast Neoplasms
Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.
Breast Neoplasms
Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.
Breast Neoplasms
Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Breast Neoplasms
Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.
Breast Neoplasms
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase.
Breast Neoplasms
Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase.
Breast Neoplasms
Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes.
Breast Neoplasms
Prognostic and clinical significance of focal adhesion kinase expression in breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer.
Breast Neoplasms
Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.
Breast Neoplasms
Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy.
Breast Neoplasms
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Breast Neoplasms
Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells.
Breast Neoplasms
Protein tyrosine kinase 6 mediates TNF?-induced endothelial barrier dysfunction.
Breast Neoplasms
Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine.
Breast Neoplasms
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Breast Neoplasms
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.
Breast Neoplasms
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Breast Neoplasms
Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.
Breast Neoplasms
PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
Breast Neoplasms
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Breast Neoplasms
Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells.
Breast Neoplasms
PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop.
Breast Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Breast Neoplasms
Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein.
Breast Neoplasms
Radiation promotes malignant phenotypes through SRC in breast cancer cells.
Breast Neoplasms
RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion.
Breast Neoplasms
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Breast Neoplasms
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Breast Neoplasms
Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Breast Neoplasms
Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Breast Neoplasms
Reconstruction of Different Modes of WNT Dependent Protein Networks from Time Series Protein Quantification.
Breast Neoplasms
Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells.
Breast Neoplasms
Reduced expression of the murine HLA-G homolog Qa-2 is associated with malignancy, epithelial-mesenchymal transition and stemness in breast cancer cells.
Breast Neoplasms
Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1.
Breast Neoplasms
Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Breast Neoplasms
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Breast Neoplasms
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Breast Neoplasms
Requirement of ER? and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Breast Neoplasms
Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.
Breast Neoplasms
Retinoic acid increases tyrosine phosphorylation of focal adhesion kinase and paxillin in MCF-7 human breast cancer cells.
Breast Neoplasms
Role of breast tumour kinase in the in vitro differentiation of HaCaT cells.
Breast Neoplasms
Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.
Breast Neoplasms
Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
Breast Neoplasms
Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Breast Neoplasms
RRR-alpha-tocopheryl succinate enhances TGF-beta 1, -beta 2, and -beta 3 and TGF-beta R-II expression by human MDA-MB-435 breast cancer cells.
Breast Neoplasms
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Breast Neoplasms
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Breast Neoplasms
Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1? pathways in breast cancer.
Breast Neoplasms
Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells.
Breast Neoplasms
Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Breast Neoplasms
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Breast Neoplasms
Signaling pathway of globo-series glycosphingolipids and ?1,3-galactosyltransferase V (?3GalT5) in breast cancer.
Breast Neoplasms
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Breast Neoplasms
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Breast Neoplasms
Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
Breast Neoplasms
Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain.
Breast Neoplasms
Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.
Breast Neoplasms
Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Breast Neoplasms
Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
Breast Neoplasms
Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.
Breast Neoplasms
Sporadic mutations and expression analysis of spleen tyrosine kinase gene in breast cancer: a preliminary report.
Breast Neoplasms
Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Breast Neoplasms
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Breast Neoplasms
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Breast Neoplasms
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
Breast Neoplasms
Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells.
Breast Neoplasms
Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer.
Breast Neoplasms
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Breast Neoplasms
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Breast Neoplasms
STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
Breast Neoplasms
Star-related lipid transfer protein 10 (STARD10): a novel key player in alcohol-induced breast cancer progression.
Breast Neoplasms
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.
Breast Neoplasms
STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner.
Breast Neoplasms
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Breast Neoplasms
Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
Breast Neoplasms
SWIM domain protein ZSWIM4 is required for JAK2 inhibition resistance in breast cancer.
Breast Neoplasms
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Breast Neoplasms
Syndecan-1 modulates ?-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.
Breast Neoplasms
Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor?positive, human epidermal growth factor receptor 2?positive breast cancer cells.
Breast Neoplasms
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Breast Neoplasms
Synthesis, Src Kinase Inhibitory and Anticancer Activities of 1-Substituted 3-(N-Alkyl-N-phenylamino)propane-2-ols.
Breast Neoplasms
TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner.
Breast Neoplasms
TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Breast Neoplasms
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Breast Neoplasms
Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
Breast Neoplasms
Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
Breast Neoplasms
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Breast Neoplasms
Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Breast Neoplasms
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
Breast Neoplasms
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Breast Neoplasms
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Breast Neoplasms
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Breast Neoplasms
Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.
Breast Neoplasms
TGF-? stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
Breast Neoplasms
TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
Breast Neoplasms
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Breast Neoplasms
TGF? isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications.
Breast Neoplasms
TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study.
Breast Neoplasms
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Breast Neoplasms
The Alternative Splice Variant of Protein Tyrosine Kinase 6 Negatively Regulates Growth and Enhances PTK6-Mediated Inhibition of ?-Catenin.
Breast Neoplasms
The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation.
Breast Neoplasms
The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells.
Breast Neoplasms
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
Breast Neoplasms
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction].
Breast Neoplasms
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.
Breast Neoplasms
The Concentration of Microvesicles Isolated from Peripheral Blood in Breast Cancer Patients is Elevated.
Breast Neoplasms
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
Breast Neoplasms
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Breast Neoplasms
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways.
Breast Neoplasms
The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.
Breast Neoplasms
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
Breast Neoplasms
The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells.
Breast Neoplasms
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Breast Neoplasms
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.
Breast Neoplasms
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
Breast Neoplasms
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Breast Neoplasms
The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.
Breast Neoplasms
The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity.
Breast Neoplasms
The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.
Breast Neoplasms
The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.
Breast Neoplasms
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Breast Neoplasms
The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex.
Breast Neoplasms
The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.
Breast Neoplasms
The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.
Breast Neoplasms
The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
Breast Neoplasms
The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.
Breast Neoplasms
Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Breast Neoplasms
TNF?/IFN? Mediated Intestinal Epithelial Barrier Dysfunction Is Attenuated by MicroRNA-93 Downregulation of PTK6 in Mouse Colonic Epithelial Cells.
Breast Neoplasms
Tracing the footprints of the breast cancer oncogene BRK - Past till present.
Breast Neoplasms
TRAF3 in T Cells Restrains Negative Regulators of LAT to Promote TCR/CD28 Signaling.
Breast Neoplasms
Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression.
Breast Neoplasms
Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Breast Neoplasms
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.
Breast Neoplasms
TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.
Breast Neoplasms
Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
Breast Neoplasms
Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways.
Breast Neoplasms
Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells.
Breast Neoplasms
Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression.
Breast Neoplasms
Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells.
Breast Neoplasms
Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.
Breast Neoplasms
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Breast Neoplasms
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
Breast Neoplasms
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
Breast Neoplasms
[Construction of the eukaryotic expression vector of human syk and its effect on MHC-I expression of human breast cancer cells.]
Breast Neoplasms
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
Breast Neoplasms
[Effect of Janus kinase inhibitor AG490 on invasion and metastasis of human breast cancer cells]
Breast Neoplasms
[Effect of SRC Kinase on Adriamycin Resistance and Invasion and Metastasis in Human Breast Cancer Cells].
Breast Neoplasms
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Breast Neoplasms
[Janus kinase 3 facilitates the migration of breast cancer cells by store-operated calcium channel].
Breast Neoplasms
[PP2 enhances intercellular communication of gap junction in breast cancer Hs578T cells].
Breast Neoplasms
[Spleen tyrosine kinase (L) suppresses breast cancer development by downregulating the expression of cyclin D1, ID1, B-myb and Fra1]
Budd-Chiari Syndrome
Association of factor V Leiden, Janus kinase 2, prothrombin, and MTHFR mutations with primary Budd-Chiari syndrome in Egyptian patients.
Budd-Chiari Syndrome
Janus Kinase 2 Mutation-Associated Budd-Chiari Syndrome Presenting as a Tumor.
Budd-Chiari Syndrome
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Budd-Chiari Syndrome
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Budd-Chiari Syndrome
Pseudocirrhosis in Chronic Budd Chiari Syndrome With Janus Tyrosine Kinase 2 (JAK2) Mutation.
Burkitt Lymphoma
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Burkitt Lymphoma
Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.
Burkitt Lymphoma
Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
Burkitt Lymphoma
Cell cycle-dependent modulation of alpha-interferon-inducible gene expression and activation of signaling components in Daudi cells.
Burkitt Lymphoma
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
Burkitt Lymphoma
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Burkitt Lymphoma
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Burkitt Lymphoma
Purification and characterization of proteins with associated tyrosine protein kinase activity from human B lymphocytes.
Burkitt Lymphoma
Rearrangements of c-myc and c-abl genes in tumour cells in Burkitt's lymphoma.
Burkitt Lymphoma
Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines.
Burkitt Lymphoma
Some questions on the significance of chromosome alterations in leukemias and lymphomas: a review.
Burkitt Lymphoma
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Bursitis
Genetic variants involved in extracellular matrix homeostasis play a role in the susceptibility to frozen shoulder: a case-control study.
Candidiasis
Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects.
Candidiasis, Chronic Mucocutaneous
Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects.
Carcinogenesis
17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Carcinogenesis
A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population.
Carcinogenesis
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Carcinogenesis
A mutation at the major phosphotyrosine in pp60v-src alters oncogenic potential.
Carcinogenesis
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Carcinogenesis
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Carcinogenesis
A Swiss 3T3 variant cell line resistant to the effects of tumor promoters cannot be transformed by src.
Carcinogenesis
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Carcinogenesis
Abelson kinase's intrinsically disordered region plays essential roles in protein function and protein stability.
Carcinogenesis
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
Carcinogenesis
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Carcinogenesis
Acacetin and pinostrobin as a promising inhibitor of cancer-associated protein kinases.
Carcinogenesis
Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors.
Carcinogenesis
Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src.
Carcinogenesis
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice.
Carcinogenesis
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinogenesis
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Carcinogenesis
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Carcinogenesis
Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
Carcinogenesis
An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1.
Carcinogenesis
Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma.
Carcinogenesis
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Carcinogenesis
BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
Carcinogenesis
Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice.
Carcinogenesis
Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Carcinogenesis
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Carcinogenesis
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Carcinogenesis
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
Carcinogenesis
Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression.
Carcinogenesis
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Carcinogenesis
Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Carcinogenesis
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Carcinogenesis
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Carcinogenesis
Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.
Carcinogenesis
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Carcinogenesis
Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Carcinogenesis
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Carcinogenesis
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy.
Carcinogenesis
Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.
Carcinogenesis
Cucurbitacin B inhibits cell proliferation and induces apoptosis in human osteosarcoma cells via modulation of the JAK2/STAT3 and MAPK pathways.
Carcinogenesis
Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
Carcinogenesis
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Carcinogenesis
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Carcinogenesis
Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Carcinogenesis
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Carcinogenesis
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Carcinogenesis
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Carcinogenesis
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Carcinogenesis
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Carcinogenesis
Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
Carcinogenesis
Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
Carcinogenesis
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Carcinogenesis
Disruption of postnatal folliculogenesis and development of ovarian tumor in a mouse model with aberrant transforming growth factor beta signaling.
Carcinogenesis
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Carcinogenesis
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Carcinogenesis
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Carcinogenesis
Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
Carcinogenesis
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Carcinogenesis
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Carcinogenesis
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Carcinogenesis
Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
Carcinogenesis
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
Carcinogenesis
Effect of ets-related transcription factor (ERT) on transforming growth factor (TGF)-beta type II receptor gene expression in human cancer cell lines.
Carcinogenesis
Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Carcinogenesis
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.
Carcinogenesis
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Carcinogenesis
Enhancement of tyrosyl phosphorylation and protein expression of eps8 by v-Src.
Carcinogenesis
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Carcinogenesis
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Carcinogenesis
Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways.
Carcinogenesis
Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis.
Carcinogenesis
Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Carcinogenesis
Examination of the role of CSF-1 independence in myc retrovirus induced monocyte tumorigenesis.
Carcinogenesis
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Carcinogenesis
Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis.
Carcinogenesis
Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Carcinogenesis
Expression of STAT3 and Bcl-6 oncoprotein in sodium arsenite-treated SV-40 immortalized human uroepithelial cells.
Carcinogenesis
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Carcinogenesis
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Carcinogenesis
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Carcinogenesis
Focal Adhesion Kinase Expression in Ameloblastoma: A Preliminary Observational Study.
Carcinogenesis
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Carcinogenesis
Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling.
Carcinogenesis
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Carcinogenesis
From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein.
Carcinogenesis
From xeroderma pigmentosum to the biological clock contributions of Dirk Bootsma to human genetics.
Carcinogenesis
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.
Carcinogenesis
Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo.
Carcinogenesis
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Carcinogenesis
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Carcinogenesis
Hepatitis C virus NS5A protein interacts with and negatively regulates the non-receptor protein tyrosine kinase Syk.
Carcinogenesis
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Carcinogenesis
High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene.
Carcinogenesis
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Carcinogenesis
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.
Carcinogenesis
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Carcinogenesis
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Carcinogenesis
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Carcinogenesis
Imaging focal adhesion kinase activation in breast cancer-promoting cell proliferation and carcinogenesis, but not migration, invasion, or metastatic predilection.
Carcinogenesis
Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
Carcinogenesis
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Carcinogenesis
Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Carcinogenesis
Important players in carcinogenesis as potential targets in cancer therapy: an update.
Carcinogenesis
In vitro phosphorylation of caveolin-rich membrane domains: identification of an associated serine kinase activity as a casein kinase II-like enzyme.
Carcinogenesis
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
Carcinogenesis
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
Carcinogenesis
Increased expression of focal adhesion kinase correlates with cellular proliferation and apoptosis during 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis.
Carcinogenesis
Increased expression of miR-551a by c-Fos reduces Focal Adhesion Kinase (FAK) levels and blocks tumorigenesis.
Carcinogenesis
Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas.
Carcinogenesis
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Carcinogenesis
Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis.
Carcinogenesis
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Carcinogenesis
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
Carcinogenesis
Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130.
Carcinogenesis
Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Carcinogenesis
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Carcinogenesis
Liver tyrosine kinase activation during early stages of chemical hepatocarcinogenesis.
Carcinogenesis
Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish.
Carcinogenesis
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Carcinogenesis
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Carcinogenesis
Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer.
Carcinogenesis
Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis.
Carcinogenesis
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Carcinogenesis
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Carcinogenesis
Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function.
Carcinogenesis
mDia1 targets v-Src to the cell periphery and facilitates cell transformation, tumorigenesis, and invasion.
Carcinogenesis
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
Carcinogenesis
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Carcinogenesis
Microsatellite alteration at chromosome 11 in primary human nasopharyngeal carcinoma in Taiwan.
Carcinogenesis
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
Carcinogenesis
Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation.
Carcinogenesis
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
Carcinogenesis
MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3.
Carcinogenesis
MiR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3.
Carcinogenesis
MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway.
Carcinogenesis
MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway.
Carcinogenesis
Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats.
Carcinogenesis
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Carcinogenesis
Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.
Carcinogenesis
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Carcinogenesis
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Carcinogenesis
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Carcinogenesis
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Carcinogenesis
Myristoylation of Src kinase mediates Src induced and high fat diet accelerated prostate tumor progression in mice.
Carcinogenesis
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Carcinogenesis
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Carcinogenesis
Over-Expression of Ephb4 Is Associated with Carcinogenesis of Gastric Cancer.
Carcinogenesis
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Carcinogenesis
Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor.
Carcinogenesis
Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Carcinogenesis
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Carcinogenesis
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.
Carcinogenesis
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Carcinogenesis
Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.
Carcinogenesis
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Carcinogenesis
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Carcinogenesis
Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.
Carcinogenesis
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Carcinogenesis
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Carcinogenesis
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.
Carcinogenesis
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Carcinogenesis
Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors.
Carcinogenesis
Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Carcinogenesis
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.
Carcinogenesis
RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Carcinogenesis
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Carcinogenesis
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Carcinogenesis
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Carcinogenesis
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma.
Carcinogenesis
Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.
Carcinogenesis
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Carcinogenesis
Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice.
Carcinogenesis
Roles of Src family kinase, Ras, and mTOR signaling in intestinal epithelial homeostasis and tumorigenesis.
Carcinogenesis
Selective elimination of cancer cells by the adenovirus E4orf4 protein in a Drosophila cancer model: a new paradigm for cancer therapy.
Carcinogenesis
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Carcinogenesis
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Carcinogenesis
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Carcinogenesis
Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes.
Carcinogenesis
Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation.
Carcinogenesis
SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.
Carcinogenesis
STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.
Carcinogenesis
Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity.
Carcinogenesis
Structure and chromosomal localization of the human gene of the phosphotyrosyl phosphatase activator (PTPA) of protein phosphatase 2A.
Carcinogenesis
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Carcinogenesis
Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Carcinogenesis
Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.
Carcinogenesis
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Carcinogenesis
Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.
Carcinogenesis
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Carcinogenesis
Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
Carcinogenesis
TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition.
Carcinogenesis
TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas.
Carcinogenesis
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
Carcinogenesis
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
Carcinogenesis
The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication.
Carcinogenesis
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
Carcinogenesis
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
Carcinogenesis
The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia.
Carcinogenesis
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
Carcinogenesis
The genomic structure of the gene encoding the human transforming growth factor beta type II receptor (TGF-beta RII).
Carcinogenesis
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
Carcinogenesis
The nonreceptor tyrosine kinase c-Src attenuates SCF(?-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Carcinogenesis
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Carcinogenesis
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Carcinogenesis
The receptor-like protein tyrosine phosphatase alpha: a role in cell proliferation and oncogenesis.
Carcinogenesis
The Src Family Kinase Inhibitors PP2 and PP1 block TGF-beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-beta Receptors.
Carcinogenesis
The SRC-family tyrosine kinase HCK shapes the landscape of SKAP2 interactome.
Carcinogenesis
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.
Carcinogenesis
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Carcinogenesis
Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
Carcinogenesis
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Carcinogenesis
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2.
Carcinogenesis
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Carcinogenesis
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinogenesis
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Carcinogenesis
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Carcinogenesis
Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis.
Carcinogenesis
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Carcinogenesis
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
Carcinogenesis
Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair.
Carcinogenesis
Tyrosine phosphorylation of growth factor receptor-bound protein-7 by focal adhesion kinase in the regulation of cell migration, proliferation, and tumorigenesis.
Carcinogenesis
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinogenesis
Vitamin D Receptor Protects Against Dysbiosis and Tumorigenesis via the JAK/STAT Pathway in Intestine.
Carcinogenesis
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Carcinogenesis
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Carcinogenesis
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
Carcinogenesis
[Effect of spleen tyrosine kinase expression re-activation by inhibition of DNA methylation on oncogenesis growth of gastric cancer]
Carcinogenesis
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Carcinogenesis
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
Carcinogenesis
[Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
Carcinogenesis
[The characteristics of focal adhesion kinase (FAK) and its role in carcinogenesis]
Carcinoid Tumor
Focal Adhesion Kinase, a Downstream Mediator of Raf-1 Signaling, Suppresses Cellular Adhesion, Migration, and Neuroendocrine Markers in BON Carcinoid Cells.
Carcinoid Tumor
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Carcinoma
15-Deoxy-?12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
Carcinoma
3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities.
Carcinoma
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Carcinoma
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.
Carcinoma
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
Carcinoma
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.
Carcinoma
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.
Carcinoma
A differential effect of the Walker 256 carcinoma on the tyrosine protein kinase activity of liver plasma membrane domains.
Carcinoma
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Carcinoma
A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGF? and FAK Pathways.
Carcinoma
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Carcinoma
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Carcinoma
A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QG90.
Carcinoma
A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK.
Carcinoma
A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas.
Carcinoma
Abl kinases are required for invadopodia formation and chemokine-induced invasion.
Carcinoma
Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer.
Carcinoma
Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma.
Carcinoma
Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR/S6 signaling pathway in an ERK1/2-independent manner.
Carcinoma
Activation of Src mediates acquired cisplatin resistance in human lung carcinoma cells.
Carcinoma
Activation of Src tyrosine kinase in esophageal carcinoma cells in different regulatory environments and corresponding occurrence mechanism.
Carcinoma
Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18.
Carcinoma
Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis.
Carcinoma
Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas.
Carcinoma
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinoma
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Carcinoma
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
Carcinoma
Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells.
Carcinoma
Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Carcinoma
Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Carcinoma
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Carcinoma
Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
Carcinoma
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
Carcinoma
An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma.
Carcinoma
An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder.
Carcinoma
Androgen deprivation modulates gene expression profile along prostate cancer progression.
Carcinoma
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Carcinoma
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Carcinoma
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Carcinoma
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage.
Carcinoma
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Carcinoma
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
Carcinoma
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Carcinoma
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
Carcinoma
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Carcinoma
Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma.
Carcinoma
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Carcinoma
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
Carcinoma
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Carcinoma
c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
Carcinoma
c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells.
Carcinoma
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling.
Carcinoma
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Carcinoma
Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation.
Carcinoma
Cell directional migration and oriented division on three-dimensional laser-induced periodic surface structures on polystyrene.
Carcinoma
Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck.
Carcinoma
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Carcinoma
Chrysin serves as a novel inhibitor of DGK?/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC).
Carcinoma
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.
Carcinoma
Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.
Carcinoma
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Carcinoma
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Carcinoma
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Carcinoma
Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
Carcinoma
Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
Carcinoma
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043.
Carcinoma
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Carcinoma
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Carcinoma
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.
Carcinoma
Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion.
Carcinoma
DDR2 overexpression in oral squamous cell carcinoma is associated to lymph node metastasis.
Carcinoma
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma.
Carcinoma
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Carcinoma
Decreased Stability of Transforming Growth Factor beta Type II Receptor mRNA in RER+ Human Colon Carcinoma Cells
Carcinoma
Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells.
Carcinoma
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Carcinoma
Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion.
Carcinoma
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Carcinoma
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Carcinoma
Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.
Carcinoma
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Carcinoma
Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines.
Carcinoma
Differentiation of normal and cancer cells induced by sulfhydryl reduction: biochemical and molecular mechanisms.
Carcinoma
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Carcinoma
Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus.
Carcinoma
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Carcinoma
Disruption of Ca2+-dependent cell-matrix adhesion enhances c-Src kinase activity, but causes dissociation of the c-Src/FAK complex and dephosphorylation of tyrosine-577 of FAK in carcinoma cells.
Carcinoma
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Carcinoma
Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma.
Carcinoma
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Carcinoma
Down-Regulation of miR-2053 Inhibits the Development and Progression of Esophageal Carcinoma by Targeting Fyn-Related Kinase (FRK).
Carcinoma
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Carcinoma
Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.
Carcinoma
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Carcinoma
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Carcinoma
Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
Carcinoma
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Carcinoma
EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion.
Carcinoma
EGFR-dependent tyrosine phosphorylation of integrin ?4 is not required for downstream signaling events in cancer cell lines.
Carcinoma
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Carcinoma
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Carcinoma
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Carcinoma
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Carcinoma
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Carcinoma
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Carcinoma
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Carcinoma
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Carcinoma
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Carcinoma
Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.
Carcinoma
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Carcinoma
Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma.
Carcinoma
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Carcinoma
Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
Carcinoma
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Carcinoma
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Carcinoma
Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance.
Carcinoma
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Carcinoma
Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.
Carcinoma
Expression of paxillin and FAK mRNA and the related clinical significance in esophageal carcinoma.
Carcinoma
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Carcinoma
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Carcinoma
Expression of the gene coding for the light chain of calpactin I (annexin II) in cell lines DiFi, HT-29, and WI-38.
Carcinoma
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Carcinoma
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
Carcinoma
Expression of Wnt11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance.
Carcinoma
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Carcinoma
Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence.
Carcinoma
Extracellular engagement of ADAM12 induces clusters of invadopodia with localized ectodomain shedding activity.
Carcinoma
Features of multiple self-healing squamous epithelioma and Loeys-Dietz syndrome in a patient with a novel TGFBR1 variant.
Carcinoma
First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Carcinoma
Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
Carcinoma
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Carcinoma
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Carcinoma
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Carcinoma
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
Carcinoma
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Carcinoma
Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas.
Carcinoma
Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Carcinoma
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Carcinoma
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Carcinoma
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Carcinoma
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Carcinoma
Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids.
Carcinoma
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Carcinoma
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Carcinoma
Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes.
Carcinoma
Gastrin-stimulated G?13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells.
Carcinoma
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients.
Carcinoma
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Carcinoma
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Carcinoma
Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor.
Carcinoma
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Carcinoma
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Carcinoma
Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells.
Carcinoma
HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
Carcinoma
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Carcinoma
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Carcinoma
HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.
Carcinoma
Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1.
Carcinoma
Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
Carcinoma
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.
Carcinoma
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Carcinoma
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Carcinoma
Immunohistochemical expression of TGF beta (TGF-?), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
Carcinoma
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.
Carcinoma
In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
Carcinoma
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Carcinoma
Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G.
Carcinoma
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Carcinoma
Inhibition of cell growth and upregulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the SRC/ABL inhibitor dasatinib.
Carcinoma
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Carcinoma
Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.
Carcinoma
Inhibition of focal adhesion kinase induces apoptosis in human gastric carcinoma cells (SGC-7901).
Carcinoma
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Carcinoma
Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways.
Carcinoma
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Carcinoma
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Carcinoma
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Carcinoma
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Carcinoma
Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway.
Carcinoma
Interleukin4R? (IL4R?) and IL13R?1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Carcinoma
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
Carcinoma
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Carcinoma
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Carcinoma
Ionizing radiation modules of the expression and tyrosine phosphorylation of the focal adhesion-associated proteins focal adhesion kinase (FAK) and its substrates p130cas and paxillin in A549 human lung carcinoma cells in vitro.
Carcinoma
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Carcinoma
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Carcinoma
Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth.
Carcinoma
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Carcinoma
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance.
Carcinoma
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Carcinoma
Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues.
Carcinoma
Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.
Carcinoma
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Carcinoma
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Carcinoma
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Carcinoma
Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population.
Carcinoma
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Carcinoma
miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma.
Carcinoma
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma
MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.
Carcinoma
Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex.
Carcinoma
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
Carcinoma
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.
Carcinoma
Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway.
Carcinoma
Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9.
Carcinoma
Multiple Self-Healing Squamous Epithelioma (MSSE): Rare Variants in an Adjacent Region of Chromosome 9q22.3 to Known TGFBR1 Mutations Suggest a Digenic or Multilocus Etiology.
Carcinoma
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.
Carcinoma
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Carcinoma
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Carcinoma
N- and C-terminal isoforms of Arg quantified by real-time PCR are specifically expressed in human normal and neoplastic cells, in neoplastic cell lines, and in HL-60 cell differentiation.
Carcinoma
Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Carcinoma
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Carcinoma
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone.
Carcinoma
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
Carcinoma
Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.
Carcinoma
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma.
Carcinoma
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Carcinoma
Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.
Carcinoma
p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.
Carcinoma
p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
Carcinoma
Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.
Carcinoma
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Carcinoma
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Carcinoma
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Carcinoma
Pleiotrophin exerts its migration and invasion effect through the neuropilin-1 pathway.
Carcinoma
Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma.
Carcinoma
Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization.
Carcinoma
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Carcinoma
Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis.
Carcinoma
Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Carcinoma
Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway.
Carcinoma
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Carcinoma
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation.
Carcinoma
Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.
Carcinoma
Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.
Carcinoma
Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain.
Carcinoma
Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association.
Carcinoma
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.
Carcinoma
Relationship between grade of microsatellite instability and target genes of mismatch repair pathways in sporadic colorectal carcinoma.
Carcinoma
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Carcinoma
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Carcinoma
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Carcinoma
Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Carcinoma
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Carcinoma
Retraction: Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Carcinoma
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice.
Carcinoma
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Carcinoma
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Carcinoma
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Carcinoma
Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK.
Carcinoma
Signal transduction through extracellular signal-regulated kinase-like pp57 blocked in differentiated colon carcinoma cells having low levels of c-src kinase.
Carcinoma
Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Carcinoma
SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma.
Carcinoma
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Carcinoma
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Carcinoma
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Carcinoma
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
Carcinoma
Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase.
Carcinoma
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Carcinoma
Src Plays a Key Role in ADAM28 Expression in v-src-Transformed Epithelial Cells and Human Carcinoma Cells.
Carcinoma
Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Carcinoma
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Carcinoma
Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Carcinoma
Taiwan cobra cardiotoxin III inhibits Src kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma Ca9-22 cells.
Carcinoma
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Carcinoma
Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Carcinoma
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Carcinoma
Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
Carcinoma
TGF-? Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.
Carcinoma
TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
Carcinoma
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Carcinoma
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinoma
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
Carcinoma
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
Carcinoma
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Carcinoma
The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites.
Carcinoma
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
Carcinoma
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
Carcinoma
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Carcinoma
The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells.
Carcinoma
The role of protein tyrosine phosphorylation in integrin-mediated gene induction in monocytes.
Carcinoma
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Carcinoma
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Carcinoma
The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer.
Carcinoma
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Carcinoma
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Carcinoma
Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells.
Carcinoma
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinoma
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Carcinoma
Transinactivation of the epidermal growth factor receptor tyrosine kinase and focal adhesion kinase phosphorylation by dietary flavonoids: effect on invasive potential of human carcinoma cells.
Carcinoma
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Carcinoma
Tyrosine protein kinase activity of human hyperplastic prostate and carcinoma cell lines PC3 and DU145.
Carcinoma
Unique Mechanism by Which TGFBR1 Variants Cause 2 Distinct System Diseases?- Loeys-Dietz Syndrome and Multiple Self-Healing Squamous Epithelioma.
Carcinoma
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Carcinoma
Wnt/?-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Carcinoma
Zeylenone inhibits proliferation and promotes apoptosis in ovarian carcinoma cells via Janus kinase 2 / signal transducers and activators of transcription 3 pathways.
Carcinoma
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
Carcinoma
[BMP7 Signaling via BMPR1A, BMPR1B Inhibits the Proliferation of Lung Large Carcinoma NCI-H460 Cell.]
Carcinoma
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Carcinoma
[Effect of focal adhesion kinase on biological characteristics of Tca8113 tongue squamous cell carcinoma]
Carcinoma
[Effect of genistein on proliferation of renal cell carcinoma cell line GRC-1 and its influence to p27 expression]
Carcinoma
[Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line].
Carcinoma
[Effects of genistein on the expressions of cell apoptosis-related proteins in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma
[Effects of genistein on the expressions of cell cycle proteins in salivary adenoid cystic carcinoma cell line SACC-83.]
Carcinoma
[Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma
[Expression and clinical significance of focal adhesion kinase in oral squamous cell carcinoma]
Carcinoma
[Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma].
Carcinoma
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
Carcinoma
[Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance]
Carcinoma
[Functional properties of the WNT11 new isoform, expressed in colon carcinoma cell line HT29].
Carcinoma
[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]
Carcinoma
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
Carcinoma
[Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]
Carcinoma
[Proteomic identification and comparison of differentiation-related proteins in gastric carcinoma cell lines]
Carcinoma
[The expression and significance of integrin beta1 and focal adhesion kinase and its clinical value in laryngeal carcinoma]
Carcinoma
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
Carcinoma
[Tyrosine kinases of the Src family, enzymes with multiple functions: from the growth of fibroblasts to the migration of epithelial cells]
Carcinoma in Situ
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinoma, Adenoid Cystic
Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.
Carcinoma, Adenoid Cystic
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
Carcinoma, Adenoid Cystic
[Effects of genistein on the expressions of cell apoptosis-related proteins in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma, Adenoid Cystic
[Effects of genistein on the expressions of cell cycle proteins in salivary adenoid cystic carcinoma cell line SACC-83.]
Carcinoma, Adenoid Cystic
[Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma, Adenoid Cystic
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
Carcinoma, Basal Cell
In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
Carcinoma, Basal Cell
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma, Ductal
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Carcinoma, Ductal
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
Carcinoma, Ductal
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinoma, Ehrlich Tumor
A tyrosine-specific protein kinase from Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Changes in c-onc expression during embryonal carcinoma cell differentiation.
Carcinoma, Embryonal
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Carcinoma, Embryonal
Complexes of gamma-tubulin with nonreceptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells.
Carcinoma, Embryonal
Differential expression of inhibin subunits and follistatin, but not of activin receptor type II, during early murine embryonic development.
Carcinoma, Embryonal
Expression of c-src and c-abl in embryonal carcinoma cells and adult mouse tissues.
Carcinoma, Embryonal
Regulation of microtubule nucleation from membranes by complexes of membrane-bound gamma-tubulin with Fyn kinase and phosphoinositide 3-kinase.
Carcinoma, Embryonal
Syk protein-tyrosine kinase is involved in neuron-like differentiation of embryonal carcinoma P19 cells.
Carcinoma, Embryonal
The effects of v-src expression on the differentiation of embryonal carcinoma cells.
Carcinoma, Endometrioid
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinoma, Hepatocellular
ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Carcinoma, Hepatocellular
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Carcinoma, Hepatocellular
Activation of c-Yes in hepatocellular carcinoma: A preliminary study.
Carcinoma, Hepatocellular
Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
Carcinoma, Hepatocellular
Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
Carcinoma, Hepatocellular
An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population.
Carcinoma, Hepatocellular
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
Carcinoma, Hepatocellular
c-src tyrosine kinase is associated with the asialoglycoprotein receptor in human hepatoma cells.
Carcinoma, Hepatocellular
Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin.
Carcinoma, Hepatocellular
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B.
Carcinoma, Hepatocellular
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043.
Carcinoma, Hepatocellular
Corrigendum to: miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-? signaling pathway via targeting TGFBR1.
Carcinoma, Hepatocellular
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.
Carcinoma, Hepatocellular
Current understanding of tyrosine kinase BMX in inflammation and its inhibitors.
Carcinoma, Hepatocellular
Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion.
Carcinoma, Hepatocellular
Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src.
Carcinoma, Hepatocellular
Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Carcinoma, Hepatocellular
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Carcinoma, Hepatocellular
Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro.
Carcinoma, Hepatocellular
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma.
Carcinoma, Hepatocellular
Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.
Carcinoma, Hepatocellular
Focal Adhesion Kinase and ?-Catenin Cooperate to Induce Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Carcinoma, Hepatocellular
Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor.
Carcinoma, Hepatocellular
Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Carcinoma, Hepatocellular
Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression.
Carcinoma, Hepatocellular
Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Carcinoma, Hepatocellular
Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells.
Carcinoma, Hepatocellular
Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.
Carcinoma, Hepatocellular
Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.
Carcinoma, Hepatocellular
Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.
Carcinoma, Hepatocellular
High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis.
Carcinoma, Hepatocellular
Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations.
Carcinoma, Hepatocellular
Identification of a human cDNA encoding a novel protein kinase with two repeats of the LIM/double zinc finger motif.
Carcinoma, Hepatocellular
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Carcinoma, Hepatocellular
Identification of p62, a phosphotyrosine independent ligand of p56lck kinase, as a major component of intracytoplasmic hyaline bodies in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Carcinoma, Hepatocellular
In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
Carcinoma, Hepatocellular
Jianpijiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase.
Carcinoma, Hepatocellular
Krüppel?like factor expression and correlation with FAK, MMP?9 and E?cadherin expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-? RII.
Carcinoma, Hepatocellular
Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea.
Carcinoma, Hepatocellular
miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4.
Carcinoma, Hepatocellular
miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-? signaling pathway via targeting TGFBR1.
Carcinoma, Hepatocellular
MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway.
Carcinoma, Hepatocellular
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Carcinoma, Hepatocellular
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Carcinoma, Hepatocellular
Overexpression of Abl2 predicts poor prognosis in hepatocellular carcinomas and is associated with cancer cell migration and invasion.
Carcinoma, Hepatocellular
Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca(2+) pathways.
Carcinoma, Hepatocellular
PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways.
Carcinoma, Hepatocellular
Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes.
Carcinoma, Hepatocellular
Prolactin Promotes Hepatocellular Carcinoma through Janus Kinase 2.
Carcinoma, Hepatocellular
Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.
Carcinoma, Hepatocellular
Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
Carcinoma, Hepatocellular
Prostaglandin E2 receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Protein kinase C-mediated tyrosine phosphorylation of paxillin and focal adhesion kinase requires cytoskeletal integrity and is uncoupled to mitogen-activated protein kinase activation in human hepatoma cells.
Carcinoma, Hepatocellular
Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Regulation of JAK2 protein expression by chronic, pulsatile GH administration in vivo: a possible mechanism for ligand enhancement of signal transduction.
Carcinoma, Hepatocellular
Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3?/Wnt/?-catenin signaling.
Carcinoma, Hepatocellular
Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes.
Carcinoma, Hepatocellular
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
Carcinoma, Hepatocellular
Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.
Carcinoma, Hepatocellular
The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice.
Carcinoma, Hepatocellular
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
Carcinoma, Hepatocellular
The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Transforming growth factor beta 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR1) in human hepatoma cell lines.
Carcinoma, Hepatocellular
Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells.
Carcinoma, Hepatocellular
Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase.
Carcinoma, Hepatocellular
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Carcinoma, Hepatocellular
Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis.
Carcinoma, Hepatocellular
Tyrosine protein kinase in preneoplastic and neoplastic rat liver.
Carcinoma, Hepatocellular
Upregulation of Focal Adhesion Kinase by 14-3-3? via NF?B Activation in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
[Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC]
Carcinoma, Hepatocellular
[Influence of focal adhesion kinase (FAK) on the biological behaviors of human hepatocellular carcinoma cells]
Carcinoma, Hepatocellular
[Inhibitory effects of antisense focal adhesion kinase oligodeoxynucleotides on the invasion of Bel 7402 hepatocellular carcinoma cells]
Carcinoma, Hepatocellular
[Liver phosphotyrosine protein phosphatase and tyrosine protein kinase in chemical hepatocarcinogenesis]
Carcinoma, Hepatocellular
[RNA interference targeting focal adhesion kinase inhibited the growth of human hepatocellular carcinoma sk-hep-1].
Carcinoma, Intraductal, Noninfiltrating
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Carcinoma, Intraductal, Noninfiltrating
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Carcinoma, Intraductal, Noninfiltrating
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
Carcinoma, Intraductal, Noninfiltrating
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinoma, Lewis Lung
Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion.
Carcinoma, Merkel Cell
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.
Carcinoma, Merkel Cell
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Carcinoma, Non-Small-Cell Lung
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Carcinoma, Non-Small-Cell Lung
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Carcinoma, Non-Small-Cell Lung
Effect of spleen tyrosine kinase on nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Carcinoma, Non-Small-Cell Lung
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Carcinoma, Non-Small-Cell Lung
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Carcinoma, Non-Small-Cell Lung
Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance.
Carcinoma, Non-Small-Cell Lung
FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis.
Carcinoma, Non-Small-Cell Lung
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Carcinoma, Non-Small-Cell Lung
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Carcinoma, Non-Small-Cell Lung
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Carcinoma, Non-Small-Cell Lung
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Carcinoma, Non-Small-Cell Lung
LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p.
Carcinoma, Non-Small-Cell Lung
Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225-3p/ErbB2 signal.
Carcinoma, Non-Small-Cell Lung
MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.
Carcinoma, Non-Small-Cell Lung
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
Carcinoma, Non-Small-Cell Lung
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
Carcinoma, Non-Small-Cell Lung
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Carcinoma, Non-Small-Cell Lung
MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway.
Carcinoma, Non-Small-Cell Lung
miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Carcinoma, Non-Small-Cell Lung
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Carcinoma, Non-Small-Cell Lung
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Carcinoma, Non-Small-Cell Lung
SOCS3 expression is inversely correlated with Pyk2 in non-small cell lung cancer and exogenous SOCS3 inhibits proliferation and invasion of A549 cells.
Carcinoma, Non-Small-Cell Lung
Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinoma, Non-Small-Cell Lung
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Carcinoma, Non-Small-Cell Lung
Up-regulation of focal adhesion kinase in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
[Association between Ephb4 gene polymorphism and non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
Carcinoma, Non-Small-Cell Lung
[Relationship between multi-slice spiral CT pulmonary perfusion imaging and the expression of EphB4 and ephrinB2 in non-small cell lung cancer].
Carcinoma, Ovarian Epithelial
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Carcinoma, Ovarian Epithelial
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.
Carcinoma, Ovarian Epithelial
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Carcinoma, Ovarian Epithelial
Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Carcinoma, Ovarian Epithelial
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression and clinical significance of focal adhesion kinase and adrenomedullin in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Carcinoma, Ovarian Epithelial
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.
Carcinoma, Pancreatic Ductal
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Carcinoma, Papillary
Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.
Carcinoma, Papillary
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.
Carcinoma, Renal Cell
15-Deoxy-?12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
Carcinoma, Renal Cell
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Carcinoma, Renal Cell
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Renal Cell
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Carcinoma, Renal Cell
Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.
Carcinoma, Renal Cell
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma, Renal Cell
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Carcinoma, Renal Cell
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Interleukin4R? (IL4R?) and IL13R?1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Carcinoma, Renal Cell
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Carcinoma, Renal Cell
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Carcinoma, Renal Cell
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Carcinoma, Renal Cell
Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.
Carcinoma, Renal Cell
Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.
Carcinoma, Renal Cell
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation.
Carcinoma, Renal Cell
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Carcinoma, Renal Cell
Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Carcinoma, Renal Cell
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Carcinoma, Renal Cell
Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Carcinoma, Renal Cell
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.
Carcinoma, Renal Cell
[Effect of genistein on proliferation of renal cell carcinoma cell line GRC-1 and its influence to p27 expression]
Carcinoma, Small Cell
A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas.
Carcinoma, Squamous Cell
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Carcinoma, Squamous Cell
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.
Carcinoma, Squamous Cell
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
Carcinoma, Squamous Cell
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
Carcinoma, Squamous Cell
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Carcinoma, Squamous Cell
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
Carcinoma, Squamous Cell
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
Carcinoma, Squamous Cell
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Carcinoma, Squamous Cell
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling.
Carcinoma, Squamous Cell
Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Carcinoma, Squamous Cell
Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells.
Carcinoma, Squamous Cell
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Carcinoma, Squamous Cell
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Carcinoma, Squamous Cell
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Carcinoma, Squamous Cell
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Carcinoma, Squamous Cell
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Carcinoma, Squamous Cell
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Carcinoma, Squamous Cell
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Carcinoma, Squamous Cell
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Carcinoma, Squamous Cell
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Carcinoma, Squamous Cell
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Carcinoma, Squamous Cell
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Carcinoma, Squamous Cell
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Carcinoma, Squamous Cell
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Carcinoma, Squamous Cell
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Carcinoma, Squamous Cell
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Carcinoma, Squamous Cell
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Carcinoma, Squamous Cell
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma, Squamous Cell
Modulation of epidermal growth factor receptor interaction with the detergent-insoluble cytoskeleton and its effects on receptor tyrosine kinase activity.
Carcinoma, Squamous Cell
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Carcinoma, Squamous Cell
p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
Carcinoma, Squamous Cell
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Carcinoma, Squamous Cell
Protein kinase C inhibition of the epidermal growth factor receptor tyrosine protein kinase activity is independent of the oligomeric state of the receptor.
Carcinoma, Squamous Cell
Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells.
Carcinoma, Squamous Cell
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Carcinoma, Squamous Cell
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Carcinoma, Squamous Cell
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase.
Carcinoma, Squamous Cell
Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Carcinoma, Squamous Cell
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
Carcinoma, Squamous Cell
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinoma, Squamous Cell
Wnt/?-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Carcinoma, Squamous Cell
[Effect of focal adhesion kinase on biological characteristics of Tca8113 tongue squamous cell carcinoma]
Carcinoma, Squamous Cell
[Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma].
Carcinoma, Transitional Cell
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Carcinoma, Transitional Cell
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinosarcoma
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Cardiac Tamponade
Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia.
Cardiomegaly
Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Cardiomegaly
Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling.
Cardiomegaly
Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy.
Cardiomegaly
Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice.
Cardiomegaly
Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy.
Cardiomegaly
Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex.
Cardiomegaly
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Cardiomegaly
Pressure overload-induced cardiac hypertrophy response requires janus kinase 2-histone deacetylase 2 signaling.
Cardiomegaly
Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.
Cardiomegaly
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
Cardiomegaly
Structure of focal adhesion kinase in healthy heart versus pathological cardiac hypertrophy: A modeling and simulation study.
Cardiomegaly
Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice.
Cardiomegaly
[Expression of focal adhesion kinase in cardiac myocytes of hypertrophic ventricle]
Cardiomegaly
[Phosphorylation and nuclear translocation of serine 722 and serine 910 of focal adhesion kinase in hypertrophic cardiac myocytes of left ventricle of spontaneously hypertensive rats]
Cardiomyopathies
Elevated expression of C3G protein in the peri-infarct myocardium of rats.
Cardiomyopathies
Impaired angiotensin II-extracellular signal-regulated kinase signaling in failing human ventricular myocytes.
Cardiomyopathies
Increased expression of Dock180 protein in the noninfarcted myocardium in rats.
Cardiomyopathies
Unsolved medical issues and new targets for further research in viral myocarditis and dilated cardiomyopathy.
Cardiomyopathy, Dilated
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Cardiomyopathy, Dilated
Inhibition of osteopontin reduce the cardiac myofibrosis in dilated cardiomyopathy via focal adhesion kinase mediated signaling pathway.
Cardiomyopathy, Dilated
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Cardiomyopathy, Dilated
[Content of myosin-activating protein kinases in myocardium of patients with dilated cardiomyopathy and in the animal heart]
Cardiomyopathy, Hypertrophic
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes.
Cardiotoxicity
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Cardiotoxicity
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Cardiotoxicity
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiotoxicity
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).
Cardiotoxicity
Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase.
Cardiotoxicity
MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte.
Cardiotoxicity
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Cardiotoxicity
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Cardiovascular Diseases
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Cardiovascular Diseases
A familial congenital heart disease with a possible multigenic origin involving a mutation in BMPR1A.
Cardiovascular Diseases
Pathophysiology of the chronic kidney disease-mineral bone disorder.
Cardiovascular Diseases
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Cardiovascular Diseases
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Cardiovascular Diseases
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Carotid Artery Diseases
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
Cataract
Coordinate signaling by Src and p38 kinases in the induction of cortical cataracts.
Cataract
Mechanism of Src kinase induction of cortical cataract following exposure to stress: destabilization of cell-cell junctions.
Cataract
Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells.
Celiac Disease
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Celiac Disease
Interleukin 15-Dependent T Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease.
Celiac Disease
Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease.
Cell Transformation, Neoplastic
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
Cerebellar Ataxia
The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia.
Cerebellar Ataxia
Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia.
Cerebral Hemorrhage
Hydrogen Inhalation Ameliorated Mast Cell-Mediated Brain Injury After Intracerebral Hemorrhage in Mice.
Cerebral Hemorrhage
Levetiracetam Reduces Early Inflammatory Response After Experimental Intracerebral Hemorrhage by Regulating the Janus Kinase 2 (JAK2)-Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Cerebral Hemorrhage
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Cerebral Hemorrhage
SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Tyrosine kinase Fyn promotes apoptosis after intracerebral hemorrhage in rats by activating Drp1 signaling.
Cerebral Infarction
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
CHARGE Syndrome
Targeted next?generation sequencing for research and diagnostics in congenital heart disease, and cleft lip and/or palate.
Chemical and Drug Induced Liver Injury
Protective effect of Chushizi (Fructus Broussonetiae) on acetaminophen-induced rat hepatitis by inhibiting the Toll-like receptor 3/c-Jun N-terminal kinase/c-jun/c-fos/janus protein tyrosine kinase/activators of transcription 3 pathway.
Cherubism
Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Cholangiocarcinoma
A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1.
Cholangiocarcinoma
Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase.
Cholangiocarcinoma
Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.
Cholangiocarcinoma
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Cholangiocarcinoma
Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1.
Cholangiocarcinoma
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Cholecystitis
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Cholera
Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation.
Cholera
Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
Cholera
[Synthesis, Cloning and Expression of a Multiple Epitope Antigen of BCR-ABL Fusion Gene]
Choline Deficiency
Dietary choline deficiency and excess induced intestinal inflammation and alteration of intestinal tight junction protein transcription potentially by modulating NF-?B, STAT and p38 MAPK signaling molecules in juvenile Jian carp.
Choline Deficiency
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Chondrosarcoma
Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I.
Chondrosarcoma
Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Chondrosarcoma
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
Chondrosarcoma
Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13.
Chondrosarcoma
The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines.
Chorioamnionitis
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
Choriocarcinoma
Expression of a fms-related oncogene in carcinogen-induced neoplastic epithelial cells.
Choriocarcinoma
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Choriocarcinoma
Gal-1 silenced trophoblast tumor cells (BeWo) show decreased syncytium formation and different miRNA production compared to non-target silenced BeWo cells.
Choriocarcinoma
Is galectin-1 a trigger for trophoblast cell fusion?: the MAP-Kinase pathway and syncytium formation in trophoblast tumor cells BeWo.
Choriocarcinoma
Optimized logic rules reveal interferon-?-induced modes regulated by histone deacetylases and protein tyrosine phosphatases.
Choroidal Neovascularization
Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Choroidal Neovascularization
Focal adhesion kinase signaling pathway participates in the formation of choroidal neovascularization and regulates the proliferation and migration of choroidal microvascular endothelial cells by acting through HIF-1 and VEGF expression in RPE cells.
Choroidal Neovascularization
Inhibition of choroidal neovascularization by anti-EphB4 monoclonal antibody.
Choroidal Neovascularization
Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization.
Chronic Kidney Disease-Mineral and Bone Disorder
Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Chronic Kidney Disease-Mineral and Bone Disorder
Pathophysiology of the chronic kidney disease-mineral bone disorder.
Chronic Kidney Disease-Mineral and Bone Disorder
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Chronic Periodontitis
CD24 activates the NLRP3 inflammasome through c-Src kinase activity in a model of the lining epithelium of inflamed periodontal tissues.
Chronic Urticaria
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.
Cleft Lip
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Cleft Palate
ACTIVIN SUBUNIT AND RECEPTOR EXPRESSION IN NORMAL AND CLEFT HUMAN FETAL PALATE TISSUES.
Cleft Palate
Activin subunit and receptor expression in normal and cleft human fetal palate tissues.
Cleft Palate
Altered BMP-Smad4 signaling causes complete cleft palate by disturbing osteogenesis in palatal mesenchyme.
Cleft Palate
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Cleft Palate
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Clubfoot
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Cockayne Syndrome
Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase.
Colitis
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1?-mediated colitis.
Colitis
Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway.
Colitis
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
Colitis
Estrogen receptor ? alleviates inflammatory lesions in a rat model of inflammatory bowel disease via down-regulating P2X7R expression in macrophages.
Colitis
Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.
Colitis
MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent alphavbeta3 integrin signaling.
Colitis
Nitrotyrosylation of Ca2+ channels prevents c-Src kinase regulation of colonic smooth muscle contractility in experimental colitis.
Colitis
Novel Pentapeptide Derived from Chicken by-Product Ameliorates DSS-Induced Colitis by Enhancing Intestinal Barrier Function via AhR-Induced Src Inactivation.
Colitis
Oxazolone-induced over-expression of focal adhesion kinase in colonic epithelial cells of colitis mouse model.
Colitis
P014. Selective Janus Kinase 1 inhibitor targets monocytes and tissue macrophages during DSS colitis.
Colitis
Role of Csk in intestinal epithelial barrier function and protection against colitis.
Colitis
T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.
Colitis
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
Colitis
The Src kinase Fyn is protective in acute chemical-induced colitis and promotes recovery from disease.
Colitis
The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Colitis, Ulcerative
A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.
Colitis, Ulcerative
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Colitis, Ulcerative
c-src tyrosine kinase activity: a marker of dysplasia in ulcerative colitis.
Colitis, Ulcerative
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Colitis, Ulcerative
Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.
Colitis, Ulcerative
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Colitis, Ulcerative
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Colitis, Ulcerative
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Colitis, Ulcerative
Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
Colitis, Ulcerative
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Colitis, Ulcerative
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Colitis, Ulcerative
Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.
Colitis, Ulcerative
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Colitis, Ulcerative
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.
Colitis, Ulcerative
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis.
Colitis, Ulcerative
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Colitis, Ulcerative
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Colitis, Ulcerative
GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
Colitis, Ulcerative
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Colitis, Ulcerative
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Colitis, Ulcerative
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.
Colitis, Ulcerative
JAK inhibitors: Novel developments in management of ulcerative colitis.
Colitis, Ulcerative
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Colitis, Ulcerative
JAK2 rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn's Disease: A Meta-analysis.
Colitis, Ulcerative
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colitis, Ulcerative
Medical therapy versus surgery in moderate-to-severe ulcerative colitis.
Colitis, Ulcerative
Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors.
Colitis, Ulcerative
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Colitis, Ulcerative
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Colitis, Ulcerative
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
Colitis, Ulcerative
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Colitis, Ulcerative
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Colitis, Ulcerative
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Colitis, Ulcerative
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Colitis, Ulcerative
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Colitis, Ulcerative
Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
Colitis, Ulcerative
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience.
Colitis, Ulcerative
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Colitis, Ulcerative
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Colitis, Ulcerative
Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model.
Colitis, Ulcerative
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
Colitis, Ulcerative
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
Colitis, Ulcerative
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Colitis, Ulcerative
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Colitis, Ulcerative
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
Colitis, Ulcerative
Tofacitinib for the treatment of tumor necrosis factor-? inhibitor refractory esophageal Crohn's disease: a case report.
Colitis, Ulcerative
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
Colitis, Ulcerative
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Colitis, Ulcerative
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Colitis, Ulcerative
Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
Colitis, Ulcerative
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
Colitis, Ulcerative
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
Colitis, Ulcerative
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Colitis, Ulcerative
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Colitis, Ulcerative
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Colitis, Ulcerative
Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
Colitis, Ulcerative
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Colitis, Ulcerative
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Colitis, Ulcerative
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib].
Colonic Neoplasms
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
Colonic Neoplasms
A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis.
Colonic Neoplasms
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Colonic Neoplasms
Acquisition of cell adhesion and induction of focal adhesion kinase of human colon cancer Colo 201 cells by retinoic acid-induced differentiation.
Colonic Neoplasms
Activation of focal adhesion kinase through an interaction with ?4 integrin contributes to tumorigenicity of colon cancer.
Colonic Neoplasms
Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.
Colonic Neoplasms
Adhesion, actin cytoskeleton organisation and the spreading of colon adenocarcinoma cells induced by EGF are mediated by alpha2beta1 integrin low clustering through focal adhesion kinase.
Colonic Neoplasms
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
Colonic Neoplasms
Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction.
Colonic Neoplasms
Analysis of signaling protein kinases in human colon or colorectal carcinomas.
Colonic Neoplasms
Bone morphogenetic protein signaling and growth suppression in colon cancer.
Colonic Neoplasms
Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells.
Colonic Neoplasms
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.
Colonic Neoplasms
Clinical and molecular characterization of individuals with recurrent genomic disorder at 10q22.3q23.2.
Colonic Neoplasms
Colon cancer cell adhesion in response to Src kinase activation and actin-cytoskeleton by non-laminar shear stress.
Colonic Neoplasms
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Colonic Neoplasms
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Colonic Neoplasms
Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.
Colonic Neoplasms
Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation.
Colonic Neoplasms
Decreased CHK protein levels are associated with Src activation in colon cancer cells.
Colonic Neoplasms
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Colonic Neoplasms
Development of a Rapid-Onset, Acid-Labile Linkage Polyplex-Mixed Micellar System for Anticancer Therapy.
Colonic Neoplasms
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
Colonic Neoplasms
Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.
Colonic Neoplasms
Early adhesion induces interaction of FAK and Fyn in lipid domains and activates raft-dependent Akt signaling in SW480 colon cancer cells.
Colonic Neoplasms
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
Colonic Neoplasms
Effect of ets-related transcription factor (ERT) on transforming growth factor (TGF)-beta type II receptor gene expression in human cancer cell lines.
Colonic Neoplasms
Effectiveness of Scutellaria barbata water extract on inhibiting colon tumor growth and metastasis in tumor-bearing mice.
Colonic Neoplasms
Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Colonic Neoplasms
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Colonic Neoplasms
Epithelial-mesenchymal transition and metastasis of colon cancer cells induced by the FAK pathway in cancer-associated fibroblasts.
Colonic Neoplasms
Eps8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase.
Colonic Neoplasms
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Colonic Neoplasms
Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407.
Colonic Neoplasms
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
Colonic Neoplasms
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.
Colonic Neoplasms
Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.
Colonic Neoplasms
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Colonic Neoplasms
Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell.
Colonic Neoplasms
Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Colonic Neoplasms
Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients.
Colonic Neoplasms
Focal adhesion kinase is not required for Src-induced formation of invadopodia in KM12C colon cancer cells and can interfere with their assembly.
Colonic Neoplasms
Focal adhesion kinase mediates defects in the force-dependent reinforcement of initial integrin-cytoskeleton linkages in metastatic colon cancer cell lines.
Colonic Neoplasms
Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
Colonic Neoplasms
Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase.
Colonic Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Colonic Neoplasms
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Colonic Neoplasms
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Colonic Neoplasms
Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
Colonic Neoplasms
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Colonic Neoplasms
Induction of colonic epithelial cell apoptosis by p47-dependent oxidants.
Colonic Neoplasms
Induction of the differentiated phenotype in human colon cancer cell is associated with the attenuation of subcellular tyrosine phosphorylation.
Colonic Neoplasms
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Colonic Neoplasms
Inhibition of c-Yes induces differentiation of HT-29 human colon cancer stem cells through midbody elongation.
Colonic Neoplasms
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Colonic Neoplasms
Lemur tyrosine kinase 2 acts as a positive regulator of NF-?B activation and colon cancer cell proliferation.
Colonic Neoplasms
Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
Colonic Neoplasms
Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to ?5?1 integrin and suppresses FAK/ERK/NF-?B signaling.
Colonic Neoplasms
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Colonic Neoplasms
MicroRNA-27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling.
Colonic Neoplasms
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
Colonic Neoplasms
MicroRNA?7 suppresses human colon cancer invasion and proliferation by targeting the expression of focal adhesion kinase.
Colonic Neoplasms
miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal transition in colon cancer cells.
Colonic Neoplasms
p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation.
Colonic Neoplasms
Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.
Colonic Neoplasms
Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.
Colonic Neoplasms
Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion.
Colonic Neoplasms
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
Colonic Neoplasms
Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells.
Colonic Neoplasms
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice.
Colonic Neoplasms
Signal Transducers and Activators of Transcription 3 Activation Is Involved in Nuclear Accumulation of {beta}-Catenin in Colorectal Cancer.
Colonic Neoplasms
Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
Colonic Neoplasms
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Colonic Neoplasms
Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Colonic Neoplasms
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Colonic Neoplasms
Src kinase pathway is involved in NFAT5-mediated S100A4 induction by hyperosmotic stress in colon cancer cells.
Colonic Neoplasms
SRC transcriptional activation in a subset of human colon cancer cell lines.
Colonic Neoplasms
Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background.
Colonic Neoplasms
Src tyrosine kinase phosphorylation of nuclear receptor HNF4? correlates with isoform-specific loss of HNF4? in human colon cancer.
Colonic Neoplasms
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Colonic Neoplasms
Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.
Colonic Neoplasms
Syndecan-2 cytoplasmic domain upregulates Matrix Metalloproteinase-7 expression via Protein KinaseC? mediated FAK/ERK signaling pathway in colon cancer.
Colonic Neoplasms
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Colonic Neoplasms
Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells Following DNA Damage.
Colonic Neoplasms
The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and ?-secretase, enhances cell proliferation and migration in colon cancer cells.
Colonic Neoplasms
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Colonic Neoplasms
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Colonic Neoplasms
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Colonic Neoplasms
The role of Src family kinases in the normal and neoplastic gastrointestinal tract.
Colonic Neoplasms
The role of the cytoskeleton in differentially regulating pressure-mediated effects on malignant colonocyte focal adhesion signaling and cell adhesion.
Colonic Neoplasms
Thrombin-dependent modulation of ?1-integrin-mediated signaling up-regulates prolidase and HIF-1? through p-FAK in colorectal cancer cells.
Colonic Neoplasms
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
Colonic Neoplasms
Transcriptional signature induced by a C-terminal c-Src mutant in a human breast cell line.
Colonic Neoplasms
[A study of gastrin-focal adhesion kinase signal pathway in human colon cancer cells.]
Colonic Neoplasms
[Effect of JAK2/STAT3/vimentin signaling pathway on proliferation and migration of human colon cancer cells.]
Colonic Neoplasms
[Influence of Pyk2 on hepatic metastasis and ultrastructure of human colonic cancer cells].
Colorectal Neoplasms
A cell-based screen for inhibitors of protein folding and degradation.
Colorectal Neoplasms
A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer risk.
Colorectal Neoplasms
A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.
Colorectal Neoplasms
A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
Colorectal Neoplasms
A Novel Netrin-1-Derived Peptide Enhances Protection against Neuronal Death and Mitigates of Intracerebral Hemorrhage in Mice.
Colorectal Neoplasms
aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.
Colorectal Neoplasms
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Colorectal Neoplasms
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
Colorectal Neoplasms
Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.
Colorectal Neoplasms
Analyses of the APC and TGF-beta type II receptor genes, and microsatellite instability in mucosal colorectal carcinomas.
Colorectal Neoplasms
Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.
Colorectal Neoplasms
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.
Colorectal Neoplasms
Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC).
Colorectal Neoplasms
Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.
Colorectal Neoplasms
AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Colorectal Neoplasms
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Colorectal Neoplasms
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
Colorectal Neoplasms
BMPR1A mutations in early-onset colorectal cancer with mismatch repair proficiency.
Colorectal Neoplasms
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Colorectal Neoplasms
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
Colorectal Neoplasms
Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.
Colorectal Neoplasms
Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
Colorectal Neoplasms
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through ?5?1 Integrin.
Colorectal Neoplasms
Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
Colorectal Neoplasms
Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells.
Colorectal Neoplasms
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Colorectal Neoplasms
Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
Colorectal Neoplasms
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
Colorectal Neoplasms
Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Colorectal Neoplasms
Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells.
Colorectal Neoplasms
Detection of Deregulated Pathways to Lymphatic Metastasis in Oral Squamous Cell Carcinoma.
Colorectal Neoplasms
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Colorectal Neoplasms
Dual inhibition of ?V integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Colorectal Neoplasms
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.
Colorectal Neoplasms
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Colorectal Neoplasms
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Colorectal Neoplasms
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Colorectal Neoplasms
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.
Colorectal Neoplasms
Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells.
Colorectal Neoplasms
Expression of C-terminal src kinase in human colorectal cancer cell lines.
Colorectal Neoplasms
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Colorectal Neoplasms
Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells.
Colorectal Neoplasms
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.
Colorectal Neoplasms
Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
Colorectal Neoplasms
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
Colorectal Neoplasms
Genetic variants in the TGF?-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue.
Colorectal Neoplasms
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer.
Colorectal Neoplasms
Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
Colorectal Neoplasms
Hamartomatous polyposis in a middle-aged female with rare colonic adenomatous spread.
Colorectal Neoplasms
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Colorectal Neoplasms
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Colorectal Neoplasms
Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells.
Colorectal Neoplasms
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Colorectal Neoplasms
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Colorectal Neoplasms
Inhibiting focal adhesion kinase: A potential target for enhancing therapeutic efficacy in colorectal cancer therapy.
Colorectal Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Colorectal Neoplasms
Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling.
Colorectal Neoplasms
Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype.
Colorectal Neoplasms
KSR1 and EPHB4 Regulate Myc and PGC1? To Promote Survival of Human Colon Tumors.
Colorectal Neoplasms
Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.
Colorectal Neoplasms
Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients.
Colorectal Neoplasms
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Colorectal Neoplasms
Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2.
Colorectal Neoplasms
Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Colorectal Neoplasms
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Colorectal Neoplasms
Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.
Colorectal Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Colorectal Neoplasms
Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.
Colorectal Neoplasms
No association between germline allele-specific expression of TGFBR1 and colorectal cancer risk in Caucasian and Ashkenazi populations.
Colorectal Neoplasms
Noncanonical TGF? Pathway Relieves the Blockade of IL1?/TGF?-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
Colorectal Neoplasms
Notch signaling promotes serrated neoplasia pathway in colorectal cancer through epigenetic modification of EPHB2 and EPHB4.
Colorectal Neoplasms
Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer.
Colorectal Neoplasms
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Colorectal Neoplasms
Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells.
Colorectal Neoplasms
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Colorectal Neoplasms
Optimization of the diagnosis of inherited colorectal cancer using NGS and capture of exonic and intronic sequences of panel genes.
Colorectal Neoplasms
Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation.
Colorectal Neoplasms
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Colorectal Neoplasms
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Colorectal Neoplasms
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Colorectal Neoplasms
Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization.
Colorectal Neoplasms
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Colorectal Neoplasms
Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Colorectal Neoplasms
Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells.
Colorectal Neoplasms
Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells.
Colorectal Neoplasms
Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.
Colorectal Neoplasms
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Colorectal Neoplasms
Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1.
Colorectal Neoplasms
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.
Colorectal Neoplasms
Screening of BMPR1a for pathogenic mutations in familial colorectal cancer type X families from Newfoundland.
Colorectal Neoplasms
Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations?
Colorectal Neoplasms
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Colorectal Neoplasms
SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC.
Colorectal Neoplasms
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Colorectal Neoplasms
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Colorectal Neoplasms
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Colorectal Neoplasms
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
Colorectal Neoplasms
TGFBR1 intralocus epistatic interaction as a risk factor for colorectal cancer.
Colorectal Neoplasms
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
Colorectal Neoplasms
TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells.
Colorectal Neoplasms
The association of polymorphisms on TGFBR1 and colorectal cancer risk: a meta-analysis.
Colorectal Neoplasms
The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas.
Colorectal Neoplasms
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Colorectal Neoplasms
Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Colorectal Neoplasms
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene.
Colorectal Neoplasms
Ursolic Acid Induces Apoptosis in Colorectal Cancer Cells Partially via Upregulation of MicroRNA-4500 and Inhibition of JAK2/STAT3 Phosphorylation.
Colorectal Neoplasms
Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
Colorectal Neoplasms
Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.
Colorectal Neoplasms
[Expression of proline-rich tyrosine kinase-2 in human primary colorectal carcinoma and its prognostic implication]
Colorectal Neoplasms
[Mutations of hMSH2 gene and hMLH1 gene in human colovectal carcinomas]
Colorectal Neoplasms
[Spleen tyrosine kinase inhibits proliferation and promotes apoptosis of colorectal cancer cells in vitro via regulating Fra-1].
Colorectal Neoplasms, Hereditary Nonpolyposis
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Colorectal Neoplasms, Hereditary Nonpolyposis
Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
Colorectal Neoplasms, Hereditary Nonpolyposis
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Colorectal Neoplasms, Hereditary Nonpolyposis
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Colorectal Neoplasms, Hereditary Nonpolyposis
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Colorectal Neoplasms, Hereditary Nonpolyposis
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Colorectal Neoplasms, Hereditary Nonpolyposis
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene.
Common Variable Immunodeficiency
Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.
Common Variable Immunodeficiency
Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects.
Common Variable Immunodeficiency
Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry.
Common Variable Immunodeficiency
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Communicable Diseases
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Congenital Abnormalities
Compound mutations in Bmpr1a and Tak1 synergize facial deformities via increased cell death.
Congenital Abnormalities
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Congenital Abnormalities
Integration of comprehensive 3D microCT and signaling analysis reveals differential regulatory mechanisms of craniofacial bone development.
Congenital Abnormalities
Modulation of noncanonical TGF-? signaling prevents cleft palate in Tgfbr2 mutant mice.
Conjunctivitis, Allergic
Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis.
Connective Tissue Diseases
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.
Connective Tissue Diseases
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Contracture
Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src.
Coronary Disease
The Expression and Clinical Significance of Spleen Tyrosine Kinase in Patients with Coronary Heart Disease.
Coronary Occlusion
Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits.
Coronavirus Infections
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.
COVID-19
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
COVID-19
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
COVID-19
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
COVID-19
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
COVID-19
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.
COVID-19
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
COVID-19
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
COVID-19
Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.
COVID-19
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
COVID-19
JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules.
COVID-19
JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations.
COVID-19
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
COVID-19
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
COVID-19
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.
COVID-19
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.
COVID-19
Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
COVID-19
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
COVID-19
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
COVID-19
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
COVID-19
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
COVID-19
Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19.
COVID-19
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
COVID-19
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
COVID-19
Perceptions and Behaviors of Patients with Inflammatory Bowel Disease during the COVID-19 Crisis.
COVID-19
Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.
COVID-19
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
COVID-19
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.
COVID-19
Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative.
COVID-19
Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19.
COVID-19
Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease.
COVID-19
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
COVID-19
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
COVID-19
The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
COVID-19
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
COVID-19
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
Craniosynostoses
BmpR1A is a major type 1 BMP receptor for BMP-Smad signaling during skull development.
Craniosynostoses
BMPR1A maintains skeletal stem cell properties in craniofacial development and craniosynostosis.
Craniosynostoses
Genetics of craniosynostosis: genes, syndromes, mutations and genotype-phenotype correlations.
Crohn Disease
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease.
Crohn Disease
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Crohn Disease
Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk.
Crohn Disease
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Crohn Disease
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Crohn Disease
JAK2 rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn's Disease: A Meta-analysis.
Crohn Disease
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Crohn Disease
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Crohn Disease
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Crohn Disease
Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study.
Crohn Disease
Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population.
Crohn Disease
Tofacitinib for the treatment of tumor necrosis factor-? inhibitor refractory esophageal Crohn's disease: a case report.
Crohn Disease
UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling.
Cryptococcosis
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Cryptococcosis
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
Cystadenoma
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Cystic Fibrosis
In silico prediction and validation of potential therapeutic genes in pancreatic ?-cells associated with type 2 diabetes.
Cystic Fibrosis
The tyrosine kinase p60c-src regulates the fast gate of the cystic fibrosis transmembrane conductance regulator chloride channel.
Cystic Fibrosis
Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis.
Cystitis
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Cysts
Csk differentially regulates Src64 during distinct morphological events in Drosophila germ cells.
Cysts
Effects of src kinase and TGFbeta1 on the differentiation and morphogenesis of MDCK cells grown in three-dimensional collagen and Matrigel environments.
Cysts
Expression of TGFBR1, TGFBR2, TGFBR3, ACVR1B and ACVR2B is altered in ovaries of cows with cystic ovarian disease.
Cysts
Impairment of Wnt11 function leads to kidney tubular abnormalities and secondary glomerular cystogenesis.
Cysts
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Cysts
JAK signaling regulates germline cyst breakdown and primordial follicle formation in mice.
Cysts
Kif3a controls murine nephron number via GLI3 repressor, cell survival, and gene expression in a lineage-specific manner.
Cysts
Properties of Transport Mediated by the Human Organic Cation Transporter 2 Studied in a Polarized Three-Dimensional Epithelial Cell Culture Model.
Cysts
Src64 controls a novel actin network required for proper ring canal formation in the Drosophila male germline.
Cysts
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Darier Disease
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Death, Sudden, Cardiac
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death.
Deficiency Diseases
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
Deficiency Diseases
Disturbed Transcription of TLRs' Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients.
Dementia
Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias.
Dementia
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Dementia
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
Dementia, Vascular
Association of intronic sequence variant in the gene encoding spleen tyrosine kinase with susceptibility to vascular dementia.
Demyelinating Diseases
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
Demyelinating Diseases
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Dengue
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
Dengue
Identification and characterization of the role of c-terminal Src kinase in dengue virus replication.
Dengue
Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection.
Dengue
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Dermatitis
Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis.
Dermatitis
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Dermatitis
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
Dermatitis, Atopic
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Dermatitis, Atopic
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials.
Dermatitis, Atopic
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Dermatitis, Atopic
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Dermatitis, Atopic
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Dermatitis, Atopic
Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib.
Dermatitis, Atopic
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis.
Dermatitis, Atopic
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
Dermatitis, Atopic
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Dermatitis, Atopic
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Dermatitis, Atopic
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Dermatitis, Atopic
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Dermatitis, Atopic
Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
Dermatitis, Atopic
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Dermatitis, Atopic
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Dermatitis, Atopic
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Dermatitis, Atopic
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Dermatitis, Atopic
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Dermatitis, Atopic
Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
Dermatitis, Atopic
Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
Dermatitis, Atopic
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Dermatitis, Atopic
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
Dermatitis, Atopic
IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis.
Dermatitis, Atopic
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Dermatitis, Atopic
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Dermatitis, Atopic
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Dermatitis, Atopic
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Dermatitis, Atopic
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Dermatitis, Atopic
Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Dermatitis, Atopic
Leveraging the nice face of Janus kinase inhibition-ruxolitinib cream in atopic dermatitis.
Dermatitis, Atopic
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Dermatitis, Atopic
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Dermatitis, Atopic
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Dermatitis, Atopic
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Dermatitis, Atopic
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Dermatitis, Atopic
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Dermatitis, Atopic
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Dermatitis, Atopic
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Dermatitis, Atopic
Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
Dermatitis, Atopic
Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.
Dermatitis, Atopic
Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Dermatitis, Atopic
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
Dermatitis, Atopic
The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
Dermatitis, Atopic
The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
Dermatitis, Atopic
The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Dermatitis, Atopic
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Dermatitis, Atopic
Topical treatment with mastic (resin from Pistacia lentiscus) elicits anti-inflammatory and anti-pruritic responses by modulating keratinocyte activation in a mouse model of allergic dermatitis.
Dermatitis, Atopic
Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
Dermatitis, Atopic
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
Dermatitis, Atopic
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
Dermatitis, Contact
Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice.
Dermatofibrosarcoma
Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion.
Dermatomyositis
Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.
Dermatomyositis
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Dermatomyositis
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Dermatomyositis
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.
Dermatomyositis
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Dermatomyositis
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
Dermatomyositis
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Dermatomyositis
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Dermatomyositis
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Dermatomyositis
[Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment].
Diabetes Complications
Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.
Diabetes Mellitus
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Diabetes Mellitus
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Diabetes Mellitus
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Diabetes Mellitus
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Diabetes Mellitus
Effects of sevoflurane pretreatment on renal Src and FAK expression in diabetic rats after renal ischemia/reperfusion injury.
Diabetes Mellitus
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Diabetes Mellitus
Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.
Diabetes Mellitus
The rs2304256 Polymorphism in TYK2 Gene Is Associated with Protection for Type 1 Diabetes Mellitus.
Diabetes Mellitus, Experimental
Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up.
Diabetes Mellitus, Type 1
Association analysis of the lymphocyte-specific protein tyrosine kinase (LCK) gene in type 1 diabetes.
Diabetes Mellitus, Type 1
Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians.
Diabetes Mellitus, Type 1
LCK rs10914542-G allele associates with type 1 diabetes in children via T cell hyporesponsiveness.
Diabetes Mellitus, Type 1
MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory ?-cell damage.
Diabetes Mellitus, Type 1
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Diabetes Mellitus, Type 1
Subtyping of Type 1 Diabetes as Classified by Anti-GAD Antibody, IgE Levels, and Tyrosine kinase 2 (TYK2) Promoter Variant in the Japanese.
Diabetes Mellitus, Type 1
The rs2304256 Polymorphism in TYK2 Gene Is Associated with Protection for Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 1
TYK2 Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Diabetes Mellitus, Type 2
Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.
Diabetes Mellitus, Type 2
Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
Glucosylpolyphenols as inhibitors of A?-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.
Diabetes Mellitus, Type 2
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Diabetes Mellitus, Type 2
Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM.
Diabetes Mellitus, Type 2
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Diabetes Mellitus, Type 2
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Diabetes Mellitus, Type 2
Vascular proliferation and transforming growth factor-beta expression in pre- and early stage of diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats.
Diabetes Mellitus, Type 2
[Effects of aerobic exercise and resveratrol on the expressions of JAK2 and TGF-?1 in renal tissue of type 2 diabetes rats].
Diabetic Angiopathies
Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells.
Diabetic Cardiomyopathies
Melatonin therapy for diabetic cardiomyopathy: A mechanism involving Syk-mitochondrial complex I-SERCA pathway.
Diabetic Foot
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Diabetic Nephropathies
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Diabetic Nephropathies
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Diabetic Nephropathies
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Diabetic Nephropathies
Inhibition of Src Kinase Blocks High Glucose-Induced EGFR Transactivation and Collagen Synthesis in Mesangial Cells and Prevents Diabetic Nephropathy in Mice.
Diabetic Nephropathies
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
Diabetic Nephropathies
miR-136 improves renal fibrosis in diabetic rats by targeting down-regulation of tyrosine kinase SYK and inhibition of TGF-?1/Smad3 signaling pathway.
Diabetic Nephropathies
Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy.
Diabetic Nephropathies
Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.
Diabetic Nephropathies
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Diabetic Nephropathies
Spleen tyrosine kinase promotes NLR family pyrin domain containing 3 inflammasome?mediated IL?1? secretion via c?Jun N?terminal kinase activation and cell apoptosis during diabetic nephropathy.
Diabetic Nephropathies
Suppressor of Cytokine Signaling-1 Ameliorates Expression of MCP-1 in Diabetic Nephropathy.
Diabetic Nephropathies
Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.
Diabetic Nephropathies
Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-beta1 and fibronectin synthesis in human mesangial cells.
Diabetic Neuropathies
Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.
Diabetic Retinopathy
Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.
Diabetic Retinopathy
Spleen Tyrosine Kinase Mediates Microglial Activation in Mice With Diabetic Retinopathy.
Diabetic Retinopathy
The effect of spleen tyrosine kinase inhibitor R406 on diabetic retinopathy in experimental diabetic rats.
Diabetic Retinopathy
The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease.
Diffuse Intrinsic Pontine Glioma
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Disorders of Sex Development
Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Diverticulum
Transforming growth factor ? receptor type 1 is essential for female reproductive tract integrity and function.
Down Syndrome
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Down Syndrome
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Down Syndrome
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
Drug-Related Side Effects and Adverse Reactions
Immunosuppressive agents in organ transplantation: past, present, and future.
Drug-Related Side Effects and Adverse Reactions
Management of Chronic Myeloid Leukemia in Childhood.
Drug-Related Side Effects and Adverse Reactions
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.
Drug-Related Side Effects and Adverse Reactions
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Drug-Related Side Effects and Adverse Reactions
The treatment of pediatric chronic myelogenous leukemia in the imatinib era.
Drug-Related Side Effects and Adverse Reactions
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Dry Eye Syndromes
Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Dry Eye Syndromes
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Dwarfism
Correlation Analysis Between Expression Levels of Hepatic Growth Hormone Receptor, Janus Kinase 2, Insulin-Like Growth Factor-I Genes and Dwarfism Phenotype in Bama Minipig.
Dwarfism, Pituitary
Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency.
Dysentery, Bacillary
Cortactin and Crk cooperate to trigger actin polymerization during Shigella invasion of epithelial cells.
Dyskinesias
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Dyskinesias
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Dyskinesias
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Dyslipidemias
Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
Dyslipidemias
Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.
Dyspnea
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Ebstein Anomaly
A case of capillary malformation-arteriovenous malformation and Ebstein's anomaly in a child with EphB4 mutation.
Ecthyma
Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature.
Eczema
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
Eczema
What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 1: prevention and topical therapies.
Ehlers-Danlos Syndrome
Identification of a novel TGFBR1 mutation in a Loeys-Dietz syndrome type II patient with vascular Ehlers-Danlos syndrome phenotype.
Ehlers-Danlos Syndrome
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Embolic Stroke
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Encephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Encephalitis
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Encephalitis
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Encephalitis, Japanese
Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism.
Encephalitis, Japanese
Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Encephalomyelitis
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Encephalomyelitis
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Encephalomyelitis
Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Encephalomyelitis, Autoimmune, Experimental
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Endometrial Hyperplasia
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.
Endometrial Neoplasms
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Endometrial Neoplasms
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Endometrial Neoplasms
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Endometrial Neoplasms
Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.
Endometrial Neoplasms
Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway.
Endometrial Neoplasms
Conditional abrogation of transforming growth factor-? receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
Endometrial Neoplasms
Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor.
Endometrial Neoplasms
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Endometrial Neoplasms
Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src.
Endometrial Neoplasms
Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor ? (ER?).
Endometrial Neoplasms
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Endometrial Neoplasms
Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Endometrial Neoplasms
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Endometrial Neoplasms
Genetic Polymorphisms of TGFB1, TGFBR1, SNAI1 and TWIST1 Are Associated with Endometrial Cancer Susceptibility in Chinese Han Women.
Endometrial Neoplasms
Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase.
Endometrial Neoplasms
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
Endometrial Neoplasms
LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal Adhesion Kinase Activity (FAK) and miRNA-200a.
Endometrial Neoplasms
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
Endometrial Neoplasms
miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1.
Endometrial Neoplasms
MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Endometrial Neoplasms
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series.
Endometrial Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Endometrial Neoplasms
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
Endometrial Neoplasms
Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Endometrial Neoplasms
Stress-induced phosphoprotein-1 maintains the stability of JAK2 in cancer cells.
Endometrial Neoplasms
The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Endometrial Neoplasms
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Endometriosis
Activin A, Activin Receptor Type II, Nodal, and Cripto mRNA Are Expressed by Eutopic and Ectopic Endometrium in Women With Ovarian Endometriosis.
Endometriosis
Alteration of focal adhesion kinase expression in eutopic endometrium of women with endometriosis.
Endometriosis
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Endometriosis
Comprehensive study of angiogenic factors in women with endometriosis compared to women without endometriosis.
Endometriosis
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Endometriosis
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
Endometriosis
Enhanced cyclooxygenase-2 expression levels and metalloproteinase 2 and 9 activation by Hexachlorobenzene in human endometrial stromal cells.
Endometriosis
Expression of focal adhesion kinase in endometrial stromal cells of women with endometriosis was adjusted by ovarian steroid hormones.
Endometriosis
Healthy women and patients with endometriosis show high concentrations of inhibin A, inhibin B, and activin A in peritoneal fluid throughout the menstrual cycle.
Endometriosis
Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signaling suppresses the vascularization and growth of endometriotic lesions.
Endometriosis
miR-96-5p regulated TGF-?/SMAD signaling pathway and suppressed endometrial cell viability and migration via targeting TGFBR1.
Endometriosis
Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.
Endometriosis
Specific Photothermal Ablation Therapy of Endometriosis by Targeting Delivery of Gold Nanospheres.
Endometriosis
Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1.
Endotoxemia
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Endotoxemia
Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research.
Endotoxemia
In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.
Endotoxemia
Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model.
Endotoxemia
Small interfering RNA targeting focal adhesion kinase prevents cardiac dysfunction in endotoxemia.
Eosinophilia
Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Epidermodysplasia Verruciformis
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Epilepsy
A non-mitotic role for aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src.
Epilepsy
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Epilepsy
BDNF selectively regulates GABAA receptor transcription by activation of the JAK/STAT pathway.
Epilepsy
Gain control of N-methyl-D-aspartate receptor activity by receptor-like protein tyrosine phosphatase alpha.
Epilepsy
Genetic Interaction of H19 and TGFBR1 Polymorphisms with Risk of Epilepsy in a Chinese Population.
Epilepsy
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epilepsy
Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy.
Epilepsy, Temporal Lobe
Altered expression of c-Abl in patients with epilepsy and in a rat model.
Epilepsy, Temporal Lobe
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epstein-Barr Virus Infections
Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.
Epstein-Barr Virus Infections
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Erectile Dysfunction
The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction.
Erythema
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Erythema
Unilateral and segmental distribution of facial erythema: is it a real port-wine stain?
Escherichia coli Infections
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Esophageal Achalasia
c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs.
Esophageal Neoplasms
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Esophageal Neoplasms
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
Esophageal Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Esophageal Neoplasms
miR-1 suppresses the proliferation and promotes the apoptosis of esophageal carcinoma cells by targeting Src.
Esophageal Squamous Cell Carcinoma
Activation of Src tyrosine kinase in esophageal carcinoma cells in different regulatory environments and corresponding occurrence mechanism.
Esophageal Squamous Cell Carcinoma
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Esophageal Squamous Cell Carcinoma
Chrysin serves as a novel inhibitor of DGK?/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC).
Esophageal Squamous Cell Carcinoma
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.
Esophageal Squamous Cell Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Esophageal Squamous Cell Carcinoma
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Esophageal Squamous Cell Carcinoma
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression of Wnt11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance.
Esophageal Squamous Cell Carcinoma
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Esophageal Squamous Cell Carcinoma
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Esophageal Squamous Cell Carcinoma
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Esophageal Squamous Cell Carcinoma
Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
Esophageal Squamous Cell Carcinoma
Inhibition of cell growth and upregulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the SRC/ABL inhibitor dasatinib.
Esophageal Squamous Cell Carcinoma
Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth.
Esophageal Squamous Cell Carcinoma
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
Exanthema
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Exanthema
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.
Exanthema
Vascular tumors produced by NIH/3T3 cells transfected with human AIDS Kaposi's sarcoma DNA.
Exostoses, Multiple Hereditary
DNA polymorphism analysis of hereditary multiple exostoses in horses.
Eye Abnormalities
Distinct developmental programs require different levels of Bmp signaling during mouse retinal development.
Fabry Disease
Sixty-nine kilobases of contiguous human genomic sequence containing the alpha-galactosidase A and Bruton's tyrosine kinase loci.
Familial Primary Pulmonary Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Familial Primary Pulmonary Hypertension
Genetics of pulmonary hypertension: from bench to bedside.
Familial Primary Pulmonary Hypertension
Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Familial Primary Pulmonary Hypertension
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Familial Primary Pulmonary Hypertension
[Pulmonary arterial hypertension and BMP system abnormality]
Fasciculation
Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system.
Fasciitis
Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.
Fasciitis
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.
Fatty Liver
CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.
Fatty Liver
Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Fatty Liver
Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
Fatty Liver
MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2.
Fatty Liver
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Fatty Liver
Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.
Fatty Liver
[Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with non-alcoholic fatty liver]
Fetal Alcohol Spectrum Disorders
Effect of pre- and postnatal ethanol exposure on protein tyrosine kinase activity and its endogenous substrates in rat cerebral cortex.
Fibroadenoma
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Fibroadenoma
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Fibromatosis, Aggressive
Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.
Fibrosarcoma
A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis.
Fibrosarcoma
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Fibrosarcoma
Alpinia officinarum Stimulates Osteoblast Mineralization and Inhibits Osteoclast Differentiation.
Fibrosarcoma
Continuous requirement for pp60-Src and phospho-paxillin during fibronectin matrix assembly by transformed cells.
Fibrosarcoma
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Fibrosarcoma
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Fibrosarcoma
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Fibrosarcoma
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene.
Fibrosarcoma
Lamivudine Inhibits the Replication of ALV-J Associated Acutely Transforming Virus and its Helper Virus and Tumor Growth In vitro and In vivo.
Fibrosarcoma
Localization of viral transforming sequences within marker chromosomes associated with tumor formation and progression in a murine fibrosarcoma.
Fibrosarcoma
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Fibrosarcoma
Rescue of avian leukosis subgroup-J-associated acutely transforming viruses carrying different lengths of the v-fps oncogene and analysis of their tumorigenicity.
Fibrosarcoma
Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor.
Fibrosarcoma
Suppression in transformed avian fibroblasts of a gene (crp) encoding a cysteine-rich protein containing LIM domains.
Fibrosarcoma
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Fibrosarcoma
Taishan Pinus Massoniana pollen polysaccharide inhibits the replication of acute tumorigenic ALV-J and its associated tumor growth.
Food Hypersensitivity
Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice.
Food Hypersensitivity
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Foot Ulcer
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Foot-and-Mouth Disease
Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-? signal transduction pathways.
Fragile X Syndrome
Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome.
Fragile X Syndrome
JAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse.
Frontotemporal Lobar Degeneration
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Gallbladder Neoplasms
JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
Gallbladder Neoplasms
The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer
Gastritis
Antral atrophy, intestinal metaplasia, and preneoplastic markers in Mexican children with Helicobacter pylori-positive and Helicobacter pylori-negative gastritis.
Gastritis
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Gastroenteritis
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Gastroesophageal Reflux
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Gastroesophageal Reflux
Proinflammatory cytokines and bile acids upregulate ?Np73 protein, an inhibitor of p53 and p73 tumor suppressors.
Gastrointestinal Diseases
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Gastrointestinal Neoplasms
A novel germline BMPR1A variant (c.72_73delGA) in a Japanese family with hereditary mixed polyposis syndrome.
Gastrointestinal Neoplasms
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Gastrointestinal Neoplasms
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Gastrointestinal Neoplasms
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
Gastrointestinal Neoplasms
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant.
Gastrointestinal Neoplasms
Translational Research in Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Gastrointestinal Neoplasms
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Gastrointestinal Stromal Tumors
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Gastrointestinal Stromal Tumors
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Gastrointestinal Stromal Tumors
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Gastrointestinal Stromal Tumors
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Gastrointestinal Stromal Tumors
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
Gastrointestinal Stromal Tumors
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Gastrointestinal Stromal Tumors
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Gastrointestinal Stromal Tumors
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Gastrointestinal Stromal Tumors
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Gastrointestinal Stromal Tumors
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Gastrointestinal Stromal Tumors
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Gastrointestinal Stromal Tumors
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Gastrointestinal Stromal Tumors
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Gastrointestinal Stromal Tumors
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Gastrointestinal Stromal Tumors
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
Gastrointestinal Stromal Tumors
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Gastrointestinal Stromal Tumors
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
Gastrointestinal Stromal Tumors
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Gastrointestinal Stromal Tumors
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Gastrointestinal Stromal Tumors
Molecular targeted therapy of gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Gastrointestinal Stromal Tumors
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Gastrointestinal Stromal Tumors
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec).
Gastrointestinal Stromal Tumors
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Gastrointestinal Stromal Tumors
Rational therapeutic intervention in cancer: kinases as drug targets.
Gastrointestinal Stromal Tumors
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Gastrointestinal Stromal Tumors
Reduced exposure of imatinib after coadministration with acetaminophen in mice.
Gastrointestinal Stromal Tumors
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Gastrointestinal Stromal Tumors
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.
Gastrointestinal Stromal Tumors
Role of protein tyrosine kinase inhibitors in cancer therapeutics.
Gastrointestinal Stromal Tumors
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
Gastrointestinal Stromal Tumors
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Gastrointestinal Stromal Tumors
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Gastrointestinal Stromal Tumors
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Gastrointestinal Stromal Tumors
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Gastrointestinal Stromal Tumors
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Gastrointestinal Stromal Tumors
The safety profile of imatinib in CML and GIST: long-term considerations.
Gastrointestinal Stromal Tumors
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Gastrointestinal Stromal Tumors
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Gaucher Disease
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
gelatinase b deficiency
Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
Genetic Diseases, Inborn
A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia.
Genetic Diseases, Inborn
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Genetic Diseases, Inborn
Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.
Gestational Trophoblastic Disease
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Glaucoma
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Glaucoma
Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma.
Glaucoma
Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma.
Glioblastoma
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Glioblastoma
A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
Glioblastoma
Activation and translocation of c-Src to the cytoskeleton by both platelet-derived growth factor and epidermal growth factor.
Glioblastoma
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Glioblastoma
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells.
Glioblastoma
Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.
Glioblastoma
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Glioblastoma
Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line.
Glioblastoma
Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9.
Glioblastoma
Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma.
Glioblastoma
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Glioblastoma
Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation.
Glioblastoma
Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma.
Glioblastoma
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Glioblastoma
Dual-Modality Micro-Positron Emission Tomography/Computed Tomography and Near-Infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models.
Glioblastoma
EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
Glioblastoma
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Glioblastoma
Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion.
Glioblastoma
Girdin, an actin-binding protein, is critical for migration, adhesion, and invasion of human glioblastoma cells.
Glioblastoma
Glycogen Synthase Kinase 3? Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway.
Glioblastoma
HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.
Glioblastoma
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Glioblastoma
Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Glioblastoma
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Glioblastoma
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Glioblastoma
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Glioblastoma
Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy.
Glioblastoma
In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation.
Glioblastoma
Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).
Glioblastoma
Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
Glioblastoma
Integrin ?v?3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells.
Glioblastoma
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Glioblastoma
LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.
Glioblastoma
Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.
Glioblastoma
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
Glioblastoma
Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
Glioblastoma
MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
Glioblastoma
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
Glioblastoma
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Glioblastoma
Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.
Glioblastoma
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.
Glioblastoma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Glioblastoma
PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma.
Glioblastoma
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex.
Glioblastoma
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Glioblastoma
Polyphenolic Compounds of Crataegus Berry, Leaf, and Flower Extracts Affect Viability and Invasive Potential of Human Glioblastoma Cells.
Glioblastoma
Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line.
Glioblastoma
PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.
Glioblastoma
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Glioblastoma
Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells.
Glioblastoma
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Glioblastoma
Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.
Glioblastoma
Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells.
Glioblastoma
Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway.
Glioblastoma
Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Glioblastoma
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Glioblastoma
SRC Family Kinase Inhibition Through a New Pyrazolo[3,4-d]Pyrimidine Derivative as a Feasible Approach for Glioblastoma Treatment.
Glioblastoma
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Glioblastoma
SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines.
Glioblastoma
The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.
Glioblastoma
The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged.
Glioblastoma
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Glioblastoma
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance.
Glioblastoma
The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma.
Glioblastoma
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation.
Glioblastoma
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Glioma
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Glioma
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Glioma
A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK.
Glioma
ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.
Glioma
Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway.
Glioma
Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells.
Glioma
Arg kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion of glioma cells.
Glioma
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Glioma
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Glioma
Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.
Glioma
CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10.
Glioma
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Glioma
Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma.
Glioma
Connexin43 recruits PTEN and Csk to inhibit c-Src activity in glioma cells and astrocytes.
Glioma
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Glioma
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Glioma
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Glioma
Effects of nonselective cation channels and PI3K on endothelin-1-induced PYK2 tyrosine phosphorylation in C6 glioma cells.
Glioma
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
Glioma
Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells.
Glioma
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Glioma
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Glioma
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival.
Glioma
Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases.
Glioma
Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor ? and Yes Kinase.
Glioma
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Glioma
Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.
Glioma
High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-?B activation and predicts poor prognosis in human glioma.
Glioma
Hyaluronate activates tyrosine phosphorylation of cellular proteins including focal adhesion kinase via CD44 in human glioma cells.
Glioma
Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
Glioma
Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
Glioma
Induction of WNT11 by hypoxia and hypoxia-inducible factor-1? regulates cell proliferation, migration and invasion.
Glioma
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Glioma
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.
Glioma
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
Glioma
Leucine-rich glioma inactivated 3 induces neurite outgrowth through Akt and focal adhesion kinase.
Glioma
Mda-9/syntenin Promotes Human Brain Glioma Migration through Focal Adhesion Kinase (FAK)-JNK and FAK-AKT Signaling.
Glioma
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
Glioma
Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition.
Glioma
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.
Glioma
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Glioma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Glioma
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
Glioma
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Glioma
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Glioma
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Glioma
PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules.
Glioma
PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow.
Glioma
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Glioma
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human malignant glioma xenograft in nude mice.
Glioma
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Glioma
Serine protease inhibitor (SERPIN) B1 suppresses cell migration and invasion in glioma cells.
Glioma
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Glioma
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.
Glioma
Store-operated Ca 2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation.
Glioma
Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase.
Glioma
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Glioma
The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway.
Glioma
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Glioma
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.
Glioma
Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells.
Glioma
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Glomerulonephritis
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
Glomerulonephritis
An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.
Glomerulonephritis
Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.
Glomerulonephritis
Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.
Glomerulonephritis
Increased expression of cell adhesion kinase beta in human and rat crescentic glomerulonephritis.
Glomerulonephritis
Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase.
Glomerulonephritis
Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Glomerulonephritis
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
Glomerulonephritis
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.
Glomerulonephritis, IGA
Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy.
Glomerulonephritis, IGA
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
Glomerulonephritis, IGA
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.
Glomerulonephritis, IGA
Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy.
Glomerulonephritis, IGA
Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients.
Glomerulonephritis, Membranous
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Glomerulosclerosis, Focal Segmental
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Glomerulosclerosis, Focal Segmental
Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.
Glucose Intolerance
Absence of Shb impairs insulin secretion by elevated FAK activity in pancreatic islets.
Glucose Intolerance
Adipocyte-Specific Deletion of Janus Kinase 2 (JAK2) Leads to Increased Adiposity and Age-Related Glucose Intolerance.
Glucose Intolerance
Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Glucose Metabolism Disorders
[Relationship between glucose metabolic disorders and expression of insulin receptor in posthepatitic cirrhosis hepatocyte and HBV DNA in pancreatic cells]
Glycogen Storage Disease Type VI
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Glycogen Storage Disease Type VI
Heterogenous expression of bcr-abl fusion mRNA in a patient with Philadelphia-chromosome-positive acute lymphoblastic leukaemia.
Goiter
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Graft vs Host Disease
Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Graft vs Host Disease
Azole antifungals and new targeted therapies for hematological malignancy.
Graft vs Host Disease
Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease.
Graft vs Host Disease
Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Graft vs Host Disease
Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease.
Graft vs Host Disease
CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-? pathway.
Graft vs Host Disease
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Graft vs Host Disease
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic Graft-Versus-Host Disease.
Graft vs Host Disease
Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Graft vs Host Disease
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Graft vs Host Disease
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.
Graft vs Host Disease
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Graft vs Host Disease
Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Graft vs Host Disease
Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
Graft vs Host Disease
Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Graft vs Host Disease
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Graft vs Host Disease
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Graft vs Host Disease
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Graft vs Host Disease
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Graft vs Host Disease
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Graft vs Host Disease
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Graft vs Host Disease
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
Graft vs Host Disease
[Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia]
Granuloma
Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis.
Granuloma Annulare
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways.
Granuloma Annulare
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Granulomatosis with Polyangiitis
Evidence for enhanced Bruton's tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis.
Granulosa Cell Tumor
Constitutively active transforming growth factor ? receptor 1 in the mouse ovary promotes tumorigenesis.
Granulosa Cell Tumor
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Hamartoma
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Hamartoma
Mutation analysis of related genes in hamartoma polyp tissue of Peutz-Jeghers syndrome.
Hamartoma Syndrome, Multiple
A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome.
Hamartoma Syndrome, Multiple
An unexpected Cowden syndrome case found among members of a large familial adenomatous polyposis kindred.
Hamartoma Syndrome, Multiple
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Hamartoma Syndrome, Multiple
BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.
Hamartoma Syndrome, Multiple
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels.
Hamartoma Syndrome, Multiple
Looking for the hidden mutation: Bannayan-Riley-Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A.
Hamartoma Syndrome, Multiple
Overlap of juvenile polyposis syndrome and cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: implications for treatment and surveillance.
Head and Neck Neoplasms
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Head and Neck Neoplasms
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Head and Neck Neoplasms
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Head and Neck Neoplasms
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
Head and Neck Neoplasms
Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.
Heart Arrest
Effects of NaHS and hydroxylamine on the expressions of brain-derived neurotrophic factor and its receptors in rats after cardiac arrest and cardiopulmonary resuscitation.
Heart Arrest
Regulation of tyrosine protein kinase receptor Trk-B and motor function in rats following cardiac arrest.
Heart Arrest
[Effects of brain necroptosis and cytokines expression array on brain injury in rats with cardiac arrest].
Heart Defects, Congenital
A familial congenital heart disease with a possible multigenic origin involving a mutation in BMPR1A.
Heart Defects, Congenital
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Heart Defects, Congenital
AcvR1-mediated BMP signaling in second heart field is required for arterial pole development: Implications for myocardial differentiation and regional identity.
Heart Defects, Congenital
BMPR1A is a candidate gene for congenital heart defects associated with the recurrent 10q22q23 deletion syndrome.
Heart Defects, Congenital
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Heart Defects, Congenital
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Heart Defects, Congenital
Wnt11 regulates cardiac chamber development and disease during perinatal maturation.
Heart Diseases
Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Heart Diseases
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Heart Failure
Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin.
Heart Failure
CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
Heart Failure
Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart.
Heart Failure
Increased expression of Dock180 protein in the noninfarcted myocardium in rats.
Heart Failure
Outflow tract cushions perform a critical valve-like function in the early embryonic heart requiring BMPRIA-mediated signaling in cardiac neural crest.
Heart Failure
Paxillin and Focal Adhesion Kinase (FAK) Regulate Cardiac Contractility in the Zebrafish Heart.
Heart Failure
Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch.
Heart Failure
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
Heart Septal Defects, Atrial
BMPR1A mutation-positive juvenile polyposis syndrome and atrial septal defect: coincidence or association?
Heart Septal Defects, Atrial
Homozygous missense variant in BMPR1A resulting in BMPR signaling disruption and syndromic features.
Hemangioma, Cavernous, Central Nervous System
Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
Hemangiosarcoma
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Hemangiosarcoma
Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.
Hemangiosarcoma
Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma.
Hematologic Diseases
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Hematologic Diseases
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Hematologic Diseases
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Hematologic Diseases
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Hematologic Diseases
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Hematologic Diseases
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
Hematologic Neoplasms
A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.
Hematologic Neoplasms
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Hematologic Neoplasms
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.
Hematologic Neoplasms
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Hematologic Neoplasms
Altered splicing in hematological malignancies reveals a tissue-specific translational block of the Src-family tyrosine kinase fyn brain isoform expression.
Hematologic Neoplasms
Azole antifungals and new targeted therapies for hematological malignancy.
Hematologic Neoplasms
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Hematologic Neoplasms
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
Hematologic Neoplasms
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Hematologic Neoplasms
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hematologic Neoplasms
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Hematologic Neoplasms
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Hematologic Neoplasms
Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.
Hematologic Neoplasms
Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Hematologic Neoplasms
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Hematologic Neoplasms
Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.
Hematologic Neoplasms
Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Hematologic Neoplasms
Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Hematologic Neoplasms
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Hematologic Neoplasms
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Hematologic Neoplasms
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Hematologic Neoplasms
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Hematologic Neoplasms
Focal adhesion kinase as a target in the treatment of hematological malignancies.
Hematologic Neoplasms
Functional aspects of apoptosis in hematopoiesis and consequences of failure.
Hematologic Neoplasms
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Hematologic Neoplasms
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Hematologic Neoplasms
GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.
Hematologic Neoplasms
Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
Hematologic Neoplasms
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Hematologic Neoplasms
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Hematologic Neoplasms
Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab.
Hematologic Neoplasms
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Hematologic Neoplasms
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Hematologic Neoplasms
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Hematologic Neoplasms
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
Hematologic Neoplasms
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Hematologic Neoplasms
JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.
Hematologic Neoplasms
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
Hematologic Neoplasms
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Hematologic Neoplasms
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Hematologic Neoplasms
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Hematologic Neoplasms
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Hematologic Neoplasms
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
Hematologic Neoplasms
Novel Association of a Familial TGFBR1 Mutation in Loeys-Dietz Syndrome with Concomitant Hematologic Malignancy.
Hematologic Neoplasms
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Hematologic Neoplasms
Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
Hematologic Neoplasms
Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Hematologic Neoplasms
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.
Hematologic Neoplasms
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes.
Hematologic Neoplasms
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country.
Hematologic Neoplasms
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Hematologic Neoplasms
Rearrangement of PDGFR? gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report.
Hematologic Neoplasms
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
Hematologic Neoplasms
Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
Hematologic Neoplasms
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Hematologic Neoplasms
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Hematologic Neoplasms
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate.
Hematologic Neoplasms
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Hematologic Neoplasms
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematologic Neoplasms
TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Hematologic Neoplasms
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
Hematologic Neoplasms
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Hematologic Neoplasms
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Hematologic Neoplasms
The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Hematologic Neoplasms
The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Hematologic Neoplasms
Therapeutic effect and mechanism of ibrutinib combined with dexamethasone on multiple myeloma.
Hematologic Neoplasms
Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
Hematologic Neoplasms
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Hematologic Neoplasms
[Quality assurance of the molecular diagnostic tests in hematological malignancies]
Hematoma, Subdural, Chronic
Inhibitory Mechanism of the Outer Membrane Growth of Chronic Subdural Hematomas.
Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.
Hemoglobinuria, Paroxysmal
Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.
Hemophilia A
Prevention of the anti-factor VIII memory B-cell response by inhibition of the Bruton's tyrosine kinase in experimental hemophilia A.
Hepatitis
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Hepatitis A
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Hepatitis B
Activation of c-myc expression by c-Abl is independent of both the DNA binding function of c-Abl and the c-myc EP site.
Hepatitis B
Activation of Focal Adhesion Kinase by Hepatitis B Virus HBx Protein: Multiple Functions in Viral Replication.
Hepatitis B
Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan.
Hepatitis B
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Hepatitis B
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Hepatitis B
HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line.
Hepatitis B
Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression.
Hepatitis B
Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway.
Hepatitis B
Hepatitis B virus promotes ?-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
Hepatitis B
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Hepatitis B
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Hepatitis B, Chronic
A deficient translocation of CD3?, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection.
Hepatitis C
Association of 49245A>G (rs868) polymorphism in the 3'UTR of donor TGFBR1 gene with course of hepatitis C following orthotopic liver transplantation.
Hepatitis C
Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells.
Hepatitis C
Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli.
Hepatitis C
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Hepatitis C
Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase.
Hepatitis C
Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction.
Hepatitis C
Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase.
Hepatitis C
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Hepatitis C
Interaction of Hepatitis C Virus Core Protein with Janus Kinase Is Required for Efficient Production of Infectious Viruses.
Hepatitis C
Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review.
Hepatitis C
Phosphorylated Ezrin (Thr567) Regulates Hippo Pathway and Yes-Associated Protein (Yap) in Liver.
Hepatitis C
Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon.
Hepatitis C
Structure of the c-Src-SH3 domain in complex with a proline-rich motif of NS5A protein from the hepatitis C virus.
Hepatitis C
Yeast Endoplasmic Reticulum Sequestration Screening for the Engineering of Proteases from Libraries Expressed in Yeast.
Hepatitis E
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Hepatitis, Alcoholic
The role of Tec kinase signaling pathways in the development of Mallory Denk Bodies in balloon cells in alcoholic hepatitis.
Hepatitis, Autoimmune
Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
Hepatitis, Chronic
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Hepatoblastoma
Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells.
Hepatoblastoma
Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells.
Hepatomegaly
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm.
Hepatomegaly
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
Hepatopulmonary Syndrome
[Splenic tyrosine kinase promotes pulmonary angiogenesis in rats with hepatopulmonary syndrome].
Hernia, Umbilical
BMPR1A-mediated BMP1 signalling is disrupted in the cadmium-induced omphalocele in the chick model.
Hernias, Diaphragmatic, Congenital
Upregulated EFNB2 and EPHB4 promotes lung development in a nitrofen-induced congenital diaphragmatic hernia rat model.
Herpes Simplex
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Herpes Simplex
Herpes Simplex Virus Type 1 Neuronal Infection Perturbs Golgi Apparatus Integrity through Activation of Src Tyrosine Kinase and Dyn-2 GTPase.
Herpes Simplex
Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase.
Herpes Simplex
Inhibitory effect of tyrphostin on the replication of herpes simplex virus type 1.
Herpes Simplex
Microarray analysis of genes with differential expression of m6A methylation in lung cancer.
Herpes Simplex
New erythroxane-type diterpenoids from Fagonia boveana (Hadidi) Hadidi & Graf.
Herpes Simplex
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Herpes Simplex
The location of v-src in a retrovirus vector determines whether the virus is toxic or transforming.
Herpes Zoster
Angiopoietin-like protein 2 promotes the progression of diabetic kidney disease.
Herpes Zoster
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Herpes Zoster
Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate.
Herpes Zoster
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Herpes Zoster
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Herpes Zoster
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review.
Herpes Zoster
[Risk profile of disease-modifying antirheumatic drugs: an update from the RABBIT register].
Hidradenitis Suppurativa
A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
Hidradenitis Suppurativa
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
HIV Infections
HIV infection in vitro enhances the activity of src-family protein tyrosine kinases.
HIV Infections
HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.
HIV Infections
HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.
HIV Infections
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Hodgkin Disease
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Hodgkin Disease
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Hodgkin Disease
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Hodgkin Disease
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Hodgkin Disease
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Hodgkin Disease
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Hodgkin Disease
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Hodgkin Disease
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Hodgkin Disease
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Hodgkin Disease
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
Hodgkin Disease
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Hodgkin Disease
Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs.
Hodgkin Disease
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
Hodgkin Disease
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Hodgkin Disease
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Hydatidiform Mole
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Hydrocephalus
Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus.
Hydrocephalus
Loss of Fyn tyrosine kinase on the C57BL/6 genetic background causes hydrocephalus with defects in oligodendrocyte development.
Hydrocephalus
Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia.
Hydrocephalus, Normal Pressure
Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus.
Hydronephrosis
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Hydrops Fetalis
EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis.
Hydrops Fetalis
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Hydrops Fetalis
Loss of function mutations in EPHB4 are responsible for vein of Galen aneurysmal malformation.
Hyper-IgM Immunodeficiency Syndrome
Absence of memory B cells in patients with common variable immunodeficiency.
Hyperalgesia
Can Src protein tyrosine kinase inhibitors be combined with opioid analgesics? Src and opioid-induced tolerance, hyperalgesia and addiction.
Hyperalgesia
CXCL13/CXCR5 signaling contributes to diabetes-induced tactile allodynia via activating pERK, pSTAT3, pAKT pathways and pro-inflammatory cytokines production in the spinal cord of male mice.
Hyperalgesia
EphrinB2 induces tyrosine phosphorylation of NR2B via Src-family kinases during inflammatory hyperalgesia.
Hyperalgesia
GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican.
Hyperalgesia
Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia.
Hyperalgesia
Involvement of a spinal brain-derived neurotrophic factor/full-length TrkB pathway in the development of nerve injury-induced thermal hyperalgesia in mice.
Hyperalgesia
JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat.
Hyperalgesia
Janus kinase 2 activation participates in prostaglandin E2-induced hyperalgesia.
Hyperalgesia
Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.
Hyperalgesia
Role of GPCR (mu-opioid)-receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II).
Hyperalgesia
Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain.
Hypereosinophilic Syndrome
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Hypereosinophilic Syndrome
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Hypereosinophilic Syndrome
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Hypereosinophilic Syndrome
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR?: roles of Mcl-1 and ?-catenin.
Hypereosinophilic Syndrome
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Hypereosinophilic Syndrome
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
Hyperglycemia
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
Hyperglycemia
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hyperglycemia
Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2.
Hyperglycemia
Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.
Hyperglycemia
The Abnormal Architecture of Healed Diabetic Ulcers Is the Result of FAK Degradation by Calpain 1.
Hyperhomocysteinemia
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Hyperinsulinism
Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
Hyperinsulinism
Decreased erythrocyte insulin binding in hypertensive subjects with hyperinsulinemia.
Hyperlipidemias
Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease.
Hyperostosis
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Hypersensitivity
(-)-Asarinin inhibits mast cells activation as a Src family kinase inhibitor.
Hypersensitivity
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
Hypersensitivity
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Hypersensitivity
Acute stress induces visceral hypersensitivity via glucocorticoid receptor-mediated membrane insertion of TRPM8: Involvement of a non-receptor tyrosine kinase Pyk2.
Hypersensitivity
Application of a pharmacogenetic test adoption model to six oncology biomarkers.
Hypersensitivity
BDNF Contributes to Spinal Long-Term Potentiation and Mechanical Hypersensitivity Via Fyn-Mediated Phosphorylation of NMDA Receptor GluN2B Subunit at Tyrosine 1472 in Rats Following Spinal Nerve Ligation.
Hypersensitivity
Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study.
Hypersensitivity
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Hypersensitivity
Effect of reduced EPHB4 expression in thymic epithelial cells on thymocyte development and peripheral T cell function.
Hypersensitivity
Electroacupuncture ameliorates mechanical hypersensitivity by down-regulating spinal Janus kinase 2/signal transducer and activation of transcription 3 and interleukin 6 in rats with spared nerve injury.
Hypersensitivity
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Hypersensitivity
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Hypersensitivity
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats.
Hypersensitivity
Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics.
Hypersensitivity
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Hypersensitivity
Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase.
Hypersensitivity
Oclacitinib (APOQUEL(®) ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.
Hypersensitivity
Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions.
Hypersensitivity
Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.
Hypersensitivity
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Hypersensitivity
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Hypersensitivity
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Hypersensitivity
TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hypersensitivity
The Possible Importance of ?3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.
Hypersensitivity
Topical treatment with mastic (resin from Pistacia lentiscus) elicits anti-inflammatory and anti-pruritic responses by modulating keratinocyte activation in a mouse model of allergic dermatitis.
Hypersensitivity
Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex.
Hypersensitivity
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Hypersensitivity, Immediate
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Hypersensitivity, Immediate
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Hypersensitivity, Immediate
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Hypersensitivity, Immediate
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Hypertelorism
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Hypertension
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Hypertension
Angiotensin II utilizes JANUS KINASE 2 in hypertension, but not in the physiologic control of blood pressure during low salt intake.
Hypertension
Angiotensin-converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression.
Hypertension
Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
Hypertension
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Hypertension
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Hypertension
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.
Hypertension
Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.
Hypertension
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Hypertension
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Hypertension
C-src tyrosine kinase gene rs1378942 polymorphism and hypertension in Asians: Review and meta-analysis.
Hypertension
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Hypertension
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Hypertension
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Hypertension
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Hypertension
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.
Hypertension
Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
Hypertension
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Hypertension
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hypertension
Erratum to: BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Hypertension
Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy.
Hypertension
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Hypertension
In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Hypertension
Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.
Hypertension
miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Hypertension
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Hypertension
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Hypertension
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Hypertension
Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.
Hypertension
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Hypertension
Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
Hypertension
Soluble form of vascular cell adhesion molecule 1 induces migration and proliferation of vascular smooth muscle cells.
Hypertension
Src Kinases Regulate Glutamatergic Input to Hypothalamic Presympathetic Neurons and Sympathetic Outflow in Hypertension.
Hypertension
Subcellular redistribution of focal adhesion kinase and its related nonkinase in hypertrophic myocardium.
Hypertension
The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Hypertension
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Hypertension
[Expression of focal adhesion kinase in cardiac myocytes of hypertrophic ventricle]
Hypertension
[NF-?B inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
Hypertension
[Phosphorylation and nuclear translocation of serine 722 and serine 910 of focal adhesion kinase in hypertrophic cardiac myocytes of left ventricle of spontaneously hypertensive rats]
Hypertension, Pulmonary
Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension.
Hypertension, Pulmonary
Augmented pulmonary vasoconstrictor reactivity following chronic hypoxia requires Src kinase and EGFR signaling.
Hypertension, Pulmonary
Critical Role of the Axonal Guidance Cue EphrinB2 in Lung Growth, Angiogenesis, and Repair.
Hypertension, Pulmonary
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Hypertension, Pulmonary
Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Hypertension, Pulmonary
Heme Biosynthesis Modulation via ?-Aminolevulinic Acid Administration Attenuates Chronic Hypoxia-induced Pulmonary Hypertension.
Hypertension, Pulmonary
Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway.
Hypertension, Pulmonary
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Hypertension, Pulmonary
Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension.
Hypertension, Pulmonary
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.
Hypertension, Pulmonary
Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia.
Hypertension, Pulmonary
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.
Hypertension, Pulmonary
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Hypertension, Pulmonary
Pyk2 aggravates hypoxia-induced pulmonary hypertension by activating HIF-1?
Hypertension, Pulmonary
RELM-? promotes human pulmonary artery smooth muscle cell proliferation via FAK-stimulated surviving.
Hypertension, Pulmonary
[Biomarker screening of rat pulmonary hypertension model by transcriptome sequencing].
Hypertension, Pulmonary
[Pulmonary Hypertension: microRNAs in Pathogenesis, Diagnosis and Therapy.]
Hypertension, Renovascular
Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.
Hypertension, Renovascular
Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Hypertrophy, Left Ventricular
CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
Hypertrophy, Left Ventricular
PYK2 regulates SERCA2 gene expression in neonatal rat ventricular myocytes.
Hypertrophy, Right Ventricular
Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice.
Hypopharyngeal Neoplasms
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
Hypospadias
Associations of TGFBR1 and TGFBR2 gene polymorphisms with the risk of hypospadias: a case-control study in a Chinese population.
Hypotension
EPHB4 Protein Expression in Vascular Smooth Muscle Cells Regulates Their Contractility, and EPHB4 Deletion Leads to Hypotension in Mice.
Hypotension
NF-?B activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.
Hypothyroidism
Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
Hypoxia, Brain
Effects of Src kinase inhibition on expression of pro-caspase-2 after brain hypoxia in a piglet animal model.
Hypoxia, Brain
Effects of Src Kinase Inhibition on Expression of Protein Tyrosine Phosphatase 1B after Brain Hypoxia in a Piglet Animal Model.
Hypoxia, Brain
Temporal Changes in Caspase-1 and Caspase-8 Activities Following Brain Hypoxia With and Without Src kinase Inhibition in a Piglet Animal Model.
Hypoxia-Ischemia, Brain
Effect of Src Kinase inhibition on Cytochrome c, Smac/DIABLO and Apoptosis Inducing Factor (AIF) Following Cerebral Hypoxia-Ischemia in Newborn Piglets.
Hypoxia-Ischemia, Brain
Neonatal cerebral hypoxia-ischemia: involvement of FAK-dependent pathway.
Idiopathic Pulmonary Fibrosis
Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.
Idiopathic Pulmonary Fibrosis
Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Ileitis
ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice.
Immune System Diseases
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Immune System Diseases
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
Immune System Diseases
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Immune System Diseases
Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
Immune System Diseases
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
Immune System Diseases
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
Immune System Diseases
[The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
Infarction, Middle Cerebral Artery
Delayed phosphorylation of p38 mitogen-activated protein kinase in the AT1a knock-out mouse striatal neurons during middle cerebral artery occlusion and reperfusion.
Infections
A de novo transcriptome analysis shows that modulation of the JAK-STAT signaling pathway by salmonid alphavirus subtype 3 favors virus replication in macrophage/dendritic-like TO-cells.
Infections
A deficient translocation of CD3?, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection.
Infections
A Dual Role for the Nonreceptor Tyrosine Kinase Pyk2 during the Intracellular Trafficking of Human Papillomavirus 16.
Infections
A new retroviral vector, CA1, to identify and select for cells expressing an inserted gene in vitro and in vivo.
Infections
A novel focal adhesion kinase from Marsupenaeus japonicus and its response to WSSV infection.
Infections
Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells.
Infections
Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms.
Infections
Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle.
Infections
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells.
Infections
Activated lck tyrosine protein kinase stimulates antigen-independent interleukin-2 production in T cells.
Infections
Activation of Abl by Helicobacter pylori: a novel kinase for CagA and crucial mediator of host cell scattering.
Infections
Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages.
Infections
Altered stem cell (CFU-S) function following infection of hematopoietic cells with a virus carrying V-src.
Infections
An immediate-early protein of white spot syndrome virus modulates the phosphorylation of focal adhesion kinase of shrimp.
Infections
Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation.
Infections
Beta Interferon-Mediated Activation of Signal Transducer and Activator of Transcription Protein 1 Interferes with Rickettsia conorii Replication in Human Endothelial Cells.
Infections
CD36 and Fyn Kinase Mediate Malaria-Induced Lung Endothelial Barrier Dysfunction in Mice Infected with Plasmodium berghei.
Infections
CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae.
Infections
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Infections
Changes in the level of apoptosis-related proteins in Jurkat cells infected with HIV-1 versus HIV-2.
Infections
Characteristics of Chikungunya virus infection in patients with established rheumatoid arthritis.
Infections
Chicken myeloid stem cells infected by retroviruses carrying the v-fps oncogene do not require exogenous growth factors to differentiate in vitro.
Infections
Chlamydial Infection of Monocytes Stimulates IL-1beta Secretion Through Activation of the NLRP3 Inflammasome.
Infections
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Infections
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Infections
Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms.
Infections
Decoding Susceptibility to Respiratory Viral Infections and Asthma Inception in Children.
Infections
Dectin-1 Activation during Leishmania amazonensis Phagocytosis Prompts Syk-Dependent Reactive Oxygen Species Production To Trigger Inflammasome Assembly and Restriction of Parasite Replication.
Infections
Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
Infections
Delayed diagnosis of X-linked agammaglobulinaemia in a boy with recurrent meningitis.
Infections
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Infections
Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection.
Infections
Disseminated Bacille Calmette-Guérin infection in a patient with severe combined immunodeficiency caused by JAK3 gene mutation.
Infections
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.
Infections
Down regulation by p60v-src of genes specifically expressed and developmentally regulated in postmitotic quail neuroretina cells.
Infections
Down-modulation of the ZAP-70 protein tyrosine kinase in macaque T lymphocytes infected with SIVsmmPBj14.
Infections
Dual microRNA Screens Reveal That the Immune-Responsive miR-181 Promotes Henipavirus Entry and Cell-Cell Fusion.
Infections
Dysregulation of focal adhesion kinase upon Toxoplasma gondii infection facilitates parasite translocation across polarised primary brain endothelial cell monolayers.
Infections
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Infections
Effect of infection with murine recombinant retroviruses containing the v-src oncogene on interleukin 2- and interleukin 3-dependent growth states.
Infections
Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.
Infections
Effects of colony-stimulating factors on leukemia progenitor cells and oncogene expression.
Infections
Endothelial Cell Proteomic Response to Rickettsia conorii Infection Reveals Activation of the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT)-Inferferon Stimulated Gene (ISG)15 Pathway and Reprogramming Plasma Membrane Integrin/Cadherin Signaling.
Infections
Enteropathogenic Escherichia coli induces modification of the focal adhesions of infected host cells.
Infections
Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.
Infections
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.
Infections
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Infections
EVALUATION OF EXPERIMENTAL INFECTION WITH L. (L.) AMAZONENSIS IN X-LINKED IMMUNODEFICIENT MICE.
Infections
Express path analysis identifies a tyrosine kinase Src-centric network regulating divergent host responses to Mycobacterium tuberculosis infection.
Infections
Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells.
Infections
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Infections
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Infections
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Infections
Expression of v-src in embryonic neural retina alters cell adhesion, inhibits histogenesis, and prevents induction of glutamine synthetase.
Infections
Extracellular pressure stimulates macrophage phagocytosis by inhibiting a pathway involving FAK and ERK.
Infections
Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase.
Infections
Focal adhesion kinase activation is required for TNF-?-induced production of matrix metalloproteinase-2 and proinflammatory cytokines in cultured human periodontal ligament fibroblasts.
Infections
Focal adhesion kinase is critical for entry of Kaposi's sarcoma-associated herpesvirus into target cells.
Infections
Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts.
Infections
Gene expression profiling in AGS cells stimulated with Helicobacter pylori isogenic strains (cagA positive or cagA negative).
Infections
Genome-Wide Gene Expression Analysis Identifies the Proto-oncogene Tyrosine-Protein Kinase Src as a Crucial Virulence Determinant of Infectious Laryngotracheitis Virus in Chicken Cells.
Infections
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Infections
Helicobacter pylori CagA Induces Cortactin Y-470 Phosphorylation-Dependent Gastric Epithelial Cell Scattering via Abl, Vav2 and Rac1 Activation.
Infections
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Infections
Helicobacter pylori infection interferes with epithelial Stat6-mediated interleukin-4 signal transduction independent of cagA, cagE, or VacA.
Infections
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Infections
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Infections
Herpes Simplex Virus Type 1 Neuronal Infection Perturbs Golgi Apparatus Integrity through Activation of Src Tyrosine Kinase and Dyn-2 GTPase.
Infections
HIV-1 down-regulates CD4 costimulation of TCR/CD3-directed tyrosine phosphorylation through CD4/p56lck dissociation.
Infections
HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.
Infections
Host Src controls gallid alpha herpesvirus 1 intercellular spread in a cellular fatty acid metabolism-dependent manner.
Infections
Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.
Infections
Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels.
Infections
Human metapneumovirus inhibits IFN-? signaling by downregulating Jak1 and Tyk2 cellular levels.
Infections
Hydroquinone regulates hemeoxygenase-1 expression via modulation of Src kinase activity through thiolation of cysteine residues.
Infections
Hypoxia Decreases Invasin-Mediated Yersinia enterocolitica Internalization into Caco-2 Cells.
Infections
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Infections
IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis.
Infections
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Infections
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
Infections
In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.
Infections
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
Infections
Incipient Diabetes Mellitus and Nascent Thyroid Disease Presenting as Beard Alopecia Areata: Case Report and Treatment Review of Alopecia Areata of the Beard.
Infections
Increased Src kinase level results in increased protein tyrosine phosphorylation in scrapie-infected neuronal cell lines.
Infections
Induction of cyclophilin A by influenza A virus infection facilitates group A Streptococcus coinfection.
Infections
Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins.
Infections
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Infections
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Infections
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Infections
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Infections
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Infections
Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells.
Infections
Intracellular invasion by Orientia tsutsugamushi is mediated by integrin signaling and actin cytoskeleton rearrangements.
Infections
Ixodes scapularis JAK-STAT Pathway Regulates Tick Antimicrobial Peptides, Thereby Controlling the Agent of Human Granulocytic Anaplasmosis.
Infections
JAK3 restrains inflammatory responses and protects against periodontal disease through Wnt3a signaling.
Infections
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Infections
JNK regulates MCP-1 expression in adenovirus type 19-infected human corneal fibroblasts.
Infections
Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity.
Infections
Laminin acts via focal adhesion kinase/phosphatidylinositol-3' kinase/protein kinase B to down-regulate beta1-adrenergic receptor signalling in cat atrial myocytes.
Infections
Leishmania donovani amastigotes impair gamma interferon-induced STAT1alpha nuclear translocation by blocking the interaction between STAT1alpha and importin-alpha5.
Infections
Leishmania donovani Exploits Tollip, a Multitasking Protein, To Impair TLR/IL-1R Signaling for Its Survival in the Host.
Infections
lncRNA AK085865 Promotes Macrophage M2 Polarization in CVB3-Induced VM by Regulating ILF2-ILF3 Complex-Mediated miRNA-192 Biogenesis.
Infections
Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis.
Infections
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
Infections
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Infections
Mice lacking protein tyrosine kinase fyn develop a T helper-type 1 response and resistLeishmania major infection.
Infections
Microarray analysis of genes with differential expression of m6A methylation in lung cancer.
Infections
Modulation of enzymatic activity of Src-family kinases in bovine T cells transformed by Theileria parva.
Infections
Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.
Infections
Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
Infections
Mutation of a site of tyrosine phosphorylation in the lymphocyte-specific tyrosine protein kinase, p56lck, reveals its oncogenic potential in fibroblasts.
Infections
Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-?B pathways.
Infections
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Infections
Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways.
Infections
Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism.
Infections
Nonmuscle Myosin Heavy Chain IIA Recognizes Sialic Acids on Sialylated RNA Viruses To Suppress Proinflammatory Responses via the DAP12-Syk Pathway.
Infections
Nonreceptor Tyrosine Kinase c-Abl- and Arg-Mediated IRF3 Phosphorylation Regulates Innate Immune Responses by Promoting Type I IFN Production.
Infections
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Infections
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Infections
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Infections
Pathogenic prions deviate PrP(C) signaling in neuronal cells and impair A-beta clearance.
Infections
PID in Disguise: Molecular Diagnosis of IRAK-4 Deficiency in an Adult Previously Misdiagnosed With Autosomal Dominant Hyper IgE Syndrome.
Infections
Population context determines cell-to-cell variability in endocytosis and virus infection.
Infections
Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Infections
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Infections
Profound differences in potassium current properties of normal and Rous sarcoma virus-transformed chicken embryo fibroblasts.
Infections
Protein kinase A-mediated inhibition of gamma interferon-induced tyrosine phosphorylation of Janus kinases and latent cytoplasmic transcription factors in human monocytes by Ehrlichia chaffeensis.
Infections
Quercetin Prevents Escherichia coli O157:H7 Adhesion to Epithelial Cells via Suppressing Focal Adhesions.
Infections
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Infections
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Infections
Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines.
Infections
Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review.
Infections
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Infections
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.
Infections
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Infections
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Infections
Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.
Infections
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Infections
Schistosoma mansoni FES Tyrosine Kinase Involvement in the Mammalian Schistosomiasis Outcome and Miracidia Infection Capability in Biomphalaria glabrata.
Infections
Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus.
Infections
Serine phosphorylation of cortactin controls focal adhesion kinase activity and cell scattering induced by Helicobacter pylori.
Infections
Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts.
Infections
Some findings of FADD knockdown in inhibition of HIV-1 replication in Jurkat cells and PBMCs.
Infections
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
Infections
Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response.
Infections
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Infections
Src-dependent Tyrosine Phosphorylation of Non-muscle Myosin Heavy Chain-IIA Restricts Listeria monocytogenes Cellular Infection.
Infections
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Infections
Taohong siwu decoction attenuates myocardial fibrosis by inhibiting fibrosis proliferation and collagen deposition via TGFBR1 signaling pathway.
Infections
Testosterone-induced persistent susceptibility to Plasmodium chabaudi malaria: long-term changes of lincRNA and mRNA expression in the spleen.
Infections
The Amino-Terminal Part of the Needle-Tip Translocator LcrV of Yersinia pseudotuberculosis Is Required for Early Targeting of YopH and In vivo Virulence.
Infections
The c-Src and Pyk2 protein tyrosine kinases play protective roles in early HIV-1 infection of CD4+ T cell lines.
Infections
The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells.
Infections
The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.
Infections
The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes.
Infections
The non-receptor tyrosine kinase Tec controls assembly and activity of the noncanonical caspase-8 inflammasome.
Infections
The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling.
Infections
The relationship of modulation of major histocompatibility complex class I antigens to retrovirus transformation in rat cell lines.
Infections
The role of p56lck in the development of gamma delta T cells and their function during an infection by Listeria monocytogenes.
Infections
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Infections
The v-src oncogene may not be responsible for the increased radioresistance of hematopoietic progenitor cells expressing v-src.
Infections
TLR2/CXCR4 coassociation facilitates Chlamydia pneumoniae infection-induced atherosclerosis.
Infections
Toxoplasma gondii inhibits mast cell degranulation by suppressing phospholipase C?-mediated Ca(2+) mobilization.
Infections
Transcriptional downregulation of the retina-specific QR1 gene by pp60v-src and identification of a novel v-src-responsive unit.
Infections
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Infections
Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice.
Infections
Transient myelodysplastic syndrome in X-linked agammaglobulinemia with a novel Btk mutation.
Infections
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Infections
Two sequential layers of antibody-mediated control of Legionella pneumophila infection.
Infections
Type II interferon signaling in the brain during a viral infection with age-dependent pathogenesis.
Infections
X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
Infections
Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.
Infections
ZAP-70, CTLA-4 and proximal T cell receptor signaling in cows infected with Mycobacterium avium subsp. paratuberculosis.
Infections
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
Infections
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Infertility
Determination of c-Abl tyrosine kinase and mTERT catalytic subunit of telomerase expression level during prenatal-postnatal mouse ovary-testis development.
Infertility
Ptk2b deletion improves mice folliculogenesis and fecundity via inhibiting follicle loss mediated by Erk pathway.
Infertility
Successful Planned Pregnancy through Vitrified-Warmed Embryo Transfer in a Woman with Chronic Myeloid Leukemia: Case Report and Literature Review.
Infertility, Male
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Inflammatory Bowel Diseases
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Inflammatory Bowel Diseases
Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey.
Inflammatory Bowel Diseases
CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease.
Inflammatory Bowel Diseases
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease.
Inflammatory Bowel Diseases
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Inflammatory Bowel Diseases
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
Inflammatory Bowel Diseases
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.
Inflammatory Bowel Diseases
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Inflammatory Bowel Diseases
Janus Kinase Inhibition With Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment.
Inflammatory Bowel Diseases
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
Inflammatory Bowel Diseases
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Inflammatory Bowel Diseases
Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase.
Inflammatory Bowel Diseases
Regulation of Janus Kinase 2 by an Inflammatory Bowel Disease Causal Non-coding Single Nucleotide Polymorphism.
Inflammatory Bowel Diseases
Role of Csk in intestinal epithelial barrier function and protection against colitis.
Inflammatory Bowel Diseases
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients.
Inflammatory Bowel Diseases
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.
Inflammatory Bowel Diseases
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Inflammatory Bowel Diseases
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Inflammatory Bowel Diseases
Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population.
Inflammatory Bowel Diseases
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Inflammatory Bowel Diseases
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis.
Inflammatory Bowel Diseases
Update on Janus kinase antagonists in inflammatory bowel disease.
Inflammatory Bowel Diseases
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Inflammatory Bowel Diseases
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
Inflammatory Bowel Diseases
[Biologics and Janus kinase inhibitor for inflammatory bowel disease -understanding the clinical guideline for IBD].
Inflammatory Breast Neoplasms
The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
Influenza in Birds
Avian influenza viruses inhibit the major cellular signalling integrator c-Abl.
Influenza in Birds
Hemagglutinin from the H5N1 Virus Activates Janus Kinase 3 to Dysregulate Innate Immunity.
Influenza in Birds
Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Coninfections: Insights Into 1918 H1N1 Pandemic?
Influenza in Birds
The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection.
Influenza, Human
CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.
Influenza, Human
Entropy Hotspots for the Binding of Intrinsically Disordered Ligands to a Receptor Domain.
Influenza, Human
Focal adhesion kinase (FAK) regulates polymerase activity of multiple influenza A virus subtypes.
Influenza, Human
In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Influenza, Human
Inhibiting Bruton's Tyrosine Kinase Rescues Mice from Lethal Influenza Induced Acute Lung Injury.
Influenza, Human
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Influenza, Human
Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review.
Influenza, Human
Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages.
Influenza, Human
Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and viral cytopathogenicity.
Influenza, Human
Structure and Dynamics of Membrane Proteins and Membrane Associated Proteins with Native Bicelles from Eukaryotic Tissues.
Insulin Resistance
Adipocyte-specific deficiency of Janus kinase (JAK) 2 in mice impairs lipolysis and increases body weight, and leads to insulin resistance with ageing.
Insulin Resistance
c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice.
Insulin Resistance
Decreased erythrocyte insulin binding in hypertensive subjects with hyperinsulinemia.
Insulin Resistance
Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.
Insulin Resistance
Focal Adhesion Kinase contributes to insulin-induced actin reorganization into a mesh harboring Glucose transporter-4 in insulin resistant skeletal muscle cells.
Insulin Resistance
Immunofluorescent visualisation of focal adhesion kinase in human skeletal muscle and its associated microvasculature.
Insulin Resistance
Impact of fasting on growth hormone signaling and action in muscle and fat.
Insulin Resistance
Insulin-Like Growth Factor Binding Protein 1 Could Improve Glucose Regulation and Insulin Sensitivity Through Its RGD Domain.
Insulin Resistance
Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1.
Insulin Resistance
Loss of BMP receptor type 1A in murine adipose tissue attenuates age-related onset of insulin resistance.
Insulin Resistance
Novel phosphorylation of PPAR? ameliorates obesity-induced adipose tissue inflammation and improves insulin sensitivity.
Insulin Resistance
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Insulin Resistance
Upregulation of IL-4 signaling contributes to aerobic exercise-induced insulin sensitivity.
Insulinoma
C-Abl inhibitor imatinib enhances insulin production by ? cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
Intellectual Disability
Abl2/Arg controls dendritic spine and dendrite arbor stability via distinct cytoskeletal control pathways.
Intellectual Disability
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Intellectual Disability
[Genetic testing and prenatal diagnosis for a family with 10q22.3q23.2 microdeletion].
Intervertebral Disc Degeneration
Wnt11 overexpression promote adipose-derived stem cells differentiating to the nucleus pulposus-like phenotype.
Intervertebral Disc Displacement
Impact of Wnt signals on human intervertebral disc cell regeneration.
Intestinal Diseases
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Intestinal Polyposis
BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.
Intracranial Aneurysm
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Intracranial Arteriovenous Malformations
Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Intracranial Hemorrhages
Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
Intracranial Hemorrhages
EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.
Invasive Fungal Infections
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Invasive Fungal Infections
Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.
Invasive Fungal Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Invasive Fungal Infections
Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors.
Invasive Fungal Infections
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Invasive Pulmonary Aspergillosis
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Iron Deficiencies
The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera.
Ischemic Stroke
A Truncated Fragment of Src Protein Kinase Generated by Calpain-Mediated Cleavage is A Mediator of Neuronal Death in Excitotoxicity.
Ischemic Stroke
Activin A improves the neurological outcome after ischemic stroke in mice by promoting oligodendroglial ACVR1B-mediated white matter remyelination.
Ischemic Stroke
Correction to: Pyruvate Kinase M2 Increases Angiogenesis, Neurogenesis, and Functional Recovery Mediated by Upregulation of STAT3 and Focal Adhesion Kinase Activities after Ischemic Stroke in Adult Mice.
Ischemic Stroke
Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.
Ischemic Stroke
Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke.
Ischemic Stroke
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
Ischemic Stroke
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation.
Ischemic Stroke
miR-129-2-3p directly targets SYK gene and associates with the risk of ischaemic stroke in a Chinese population.
Ischemic Stroke
Overexpression of EphB4 promotes neurogenesis, but inhibits neuroinflammation in mice with acute ischemic stroke.
Ischemic Stroke
Perlecan, a modular instructive proteoglycan with diverse functional properties.
Ischemic Stroke
Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke.
Ischemic Stroke
Pyruvate Kinase M2 Increases Angiogenesis, Neurogenesis, and Functional Recovery Mediated by Upregulation of STAT3 and Focal Adhesion Kinase Activities After Ischemic Stroke in Adult Mice.
Ischemic Stroke
Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice.
Jacobsen Distal 11q Deletion Syndrome
Janus kinase 3 missense mutation in a child with Jacobsen syndrome.
Job Syndrome
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Job Syndrome
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
Job Syndrome
The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency.
Joint Diseases
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Joint Diseases
The osteoclast: a potential therapeutic target of bone and joint destruction in rheumatoid arthritis.
Keloid
A Role for Neuregulin-1 in Promoting Keloid Fibroblast Migration via ErbB2-mediated Signaling.
Keloid
Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation.
Keloid
Mechanical coupling of cytoskeletal elasticity and force generation is crucial for understanding the migrating nature of keloid fibroblasts.
Keloid
Upregulated periostin promotes angiogenesis in keloids through activation of the ERK 1/2 and focal adhesion kinase pathways, as well as the upregulated expression of VEGF and angiopoietin?1.
Keratitis
Correlation between matrix metalloproteinase expression and activation of the focal adhesion kinase signaling pathway in herpes stromal keratitis.
Keratosis
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Keratosis, Actinic
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ?-tubulin explains KXO1's low clinical toxicity.
Keratosis, Actinic
Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
Kidney Diseases
Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice.
Kidney Diseases
MicroRNA-140-5p Mediates Renal Fibrosis Through TGF-?1/Smad Signaling Pathway by Directly Targeting TGFBR1.
Kidney Failure, Chronic
Pharmacokinetics of tofacitinib, a Janus Kinase inhibitor, in PATIENTS with impaired renal function and end stage renal disease.
Kidney Failure, Chronic
Prevalence of the Janus Kinase 2 V617F Mutation in Patients with End-Stage Renal Disease.
Kidney Neoplasms
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Kidney Neoplasms
Expression and prognostic significance of Src family members in renal clear cell carcinoma.
Kidney Neoplasms
Expression of bone morphogenetic protein-7, its receptors and Smad1/5/8 in normal human kidney and renal cell cancer.
Kidney Neoplasms
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Kidney Neoplasms
Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Laryngeal Neoplasms
Basement membrane protein ladinin-1 and the MIF-CD44-?1 integrin signaling axis are implicated in laryngeal cancer metastasis.
Laryngeal Neoplasms
Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp2.
Laryngeal Neoplasms
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Laryngeal Neoplasms
Immunohistochemical Expression of Cortactin and Focal Adhesion Kinase Predicts Recurrence Risk and Laryngeal Cancer Risk Beyond Histologic Grading.
Laryngeal Neoplasms
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Laryngomalacia
Homozygous missense variant in BMPR1A resulting in BMPR signaling disruption and syndromic features.
Latent Tuberculosis
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Leiomyoma
Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta.
Leiomyoma
Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma.
Leiomyoma
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.
Leiomyoma
Paracrine activation of WNT/?-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.
Leiomyoma
Wnt/?-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
Lens Diseases
The effects of c-Src kinase on EMT signaling pathway in human lens epithelial cells associated with lens diseases.
Lentivirus Infections
IGHG1 functions as an oncogene in tongue squamous cell carcinoma via JAK1/STAT5 signaling.
Leprosy
Disruption of HLA-DR raft, deregulations of Lck-ZAP-70-Cbl-b cross-talk and miR181a towards T cell hyporesponsiveness in leprosy.
Leukemia
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Leukemia
3rd generation ABL kinase inhibitor and Philadelphia chromosome positive leukemia.
Leukemia
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
Leukemia
9;22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors.
Leukemia
A 77-kDa protein associates with pp125FAK in mast cells and becomes tyrosine-phosphorylated by high affinity IgE receptor aggregation.
Leukemia
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Leukemia
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
Leukemia
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
Leukemia
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Leukemia
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
Leukemia
A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
Leukemia
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
Leukemia
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Leukemia
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Leukemia
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Leukemia
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
Leukemia
A Study on the Expression of BCR-ABL Transcript in Mixed Phenotype Acute Leukemia (MPAL) Cases Using the Reverse Transcriptase Polymerase Reaction Assay (RT-PCR) and its Correlation with Hematological Remission Status Post Initial Induction Therapy.
Leukemia
A transgenic mouse model of human T cell leukemia virus type 1-associated diseases.
Leukemia
Abelson murine leukemia virus induces platelet-derived growth factor-independent fibroblast growth: correlation with kinase activity and dissociation from full morphologic transformation.
Leukemia
Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.
Leukemia
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Leukemia
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Leukemia
ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles.
Leukemia
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Leukemia
Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.
Leukemia
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Leukemia
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Leukemia
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.
Leukemia
Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.
Leukemia
Accumulation of p60lck in HTLV-I-transformed T cell lines detected by an anti-lck monoclonal antibody, MOL 171.
Leukemia
Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-?B signaling.
Leukemia
Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event.
Leukemia
Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines.
Leukemia
Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.
Leukemia
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Leukemia
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Leukemia
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Leukemia
Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes.
Leukemia
Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase.
Leukemia
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
Leukemia
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Leukemia
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Leukemia
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Leukemia
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Leukemia
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Leukemia
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Leukemia
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl.
Leukemia
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Leukemia
Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase.
Leukemia
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Leukemia
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Leukemia
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Leukemia
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
Leukemia
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Leukemia
Altered protein kinase activities of lymphoid cells transformed by Abelson and Moloney leukemia viruses.
Leukemia
Ameliorating effect of Kalpaamruthaa on altered energy metabolism in BCR-ABL(+) cell line induced leukemic mouse model.
Leukemia
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Leukemia
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
Leukemia
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Leukemia
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
Leukemia
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
Leukemia
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.
Leukemia
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Leukemia
Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy.
Leukemia
Anti-ganglioside monoclonal antibody AA4 selectively inhibits IgE-induced signal transduction pathways in rat basophilic leukemia cells.
Leukemia
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
Leukemia
Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR/ABL kinase and NF-?B inactivation.
Leukemia
Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
Leukemia
Antileukemic Activity and Molecular Docking Study of a Polyphenolic Extract from Coriander Seeds.
Leukemia
Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Leukemia
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
Leukemia
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Leukemia
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Leukemia
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Leukemia
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Leukemia
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Leukemia
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Leukemia
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks.
Leukemia
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
Leukemia
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Leukemia
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Leukemia
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.
Leukemia
Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Leukemia
Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility.
Leukemia
Association of p93c-fes tyrosine protein kinase with granulocytic/monocytic differentiation and resistance to differentiating agents in HL-60 leukemia cells.
Leukemia
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
Leukemia
Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).
Leukemia
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Leukemia
Automated analysis of lipid drug-response markers by combined fast and high-resolution whole cell MALDI mass spectrometry biotyping.
Leukemia
Bcr - Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity.
Leukemia
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
Leukemia
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
Leukemia
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Leukemia
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Leukemia
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Leukemia
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Leukemia
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
Leukemia
BCR-ABL induces neurite-like structures and BCR lacking the SH2-binding domain induces cell rounding in PC12 cells.
Leukemia
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Leukemia
bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.
Leukemia
bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of ?-catenin and STAT1 in chronic myeloid leukemia cells.
Leukemia
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
Leukemia
BCR-ABL rearrangement and HLA antigens: a possible link to leukemia pathogenesis and immunotherapy.
Leukemia
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
Leukemia
BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
Leukemia
Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
Leukemia
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Leukemia
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.
Leukemia
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Leukemia
Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.
Leukemia
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
Leukemia
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Leukemia
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Leukemia
Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.
Leukemia
Betulin, a Newly Characterized Compound in Acacia auriculiformis Bark, Is a Multi-Target Protein Kinase Inhibitor.
Leukemia
Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Leukemia
Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.
Leukemia
Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Leukemia
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Leukemia
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Leukemia
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Leukemia
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.
Leukemia
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin.
Leukemia
c-Abl tyrosine kinase promotes adipocyte differentiation by targeting PPAR-gamma 2.
Leukemia
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
Leukemia
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.
Leukemia
CaMKII ?, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Leukemia
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Leukemia
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Leukemia
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
Leukemia
cDNA array analysis identifies thymic LCK as upregulated in moderate murine zinc deficiency before T-lymphocyte population changes.
Leukemia
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Leukemia
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Leukemia
Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
Leukemia
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Leukemia
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors.
Leukemia
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Leukemia
Characterization of the Abelson murine leukemia virus-encoded tyrosine-specific protein kinase.
Leukemia
Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL).
Leukemia
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Leukemia
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Leukemia
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Leukemia
Chromosome marker and enhanced expression of c-Ha-ras in a DMBA-induced erythroleukemia cell line (D5A1).
Leukemia
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Leukemia
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review.
Leukemia
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
Leukemia
Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Leukemia
Chronic neutrophilic leukemia: case report documenting the absence of bcr-abl rearrangement.
Leukemia
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Leukemia
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Leukemia
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Leukemia
Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.
Leukemia
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
Leukemia
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Leukemia
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Leukemia
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Leukemia
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Leukemia
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Leukemia
Cloning of the cDNA for the deleted syk kinase homologous to ZAP-70 from human basophilic leukemia cell line (KU812).
Leukemia
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Leukemia
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Leukemia
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Leukemia
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Leukemia
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Leukemia
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Leukemia
Comparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias.
Leukemia
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Leukemia
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Leukemia
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Leukemia
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia
Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement?
Leukemia
Complex phosphorylation dynamics control the composition of the Syk interactome in B cells.
Leukemia
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Leukemia
Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias.
Leukemia
Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
Leukemia
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Leukemia
Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Leukemia
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Leukemia
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Leukemia
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.
Leukemia
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Leukemia
Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.
Leukemia
Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Leukemia
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Leukemia
Critical role of Ser-520 phosphorylation for membrane recruitment and activation of the ZAP-70 tyrosine kinase in T cells.
Leukemia
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell.
Leukemia
Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.
Leukemia
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Leukemia
Cyclic AMP negatively controls c-myc transcription and G1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4.
Leukemia
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Leukemia
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Leukemia
Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.
Leukemia
Denbinobin-mediated anticancer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity.
Leukemia
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Leukemia
Depletion of ?-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Leukemia
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Leukemia
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Leukemia
Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.
Leukemia
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Leukemia
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Leukemia
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
Leukemia
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Leukemia
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Leukemia
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Leukemia
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Leukemia
Detection of minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view.
Leukemia
Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR).
Leukemia
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Leukemia
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Leukemia
Detection of tyrosine protein kinase substrates in fresh leukemia cells and normal blood cells using an immunoblotting technique.
Leukemia
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
Leukemia
Development and application of a rapid molecular method for detection of fusion genes in pediatric leukemia.
Leukemia
Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia.
Leukemia
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Leukemia
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Leukemia
Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Leukemia
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Leukemia
Differentiation stage specificity of tyrosine phosphorylation in response to granulocyte macrophage colony stimulating factor (GM-CSF).
Leukemia
Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.
Leukemia
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Leukemia
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Leukemia
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Leukemia
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Leukemia
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Leukemia
Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Leukemia
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Leukemia
Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Leukemia
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Leukemia
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Leukemia
Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
Leukemia
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Leukemia
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Leukemia
Downregulation of miR-217 correlates with resistance of ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Leukemia
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells.
Leukemia
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Leukemia
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Leukemia
E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.
Leukemia
Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.
Leukemia
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Leukemia
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Leukemia
Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.
Leukemia
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Leukemia
Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.
Leukemia
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Leukemia
Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
Leukemia
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Leukemia
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Leukemia
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Leukemia
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Leukemia
Electrochemical Branched-DNA Assay for Polymerase Chain Reaction-Free Detection and Quantification of Oncogenes in Messenger RNA.
Leukemia
Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
Leukemia
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia
Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Leukemia
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
Leukemia
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.
Leukemia
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Leukemia
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
Leukemia
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Leukemia
Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Leukemia
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Leukemia
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Leukemia
Evidence for involvement of two isoforms of Syk protein-tyrosine kinase in signal transduction through the high affinity IgE receptor on rat basophilic leukemia cells.
Leukemia
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
Leukemia
Expression analysis of Akirin-2, NF?B-p65 and ?-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Leukemia
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Leukemia
Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Leukemia
Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
Leukemia
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Leukemia
Expression of the c-fes proto-oncogene in granulocyte-macrophage colony-stimulating factor-dependent acute myelogenous leukemia cells grown autonomously.
Leukemia
Expression of the human T-cell-specific tyrosine kinase YT16 (lck) message in leukemic T-cell lines.
Leukemia
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Leukemia
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Leukemia
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
Leukemia
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.
Leukemia
Fibroblast and hematopoietic cell transformation by the fms oncogene (CSF-1 receptor).
Leukemia
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.
Leukemia
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Leukemia
Flotillin-1 regulates IgE receptor-mediated signaling in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients.
Leukemia
Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials.
Leukemia
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Leukemia
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia
Friend Spleen Focus-Forming Virus Activates the Tyrosine Kinase sf-Stk and the Transcription Factor PU.1 to Cause a Multi-Stage Erythroleukemia in Mice.
Leukemia
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Leukemia
Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Leukemia
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Leukemia
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Leukemia
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Leukemia
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Leukemia
Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms.
Leukemia
Generation and characterization of transforming variants of the lck tyrosine protein kinase.
Leukemia
Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo.
Leukemia
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.
Leukemia
Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.
Leukemia
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
Leukemia
Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia.
Leukemia
Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR.
Leukemia
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.
Leukemia
Global phosphoproteomics reveals crosstalk between bcr-abl and negative feedback mechanisms controlling SRC signaling.
Leukemia
Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association.
Leukemia
Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Leukemia
Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.
Leukemia
HDAC Inhibitors potentiate the activity of the Bcr/Abl Kinase Inhibitor KW-2449 in imatinib-sensitive and -resistant Bcr/Abl+ leukemia cells in vitro and in vivo.
Leukemia
Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.
Leukemia
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Leukemia
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Leukemia
High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A.
Leukemia
High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukemia virus.
Leukemia
High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene.
Leukemia
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Leukemia
Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Leukemia
Highly specific characterization of tyrosine phosphoproteins in tumor cells based on monoclonal antibodies defined by conjugated phosphotyramine.
Leukemia
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Leukemia
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Leukemia
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Leukemia
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Leukemia
Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death.
Leukemia
HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
Leukemia
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
Leukemia
Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF/MEK/ERK Pathway in Ph+ Leukemia Cells.
Leukemia
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Leukemia
Human leukemia K562 cells: relationship between hemin-mediated erythroid induction, cell proliferation and expression of c-abl and c-myc oncogenes.
Leukemia
Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias.
Leukemia
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Leukemia
Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?
Leukemia
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Leukemia
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Leukemia
Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line.
Leukemia
Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.
Leukemia
Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.
Leukemia
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Leukemia
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Leukemia
Identification of Natural inhibitors of Bcr-Abl for the treatment of Chronic Myeloid Leukemia.
Leukemia
Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein-Protein Interaction.
Leukemia
Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells.
Leukemia
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Leukemia
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Leukemia
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Leukemia
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Leukemia
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Leukemia
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Leukemia
Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
Leukemia
Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor.
Leukemia
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
Leukemia
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Leukemia
In vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
Leukemia
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
Leukemia
Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Leukemia
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Leukemia
Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity.
Leukemia
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Leukemia
Induction of hyperphosphorylation and activation of the p56lck protein tyrosine kinase by phenylarsine oxide, a phosphotyrosine phosphatase inhibitor.
Leukemia
Inhibition of Bcr-Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4-d]pyrimidines in Human Leukemia Cells.
Leukemia
Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.
Leukemia
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Leukemia
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Leukemia
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells.
Leukemia
Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model.
Leukemia
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Leukemia
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Leukemia
Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells.
Leukemia
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.
Leukemia
Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.
Leukemia
Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Leukemia
Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines.
Leukemia
Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient.
Leukemia
Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism.
Leukemia
Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor.
Leukemia
Isolation and characterization of flat revertant cell lines from A-MuLV-transformed fibroblasts.
Leukemia
JAK-STAT signaling pathway mediates astrogliosis in brains of scrapie-infected mice.
Leukemia
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Leukemia
JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.
Leukemia
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Leukemia
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
Leukemia
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Leukemia
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Leukemia
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Leukemia
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Leukemia
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.
Leukemia
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Leukemia
Kinase-Addiction and Bi-Phasic Sensitivity-Resistance of Bcr-Abl-and Raf-1-Expressing Cells to Imatinib and Geldanamycin.
Leukemia
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Leukemia
Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway.
Leukemia
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Leukemia
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Leukemia
Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Leukemia
Light microscopic detection of BCR-ABL transcripts after in-cell RT-PCR: fusion gene expression might correlate with clinical evolution of chronic myeloid leukemia.
Leukemia
Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors.
Leukemia
Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Leukemia
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
Leukemia
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.
Leukemia
Loss function of Bcr mutation causes gastrointestinal dysmotility and brain developmental defects.
Leukemia
Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts.
Leukemia
Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Leukemia
Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.
Leukemia
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Leukemia
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Leukemia
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Leukemia
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
Leukemia
MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.
Leukemia
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Leukemia
Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations.
Leukemia
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
Leukemia
miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R.
Leukemia
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Leukemia
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Leukemia
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Leukemia
Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming.
Leukemia
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Leukemia
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Leukemia
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Leukemia
Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Leukemia
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Leukemia
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Leukemia
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Leukemia
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Leukemia
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Leukemia
Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Leukemia
Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Leukemia
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Leukemia
Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.
Leukemia
Myeloid differentiation associated tyrosine protein kinase activity in WEHI-3B murine monomyelocytic leukemia cells.
Leukemia
N- and C-terminal isoforms of Arg quantified by real-time PCR are specifically expressed in human normal and neoplastic cells, in neoplastic cell lines, and in HL-60 cell differentiation.
Leukemia
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Leukemia
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.
Leukemia
Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.
Leukemia
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Leukemia
Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.
Leukemia
New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.
Leukemia
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Leukemia
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia
New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time.
Leukemia
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.
Leukemia
Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.
Leukemia
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Leukemia
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Leukemia
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Leukemia
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Leukemia
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Leukemia
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Leukemia
Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
Leukemia
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
Leukemia
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Leukemia
Nuclear lymphocyte-specific protein tyrosine kinase and its interaction with CR6-interacting factor 1 promote the survival of human leukemic T cells.
Leukemia
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Leukemia
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Leukemia
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Leukemia
On the cellular uptake and membrane effect of the multifunctional peptide, TatLK15.
Leukemia
Oncogene expression in Rauscher murine leukemia virus induced erythroid, myeloid and lymphoid cell lines.
Leukemia
Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.
Leukemia
Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Leukemia
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Leukemia
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Leukemia
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Leukemia
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Leukemia
Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.
Leukemia
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
Leukemia
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Leukemia
Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells.
Leukemia
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Leukemia
p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
Leukemia
p210(BCR-ABL) reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription.
Leukemia
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Leukemia
p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
Leukemia
Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
Leukemia
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Leukemia
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.
Leukemia
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Leukemia
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Leukemia
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Leukemia
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Leukemia
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Leukemia
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Leukemia
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Leukemia
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Leukemia
Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.
Leukemia
Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA.
Leukemia
Phosphorylation of ribosomal protein S6 on serine after microinjection of the Abelson murine leukemia virus tyrosine-specific protein kinase into Xenopus oocytes.
Leukemia
Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro.
Leukemia
PKC-?/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Leukemia
Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins.
Leukemia
Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells.
Leukemia
Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Leukemia
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene.
Leukemia
Potent antiproliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation.
Leukemia
Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase.
Leukemia
Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Leukemia
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Leukemia
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
Leukemia
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Leukemia
Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran.
Leukemia
Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.
Leukemia
Proposed Algorithm for the Best Detection of Different bcr-abl Gene Fusion Transcripts in Molecular Diagnostics Laboratories: Experience of a Major Referral Center.
Leukemia
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
Leukemia
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Leukemia
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Leukemia
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Leukemia
Proto-oncogene expression and dissection of the myeloid growth to differentiation developmental cascade.
Leukemia
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
Leukemia
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Leukemia
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Leukemia
Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus.
Leukemia
Purification and characterization of p93fes- and p60src-related tyrosine protein kinase activities in differentiated HL-60 leukemia cells.
Leukemia
Purinostat Mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia.
Leukemia
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Leukemia
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Leukemia
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Leukemia
Quantitative real time-polymerase chain reaction method in Bcr-Abl translocation diagnostics.
Leukemia
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Leukemia
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
Leukemia
Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Leukemia
Rearrangement of bcr and c-abl sequences in Ph-positive acute leukemias and Ph-negative CML--an update.
Leukemia
Rearrangement of the c-abl and bcr genes in Ph-negative CML and Ph-positive acute leukemias.
Leukemia
Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.
Leukemia
Recurring proviral integration suggests a role for proto-oncogene activation in thymomas induced with Mo-MuLV-rescued BCR/ABL virus.
Leukemia
Regional localization and developmental expression of the BCR gene in rodent brain.
Leukemia
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Leukemia
Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
Leukemia
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Leukemia
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
Leukemia
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Leukemia
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Leukemia
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Leukemia
Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice.
Leukemia
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Leukemia
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
Leukemia
RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Leukemia
RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Leukemia
Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.
Leukemia
Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture.
Leukemia
Roles of C-terminal Src kinase in the initiation and the termination of the high affinity IgE receptor-mediated signaling.
Leukemia
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Leukemia
Secondary activation of c-abl may be related to translocation to the nucleolar organizer region in an in vitro cultured rat leukemia cell line (K3D).
Leukemia
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Leukemia
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Leukemia
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Leukemia
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Leukemia
Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins.
Leukemia
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Leukemia
Self-renewal of embryonic stem cells through culture on nanopattern polydimethylsiloxane substrate.
Leukemia
Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Leukemia
Serum Inter-?-inhibitor activates the Yes tyrosine kinase and YAP/TEAD transcriptional complex in mouse embryonic stem cells.
Leukemia
Severe hyperlipemia-induced pseudoerythrocytosis - Implication for misdiagnosis and blood transfusion: A case report and literature review.
Leukemia
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Leukemia
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Leukemia
SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways.
Leukemia
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
Leukemia
Significance of the Philadelphia chromosome in acute leukemias: variable correlation with rearrangements involving the c-abl and bcr genes.
Leukemia
Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
Leukemia
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Leukemia
Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.
Leukemia
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Leukemia
Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Leukemia
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
Leukemia
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Leukemia
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Leukemia
Some lymphoid cell lines transformed by Abelson murine leukemia virus lack a major 36,000-dalton tyrosine protein kinase substrate.
Leukemia
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Leukemia
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Leukemia
Specificity of arachidonic acid-induced inhibition of growth and activation of c-jun kinases and p38 mitogen-activated protein kinase in hematopoietic cells.
Leukemia
Specificity of disease induced by M-MuLV chimeric retroviruses containing v-myc or v-src is not determined by the LTR.
Leukemia
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Leukemia
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
Leukemia
Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
Leukemia
SPR Detection and Discrimination of the Oligonucleotides Related to the Normal and the Hybrid bcr-abl Genes by Two Stringency Control Strategies.
Leukemia
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Leukemia
Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
Leukemia
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Leukemia
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.
Leukemia
Src family tyrosine kinase Lyn binds several proteins including paxillin in rat basophilic leukemia cells.
Leukemia
Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
Leukemia
ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
Leukemia
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Leukemia
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Leukemia
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Leukemia
Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields.
Leukemia
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Leukemia
Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential.
Leukemia
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.
Leukemia
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Leukemia
Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
Leukemia
Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells.
Leukemia
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Leukemia
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Leukemia
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Leukemia
Suppressor of cytokine signalling 4 (SOCS4): moderator of ovarian primordial follicle activation.
Leukemia
SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
Leukemia
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Leukemia
Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Leukemia
Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Leukemia
Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Leukemia
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Leukemia
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Leukemia
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Leukemia
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Leukemia
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Leukemia
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Leukemia
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Leukemia
TARGETS AND EFFECTORS OF THE CELLULAR RESPONSE TO AURORA KINASE INHIBITOR MK-0457 (VX-680) IN IMATINIB SENSITIVE AND RESISTANT CHRONIC MYELOGENOUS LEUKEMIA.
Leukemia
The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation.
Leukemia
The anti-apoptotic role of the unfolded protein response in Bcr-Abl-positive leukemia cells.
Leukemia
The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
Leukemia
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Leukemia
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Leukemia
The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells.
Leukemia
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Leukemia
The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
Leukemia
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Leukemia
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Leukemia
The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Leukemia
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
Leukemia
The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain.
Leukemia
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Leukemia
The emerging role of Bcr-Abl-induced cystoskeletal remodeling in systemic persistence of leukemic stem cells.
Leukemia
The Fab fragment of anti-IgE C?2 domain prevents allergic reactions through interacting with IgE-Fc?RI? complex on rat mast cells.
Leukemia
The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network.
Leukemia
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
Leukemia
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.
Leukemia
The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia.
Leukemia
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.
Leukemia
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Leukemia
The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.
Leukemia
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
Leukemia
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
Leukemia
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
Leukemia
The Philadelphia (Ph) chromosome in leukemia. I. A new mechanism due to interstitial deletion and insertion in chronic myelocytic leukemia.
Leukemia
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Leukemia
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Leukemia
The signaling axis atypical protein kinase C ?/?-Satb2 mediates leukemic transformation of B-cell progenitors.
Leukemia
The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.
Leukemia
The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Leukemia
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.
Leukemia
The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells.
Leukemia
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Leukemia
The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
Leukemia
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Leukemia
The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
Leukemia
Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia.
Leukemia
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Leukemia
Thrombopoietin acts synergistically with LIF to maintain an undifferentiated state of embryonic stem cells homozygous for a Shp-2 deletion mutation.
Leukemia
Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/p56lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells.
Leukemia
TNF? activates MAPK and Jak-Stat pathways to promote mouse Müller cell proliferation.
Leukemia
Tocotrienol-rich fraction from annatto ameliorates expression of lysyl oxidase in human osteoblastic MG-63 cells.
Leukemia
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Leukemia
Transcriptional activation of lck by retrovirus promoter insertion between two lymphoid-specific promoters.
Leukemia
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Leukemia
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Leukemia
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Leukemia
Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes.
Leukemia
Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
Leukemia
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.
Leukemia
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
Leukemia
Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Leukemia
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
Leukemia
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Leukemia
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Unperturbed immune function despite mutation of C-terminal tyrosines in Syk previously implicated in signaling and activity regulation.
Leukemia
Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
Leukemia
Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila.
Leukemia
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Leukemia
What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?
Leukemia
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Leukemia
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Leukemia
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Leukemia
[A Modified Protocol for Rapid Establishing Mouse Model with Ph+ Positive Acute Lymphoblastic Leukemia].
Leukemia
[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes]
Leukemia
[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]
Leukemia
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.]
Leukemia
[Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia]
Leukemia
[Clinical Analysis of 12 Cases of Acute Myeloid Leukemia with Ph Chromosome and BCR-ABL Positive].
Leukemia
[Clinical and laboratorial analysis for 15 adult cases of mixed phenotypic acute leukemia with Ph chromosome and/or positive BCR-ABL].
Leukemia
[Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile]
Leukemia
[Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications]
Leukemia
[Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction]
Leukemia
[Effect of methylation inhibitor on EphB4 gene expression, proliferation and apoptosis in CEM cells].
Leukemia
[Effect of Stably Down-regulating FMI Expression of K562 Cells on Sensitivity of K562 cells to Imatinib Mesylate].
Leukemia
[Expression and Clinical Significance of Focal Adhesion Kinase in Patients with Acute Leukemia].
Leukemia
[Expression of the Wilms' Tumor Gene WT1 and Detection of Minimal Residual Disease in Acute Leukemia]
Leukemia
[Identification bcr-abl fusion gene in leukemia cells with oligonucleotide microarray]
Leukemia
[Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
Leukemia
[Molecular detection of the BCR-ABL gen by RT-PCR in Costa Rican children with leukemia]
Leukemia
[Quality assurance of the molecular diagnostic tests in hematological malignancies]
Leukemia
[Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia]
Leukemia
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
Leukemia
[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
Leukemia
[Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl.]
Leukemia
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
Leukemia
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
Leukemia
[The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells]
Leukemia
[The role of EGF receptor-dependent e3B1/Abi1 protein as a tumor suppressor protein in malignant tumors]
Leukemia, B-Cell
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Leukemia, B-Cell
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Leukemia, B-Cell
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Leukemia, B-Cell
ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
Leukemia, Basophilic, Acute
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Leukemia, Biphenotypic, Acute
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
Leukemia, Biphenotypic, Acute
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Leukemia, Biphenotypic, Acute
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.]
Leukemia, Erythroblastic, Acute
?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
Leukemia, Erythroblastic, Acute
A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation.
Leukemia, Erythroblastic, Acute
A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells.
Leukemia, Erythroblastic, Acute
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
Leukemia, Erythroblastic, Acute
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
Leukemia, Erythroblastic, Acute
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Leukemia, Erythroblastic, Acute
Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells.
Leukemia, Erythroblastic, Acute
Friend Spleen Focus-Forming Virus Activates the Tyrosine Kinase sf-Stk and the Transcription Factor PU.1 to Cause a Multi-Stage Erythroleukemia in Mice.
Leukemia, Erythroblastic, Acute
Increased ERK phosphorylation and caveolin-1 expression on K562 human chronic myelogenous leukemia cells by jacalin, a dietary plant lectin.
Leukemia, Erythroblastic, Acute
Methylation status of RASSF1A in patients with chronic myeloid leukemia.
Leukemia, Erythroblastic, Acute
Mutation of the Lyn tyrosine kinase delays the progression of Friend virus induced erythroleukemia without affecting susceptibility.
Leukemia, Erythroblastic, Acute
NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
Leukemia, Erythroblastic, Acute
Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
Leukemia, Erythroblastic, Acute
Sustained mitogenic effect on K562 human chronic myelogenous leukemia cells by dietary lectin, jacalin.
Leukemia, Erythroblastic, Acute
v-abl activates embryonic globin gene expression in mouse erythroleukemia cells.
Leukemia, Feline
Colony stimulating factor-1 induced growth stimulation of v-fms transformed fibroblasts.
Leukemia, Feline
Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene.
Leukemia, Feline
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Leukemia, Feline
Nucleotide sequence of the feline retroviral oncogene v-fms shows unexpected homology with oncogenes encoding tyrosine-specific protein kinases.
Leukemia, Feline
The amino-terminal domain of the v-fms oncogene product includes a functional signal peptide that directs synthesis of a transforming glycoprotein in the absence of feline leukemia virus gag sequences.
Leukemia, Hairy Cell
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Leukemia, Hairy Cell
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Leukemia, Large Granular Lymphocytic
Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Leukemia, Lymphocytic, Chronic, B-Cell
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Leukemia, Lymphocytic, Chronic, B-Cell
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Leukemia, Lymphocytic, Chronic, B-Cell
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Activity of the janus kinase inhibitor Ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
Leukemia, Lymphocytic, Chronic, B-Cell
Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Leukemia, Lymphocytic, Chronic, B-Cell
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Leukemia, Lymphocytic, Chronic, B-Cell
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Leukemia, Lymphocytic, Chronic, B-Cell
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Leukemia, Lymphocytic, Chronic, B-Cell
BTK Inhibitors, Irrespective of ITK Inhibition, Increase Efficacy of a CD19/CD3 Bispecific Antibody in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Leukemia, Lymphocytic, Chronic, B-Cell
c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Leukemia, Lymphocytic, Chronic, B-Cell
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
Changing landscape of frontline therapy in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined BTK and PI3K? Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Cortactin, another player in the Lyn signaling pathway, is overexpressed and alternatively spliced in leukemic cells from patients with B-cell Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Leukemia, Lymphocytic, Chronic, B-Cell
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.
Leukemia, Lymphocytic, Chronic, B-Cell
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Leukemia, Lymphocytic, Chronic, B-Cell
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Detection methods of ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Detection of ZAP-70 in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70.
Leukemia, Lymphocytic, Chronic, B-Cell
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.
Leukemia, Lymphocytic, Chronic, B-Cell
Discordance of ZAP-70 in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied.
Leukemia, Lymphocytic, Chronic, B-Cell
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of ibrutinib on humoral dysfunction in patients with chronic lymphocytic leukemia: A single-center experience.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Leukemia, Lymphocytic, Chronic, B-Cell
Elevated IL-17A and IL-22 regulate expression of inducible CD38 and Zap-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Leukemia, Lymphocytic, Chronic, B-Cell
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.
Leukemia, Lymphocytic, Chronic, B-Cell
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Expression feature of CD3, Fc?RI?, and Zap-70 in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of BTK/p-BTK is different between CD5+ and CD5- B lymphocytes from Autoimmune Hemolytic Anemia/Evans syndromes.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Leukemia, Lymphocytic, Chronic, B-Cell
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: a methodological approach.
Leukemia, Lymphocytic, Chronic, B-Cell
Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Leukemia, Lymphocytic, Chronic, B-Cell
Flow Cytometric Analysis of ZAP-70 Protein Expression for B-Cell Chronic Lymphocytic Leukemia Prognostication: Usefulness and Limitations.
Leukemia, Lymphocytic, Chronic, B-Cell
Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC? subversion induces an upregulation of PKC?II expression in B lymphocytes.
Leukemia, Lymphocytic, Chronic, B-Cell
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker?
Leukemia, Lymphocytic, Chronic, B-Cell
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Leukemia, Lymphocytic, Chronic, B-Cell
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Hydroa Vacciniforme-Like Lymphoproliferative Disorder in an Adult Patient With Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib dose modifications in the management of CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib for treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5?years on.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin ?IIb?3 in mice and humans.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-induced acute kidney injury via interstitial nephritis.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
Leukemia, Lymphocytic, Chronic, B-Cell
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Leukemia, Lymphocytic, Chronic, B-Cell
Improved flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia using experimentally optimized isotypic control antibodies.
Leukemia, Lymphocytic, Chronic, B-Cell
In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.
Leukemia, Lymphocytic, Chronic, B-Cell
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Invasive Fungal Infection Complicating Treatment With Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status.
Leukemia, Lymphocytic, Chronic, B-Cell
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Leukemia, Lymphocytic, Chronic, B-Cell
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Leukemia, Lymphocytic, Chronic, B-Cell
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse.
Leukemia, Lymphocytic, Chronic, B-Cell
Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Leukemia, Lymphocytic, Chronic, B-Cell
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Leukemia, Lymphocytic, Chronic, B-Cell
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Managing toxicities of Bruton tyrosine kinase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression.
Leukemia, Lymphocytic, Chronic, B-Cell
Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Leukemia, Lymphocytic, Chronic, B-Cell
Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.
Leukemia, Lymphocytic, Chronic, B-Cell
Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Leukemia, Lymphocytic, Chronic, B-Cell
Non-catalytic Bruton's tyrosine kinase activates PLC?2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Leukemia, Lymphocytic, Chronic, B-Cell
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Optimization of flow cytometric measurement of ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation.
Leukemia, Lymphocytic, Chronic, B-Cell
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Leukemia, Lymphocytic, Chronic, B-Cell
Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Leukemia, Lymphocytic, Chronic, B-Cell
Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study.
Leukemia, Lymphocytic, Chronic, B-Cell
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Leukemia, Lymphocytic, Chronic, B-Cell
p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
Leukemia, Lymphocytic, Chronic, B-Cell
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Leukemia, Lymphocytic, Chronic, B-Cell
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Profound Sinoatrial Arrest Associated with Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic value of lipoprotein lipase expression among egyptian B-chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome.
Leukemia, Lymphocytic, Chronic, B-Cell
Real--world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program.
Leukemia, Lymphocytic, Chronic, B-Cell
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.
Leukemia, Lymphocytic, Chronic, B-Cell
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Leukemia, Lymphocytic, Chronic, B-Cell
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Leukemia, Lymphocytic, Chronic, B-Cell
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Leukemia, Lymphocytic, Chronic, B-Cell
Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Leukemia, Lymphocytic, Chronic, B-Cell
SLP76 integrates into the B-Cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with aggressive disease course.
Leukemia, Lymphocytic, Chronic, B-Cell
Smudge cell percentage as a surrogate marker for ZAP-70 expression in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Leukemia, Lymphocytic, Chronic, B-Cell
T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression.
Leukemia, Lymphocytic, Chronic, B-Cell
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeted drugs in concert with chemo: opposites attract.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Leukemia, Lymphocytic, Chronic, B-Cell
Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
Leukemia, Lymphocytic, Chronic, B-Cell
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Leukemia, Lymphocytic, Chronic, B-Cell
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Leukemia, Lymphocytic, Chronic, B-Cell
The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Leukemia, Lymphocytic, Chronic, B-Cell
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NF?B inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Leukemia, Lymphocytic, Chronic, B-Cell
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
The Phospholipase C-?2 Mutants R665W and L845F Identified in Ibrutinib-Resistant Chronic Lymphocytic Leukemia Patients are Hypersensitive to the Rho GTPase Rac2.
Leukemia, Lymphocytic, Chronic, B-Cell
THE PROGNOSTIC SIGNIFICANCE OF COMBAIND EXPRESSION OF ZAP-70 AND CD38 IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Leukemia, Lymphocytic, Chronic, B-Cell
The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents.
Leukemia, Lymphocytic, Chronic, B-Cell
Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse.
Leukemia, Lymphocytic, Chronic, B-Cell
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Leukemia, Lymphocytic, Chronic, B-Cell
US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
Leukemia, Lymphocytic, Chronic, B-Cell
Using high-sensitivity sequencing for the detection of mutations in BTK and PLC?2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review.
Leukemia, Lymphocytic, Chronic, B-Cell
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase.
Leukemia, Lymphocytic, Chronic, B-Cell
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 in chronic lymphocytic leukemia: A meta-analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 methylation and expression status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
[Abnormality of serum immunoglobulin in peripheral blood of patients with chronic lymphocytic leukemia.]
Leukemia, Lymphocytic, Chronic, B-Cell
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
Leukemia, Lymphocytic, Chronic, B-Cell
[Immunohistochemical detection of ZAP-70 protein and its importance in the diagnostics of B-CLL]
Leukemia, Lymphocytic, Chronic, B-Cell
[Molecular diagnosis of and molecular targeting therapy for leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
[Prognostic significance of telomere length in patients with chronic lymphocytic leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
Leukemia, Lymphocytic, Chronic, B-Cell
[ZAP-70 expression in 24 patients with B cell chronic lymphocytic leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
[ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection]
Leukemia, Lymphoid
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
Leukemia, Lymphoid
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
Leukemia, Lymphoid
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
Leukemia, Lymphoid
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
Leukemia, Lymphoid
Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Leukemia, Lymphoid
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia, Lymphoid
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Leukemia, Lymphoid
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
Leukemia, Lymphoid
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.
Leukemia, Lymphoid
Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia.
Leukemia, Lymphoid
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Leukemia, Lymphoid
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Leukemia, Lymphoid
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Leukemia, Lymphoid
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Leukemia, Lymphoid
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Leukemia, Lymphoid
T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk.
Leukemia, Lymphoid
Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia.
Leukemia, Lymphoid
ZAP-70 Protein Expression in B-cell Chronic Lymphoid Leukemia: a Single Center Experience from Pakistan.
Leukemia, Lymphoid
[Expression of c-fes gene in leukemia cells and its clinical significance]
Leukemia, Lymphoid
[Expression of CLLU1 in patients with chronic lymphocytic leukemia and its prognostic significance]
Leukemia, Megakaryoblastic, Acute
Association between Lyn protein tyrosine kinase (p53/56lyn) and the beta subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human megakaryocytic leukemia cell line (M-07e).
Leukemia, Megakaryoblastic, Acute
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Leukemia, Megakaryoblastic, Acute
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Leukemia, Megakaryoblastic, Acute
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
"Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1,3-Butadiene metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22) translocations in human cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14-3-3 LIGAND PREVENTS NUCLEAR IMPORT OF C-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Bead-Based Activity Screen for Small-Molecule Inhibitors of Signal Transduction in Chronic Myelogenous Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Case of Childhood Blastic Phase Chronic Myeloid Leukemia With Minor BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A common phosphotyrosine signature for the Bcr-Abl kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A complex three-way translocation with deletion of the TP53 gene in a blast crisis chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A historical overview of protein kinases and their targeted small molecule inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Multiple Reaction Monitoring (MRM) Method to Detect Bcr-Abl Kinase Activity in CML Using a Peptide Biosensor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A NEW NON-PEPTIDIC INHIBITOR OF THE 14-3-3 DOCKING SITE INDUCES APOPTOTIC CELL DEATH IN CHRONIC MYELOID LEUKEMIA SENSITIVE OR RESISTANT TO IMATINIB.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel BCR-ABL fusion transcript (e18a2) in a child with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel fusion circular RNA F-circBA1 derived from the BCR-ABL fusion gene displayed an oncogenic role in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A peptide biosensor for detecting intracellular Abl kinase activity using MALDI-TOF MS.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Ph-negative chronic myeloid leukemia patient with a non-classical BCR-ABL rearrangement characterized by fluorescence in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Pipeline for Drug Target Identification and Validation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A research-inspired laboratory sequence investigating acquired drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A role for c-Abl in cell senescence and spontaneous immortalization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A screen to identify drug resistant variants to target-directed anti-cancer agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Src-like inactive conformation in the abl tyrosine kinase domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aberrant BCR-ABL transcript with intronic insertion in a patient with philadelphia chromosome-positive chronic myeloid leukemia: implications for disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activated c-Abl tyrosine kinase in malignant solid tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of bcr-abl fusion gene and ras oncogenes in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Advances in Immunotherapy of Chronic Myeloid Leukemia CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Advances in targeted therapy for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aleukemic bcr-abl positive granulocytic sarcoma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic stem cell transplants in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosteric Inhibition of Bcr-Abl Kinase by High-Affinity Monobody Inhibitors Directed to the SH2-Kinase Interface.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosterically controlled single-chained maxizymes with extremely high and specific activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alternative expression of TCR? related genes in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An ent-Kaurane Diterpenoid Isolated from Rabdosia excisa Suppresses Bcr-Abl Protein Expression in Vitro and in Vivo and Induces Apoptosis of CML Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analogs, formulations and derivatives of imatinib: a patent review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-related sequence in human DNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/?-catenin signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of FISH to complex chromosomal rearrangements associated with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Applying the discovery of the Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Assessment of Oxidative Stress in Patients with Chronic Myeloid Leukemia Depending on Associated Comorbidities.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bacterial expression and purification of active hematopoietic cell kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bag1 directly routes immature BCR-ABL for proteasomal degradation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR gene recombines with genomically distinct sites on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL breakpoint and prognosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL in chronic myelogenous leukemia--how does it work?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl induced tyrosine phosphorylation of emi1 to stabilize skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl induces autocrine IGF-1 signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL insufficiency for the transformation of human stem cells into CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutations in chronic myeloid leukemia - not only detection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutations in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of ?-catenin and STAT1 in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl RNA in patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-Abl Silencing by Short Interfering RNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA end processing factor CtIP.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL translocation in a dog with chronic monocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562?cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Benchmarking 2D/3D/MD-QSAR Models for Imatinib Derivatives: How Far Can We Predict?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Betulinic acid induces apoptosis in human chronic myelogenous leukemia (CML) cell line K-562 without altering the levels of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biological therapy for pediatric malignancy: current perspectives.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology and treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology and treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib in the management of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib treatment for Philadelphia chromosome-positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bothrops moojeni L-amino acid oxidase induces apoptosis and epigenetic modulation on Bcr-Abl+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl in oxidative stress, aging and cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-abl Oncogene and chromosome 22 "bcr" juxtaposition in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl-dependent Molecular Circuitry Involving Smad5 and Phosphatidylinositol 3-Kinase Regulates Bone Morphogenetic Protein-2-induced Osteogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C/EBP? is a critical mediator of IFN-?-induced exhaustion of chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C/EBP? promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C3G forms complexes with Bcr-Abl and p38? MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CaMKII ?, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can clues to the molecular defects in chronic myelogenous leukemia come from genetic studies on the Abelson tyrosine kinase in fruit flies?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CCN3 - A key regulator of the hematopoietic compartment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changing the subcellular location of the oncoprotein bcr-abl using rationally designed capture motifs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization and selection of benign stem cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of dasatinib and its structural analogs as CYP3A4 mechanism based inactivators and the proposed bio-activation pathways.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Charting the molecular network of the drug target Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chibby drives ? catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chitosan encapsulated quantum dots platform for leukemia detection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC???
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal approaches to the molecular basis of neoplasia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal in situ hybridization and Southern blot analyses using c-abl, c-sis, or bcr probe in chronic myelogenous leukemia cells with variant Philadelphia translocations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: Effect of vascular endothelial growth factor on development of the microenvironment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: biology and therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: mechanisms underlying disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: treatment and monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells and developing therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with p210 BCR-ABL and monocytosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with unusual variant Ph translocation (22;22)(q11;q13). Two cases with chimeric BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: Existing therapeutic options and strategies to overcome drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: overview of new agents and comparative analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: past, present, future.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: reminiscences and dreams.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: state of the art in 2012.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CircBA1 derived from BCR-ABL fusion gene inhibits cell proliferation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical development of imatinib: an anticancer drug.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical experience to date with nilotinib in gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinico-hematological profile in biphenotypic acute leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Commonly used drugs in hematologic disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational and Biological Investigations on Abl1 Tyrosine Kinase: A Review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Conventional and fluorescence in situ hybridization analysis of three-way complex BCR-ABL rearrangement in a chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crosstalk between CML cells with HUVECS and BMSCs through CML derived exosomes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cryptotanshinone suppresses key onco-proliferative and drugresistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current status of agents active against the T315I chronic myeloid leukemia phenotype.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current status of vaccination therapy for leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current therapy of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetic and molecular genetic aspects of essential thrombocythemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetic and molecular mechanisms of resistance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib in chronic myeloid leukemia: a review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib: a new step in molecular target therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
De novo Philadelphia chromosome positive myelodysplastic syndrome: Report of two cases with brief literature review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deciphering the internal complexity of living cells with quantitative phase microscopy: a multiscale approach.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Delayed cytogenetic response with prolonged interferon-alpha treatment in chronic myeloid leukemia patients: quantification of BCR-ABL transcript by competitive reverse transcription-polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deletion of the derivative chromosome 9 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr-abl fusion gene in Chronic Myeloid Leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Denbinobin-mediated anticancer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dendritic cell vaccination for patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Depletion of ?-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Depletion of pleckstrin homology domain leucine-rich repeat protein phosphatase 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Design, Synthesis, and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of bcr-abl fusion mRNA in chronic myelogenous leukemia by reverse transcription polymerase chain reaction using nested primers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL mutations and resistance to imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of bcr/c-abl mRNA in chronic myelogenous leukemia by polymerase chain reaction to identify chromosome translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of Philadelphia chromosome-positive cells from glass slide smears using the polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Detection of tyrosine protein kinase substrates in fresh leukemia cells and normal blood cells using an immunoblotting technique.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of a rapid and sensitive one-step reverse transcription-nested polymerase chain reaction in a single tube using the droplet-polymerase chain reaction machine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of an integrated assay for detection of BCR-ABL RNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diagnostic utility of oncogenes and their products in human cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differential effects of tumor promoters on P210bcr-abl expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disappearance of Ph1 chromosome with intensive chemotherapy and detection of minimal residual disease by polymerase chain reaction in a patient with blast crisis of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diversity of Long-Lived Intermediates along the Binding Pathway of Imatinib to Abl Kinase Revealed by MD Simulations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse post bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Down-regulation of thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dual tyrosine kinase inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of As(2)O(3) on BCR-ABL protein level and signal transduction in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of herbimycin A derivatives on growth and differentiation of K562 human leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of imatinib on bone marrow engraftment in syngeneic mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emerging drugs for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enhanced SH3/Linker Interaction Overcomes Abl Kinase Activation by Gatekeeper and Myristic Acid Binding Pocket Mutations and Increases Sensitivity to Small Molecule Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Erratum: BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Estimation of the distribution of longitudinal biomarker trajectories prior to disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evaluation of the Cepheid GeneXpert BCR-ABL assay.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ever-advancing chronic myeloid leukemia treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expanding the diversity of allosteric bcr-abl inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of inducible NOS is indispensable for the antiproliferative and proapoptotic effect of imatinib in BCR-ABL positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
First-line therapy for chronic myeloid leukemia: Past, present, and future.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
FLT3 as a therapeutic target in childhood acute leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Four-channel asymmetric Real-Time PCR hybridization probe assay: A rapid pre-screening method for critical BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
From 'Targeted Therapy' to Targeted Therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
From xeroderma pigmentosum to the biological clock contributions of Dirk Bootsma to human genetics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional genomics of hTERT gene in leukemic myelopoiesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fusion FISH Imaging: Single-Molecule Detection of Gene Fusion Transcripts In Situ.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene expression signatures associated with the resistance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene therapy for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genomic targeting and genetic conversion in cancer therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in k562 human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Growth arrest specific 2 is up-regulated in chronic myeloid leukemia cells and required for their growth.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Growth factor-mediated terminal differentiation of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hedgehog pathway activation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematological and molecular response evaluation of CML patients on imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematopoietic stem cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HLA risk markers for chronic myelogenous leukemia in Eastern Canada.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hsp90 inhibitors as selective anticancer drugs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human leukocyte antigens in Indian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hypereosinophilia associated with monosomy 7.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of BCR-ABL fusion on chromosome 9 by fluorescence in situ hybridization in two chronic myeloid leukemia cases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of Natural inhibitors of Bcr-Abl for the treatment of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of several genes differentially expressed during progression of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identification of TopBP1 as a c-Abl-interacting protein and a repressor for c-Abl expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib and its successors--how modern chemistry has changed drug development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib as a paradigm of targeted therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K(+) channels in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib in Chronic Myeloid Leukemia: an Overview.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate for the treatment of pulmonary arterial hypertension.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate in children and adolescents with cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib resistance in gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib use during pregnancy and breast feeding: a case report and review of the literature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib-Induced Changes in Protein Expression and ATP-Binding Affinities of Kinases in Chronic Myelocytic Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immunohistochemical characterization of cutaneous drug eruptions by STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In defense of the somatic mutation theory of cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In Search of CML Stem Cells' Deadly Weakness.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vivo differentiation of blast-phase chronic granulocytic leukemia. Expression of c-myc and c-abl protooncogenes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Increased expression of a novel c-abl-related RNA in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of autophagy by imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of BCR-ABL fusion genes by in vitro X-irradiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Induction of p53 suppresses chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of autophagy augments the anticancer activity of ?-mangostin in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of protein tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Insight into the allosteric inhibition of Abl kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Integrative analyses for omics data: a Bayesian mixture model to assess the concordance of ChIP-chip and ChIP-seq measurements.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Integrin engagement-induced inhibition of human myelopoiesis is mediated by proline-rich tyrosine kinase 2 gene products.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon alpha and T-cell responses in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon in the treatment of myeloproliferative diseases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intramolecular Dynamics within the N-Cap-SH3-SH2 Regulatory Unit of the c-Abl Tyrosine Kinase Reveal Targeting to the Cellular Membrane.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Investigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Investigation of bcr-abl transcription by Ph-positive chronic myeloid leukemia progenitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Involvement of Oxidative Stress in Resistance to Tyrosine-Kinase Inhibitors Therapy in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is going for cure in chronic myeloid leukemia possible and justifiable?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is going for cure in CML targeting aberrant Glycogen Synthase Kinase 3??
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is there horizontal transfer of the oncogene BCR-ABL mediated by extracellular vesicles released by chronic myeloid leukemia cells?: PS203.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
JAK2V617F Mutation in Chronic Myeloid Leukemia Predicts Early Disease Progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Janus kinase 2: a critical target in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
K356dup - an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase drug discovery approaches in chronic myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase inhibitors translate lab discoveries into exciting new cures for cancers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lack of Bcr-Abl point mutations in imatinib chronic myeloid leukemia patients in chronic phase before initiation of treatment is not predictive of response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia stem cells in a genetically defined murine model of blast-crisis CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia Stem Cells in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia stem cells: the root of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia: stem cells, maturation arrest, and differentiation therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34(+)CD38(-) stem and progenitor cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Light microscopic detection of BCR-ABL transcripts after in-cell RT-PCR: fusion gene expression might correlate with clinical evolution of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Limited synergistic effect of antisense oligonucleotides against bcr-abl and transferrin receptor mRNA in leukemic cells in culture.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lineage-specific requirement of c-abl function in normal hematopoiesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Liposomal delivery of oligodeoxynucleotides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Localization of BCR-ABL to Stress Granules Contributes to Its Oncogenic Function.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Localization of the human c-sis oncogene in Ph1-positive and Ph1-negative chronic myelocytic leukemia by in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Location of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long term outcome of chronic myeloid leukemia patients treated with imatinib: Report from a developing country.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Loss of Gadd45b accelerates BCR-ABL-driven CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Management of chronic myeloid leukemia in blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Maximal entropy inference of oncogenicity from phosphorylation signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mean residual life regression with functional principal component analysis on longitudinal data for dynamic prediction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms and impacts of chromosomal translocations in cancers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Metal chelator TPEN selectively induces apoptosis in K562 cells through reactive oxygen species signaling mechanism: implications for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Microarray analysis reveals distinct immune signatures in BCR-ABL positive and negative myeloproliferative neoplasms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Microparticle-based RT-qPCR for highly selective rare mutation detection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
miR-155 effectively induces apoptosis in K562 Philadelphia positive cell line through upregulation of p27kip1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Miscreant myeloproliferative disorder stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Missing Y chromosome in Ph1-negative chronic myeloid leukemia with bcr rearrangement. Evidence for a bcr-abl recombination on chromosome 22 by in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mixed myelodysplastic and myeloproliferative syndromes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Modeling the low-LET dose-response of BCR-ABL formation: predicting stem cell numbers from A-bomb data.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Modulating autophagy for therapeutic benefit.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular biology of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular characteristics of chronic myelogenous leukemia in blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular cloning of a human immunoglobulin lambda chain variable sequence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular confirmation of BCR-ABL fusion in a chronic myeloid leukemia with a complex translocation involving chromosomes 9, 15, and 22.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular demonstration of BCR/ABL fusion in two cases with chronic myeloproliferative disorder carrying variant Philadelphia t(14;22)(q32;q11).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular diagnosis of chronic myeloid leukemia using a 3'bcr probe.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular interactions in imatinib-DPPC liposomes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular mechanisms of Bcr-Abl-induced oncogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular mechanisms of transformation by the BCR-ABL oncogene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Monitoring of BCR-ABL Fusion Transcripts in Patients with Chronic Myeloid Leukemia During Treatment Using the Endpoint Fluorescence Method.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular monitoring of Tunisian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular oncology: current trends in diagnostics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular profiling of chronic myeloid leukemia in eastern India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular research directions in the management of gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular signatures of chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular targets in acute myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecularly targeted therapy for gastrointestinal cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring response and resistance to treatment in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mosaicicm in bcr-abl protein expression in B cells in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multidomain Targeting of Bcr-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multidrug resistance in chronic myeloid leukemia: How much can we learn from MDR - CML cell lines?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutant BCR-ABL clones in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutated BCR-ABL Generates Immunogenic T Cell Epitopes In CML Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Natural product origins of Hsp90 inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Naturally occurring CD4(+) CD25(+) FOXP3(+) T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NCCN and ELN: What do the guidelines tell us?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New agents in the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New approved dasatinib regimen available for clinical use.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New insights into small-molecule inhibitors of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New lanthanum (III) complex--synthesis, characterization, and cytotoxic activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New Methodologies in the Molecular Monitoring of CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New Oral Anti-Cancer Drugs and Medication Safety.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New strategies in controlling drug resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
new Strategies in Controlling drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NF-?B suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NF?B pathway and microRNA-9 and -21 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib (AMN107, Tasigna((R))) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib based pharmacophore models for BCRABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib therapy in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib-induced liver injury: A case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib-induced panniculitis in a patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib: a novel, selective tyrosine kinase inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No evidence for genomic imprinting of the human BCR gene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel conventional therapies in onco-hemathology.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel therapies for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel therapies for patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
On the topology of normal chromatids and on their translocations in myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Opening the door to the development of novel Abl kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimized Digital Droplet PCR for BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimizing therapy of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Origin of hematopoietic progenitor cells after bone marrow transplantation: analysis by means of a Y-chromosome specific DNA probe.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overcoming resistance in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overcoming Resistance to Targeted Therapies in Cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p210bcr-abl induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pediatric malignancies provide unique cancer therapy targets.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pepsi® or Coke®? Influence of acid on dasatinib absorption.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Peripheral blood progenitor cells mobilized early at diagnosis in patients with chronic myelogenous leukemia contain very low amounts of BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Perspectives on the development of a molecularly targeted agent.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia chromosome as the sole abnormality and p210 bcr-abl chimeric protein expression in an Epstein-Barr virus-transformed B cell line from a patient with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia negative, Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia-positive acute leukemia: lineage promiscuity and inconsistently rearranged breakpoint cluster region.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk(348)) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Physiological signals and oncogenesis mediated through Crk family adapter proteins.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PKC-?/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polycythemia vera masked due to severe iron deficiency anemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymorphism of the human c-abl gene: relation to incidence and course of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib-induced neutrophilic panniculitis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Possible correlation of b3-a2-type bcr-abl messenger RNA defined by semiquantitative RT-PCR to platelet and megakaryocyte counts in Philadelphia-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Possible evidence for acquired genetic activity at both chromosomal breakpoints of the Philadelphia translocation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Potential role of Wnt/?-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between ?-catenin and BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Practical management of dasatinib for maximum patient benefit.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Presence of P210bcrabl is associated with decreased expression of a beta chemokine C10 gene in a P210bcrabl-positive myeloid leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prevention of product carry-over by single tube two-round (ST-2R) PCR: application to BCR-ABL analysis in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Priapismus as Leukostasis Manifestation in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Probing of the secondary structure of maxizymes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib.
A First of Its Kind Study on CML Patients of Kashmir
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prognostic significance of BCR-ABL rearrangement in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prognostic significance of c-ABL methylation in chronic myelogenous leukemia: still an open question.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prolonged preleukemic phase of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein tyrosine kinases: autoregulation and small-molecule inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteins phosphorylated on tyrosine as markers of human tumor cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pyrrolo-1,5-Benzoxazepines Induce Apoptosis in Chronic Myeloid Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Qualitative and quantitative evaluation of the BCR-ABL fusion gene in chronic myelogenous leukemia by flourescence in situ hybridization and molecular genetic methods.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio values.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative Proteomics Analysis of Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative- and Phospho-Proteomic Analysis of the Yeast Response to the Tyrosine Kinase Inhibitor Imatinib to Pharmacoproteomics-Guided Drug Line Extension.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantum dots self assembly based interface for blood cancer detection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rapid quantitative detection of the T315I mutation in patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: The threats and challenges in monitoring minimal residual disease (MRD).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rare frameshift mutation Cys475Tyrfs(*)11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ras as a therapeutic target in hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rational therapeutic intervention in cancer: kinases as drug targets.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Re-arrangements of podosome structures are observed when Hck is activated in myeloid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rearrangement of PDGFR? gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rearrangements of immunoglobulin- and BCR-genes in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recent advancements in the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reduced exposure of imatinib after coadministration with acetaminophen in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulating Apoptosis by Degradation: The N-End Rule-Mediated Regulation of Apoptotic Proteolytic Fragments in Mammalian Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulation of the Fas apoptotic cell death pathway by Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rejoining between 9q+ and Philadelphia chromosomes results in normal-looking chromosomes 9 and 22 in Ph1-negative chronic myelocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Relationship between the type of BCR-ABL rearrangement and bone marrow histopathological features in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Relationship of serum imatinib trough level and response in CML patients: Long term follow-up.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Renal tuberculosis in an imatinib-treated chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reproductive fitness advantage of BCR-ABL expressing leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Requirement of lipocalin 2 for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Resistance in the land of molecular cancer therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Resistance to imatinib: mechanisms and management.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Resistance to targeted therapy in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Restoration of energy metabolism in leukemic mice treated by a siddha drug--Semecarpus anacardium Linn. nut milk extract.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
RNA quantification using gold nanoprobes - application to cancer diagnostics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
RNA quantification using noble metal nanoprobes: simultaneous identification of several different mRNA targets using color multiplexing and application to cancer diagnostics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
RNA Quantification Using Noble Metal Nanoprobes: Simultaneous Identification of Several Different mRNA Targets Using Color Multiplexing and Application to Chronic Myeloid Leukemia Diagnostics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of cancer immunology in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of Dok-1 and Dok-2 in leukemia suppression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of protein tyrosine kinase inhibitors in cancer therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of STAT3 in Transformation and Drug Resistance in CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of the hybrid Bcr/Abl kinase in the pathogenesis of chronic myeloid leukemia lacking C-Abl and CXCR4 proteins.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ROLES OF INTERFERON REGULATORY FACTORS IN CHRONIC MYELOID LEUKEMIA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Roots of imatinib resistance: A question of self-renewal?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ruxolitinib induces autophagy in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
S100A8 may govern hyper-inflammation in severe COVID-19.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
S6K1 determines the metabolic requirements for BCR-ABL survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Safranal, a Crocus sativus L constituent suppresses the growth of K-562 cells of chronic myelogenous leukemia. In silico and in vitro study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Secondary malignancy after imatinib therapy: Eight cases and review of the literature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Secretion of IL-1? from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective leukemia cell death by activation of the double-stranded RNA-dependent protein kinase PKR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Signal transduction inhibitors (STI571): molecularly targeted therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Single-cell analysis of K562 cells: An imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SIRT1 and LSD1 competitively regulate KU70 functions in DNA repair and mutation acquisition in cancer cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Small-Molecule Screening for Genetic Diseases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Somatic mutations and the hierarchy of hematopoiesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Some questions on the significance of chromosome alterations in leukemias and lymphomas: a review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Specific inhibition of bcr-abl gene expression by small interfering RNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Specificity of arachidonic acid-induced inhibition of growth and activation of c-jun kinases and p38 mitogen-activated protein kinase in hematopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Spotlight on imatinib mesylate in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cell persistence in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem-cell driven cancer: "hands-off" regulation of cancer development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI-571: an anticancer protein-tyrosine kinase inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI571 (Gleevec) as a paradigm for cancer therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI571: a gene product-targeted therapy for leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI571: a paradigm of new agents for cancer therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
STI571: targeting BCR-ABL as therapy for CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural characterization of the BCR gene product.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structure and dynamic regulation of abl kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structure of the ABL2/ARG kinase in complex with dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structure of the Bcr-Abl oncoprotein oligomerization domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Studying the enhancement of programmed cell death by combined AG1024 and paclitaxel in a model of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SUPPRESSION OF SURVIVIN INDUCED BY A BCR-ABL/JAK2/STAT3 PATHWAY SENSITIZES IMATINIB RESISTANT CML CELLS TO DIFFERENT CYTOTOXIC DRUGS.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Surrogate end points for long-term outcomes in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Survey of early disapearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1? axis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synthesis and antileukemic activity of an ursolic acid derivative: A potential co-drug in combination with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synthesis and Characterization of a BODIPY Conjugate of the BCR-ABL Kinase Inhibitor Tasigna (Nilotinib): Evidence for Transport of Tasigna and Its Fluorescent Derivative by ABC Drug Transporters.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T-cell immunity to the joining region of p210BCR-ABL protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted cancer therapy: promise and reality.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted chemotherapy: chronic myelogenous leukemia as a model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted Chronic Myeloid Leukemia Therapy: Seeking a Cure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted therapy in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeted therapy of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting chronic myeloid leukemia stem cells: can transcriptional program be a druggable target for cancers?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting of GSK3? promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/??catenin/TCF7/ABC transporter signaling axis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The ABL genes in normal and abnormal cell development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The allometry of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The BCR-ABL/NF-?B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The biology of signal transduction inhibition: basic science to novel therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The c-abl oncogene in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFR?.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The detection and significance of minimal residual disease in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL positive) cells sensitive and resistant to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The fundamental prevalence of chronic myeloid leukemia-generating clonogenic cells in the light of the neutrality theory of evolution.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The involvement of Bcr in leukemias with the Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The mystery of chromosomal translocations in cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The PERK-eIF2? phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Perplexity of Synergistic Duality: Inter-Molecular Mechanisms of Communication in BCR-ABL1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The potentiation of menadione on imatinib by down-regulation of ABCB1 expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The regulation of bcr-abl in hypoxia is through the mTOR pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The relationship of bone marrow histology with the molecular pattern in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of myc in transformation by BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of natural killer cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-? in CML cell line, KT-1 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The second generation of BCR-ABL tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Significance of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutic inhibition of Fc?RIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Three-dimensional structure of the Hck SH2 domain in solution.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Time-resolved fluorometric hybridization assays with RNA probes synthesized from polymerase chain reaction-generated DNA templates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Translating Trial-Based Molecular Monitoring Into Clinical Practice: Importance of International Standards and Practical Considerations for Community Practitioners.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Translocation (4;15)(p16;q24): a novel reciprocal translocation in a patient with BCR/ABL negative myeloproliferative syndrome progressing to blastic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Translocation of c-abl to "masked" Ph in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment options for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment options for newly diagnosed patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibitor Thiotanib targets Bcr-Abl and induces apoptosis and autophagy in human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibitors induce alternative spliced BCR-ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine kinase inhibitors: from rational design to clinical trials.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tyrosine protein kinase substrates in Philadelphia-positive human chronic granulocytic leukemia derived cell lines (K562 and BV173): detection by using an immunoblotting technique.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Uptake of synthetic Low Density Lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
v-abl activates embryonic globin gene expression in mouse erythroleukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Validating cancer drug targets through chemical genetics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Vitamin ? activates expression of ?/EBP alpha transcription factor and G-CSF receptor in leukemic K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Whole Exome Sequencing of Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ZnPcS2P2-based photodynamic therapy induces mitochondria-dependent apoptosis in K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[A comparative study of different intervention regimens for chronic myelogenous leukemia post allogeneic hematopoietic stem cell transplantation.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[A multicenter study on the validation of conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[A new drug in the therapy of chronic myeloid leukemia: ST1571]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Autologous hemopoietic stem cell transplantation in treatment of chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Chronic myelogenous leukemia expressing two bcr-abl chimeric mRNA; a case report]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Chronic myeloid leukemia: "Archetype" of the impact of targeted therapies].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Chronic myeloid leukemia: aiming for treatment free remission].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Clinical significance of analysis of BCR- ABL kinase domain mutation in chronic myeloid leukemia patients].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Constructing a Competitor of BCR-ABL cDNA by PCR Site-Directed Mutagenesis]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Correlation between point mutation in ABL kinase and clinical outcome of chronic myeloid leukemia patients].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Cytogenetic and clinical features of Philadelphia chromosome positive leukemias]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Demonstration of BCR-ABL rearrangement in a patient with apparently Ph-negative chronic myeloid leukemia of 15 years' duration]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Detection of Abl kinase domain point mutations in chronic myeloid leukemia patients with imatinib resistance and its clinical significance].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Detection of bcr-abl Fusion Gene mRNA Level in K562/A02 Cell Line by Real-time Quantitative RT-PCR.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Detection of BCR-ABL gene mutations in chronic myeloid leukemia using biochips].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Detection of bcr-abl transcripts in "minimal residual disease" in chronic myelogenous leukemia by nested polymerase chain reaction (PCR)]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of A Novel Tyrosine Kinase Inhibitor HHGV678 on Growth Inhibition of Bcr-Abl Wild Type and IM-resistant Cell Lines In Vitro.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of Targeted Activation of Protein Kinase PKR on Proliferation of Leukemia Cell Line K562 and Its Mechanism.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Experimental advance of targeted medicines for chronic myeloid leukemia--review]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Gene rearrangement and radiation carcinogenesis]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Imatinib therapy for patients with chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Imatinib therapy in chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Imatinib--a new perspective in the treatment of tumors]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Implications of ALK (anaplastic lymphoma kinase) in oncohematology]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[JAK2 positive chronic myeloid leukemia complicated with suspected BCR-ABL variant: one case report].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Mechanisms of recombinant adenovirus-mediated SD-HA fusion protein proliferation inhibition and induced apoptosis of K562 cells].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[microRNA targeted to chronic myeloid leukemia Bcr-Abl oncogene screen using deacetylase inhibitor].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Molecular analysis of bcr-abl mRNA during long-term follow-up of cases of chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Molecular diagnosis of leukemia and lymphoma]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Molecular Targeted Therapy and Laboratory Tests].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Monitoring the chronic myeloid leukemia patients between 2008 and 2018; the experience of the Hematology and Bone Marrow Transplantation Unit Târgu-Mure?].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Polymorphism analysis of 5' promotor region of BCR gene]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Pro-survival signaling pathways activated by BCR-ABL oncogene in chronic myelogenous leukemia cells: the role of the perk-EIF2? signal path and acetylation of p53].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Relationship between thymus output function in CML patients and their bcr-abl mRNA levels]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Research Advance on Molecular Genetics of CML Blast Crisis - Review.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[RT-PCR use for the diagnostic of chronic myeloid leukaemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Signal transduction of BCR-ABL in chronic myelogenous leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Significance of BCR-ABL fusion gene detection in CD34 (+) cells of chronic myelogenous leukemia patients].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Significance of Quantitative Detection of bcr-abl mRNA in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplant.]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[State-of-the-art management of CML in 2015 and future prospects].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Study of adhesion-related molecule beta1-integrin and focal adhesion kinase in chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The development history and future perspective of molecularly targeted therapy].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The influence of peripheral blood sample storage and delivery on the quantitative detection result of BCR-ABL (P210) transcript levels].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The mechanisms of the resistance to molecular targeting agents]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Types of bcr-abl and their correlations with the blood count in chronic myeloid leukemia (CML) in Togo].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Tyrosine kinase inhibitors--solid cancers]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Use of cytogenetic and molecular biology in the detection of chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Using real-time polymerase chain reaction to quantitate bcr-abl mRNA]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].
Leukemia, Myeloid
A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Leukemia, Myeloid
A novel crosstalk between calcium/calmodulin kinases II and IV regulates cell proliferation in myeloid leukemia cells.
Leukemia, Myeloid
A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells.
Leukemia, Myeloid
Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571.
Leukemia, Myeloid
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Leukemia, Myeloid
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Leukemia, Myeloid
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Leukemia, Myeloid
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Leukemia, Myeloid
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown.
Leukemia, Myeloid
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
Leukemia, Myeloid
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Leukemia, Myeloid
Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.
Leukemia, Myeloid
Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes.
Leukemia, Myeloid
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Leukemia, Myeloid
Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells.
Leukemia, Myeloid
Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Leukemia, Myeloid
Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.
Leukemia, Myeloid
Effects of hibarimicins and hibarimicin-related compounds produced by Microbispora on v-Src kinase activity and growth and differentiation of human myeloid leukemia HL-60 cells.
Leukemia, Myeloid
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia, Myeloid
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
Leukemia, Myeloid
Ephrin type-B receptor 4 is an essential mediator in drug-resistance of acute myeloid leukemia cells to Adriamycin.
Leukemia, Myeloid
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Leukemia, Myeloid
Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias.
Leukemia, Myeloid
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
Leukemia, Myeloid
FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.
Leukemia, Myeloid
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
Leukemia, Myeloid
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Leukemia, Myeloid
GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.
Leukemia, Myeloid
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.
Leukemia, Myeloid
Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.
Leukemia, Myeloid
Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells.
Leukemia, Myeloid
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Leukemia, Myeloid
Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine.
Leukemia, Myeloid
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
Leukemia, Myeloid
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Leukemia, Myeloid
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Leukemia, Myeloid
Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib.
Leukemia, Myeloid
Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia.
Leukemia, Myeloid
Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling.
Leukemia, Myeloid
Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
Leukemia, Myeloid
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Leukemia, Myeloid
Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases.
Leukemia, Myeloid
Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.
Leukemia, Myeloid
Regulation of c-Fes tyrosine kinase and biological activities by N-terminal coiled-coil oligomerization domains.
Leukemia, Myeloid
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Leukemia, Myeloid
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Leukemia, Myeloid
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
Leukemia, Myeloid
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Leukemia, Myeloid
Targeting RSK2 in myeloid leukemia: right for FLT3 but wrong for BCR-ABL.
Leukemia, Myeloid
The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
Leukemia, Myeloid
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Leukemia, Myeloid
Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck.
Leukemia, Myeloid
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Leukemia, Myeloid
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Leukemia, Myeloid
[Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Leukemia, Myeloid
[Coexistence of p210 BCR-ABL and CBF?-MYH11 fusion genes in myeloid leukemia: two cases report and literatures review].
Leukemia, Myeloid
[Expression of c-fes gene in leukemia cells and its clinical significance]
Leukemia, Myeloid, Acute
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Leukemia, Myeloid, Acute
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
Leukemia, Myeloid, Acute
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia.
Leukemia, Myeloid, Acute
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog.
Leukemia, Myeloid, Acute
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations.
Leukemia, Myeloid, Acute
Azole antifungals and new targeted therapies for hematological malignancy.
Leukemia, Myeloid, Acute
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Leukemia, Myeloid, Acute
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Leukemia, Myeloid, Acute
Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
Leukemia, Myeloid, Acute
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Leukemia, Myeloid, Acute
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Leukemia, Myeloid, Acute
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Leukemia, Myeloid, Acute
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Leukemia, Myeloid, Acute
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Leukemia, Myeloid, Acute
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Correction to "Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms".
Leukemia, Myeloid, Acute
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Leukemia, Myeloid, Acute
Deletion of chromosome 22 without bcr rearrangement and without juxtaposition of c-abl in a case of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Leukemia, Myeloid, Acute
Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement.
Leukemia, Myeloid, Acute
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Leukemia, Myeloid, Acute
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Leukemia, Myeloid, Acute
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Leukemia, Myeloid, Acute
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia, Myeloid, Acute
Enhancement of the TCR? Expression, Polyclonal Expansion, and Activation of T Cells from Patients with AML After IL-2, IL-7, and IL-12 Induction.
Leukemia, Myeloid, Acute
Entospletinib in Combination With Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 expression.
Leukemia, Myeloid, Acute
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Leukemia, Myeloid, Acute
Ephrin type-B receptor 4 is an essential mediator in drug-resistance of acute myeloid leukemia cells to Adriamycin.
Leukemia, Myeloid, Acute
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Leukemia, Myeloid, Acute
Expression of c-abl in Philadelphia-positive acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis.
Leukemia, Myeloid, Acute
Expression of the c-fes proto-oncogene in granulocyte-macrophage colony-stimulating factor-dependent acute myelogenous leukemia cells grown autonomously.
Leukemia, Myeloid, Acute
Expression of the human fes cellular oncogene in renal cell tumors.
Leukemia, Myeloid, Acute
Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered wnt signaling.
Leukemia, Myeloid, Acute
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Leukemia, Myeloid, Acute
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
Leukemia, Myeloid, Acute
High expression of GTPase regulator associated with the focal adhesion kinase (GRAF) is a favorable prognostic factor in acute myeloid leukemia.
Leukemia, Myeloid, Acute
High levels of p-JAK2 are associated with adverse clinical outcome and can be a molecular target in individuals with acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Leukemia, Myeloid, Acute
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Leukemia, Myeloid, Acute
In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-Family Kinase C-Helix-out Inhibitor Resistance.
Leukemia, Myeloid, Acute
Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
Leukemia, Myeloid, Acute
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Leukemia, Myeloid, Acute
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Leukemia, Myeloid, Acute
Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Leukemia, Myeloid, Acute
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
Leukemia, Myeloid, Acute
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Leukemia, Myeloid, Acute
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
Leukemia, Myeloid, Acute
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Leukemia, Myeloid, Acute
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Leukemia, Myeloid, Acute
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
Leukemia, Myeloid, Acute
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Leukemia, Myeloid, Acute
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Leukemia, Myeloid, Acute
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Leukemia, Myeloid, Acute
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) treated with imatinib mesylate (IM) A report with IM plasma concentration and bcr-abl transcripts.
Leukemia, Myeloid, Acute
Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
Leukemia, Myeloid, Acute
Philadelphia-positive acute leukemia: lineage promiscuity and inconsistently rearranged breakpoint cluster region.
Leukemia, Myeloid, Acute
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Leukemia, Myeloid, Acute
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Leukemia, Myeloid, Acute
Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia.
Leukemia, Myeloid, Acute
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Leukemia, Myeloid, Acute
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Leukemia, Myeloid, Acute
Simultaneous occurrence of bcr-abl and inv16 in a case of M1 acute myeloid leukemia.
Leukemia, Myeloid, Acute
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1.
Leukemia, Myeloid, Acute
SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Leukemia, Myeloid, Acute
Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34.
Leukemia, Myeloid, Acute
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Leukemia, Myeloid, Acute
The Philadelphia chromosome as a secondary abnormality in inv(3)(q21q26) acute myeloid leukemia at diagnosis: confirmation of p190 BCR-ABL mRNA by real-time quantitative polymerase chain reaction.
Leukemia, Myeloid, Acute
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Leukemia, Myeloid, Acute
The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.
Leukemia, Myeloid, Acute
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Leukemia, Myeloid, Acute
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Leukemia, Myeloid, Acute
[Clinical Analysis of 12 Cases of Acute Myeloid Leukemia with Ph Chromosome and BCR-ABL Positive].
Leukemia, Myeloid, Acute
[Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease]
Leukemia, Myeloid, Acute
[Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21).]
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review.
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
Leukemia, Myelomonocytic, Chronic
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
Leukemia, Myelomonocytic, Chronic
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.
Leukemia, Myelomonocytic, Chronic
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
Leukemia, Myelomonocytic, Chronic
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Leukemia, Myelomonocytic, Chronic
Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.
Leukemia, Myelomonocytic, Chronic
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Leukemia, Myelomonocytic, Chronic
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Leukemia, Neutrophilic, Chronic
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Leukemia, Neutrophilic, Chronic
Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Leukemia, Neutrophilic, Chronic
Chronic neutrophilic leukemia: case report documenting the absence of bcr-abl rearrangement.
Leukemia, Prolymphocytic, B-Cell
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
Leukemia, Prolymphocytic, T-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Leukemia, Promyelocytic, Acute
Antiapoptotic effect of c-fes protooncogene during granulocytic differentiation.
Leukemia, Promyelocytic, Acute
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Leukemia, Promyelocytic, Acute
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Leukemia, Promyelocytic, Acute
Biological therapy for pediatric malignancy: current perspectives.
Leukemia, Promyelocytic, Acute
Chromosomal localization of the human genes for lipocortin I and lipocortin II.
Leukemia, Promyelocytic, Acute
Coexistence of PML-RAR? and BCR-ABL in acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.
Leukemia, Promyelocytic, Acute
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Leukemia, Promyelocytic, Acute
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Leukemia, Promyelocytic, Acute
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Leukemia, Promyelocytic, Acute
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Leukemia, Promyelocytic, Acute
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Leukemia, Promyelocytic, Acute
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.
Leukemia, T-Cell
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Leukemia, T-Cell
Accumulation of p60lck in HTLV-I-transformed T cell lines detected by an anti-lck monoclonal antibody, MOL 171.
Leukemia, T-Cell
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Leukemia, T-Cell
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
Leukemia, T-Cell
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
Leukemia, T-Cell
Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Leukemia, T-Cell
Human T-cell leukemia virus type-I-infected T-cell lines scarcely produce p56lck, whether or not they express lck mRNA.
Leukemia, T-Cell
Lymphocyte antigen receptor activation of a focal adhesion kinase-related tyrosine kinase substrate.
Leukemia, T-Cell
Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays.
Leukemia, T-Cell
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Leukemia, T-Cell
The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.
Leukemia, T-Cell
Transrepression of lck gene expression by human T-cell leukemia virus type 1-encoded p40tax.
Leukemia-Lymphoma, Adult T-Cell
Anti-adult T?cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Leukemia-Lymphoma, Adult T-Cell
Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries.
Leukemic Infiltration
CREB is a critical regulator of normal hematopoiesis and leukemogenesis.
Leukocytosis
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
Leukocytosis
Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
Leukocytosis
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Leukocytosis
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Leukocytosis
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
Leukocytosis
Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
Leukocytosis
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review.
Leukocytosis
Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review.
Leukocytosis
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Leukocytosis
Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey.
Leukocytosis
MIP-1?/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia.
Leukocytosis
Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Leukocytosis
Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Leukocytosis
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Leukocytosis
Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia.
Leukocytosis
[Exacerbation of acute leukemia bearing isolated i(17q) along with proliferation of blasts with high BMI-1 expression]
Leukoencephalopathies
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Lewy Body Disease
Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.
Lipoma
Angiotensin II, focal adhesion kinase, and PRX1 enhance smooth muscle expression of lipoma preferred partner and its newly identified binding partner palladin to promote cell migration.
Lipoma
Identification of Novel Genes in Osteoarthritic Fibroblast-Like Synoviocytes Using Next-Generation Sequencing and Bioinformatics Approaches.
Liposarcoma
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Liposarcoma
miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells.
Liver Cirrhosis
A cAbl-MRTF-A Feedback Loop Contributes to Hepatic Stellate Cell Activation.
Liver Cirrhosis
Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion.
Liver Cirrhosis
Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout.
Liver Cirrhosis
Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis.
Liver Cirrhosis
Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis.
Liver Cirrhosis
Inhibition of PDGF, TGF-? and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.
Liver Cirrhosis
Long Noncoding RNA HOTTIP Promotes Mouse Hepatic Stellate Cell Activation via Downregulating miR-148a.
Liver Cirrhosis
Lyn kinase enhanced hepatic fibrosis by modulating the activation of hepatic stellate cells.
Liver Cirrhosis
Proline-rich tyrosine kinase 2 mediates transforming growth factor-beta-induced hepatic stellate cell activation and liver fibrosis.
Liver Cirrhosis
Regulation of activin receptor-interacting protein 2 expression in mouse hepatoma Hepa1-6 cells and its relationship with collagen type IV.
Liver Cirrhosis
Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
Liver Cirrhosis
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Liver Cirrhosis
Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.
Liver Cirrhosis
[Quantitative analysis of the expression of insulin receptor and tyrosine protein kinase of patients with hepatic cirrhosis]
Liver Diseases
Anti-oxidants do not prevent bile acid-induced cell death in rat hepatocytes.
Liver Diseases
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
Liver Diseases
CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.
Liver Diseases
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Liver Diseases
Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism.
Liver Diseases
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Liver Diseases, Alcoholic
Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.
Liver Failure
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
Liver Failure, Acute
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Liver Neoplasms
c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer.
Liver Neoplasms
Downregulation of SRC Kinase Signaling Inhibitor 1 (SRCIN1) Expression By MicroRNA-32 Promotes Proliferation and Epithelial-Mesenchymal Transition in Human Liver Cancer Cells.
Liver Neoplasms
Epidermal Growth Factor Activates the Rho GTPase-activating Protein (GAP) Deleted in Liver Cancer 1 via Focal Adhesion Kinase and Protein Phosphatase 2A.
Liver Neoplasms
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Liver Neoplasms
HOXA11-AS regulates JAK-STAT pathway by miR-15a-3p/STAT3 axis to promote the growth and metastasis in liver cancer.
Liver Neoplasms
IL?6 plays a crucial role in epithelial?mesenchymal transition and pro?metastasis induced by sorafenib in liver cancer.
Liver Neoplasms
LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling.
Liver Neoplasms
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Liver Neoplasms
MicroRNA-543 suppresses liver cancer growth and induces apoptosis via the JAK2/STAT3 signaling pathway.
Liver Neoplasms
miR24-2 Promotes Malignant Progression of Human Liver Cancer Stem Cells by Enhancing Tyrosine Kinase Src Epigenetically.
Liver Neoplasms
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Liver Neoplasms
Saffron carotenoids inhibit STAT3 activation and promote apoptotic progression in IL-6-stimulated liver cancer cells.
Liver Neoplasms
The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
Liver Neoplasms
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Loeys-Dietz Syndrome
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Loeys-Dietz Syndrome
Activation of TGF-? signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1.
Loeys-Dietz Syndrome
Analysis of TFGBR1*6A variant in individuals evaluated for Marfan syndrome.
Loeys-Dietz Syndrome
Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome.
Loeys-Dietz Syndrome
Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes.
Loeys-Dietz Syndrome
Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma.
Loeys-Dietz Syndrome
Duplication of the TGFBR1 gene causes features of Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
Dural ectasia in individuals with Marfan-like features but exclusion of mutations in the genes FBN1, TGFBR1 and TGFBR2.
Loeys-Dietz Syndrome
Dural ectasia in Loeys-Dietz syndrome: Comprehensive study of 30 patients with a TGFBR1 or TGFBR2 mutation.
Loeys-Dietz Syndrome
Evolution of the face in Loeys-Dietz syndrome type II: longitudinal observations from infancy in seven cases.
Loeys-Dietz Syndrome
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Loeys-Dietz Syndrome
Features of multiple self-healing squamous epithelioma and Loeys-Dietz syndrome in a patient with a novel TGFBR1 variant.
Loeys-Dietz Syndrome
First evidence of maternally inherited mosaicism in TGFBR1 and subtle primary myocardial changes in Loeys-Dietz syndrome: a case report.
Loeys-Dietz Syndrome
Generation of three induced pluripotent stem cell lines (MHHi012-A, MHHi013-A, MHHi014-A) from a family with Loeys-Dietz syndrome carrying a heterozygous p.M253I (c.759G>A) mutation in the TGFBR1 gene.
Loeys-Dietz Syndrome
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Loeys-Dietz Syndrome
Identification of a novel TGFBR1 mutation in a Loeys-Dietz syndrome type II patient with vascular Ehlers-Danlos syndrome phenotype.
Loeys-Dietz Syndrome
Loeys-Dietz syndrome: life threatening aortic dissection diagnosed on routine family screening.
Loeys-Dietz Syndrome
Marfan syndrome type II: there is more to Marfan syndrome than fibrillin 1.
Loeys-Dietz Syndrome
Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9.
Loeys-Dietz Syndrome
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Loeys-Dietz Syndrome
Novel Association of a Familial TGFBR1 Mutation in Loeys-Dietz Syndrome with Concomitant Hematologic Malignancy.
Loeys-Dietz Syndrome
Novel pathogenic TGFBR1 and SMAD3 variants identified after cerebrovascular events in adult patients with Loeys-dietz syndrome.
Loeys-Dietz Syndrome
Optimising the mutation screening strategy in Marfan syndrome and identifying genotypes with more severe aortic involvement.
Loeys-Dietz Syndrome
Overexpression of Gremlin-1 in patients with Loeys-Dietz syndrome: implications on pathophysiology and early disease detection.
Loeys-Dietz Syndrome
Pathogenic effect of a TGFBR1 mutation in a family with Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
Pregnancy after aortic root replacement in Loeys-Dietz syndrome: High risk of aortic dissection.
Loeys-Dietz Syndrome
Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations.
Loeys-Dietz Syndrome
Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.
Loeys-Dietz Syndrome
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome in a boy with Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
Loeys-Dietz Syndrome
SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction.
Loeys-Dietz Syndrome
Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome.
Loeys-Dietz Syndrome
Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center.
Loeys-Dietz Syndrome
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Loeys-Dietz Syndrome
TGF? signaling and congenital heart disease: Insights from mouse studies.
Loeys-Dietz Syndrome
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
Loeys-Dietz Syndrome
TGFBR1 mutations associated with Loeys-Dietz syndrome are inactivating.
Loeys-Dietz Syndrome
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Loeys-Dietz Syndrome
Unique Mechanism by Which TGFBR1 Variants Cause 2 Distinct System Diseases?- Loeys-Dietz Syndrome and Multiple Self-Healing Squamous Epithelioma.
Lordosis
Lordosis facilitation by leptin in ovariectomized, estrogen-primed rats requires simultaneous or sequential activation of several protein kinase pathways.
Lung Diseases
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
Lung Diseases
DNA Methylation Profiling for the Diagnosis and Prognosis of Patients with Nontuberculous Mycobacterium Lung Disease.
Lung Diseases
Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK.
Lung Diseases
Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib.
Lung Diseases, Interstitial
Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.
Lung Injury
Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity.
Lung Injury
c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury.
Lung Injury
Differential effects of the Src family tyrosine kinases Yes and Fyn on lipopolysaccharide-induced lung injury in ice.
Lung Injury
Effect of SOCS3 on lung injury in rats with severe acute pancreatitis through regulating JAK2/STAT3 signaling pathway.
Lung Injury
Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress.
Lung Injury
Inhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in rats.
Lung Injury
Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension.
Lung Injury
Lung Epithelial Cell Focal Adhesion Kinase Signaling Inhibits Lung Injury and Fibrosis.
Lung Injury
Neuronal Wiskott-Aldrich syndrome protein regulates TGF-?1-mediated lung vascular permeability.
Lung Injury
Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.
Lung Injury
Protective effects of SOCS3 overexpression in high glucose?induced lung epithelial cell injury through the JAK2/STAT3 pathway.
Lung Injury
Src Regulates Cigarette Smoke-induced Ceramide Generation via nSMase2 in the Airway Epithelium.
Lung Injury
Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury.
Lung Injury
[Regulation of paxillin tyrosine phosphorylation via inhibition of c-Abl kinase to protect ventilator induce lung injury in vivo in rats].
Lung Neoplasms
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
Lung Neoplasms
?-elemene inhibits non-small cell lung cancer cell migration and invasion by inactivating the FAK-Src pathway.
Lung Neoplasms
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Lung Neoplasms
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Lung Neoplasms
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
Lung Neoplasms
Activated cdc42-associated kinase is up-regulated in non-small-cell lung cancer and necessary for FGFR-mediated AKT activation.
Lung Neoplasms
Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events.
Lung Neoplasms
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Lung Neoplasms
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Lung Neoplasms
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Lung Neoplasms
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Lung Neoplasms
Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.
Lung Neoplasms
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Lung Neoplasms
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Lung Neoplasms
Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells.
Lung Neoplasms
Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.
Lung Neoplasms
Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.
Lung Neoplasms
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
Lung Neoplasms
Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Lung Neoplasms
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Lung Neoplasms
Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Lung Neoplasms
Cryptotanshinone inhibits lung tumor growth by increasing CD4(+) T cell cytotoxicity through activation of the JAK2/STAT4 pathway.
Lung Neoplasms
Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Lung Neoplasms
Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK).
Lung Neoplasms
Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.
Lung Neoplasms
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer.
Lung Neoplasms
DOK7V1 influences the malignant phenotype of lung cancer cells through PI3K/AKT/mTOR and FAK/paxillin signaling pathways.
Lung Neoplasms
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Lung Neoplasms
DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin ?1/FAK Signaling.
Lung Neoplasms
Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Lung Neoplasms
Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Lung Neoplasms
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Lung Neoplasms
Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis.
Lung Neoplasms
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Lung Neoplasms
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Lung Neoplasms
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
Lung Neoplasms
Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells.
Lung Neoplasms
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Lung Neoplasms
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Lung Neoplasms
Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells.
Lung Neoplasms
Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance.
Lung Neoplasms
FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.
Lung Neoplasms
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Lung Neoplasms
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Lung Neoplasms
Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
Lung Neoplasms
FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis.
Lung Neoplasms
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Lung Neoplasms
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Lung Neoplasms
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Lung Neoplasms
Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Lung Neoplasms
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Lung Neoplasms
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Lung Neoplasms
Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer.
Lung Neoplasms
Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549.
Lung Neoplasms
Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells.
Lung Neoplasms
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Lung Neoplasms
JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
Lung Neoplasms
Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Lung Neoplasms
Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation.
Lung Neoplasms
LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p.
Lung Neoplasms
Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225-3p/ErbB2 signal.
Lung Neoplasms
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Lung Neoplasms
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.
Lung Neoplasms
Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway.
Lung Neoplasms
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Lung Neoplasms
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Lung Neoplasms
MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
Lung Neoplasms
MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.
Lung Neoplasms
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
Lung Neoplasms
MicroRNA?208a directly targets Src kinase signaling inhibitor 1 to facilitate cell proliferation and invasion in non?small cell lung cancer.
Lung Neoplasms
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
Lung Neoplasms
miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1.
Lung Neoplasms
MiR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITG?8- JAK2/STAT3 axis.
Lung Neoplasms
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Lung Neoplasms
MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway.
Lung Neoplasms
Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Lung Neoplasms
NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition.
Lung Neoplasms
Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines.
Lung Neoplasms
Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells.
Lung Neoplasms
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.
Lung Neoplasms
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.
Lung Neoplasms
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Lung Neoplasms
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Lung Neoplasms
Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner.
Lung Neoplasms
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Lung Neoplasms
Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.
Lung Neoplasms
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
Lung Neoplasms
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Lung Neoplasms
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Lung Neoplasms
Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility.
Lung Neoplasms
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Lung Neoplasms
Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.
Lung Neoplasms
Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Lung Neoplasms
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lung Neoplasms
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Lung Neoplasms
Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival.
Lung Neoplasms
Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.
Lung Neoplasms
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Lung Neoplasms
Regulatory interplay between Vav1, Syk and ?-catenin occurs in lung cancer cells.
Lung Neoplasms
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Lung Neoplasms
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Lung Neoplasms
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Lung Neoplasms
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Lung Neoplasms
Serum starvation regulates E-cadherin upregulation via activation of c-Src in non-small-cell lung cancer A549 cells.
Lung Neoplasms
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Lung Neoplasms
SOCS3 expression is inversely correlated with Pyk2 in non-small cell lung cancer and exogenous SOCS3 inhibits proliferation and invasion of A549 cells.
Lung Neoplasms
Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Lung Neoplasms
Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.
Lung Neoplasms
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Lung Neoplasms
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
Lung Neoplasms
Src Regulates Cigarette Smoke-induced Ceramide Generation via nSMase2 in the Airway Epithelium.
Lung Neoplasms
Stimulation of beta1 integrin down-regulates ICAM-1 expression and ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase.
Lung Neoplasms
Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.
Lung Neoplasms
Syntenin increases the invasiveness of small cell lung cancer cells by activating p38, AKT, focal adhesion kinase and SP1.
Lung Neoplasms
Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.
Lung Neoplasms
Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.
Lung Neoplasms
The 150 most important questions in cancer research and clinical oncology series: questions 57-66 : Edited by Chinese Journal of Cancer.
Lung Neoplasms
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Lung Neoplasms
The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.
Lung Neoplasms
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Lung Neoplasms
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Lung Neoplasms
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Lung Neoplasms
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Lung Neoplasms
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Lung Neoplasms
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Lung Neoplasms
Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis.
Lung Neoplasms
Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
Lung Neoplasms
Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity.
Lung Neoplasms
[Association between Ephb4 gene polymorphism and non-small cell lung cancer]
Lung Neoplasms
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
Lung Neoplasms
[Effect of Src Tyrosine Kinase Inhibition on the Drug-resistance as well as MDR1 and LRP Expression of the Human Cis-platinum-resistant Lung Cancer Cell Line A549/DDP].
Lung Neoplasms
[Expression of KAI1, MRP-1, and FAK proteins in lung cancer detected by high-density tissue microarray]
Lung Neoplasms
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
Lung Neoplasms
[Relationship between multi-slice spiral CT pulmonary perfusion imaging and the expression of EphB4 and ephrinB2 in non-small cell lung cancer].
Lung Neoplasms
[SRC kinase inhibitor PP2 inhibits invasion and metastasis of lung cancer A549 cells by upregulating connexin43 expression].
Lupus Erythematosus, Cutaneous
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Lupus Erythematosus, Cutaneous
Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study.
Lupus Erythematosus, Cutaneous
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study.
Lupus Erythematosus, Cutaneous
Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Lupus Erythematosus, Cutaneous
Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus.
Lupus Erythematosus, Discoid
Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus.
Lupus Erythematosus, Systemic
A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis.
Lupus Erythematosus, Systemic
Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Altered recruitment of Lyn, Syk and ZAP-70 into lipid rafts of activated B cells in Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis.
Lupus Erythematosus, Systemic
Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families.
Lupus Erythematosus, Systemic
Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis.
Lupus Erythematosus, Systemic
B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice.
Lupus Erythematosus, Systemic
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lupus Erythematosus, Systemic
c-Jun and Ets2 regulate the expression of spleen tyrosine kinase in T cells.
Lupus Erythematosus, Systemic
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Lupus Erythematosus, Systemic
CREM? suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells.
Lupus Erythematosus, Systemic
Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.
Lupus Erythematosus, Systemic
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Lupus Erythematosus, Systemic
Dysregulation of p56lck kinase in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Lupus Erythematosus, Systemic
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Lupus Erythematosus, Systemic
Expression and activation of proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Interferon-? activates interleukin-1 receptor-associated kinase 1 to induce regulatory T-cell apoptosis in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Lack of association between tyrosine kinase 2 (TYK2) gene polymorphisms and susceptibility to SLE in a Japanese population.
Lupus Erythematosus, Systemic
p56lck activity and expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling.
Lupus Erythematosus, Systemic
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Lupus Erythematosus, Systemic
The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development.
Lupus Erythematosus, Systemic
The Potential Role of Lyn Kinase in Systemic Lupus Erythematosus and Autoimmunity.
Lupus Erythematosus, Systemic
Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus.
Lupus Nephritis
A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis.
Lupus Nephritis
Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
Lupus Nephritis
Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice.
Lupus Nephritis
Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.
Lupus Nephritis
MicroRNA-183 exerts a protective role in lupus nephritis through blunting the activation of TGF-?/Smad/TLR3 pathway via reducing Tgfbr1.
Lupus Nephritis
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Lymphadenopathy
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
Lymphadenopathy
Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia.
Lymphadenopathy
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Lymphadenopathy
Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients.
Lymphadenopathy
Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Lymphadenopathy
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Lymphangioleiomyomatosis
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
Lymphangioleiomyomatosis
SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
Lymphangioma
Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis in vitro and in vivo.
Lymphatic Metastasis
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF?R1/VEGF-D signaling.
Lymphatic Metastasis
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Lymphatic Metastasis
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Lymphatic Metastasis
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Lymphatic Metastasis
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
Lymphatic Metastasis
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Lymphatic Metastasis
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Lymphatic Metastasis
Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Lymphatic Metastasis
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Lymphatic Metastasis
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Lymphatic Metastasis
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Lymphatic Metastasis
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Lymphatic Metastasis
Identification of lymphatic metastasis-associated genes in a metastatic ovarian cancer cell line.
Lymphatic Metastasis
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Lymphatic Metastasis
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Lymphatic Metastasis
Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.
Lymphatic Metastasis
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Lymphatic Metastasis
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Lymphatic Metastasis
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
Lymphatic Metastasis
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
Lymphatic Metastasis
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
Lymphedema
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Lymphocytosis
Significance of zeta-associated protein (ZAP-70) and CD38 expression in chronic lymphocytic leukemia.
Lymphocytosis
Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia.
Lymphocytosis
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Lymphohistiocytosis, Hemophagocytic
A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.
Lymphohistiocytosis, Hemophagocytic
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Lymphohistiocytosis, Hemophagocytic
Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Lymphoma
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
Lymphoma
A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA.
Lymphoma
A lymphoma cell line expressing elevated levels of tyrosine protein kinase activity.
Lymphoma
A lymphoma protein with an in vitro site of tyrosine phosphorylation homologous to that in pp60src.
Lymphoma
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Lymphoma
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.
Lymphoma
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Lymphoma
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Lymphoma
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lymphoma
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Lymphoma
Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.
Lymphoma
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Lymphoma
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Lymphoma
Altered protein kinase activities of lymphoid cells transformed by Abelson and Moloney leukemia viruses.
Lymphoma
An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases.
Lymphoma
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
Lymphoma
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Lymphoma
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Lymphoma
BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells.
Lymphoma
Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity.
Lymphoma
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Lymphoma
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Lymphoma
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Lymphoma
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Lymphoma
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Lymphoma
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Lymphoma
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Lymphoma
Bruton's tyrosine kinase activity and inositol 1,4,5-trisphosphate production are not altered in DT40 lymphoma B cells exposed to power line frequency magnetic fields.
Lymphoma
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Lymphoma
Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
Lymphoma
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Lymphoma
c-Casitas b-Lineage Lymphoma Downregulation Improves the Ability of Long-term Cultured Mesenchymal Stem Cells for Promoting Angiogenesis and Diabetic Wound Healing.
Lymphoma
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Lymphoma
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Lymphoma
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Lymphoma
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Lymphoma
Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.
Lymphoma
Characteristics of TCR?, ZAP-70, and Fc?RI? Gene Expression in Patients with T- and NK/T-Cell Lymphoma.
Lymphoma
Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells.
Lymphoma
CircRNA?0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR?107.
Lymphoma
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Lymphoma
Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.
Lymphoma
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Lymphoma
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
Lymphoma
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Lymphoma
Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Lymphoma
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
Lymphoma
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
Lymphoma
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib.
Lymphoma
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Lymphoma
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Lymphoma
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Lymphoma
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
Lymphoma
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Lymphoma
Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
Lymphoma
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Lymphoma
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Lymphoma
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Lymphoma
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).
Lymphoma
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
Lymphoma
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Lymphoma
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
Lymphoma
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Lymphoma
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Lymphoma
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Lymphoma
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Lymphoma
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Lymphoma
Efficient Preparation of (S)-N-Boc-3-Hydroxylpiperidine Through Bioreduction by a Thermostable Aldo-KetoReductase.
Lymphoma
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Lymphoma
Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma.
Lymphoma
Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Lymphoma
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Lymphoma
Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.
Lymphoma
Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines.
Lymphoma
Expression of protein tyrosine kinases in the Ig complex of anti-mu-sensitive and anti-mu-resistant B-cell lymphomas: role of the p55blk kinase in signaling growth arrest and apoptosis.
Lymphoma
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Lymphoma
Expression pattern of adaptor protein PAG: correlation between secondary lymphatic follicle and histogenetically related malignant lymphomas.
Lymphoma
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
Lymphoma
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Lymphoma
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Lymphoma
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Lymphoma
Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling.
Lymphoma
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Lymphoma
Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
Lymphoma
High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukemia virus.
Lymphoma
High ZAP-70 expression correlates with worse clinical outcome in mantle cell lymphoma.
Lymphoma
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Lymphoma
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Lymphoma
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Lymphoma
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in syngeneic mouse lymphoma model.
Lymphoma
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Lymphoma
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.
Lymphoma
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Lymphoma
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Lymphoma
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Lymphoma
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Lymphoma
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Lymphoma
Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line.
Lymphoma
Identification of the tyrosine protein kinase from LSTRA cells by use of site-specific antibodies.
Lymphoma
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Lymphoma
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Lymphoma
Immunochemical detection of adenine nucleotide-binding proteins with antibodies to 5'-p-fluorosulfonylbenzoyladenosine.
Lymphoma
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma
In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: technical approach and comparison with results with anti-oncoprotein antibodies.
Lymphoma
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.
Lymphoma
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Lymphoma
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Lymphoma
Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.
Lymphoma
Interleukin 15-Dependent T Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease.
Lymphoma
Janus Reveals Another Face: The Biologic Rationale for Targeting Janus Kinase 2 in Lymphoma.
Lymphoma
Kinase group protooncogenes in non-hodgkins-lymphomas and nonmalignant lymphoid-tissues - analysis of their expression by insitu hybridization assays.
Lymphoma
Kinase-independent potentiation of B cell antigen receptor-mediated signal transduction by the protein tyrosine kinase Src.
Lymphoma
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Lymphoma
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Lymphoma
Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas.
Lymphoma
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Lymphoma
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Lymphoma
Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.
Lymphoma
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Lymphoma
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Lymphoma
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Lymphoma
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Lymphoma
MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway.
Lymphoma
MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.
Lymphoma
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-?b signaling pathway in mantle cell lymphoma.
Lymphoma
Molecular basis of targeted chemotherapy: novel concepts with special reference to the treatment of Hodgkin's disease.
Lymphoma
Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction.
Lymphoma
MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.
Lymphoma
Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis.
Lymphoma
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Lymphoma
Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.
Lymphoma
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Lymphoma
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Lymphoma
Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
Lymphoma
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Lymphoma
Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts.
Lymphoma
p110? inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma.
Lymphoma
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Lymphoma
Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation.
Lymphoma
Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma.
Lymphoma
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Lymphoma
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes.
Lymphoma
Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa bcr-abl protein.
Lymphoma
Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA.
Lymphoma
Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line.
Lymphoma
Phosphorylation of the lymphoid cell kinase p56lck is stimulated by micromolar concentrations of Zn2+.
Lymphoma
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Lymphoma
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Lymphoma
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Lymphoma
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Lymphoma
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene.
Lymphoma
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Lymphoma
PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
Lymphoma
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Lymphoma
Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry.
Lymphoma
Production of nitric oxide by differentiated LSTRA cells is associated with expression of macrophage-inducible nitric oxide synthase.
Lymphoma
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Lymphoma
Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells.
Lymphoma
Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase.
Lymphoma
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.
Lymphoma
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Lymphoma
Recurring proviral integration suggests a role for proto-oncogene activation in thymomas induced with Mo-MuLV-rescued BCR/ABL virus.
Lymphoma
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Lymphoma
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Lymphoma
Restoration of surface IgM-mediated apoptosis in an anti-IgM-resistant variant of WEHI-231 lymphoma cells by HS1, a protein-tyrosine kinase substrate.
Lymphoma
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Lymphoma
RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.
Lymphoma
Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.
Lymphoma
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Lymphoma
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Lymphoma
Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway.
Lymphoma
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Lymphoma
Single and combined BTK and PI3K? inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Lymphoma
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
Lymphoma
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Lymphoma
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Lymphoma
Src Kinase and Syk Activation Initiate PI3K Signaling by a Chimeric Latent Membrane Protein 1 in Epstein-Barr Virus (EBV)+ B Cell Lymphomas.
Lymphoma
Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells.
Lymphoma
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
Lymphoma
STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Lymphoma
Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields.
Lymphoma
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Lymphoma
T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.
Lymphoma
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Lymphoma
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Lymphoma
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Lymphoma
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Lymphoma
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Lymphoma
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
Lymphoma
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Lymphoma
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Lymphoma
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Lymphoma
The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Lymphoma
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Lymphoma
The retarded electrophoretic migration of p56lck induced by vanadate in lymphoma cells correlates with modified kinase activity.
Lymphoma
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Lymphoma
The sphingolipid-rich rafts of ALK+ lymphomas downregulate the Lyn-Cbp/PAG signalosome.
Lymphoma
The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.
Lymphoma
The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma.
Lymphoma
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Lymphoma
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Lymphoma
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.
Lymphoma
Tumor promoters cause changes in the state of phosphorylation and apparent molecular weight of a tyrosine protein kinase in T lymphocytes.
Lymphoma
Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene.
Lymphoma
Tyrosine protein kinase is involved in anti-IgM-mediated signaling in BAL17 B lymphoma cells.
Lymphoma
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Lymphoma
Vesicular stomatitis virus produced from infected LSTRA lymphoma cells bear tyrosine protein kinase activity (p56).
Lymphoma
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
Lymphoma
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
Lymphoma
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Lymphoma
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Lymphoma
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
Lymphoma
[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Lymphoma, B-Cell
A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.
Lymphoma, B-Cell
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Lymphoma, B-Cell
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Lymphoma, B-Cell
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Lymphoma, B-Cell
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Lymphoma, B-Cell
B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Lymphoma, B-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma, B-Cell
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.
Lymphoma, B-Cell
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Lymphoma, B-Cell
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Lymphoma, B-Cell
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Lymphoma, B-Cell
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Lymphoma, B-Cell
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Lymphoma, B-Cell
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
Lymphoma, B-Cell
Cross Talk Between TGF-? and JAK Expressions and Nepherotoxicity Induced by Tetrachloromethane: Role of Phytotherapy.
Lymphoma, B-Cell
Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Lymphoma, B-Cell
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.
Lymphoma, B-Cell
Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
Lymphoma, B-Cell
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Lymphoma, B-Cell
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Lymphoma, B-Cell
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Lymphoma, B-Cell
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant Janus kinase 2 activation.
Lymphoma, B-Cell
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.
Lymphoma, B-Cell
Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Lymphoma, B-Cell
Expression of protein tyrosine kinases in the Ig complex of anti-mu-sensitive and anti-mu-resistant B-cell lymphomas: role of the p55blk kinase in signaling growth arrest and apoptosis.
Lymphoma, B-Cell
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Lymphoma, B-Cell
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Lymphoma, B-Cell
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Lymphoma, B-Cell
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Lymphoma, B-Cell
Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.
Lymphoma, B-Cell
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.
Lymphoma, B-Cell
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.
Lymphoma, B-Cell
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Lymphoma, B-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, B-Cell
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Lymphoma, B-Cell
Interdisciplinary approach to the current management of chronic lymphocytic leukemia
Lymphoma, B-Cell
Lyn tyrosine kinase signals cell cycle arrest in mouse and human B-cell lymphoma.
Lymphoma, B-Cell
Maslinic acid suppresses the growth of human gastric cells by inducing apoptosis via inhibition of the interleukin-6 mediated Janus kinase/signal transducer and activator of transcription 3 signaling pathway.
Lymphoma, B-Cell
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Lymphoma, B-Cell
MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway.
Lymphoma, B-Cell
MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway.
Lymphoma, B-Cell
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Lymphoma, B-Cell
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Lymphoma, B-Cell
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Lymphoma, B-Cell
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Lymphoma, B-Cell
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Lymphoma, B-Cell
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Lymphoma, B-Cell
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Lymphoma, B-Cell
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Lymphoma, B-Cell
Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway.
Lymphoma, B-Cell
STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Lymphoma, B-Cell
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Lymphoma, B-Cell
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Lymphoma, B-Cell
Targeting phosphatidylinositol 3 kinase-? and -? for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Lymphoma, B-Cell
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Lymphoma, B-Cell
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Lymphoma, B-Cell
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Lymphoma, B-Cell
The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.
Lymphoma, B-Cell
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Lymphoma, B-Cell
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Lymphoma, B-Cell
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Lymphoma, B-Cell
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Lymphoma, B-Cell
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Lymphoma, B-Cell, Marginal Zone
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, Follicular
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lymphoma, Follicular
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Lymphoma, Follicular
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Lymphoma, Follicular
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Lymphoma, Follicular
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Lymphoma, Follicular
Follicular lymphoma-associated BTK mutations are inactivating resulting in augmented AKT activation.
Lymphoma, Follicular
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Lymphoma, Follicular
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, Follicular
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Lymphoma, Large B-Cell, Diffuse
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Lymphoma, Large B-Cell, Diffuse
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma, Large B-Cell, Diffuse
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Lymphoma, Large B-Cell, Diffuse
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Lymphoma, Large B-Cell, Diffuse
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Lymphoma, Large B-Cell, Diffuse
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency.
Lymphoma, Large B-Cell, Diffuse
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Lymphoma, Large B-Cell, Diffuse
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant Janus kinase 2 activation.
Lymphoma, Large B-Cell, Diffuse
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Lymphoma, Large B-Cell, Diffuse
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, Large B-Cell, Diffuse
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Lymphoma, Large B-Cell, Diffuse
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Lymphoma, Large B-Cell, Diffuse
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
Lymphoma, Large B-Cell, Diffuse
STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Lymphoma, Large B-Cell, Diffuse
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Lymphoma, Large B-Cell, Diffuse
Targeting phosphatidylinositol 3 kinase-? and -? for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Lymphoma, Large-Cell, Anaplastic
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3.
Lymphoma, Large-Cell, Anaplastic
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, Large-Cell, Anaplastic
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Lymphoma, Mantle-Cell
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
Lymphoma, Mantle-Cell
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Lymphoma, Mantle-Cell
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Lymphoma, Mantle-Cell
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Lymphoma, Mantle-Cell
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lymphoma, Mantle-Cell
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Lymphoma, Mantle-Cell
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Lymphoma, Mantle-Cell
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Lymphoma, Mantle-Cell
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Lymphoma, Mantle-Cell
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Lymphoma, Mantle-Cell
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?
Lymphoma, Mantle-Cell
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Lymphoma, Mantle-Cell
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib.
Lymphoma, Mantle-Cell
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Lymphoma, Mantle-Cell
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Lymphoma, Mantle-Cell
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Lymphoma, Mantle-Cell
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Lymphoma, Mantle-Cell
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Lymphoma, Mantle-Cell
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Lymphoma, Mantle-Cell
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Lymphoma, Mantle-Cell
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Lymphoma, Mantle-Cell
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Lymphoma, Mantle-Cell
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Lymphoma, Mantle-Cell
Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
Lymphoma, Mantle-Cell
High ZAP-70 expression correlates with worse clinical outcome in mantle cell lymphoma.
Lymphoma, Mantle-Cell
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Lymphoma, Mantle-Cell
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.
Lymphoma, Mantle-Cell
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Lymphoma, Mantle-Cell
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Lymphoma, Mantle-Cell
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Lymphoma, Mantle-Cell
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Lymphoma, Mantle-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, Mantle-Cell
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Lymphoma, Mantle-Cell
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Lymphoma, Mantle-Cell
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Lymphoma, Mantle-Cell
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Lymphoma, Mantle-Cell
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Lymphoma, Mantle-Cell
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Lymphoma, Mantle-Cell
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Lymphoma, Mantle-Cell
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Lymphoma, Mantle-Cell
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-?b signaling pathway in mantle cell lymphoma.
Lymphoma, Mantle-Cell
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Lymphoma, Mantle-Cell
NF-?B signaling and its relevance to the treatment of mantle cell lymphoma.
Lymphoma, Mantle-Cell
Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
Lymphoma, Mantle-Cell
p110? inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Lymphoma, Mantle-Cell
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Lymphoma, Mantle-Cell
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Lymphoma, Mantle-Cell
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Lymphoma, Mantle-Cell
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Lymphoma, Mantle-Cell
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Lymphoma, Mantle-Cell
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Lymphoma, Mantle-Cell
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Lymphoma, Mantle-Cell
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Lymphoma, Mantle-Cell
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
Lymphoma, Mantle-Cell
Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Lymphoma, Mantle-Cell
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Lymphoma, Mantle-Cell
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Lymphoma, Mantle-Cell
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Lymphoma, Mantle-Cell
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Lymphoma, Mantle-Cell
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Lymphoma, Mantle-Cell
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Lymphoma, Mantle-Cell
The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma.
Lymphoma, Mantle-Cell
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Lymphoma, Mantle-Cell
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Lymphoma, Mantle-Cell
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
Lymphoma, Mantle-Cell
Zanubrutinib-induced liver injury: a case report and literature review.
Lymphoma, Mantle-Cell
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Lymphoma, Mantle-Cell
[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Lymphoma, Non-Hodgkin
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Lymphoma, Non-Hodgkin
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Lymphoma, Non-Hodgkin
Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Lymphoma, Non-Hodgkin
Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.
Lymphoma, Non-Hodgkin
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Lymphoma, Non-Hodgkin
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Lymphoma, Non-Hodgkin
Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.
Lymphoma, Non-Hodgkin
New lanthanum (III) complex--synthesis, characterization, and cytotoxic activity.
Lymphoma, Non-Hodgkin
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Lymphoma, Non-Hodgkin
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Lymphoma, Primary Effusion
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
Lymphoma, Primary Effusion
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Lymphoma, T-Cell
A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA.
Lymphoma, T-Cell
Characteristics of TCR?, ZAP-70, and Fc?RI? Gene Expression in Patients with T- and NK/T-Cell Lymphoma.
Lymphoma, T-Cell
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Lymphoma, T-Cell
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Lymphoma, T-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, T-Cell
MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.
Lymphoma, T-Cell
Neoplastic transformation induced by an activated lymphocyte-specific protein tyrosine kinase (pp56lck).
Lymphoma, T-Cell
RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.
Lymphoma, T-Cell
TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.
Lymphoma, T-Cell
Tumor promoters cause changes in the state of phosphorylation and apparent molecular weight of a tyrosine protein kinase in T lymphocytes.
Lymphoma, T-Cell, Cutaneous
Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl.
Lymphoma, T-Cell, Peripheral
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
Lymphoma, T-Cell, Peripheral
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, T-Cell, Peripheral
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Lymphomatoid Granulomatosis
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
Lymphopenia
Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia.
Lymphopenia
Dietary zinc deficiency and expression of T lymphocyte signal transduction proteins.
Lymphopenia
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.
Lymphopenia
Studies of patients' thymi aid in the discovery and characterization of immunodeficiency in humans.
Lymphopenia
The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19.
Lymphopenia
The expression of the non-receptor tyrosine kinases Arg and c-abl is differently modulated in B lymphoid cells at different stages of differentiation.
Lymphoproliferative Disorders
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Lymphoproliferative Disorders
Association of cytogenetic abnormalities with detection of BCR-ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL).
Lymphoproliferative Disorders
CRL3IBTK Regulates the Tumor Suppressor Pdcd4 through Ubiquitylation Coupled to Proteasomal Degradation.
Lymphoproliferative Disorders
Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events.
Lymphoproliferative Disorders
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia.
Lymphoproliferative Disorders
Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.
Lymphoproliferative Disorders
Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
Lymphoproliferative Disorders
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Lymphoproliferative Disorders
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Lymphoproliferative Disorders
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
Lymphoproliferative Disorders
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Lymphoproliferative Disorders
IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
Lymphoproliferative Disorders
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Lymphoproliferative Disorders
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
Lymphoproliferative Disorders
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.
Lymphoproliferative Disorders
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Macular Degeneration
Shared genetic variants for polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration in East Asians.
Macular Edema
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Malaria
CD36 and Fyn Kinase Mediate Malaria-Induced Lung Endothelial Barrier Dysfunction in Mice Infected with Plasmodium berghei.
Malnutrition
Dietary zinc deficiency and expression of T lymphocyte signal transduction proteins.
Malnutrition
[Role of the cytokine-3 signaling suppressor protein (SOCS 3) in growth hormone resistance induced by malnutrition]
Malocclusion
Potential interactions among single nucleotide polymorphisms in bone- and cartilage-related genes in skeletal malocclusions.
Marfan Syndrome
A single heterozygous nucleotide substitution displays two different altered mechanisms in the FBN1 gene of five Italian marfan patients.
Marfan Syndrome
Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome.
Marfan Syndrome
Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes.
Marfan Syndrome
Dural ectasia in individuals with Marfan-like features but exclusion of mutations in the genes FBN1, TGFBR1 and TGFBR2.
Marfan Syndrome
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Marfan Syndrome
Fibroblast autofluorescence in connective tissue disorders: a future tool for clinical and differential diagnosis?
Marfan Syndrome
Gene panel sequencing in heritable thoracic aortic disorders and related entities ¿ results of comprehensive testing in a cohort of 264 patients.
Marfan Syndrome
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Marfan Syndrome
Marfan syndrome type II: there is more to Marfan syndrome than fibrillin 1.
Marfan Syndrome
Molecular analysis for diagnosis of Marfan syndrome and Marfan-associated disorders.
Marfan Syndrome
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Marfan Syndrome
SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction.
Marfan Syndrome
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
Marfan Syndrome
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Marfan Syndrome
WES/WGS Reporting of Mutations from Cardiovascular "Actionable" Genes in Clinical Practice: A Key Role for UMD Knowledgebases in the era of Big Databases.
Marfan Syndrome
[Interactions between fibrillin-1 and tgf-beta: consequences and human pathology]
Massive Hepatic Necrosis
The vagus nerve attenuates fulminant hepatitis by activating the Src kinase in Kuppfer cells.
Mastitis
Three Novel Players: PTK2B, SYK, and TNFRSF21 Were Identified to Be Involved in the Regulation of Bovine Mastitis Susceptibility via GWAS and Post-transcriptional Analysis.
Mastocytosis, Systemic
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Medulloblastoma
Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.
Medulloblastoma
Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
Medulloblastoma
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Medulloblastoma
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.
Medulloblastoma
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Medulloblastoma
New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.
Medulloblastoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Megalencephaly
A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome.
Melanoma
A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis.
Melanoma
A therapeutic trial of human melanomas with combined small interfering RNAs targeting adaptor molecules p130Cas and paxillin activated under expression of ganglioside GD3.
Melanoma
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Melanoma
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
Melanoma
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Melanoma
Anoikis induction and metastasis suppression by a new integrin ?v?3 inhibitor in human melanoma cell line M21.
Melanoma
Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition.
Melanoma
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
Melanoma
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
Melanoma
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Melanoma
Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.
Melanoma
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
Melanoma
c-Abl Kinase Is a Regulator of ?v?3 Integrin Mediated Melanoma A375 Cell Migration.
Melanoma
CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase.
Melanoma
Changes in the levels of integrin and focal adhesion kinase (FAK) in human melanoma cells following 532 nm laser treatment.
Melanoma
Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Melanoma
Circ_0002770, acting as a competitive endogenous RNA, promotes proliferation and invasion by targeting miR-331-3p in melanoma.
Melanoma
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Melanoma
Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
Melanoma
Conservation of structure and expression of the c-yes and fyn genes in lower vertebrates.
Melanoma
Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation.
Melanoma
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.
Melanoma
Development of a Bifunctional Andrographolide-Based Chemical Probe for Pharmacological Study.
Melanoma
Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.
Melanoma
Doxycycline inhibits leukemic cell migration via inhibition of matrix metalloproteinases and phosphorylation of focal adhesion kinase.
Melanoma
Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK).
Melanoma
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Melanoma
Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma.
Melanoma
Echistatin induces decrease of pp125FAK phosphorylation, disassembly of actin cytoskeleton and focal adhesions, and detachment of fibronectin-adherent melanoma cells.
Melanoma
Echistatin inhibits pp125FAK autophosphorylation, paxillin phosphorylation and pp125FAK-paxillin interaction in fibronectin-adherent melanoma cells.
Melanoma
Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.
Melanoma
Effect of SOCS1 silencing on proliferation and apoptosis of melanoma cells: An in vivo and in vitro study.
Melanoma
Effect of synthetic sialyl 2-->1 sphingosine and other glycosylsphingosines on the structure and function of the "glycosphingolipid signaling domain (GSD)" in mouse melanoma B16 cells.
Melanoma
Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.
Melanoma
Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression.
Melanoma
EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Melanoma
EphB4 Promotes Site-Specific Metastatic Tumor Cell Dissemination by Interacting with Endothelial Cell-Expressed EphrinB2.
Melanoma
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Melanoma
Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro.
Melanoma
Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
Melanoma
Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
Melanoma
FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression.
Melanoma
Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4.
Melanoma
Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines.
Melanoma
Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells.
Melanoma
Focal adhesion kinase-dependent apoptosis of melanoma induced by tyrosine and phenylalanine deficiency.
Melanoma
Functional activation of SRC family kinase yes is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3.
Melanoma
Geraniin-mediated apoptosis by cleavage of focal adhesion kinase through up-regulation of Fas ligand expression in human melanoma cells.
Melanoma
Glucose-6-phosphate dehydrogenase and NADPH oxidase 4 control STAT3 activity in melanoma cells through a pathway involving reactive oxygen species, c-SRC and SHP2.
Melanoma
GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity.
Melanoma
Heparin plays a key regulatory role via a p53/FAK-dependent signaling in melanoma cell adhesion and migration.
Melanoma
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.
Melanoma
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Melanoma
In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Melanoma
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Melanoma
Inhibition of mTORC1 by SU6656, the Selective Src Kinase Inhibitor, Is Not Accompanied by Activation of Akt/PKB Signalling in Melanoma Cells.
Melanoma
Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Melanoma
Insulin receptor internalization defect in an insulin-resistant mouse melanoma cell line.
Melanoma
Irradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivo.
Melanoma
Irradiation affects cellular properties and Eph receptor expression in human melanoma cells.
Melanoma
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Melanoma
Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells.
Melanoma
Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Melanoma
Lipid rafts couple store-operated Ca2+ entry to constitutive activation of PKB/Akt in a Ca2+/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth.
Melanoma
Lyn Kinase Promotes the Proliferation of Malignant Melanoma Cells through Inhibition of Apoptosis and Autophagy via the PI3K/Akt Signaling Pathway.
Melanoma
mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB.
Melanoma
Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK).
Melanoma
Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis.
Melanoma
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Melanoma
Osteonectin downregulates E-cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype.
Melanoma
Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
Melanoma
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Melanoma
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Melanoma
Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr?²?.
Melanoma
Polyethylenimine-complexed Plasmid Particles Targeting Focal Adhesion Kinase Function as Melanoma Tumor Therapeutics.
Melanoma
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Melanoma
Reconstitution of membranes simulating "glycosignaling domain" and their susceptibility to lyso-GM3.
Melanoma
Role of zyxin in differential cell spreading and proliferation of melanoma cells and melanocytes.
Melanoma
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.
Melanoma
Selective Killing of Melanoma Cells With Non-Thermal Atmospheric Pressure Plasma and p-FAK Antibody Conjugated Gold Nanoparticles.
Melanoma
SERINE-910 Phosphorylated Focal Adhesion Kinase Expression Predicts Better Overall and Disease-free Survival in Melanoma.
Melanoma
Silencing of microRNA-27a facilitates autophagy and apoptosis of melanoma cells through the activation of the SYK-dependent mTOR signaling pathway.
Melanoma
Soft matrices downregulate FAK activity to promote growth of tumor-repopulating cells.
Melanoma
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Melanoma
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Melanoma
Src Family Tyrosine Kinase Signaling Regulates FilGAP through Association with RBM10.
Melanoma
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Melanoma
Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Melanoma
Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells.
Melanoma
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Melanoma
The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.
Melanoma
The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.
Melanoma
The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma.
Melanoma
The oncogenic epidermal growth factor receptor variant xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions.
Melanoma
Triptolide-Mediated Apoptosis by Suppression of Focal Adhesion Kinase through Extrinsic and Intrinsic Pathways in Human Melanoma Cells.
Melanoma
VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression.
Melanoma
[Construction of stable focal adhesion kinase knockdown cell line and preliminary study of its properties].
Melanoma, Experimental
Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity.
Melanoma, Experimental
EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Melanoma, Experimental
Inhibiting focal adhesion kinase (FAK) blocks IL-4 induced VCAM-1 expression and eosinophil recruitment in vitro and in vivo.
Melanoma, Experimental
PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
Memory Disorders
Identification of novel inhibitor targeting Fyn kinase using molecular docking analysis.
Memory Disorders
Increased Src Family Kinase Activity Disrupts Excitatory Synaptic Transmission and Impairs Remote Fear Memory in Forebrain Shp2-Deficient Mice.
Memory Disorders
Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin.
Memory Disorders
Voluntary exercise rescues sevoflurane-induced memory impairment in aged male mice.
Meningioma
Curcumin Inhibits HGF-Induced EMT by Regulating c-MET-Dependent PI3K/Akt/mTOR Signaling Pathways in Meningioma.
Meningitis
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Meningoencephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Meningoencephalitis
Fatal Progressive Meningoencephalitis Diagnosed in Two Members of a Family With X-Linked Agammaglobulinemia.
Mesenteric Ischemia
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
Mesothelioma
Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Mesothelioma
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Mesothelioma
Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA.
Mesothelioma
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Mesothelioma, Malignant
Correction: Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.
Mesothelioma, Malignant
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.
Mesothelioma, Malignant
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Mesothelioma, Malignant
Human malignant mesothelioma cell growth: activation of janus kinase 2 and signal transducer and activator of transcription 1alpha for inhibition by interferon-gamma.
Mesothelioma, Malignant
Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.
Metabolic Syndrome
Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.
Metrorrhagia
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice.
Metrorrhagia
The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase.
Microcephaly
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Mitral Valve Prolapse
Screening of TGFBR1, TGFBR2, and FLNA in familial mitral valve prolapse.
Molluscum Contagiosum
A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
Molluscum Contagiosum
Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor.
Mouth Neoplasms
Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.
Mouth Neoplasms
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Mouth Neoplasms
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Mouth Neoplasms
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Mouth Neoplasms
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation.
Mouth Neoplasms
Insights From Studies With Oral Cleft Genes Suggest Associations between WNT-pathway Genes and Risk of Oral Cancer.
Mouth Neoplasms
Polymorphisms associated with oral clefts as potential susceptibility markers for oral and breast cancer.
Mouth Neoplasms
Prognostic implication of the loss of TGFBR2 expression in oral carcinoma.
Mouth Neoplasms
Prognostic value of transforming growth factor beta receptor 1 polymorphisms in patients with oral cancer.
Movement Disorders
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
Movement Disorders
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Mucocutaneous Lymph Node Syndrome
Non-receptor type, proline-rich protein tyrosine kinase 2 (Pyk2) is a possible therapeutic target for Kawasaki disease.
Multiple Endocrine Neoplasia
Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Multiple Endocrine Neoplasia Type 2a
Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Multiple Myeloma
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Multiple Myeloma
A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis.
Multiple Myeloma
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Multiple Myeloma
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Multiple Myeloma
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Multiple Myeloma
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Multiple Myeloma
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Multiple Myeloma
An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature.
Multiple Myeloma
Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells.
Multiple Myeloma
As4S4 Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway.
Multiple Myeloma
Asiatic acid, a triterpene, inhibits cell proliferation through regulating the expression of focal adhesion kinase in multiple myeloma cells.
Multiple Myeloma
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Multiple Myeloma
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Multiple Myeloma
Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
Multiple Myeloma
Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses Apoptosis via Activating MicroRNA-638 Mediated MEK/ERK, WNT/?-Catenin Signaling Pathways in Multiple Myeloma.
Multiple Myeloma
Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells.
Multiple Myeloma
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
Multiple Myeloma
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.
Multiple Myeloma
Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration.
Multiple Myeloma
From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Multiple Myeloma
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Multiple Myeloma
Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-?B and STAT3.
Multiple Myeloma
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Multiple Myeloma
Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
Multiple Myeloma
Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment.
Multiple Myeloma
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
Multiple Myeloma
P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma.
Multiple Myeloma
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
Multiple Myeloma
Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage.
Multiple Myeloma
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Multiple Myeloma
STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.
Multiple Myeloma
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
Multiple Myeloma
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway.
Multiple Myeloma
The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
Multiple Myeloma
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Multiple Myeloma
The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.
Multiple Myeloma
The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma.
Multiple Myeloma
Therapeutic effect and mechanism of ibrutinib combined with dexamethasone on multiple myeloma.
Multiple Myeloma
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Multiple Myeloma
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
Multiple Pulmonary Nodules
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
Multiple Sclerosis
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
Multiple Sclerosis
Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis.
Multiple Sclerosis
Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis.
Multiple Sclerosis
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Multiple Sclerosis
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
Multiple Sclerosis
Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures.
Multiple Sclerosis
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Multiple Sclerosis
Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation.
Multiple Sclerosis
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Multiple Sclerosis
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.
Multiple Sclerosis
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Multiple System Atrophy
A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor.
Mumps
STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.
Murine Acquired Immunodeficiency Syndrome
Altered brain fyn kinase in a murine acquired immunodeficiency syndrome.
Murine Acquired Immunodeficiency Syndrome
Analysis of antigen receptor signaling in B cells from mice with a retrovirus-induced acquired immunodeficiency syndrome.
Murine Acquired Immunodeficiency Syndrome
Reciprocal regulation of protein tyrosine kinases p56lck and p59fyn, and altered tyrosine phosphorylation in murine AIDS.
Murine Acquired Immunodeficiency Syndrome
The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl.
Murine Acquired Immunodeficiency Syndrome
The xid mutation plays an important role in delayed development of murine acquired immunodeficiency syndrome.
Muscle Cramp
Cathelicidin Modulates Vascular Smooth Muscle Cell Phenotypic Switching through ROS/IL-6 Pathway.
Muscle Hypotonia
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Muscle Weakness
Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Muscle Weakness
Janus Kinase Inhibition Prevents Cancer- and Myocardial Infarction-Mediated Diaphragm Muscle Weakness in Mice.
Muscular Atrophy
Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy.
Muscular Atrophy
Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction.
Muscular Atrophy, Spinal
Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Muscular Dystrophies
[Personalized medicine based on genomic information: the present status in terms of clinical application]
Muscular Dystrophy, Duchenne
TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy.
Myasthenia Gravis
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Mycobacterium Infections
Mycobacterium Intracellulare Infection Associated with TYK2 Deficiency: A Case Report and Review of the Literature.
Mycoses
Dectin-1 is required for human dendritic cells to initiate immune response to Candida albicans through Syk activation.
Mycoses
Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection.
Mycoses
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Mycoses
Recombinant human granulocyte macrophage-colony stimulating factor expressed in yeast (sargramostim): A potential ally to combat serious infections.
Mycoses
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Mycoses
Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to Candida Species.
Mycosis Fungoides
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Myelodysplastic Syndromes
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Myelodysplastic Syndromes
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Myelodysplastic Syndromes
Aberrant methylation of GTPase regulator associated with the focal adhesion kinase (GRAF) promoter is an adverse prognostic factor in myelodysplastic syndrome.
Myelodysplastic Syndromes
Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia.
Myelodysplastic Syndromes
Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
Myelodysplastic Syndromes
Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia.
Myelodysplastic Syndromes
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Myelodysplastic Syndromes
Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Myelodysplastic Syndromes
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
Myelodysplastic Syndromes
Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase.
Myelodysplastic Syndromes
Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Myelodysplastic Syndromes
Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients.
Myelodysplastic Syndromes
Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation.
Myelodysplastic Syndromes
Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
Myelodysplastic Syndromes
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.
Myelodysplastic Syndromes
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Myelodysplastic Syndromes
Progression from myelodysplastic syndrome to acute lymphoblastic leukaemia with Philadelphia chromosome and p190 BCR-ABL transcript.
Myelodysplastic Syndromes
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Myelodysplastic Syndromes
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Myelodysplastic Syndromes
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Myelodysplastic Syndromes
The implication of 'unknown significance' variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene.
Myelodysplastic Syndromes
[Granulocyte abnormal chromatin clumping syndrome: report of a new case and review of the literature]
Myeloproliferative Disorders
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Myeloproliferative Disorders
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Myeloproliferative Disorders
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
Myeloproliferative Disorders
A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
Myeloproliferative Disorders
A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Myeloproliferative Disorders
A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation.
Myeloproliferative Disorders
A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.
Myeloproliferative Disorders
Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
Myeloproliferative Disorders
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
Myeloproliferative Disorders
Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Myeloproliferative Disorders
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Myeloproliferative Disorders
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.
Myeloproliferative Disorders
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Myeloproliferative Disorders
Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
Myeloproliferative Disorders
Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera.
Myeloproliferative Disorders
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Myeloproliferative Disorders
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Myeloproliferative Disorders
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Myeloproliferative Disorders
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Myeloproliferative Disorders
B cell lymphoproliferation and organ-directed self-recognition to explain autoimmunity: Back to the past.
Myeloproliferative Disorders
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Myeloproliferative Disorders
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
Myeloproliferative Disorders
Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Myeloproliferative Disorders
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Myeloproliferative Disorders
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
Myeloproliferative Disorders
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Myeloproliferative Disorders
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Myeloproliferative Disorders
Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.
Myeloproliferative Disorders
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Myeloproliferative Disorders
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Myeloproliferative Disorders
Clinical implications of JAK2 mutations in myeloproliferative disorders.
Myeloproliferative Disorders
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
Myeloproliferative Disorders
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Myeloproliferative Disorders
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Myeloproliferative Disorders
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Myeloproliferative Disorders
Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors.
Myeloproliferative Disorders
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Myeloproliferative Disorders
Deletion of exon b3 of the BCR gene in CML: easy breakpoint mapping by a two-round PCR.
Myeloproliferative Disorders
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Myeloproliferative Disorders
Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Myeloproliferative Disorders
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Myeloproliferative Disorders
Detection of Janus Kinase 2 gene single point mutation in real samples with electrochemical DNA biosensor.
Myeloproliferative Disorders
Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.
Myeloproliferative Disorders
Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.
Myeloproliferative Disorders
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Myeloproliferative Disorders
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Myeloproliferative Disorders
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Myeloproliferative Disorders
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.
Myeloproliferative Disorders
Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
Myeloproliferative Disorders
Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
Myeloproliferative Disorders
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
Myeloproliferative Disorders
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Myeloproliferative Disorders
Dissecting the role of aberrant DNA methylation in human leukaemia.
Myeloproliferative Disorders
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Myeloproliferative Disorders
Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-Cas13a.
Myeloproliferative Disorders
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
Myeloproliferative Disorders
Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Myeloproliferative Disorders
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Myeloproliferative Disorders
Erosion of the chronic myeloid leukaemia stem cell pool by PPAR? agonists.
Myeloproliferative Disorders
Essential thrombocythemia: scientific advances and current practice.
Myeloproliferative Disorders
Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
Myeloproliferative Disorders
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Myeloproliferative Disorders
Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells.
Myeloproliferative Disorders
Expression analysis of Akirin-2, NF?B-p65 and ?-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Myeloproliferative Disorders
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Myeloproliferative Disorders
Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
Myeloproliferative Disorders
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Myeloproliferative Disorders
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Myeloproliferative Disorders
Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Myeloproliferative Disorders
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Myeloproliferative Disorders
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Myeloproliferative Disorders
Imatinib effect on growth and signal transduction in polycythemia vera.
Myeloproliferative Disorders
Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1.
Myeloproliferative Disorders
Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Myeloproliferative Disorders
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
Myeloproliferative Disorders
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Myeloproliferative Disorders
Inhibition of protein tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl.
Myeloproliferative Disorders
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Myeloproliferative Disorders
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
Myeloproliferative Disorders
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
Myeloproliferative Disorders
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Myeloproliferative Disorders
JAK2 in myeloproliferative disorders is not just another kinase.
Myeloproliferative Disorders
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
Myeloproliferative Disorders
JAK2 V617F "Indeterminate" Results by MutaScreen Can Be Easily Resolved Using MutaQuant Kits.
Myeloproliferative Disorders
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Myeloproliferative Disorders
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Myeloproliferative Disorders
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Myeloproliferative Disorders
JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Myeloproliferative Disorders
Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders.
Myeloproliferative Disorders
Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey.
Myeloproliferative Disorders
Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: Clinical implications.
Myeloproliferative Disorders
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Myeloproliferative Disorders
Kinases as drug discovery targets in hematologic malignancies.
Myeloproliferative Disorders
L-amino acid oxidase isolated from Bothrops pirajai induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect.
Myeloproliferative Disorders
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Myeloproliferative Disorders
Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
Myeloproliferative Disorders
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Myeloproliferative Disorders
MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.
Myeloproliferative Disorders
miR-155 effectively induces apoptosis in K562 Philadelphia positive cell line through upregulation of p27kip1.
Myeloproliferative Disorders
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Myeloproliferative Disorders
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Myeloproliferative Disorders
Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
Myeloproliferative Disorders
New insights into the pathogenesis and drug treatment of myelofibrosis.
Myeloproliferative Disorders
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Myeloproliferative Disorders
NF?B pathway and microRNA-9 and -21 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines.
Myeloproliferative Disorders
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
Myeloproliferative Disorders
p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia.
Myeloproliferative Disorders
p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation.
Myeloproliferative Disorders
Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
Myeloproliferative Disorders
Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
Myeloproliferative Disorders
PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia.
Myeloproliferative Disorders
Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Myeloproliferative Disorders
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Myeloproliferative Disorders
Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.
Myeloproliferative Disorders
Reciprocal translocation between chromosomes 8 and 9 in atypical chronic myeloid leukaemia.
Myeloproliferative Disorders
Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Myeloproliferative Disorders
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Myeloproliferative Disorders
Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.
Myeloproliferative Disorders
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Myeloproliferative Disorders
ROLES OF INTERFERON REGULATORY FACTORS IN CHRONIC MYELOID LEUKEMIA.
Myeloproliferative Disorders
Routine fluorescence in situ hybridization analysis for detection of BCR-ABL rearrangement in myeloproliferative disorders.
Myeloproliferative Disorders
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.
Myeloproliferative Disorders
Shooting the messenger: Targeting signal transduction pathways in leukemia and related disorders.
Myeloproliferative Disorders
Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
Myeloproliferative Disorders
siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Myeloproliferative Disorders
Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.
Myeloproliferative Disorders
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Myeloproliferative Disorders
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Myeloproliferative Disorders
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells.
Myeloproliferative Disorders
Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.
Myeloproliferative Disorders
Studies of some mechanisms of drug resistance in chronic myeloid leukemia (CML).
Myeloproliferative Disorders
SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1? axis.
Myeloproliferative Disorders
Targeting Survival Pathways in Chronic Myeloid Leukaemia Stem Cells.
Myeloproliferative Disorders
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Myeloproliferative Disorders
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
Myeloproliferative Disorders
The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders.
Myeloproliferative Disorders
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Myeloproliferative Disorders
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.
Myeloproliferative Disorders
The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.
Myeloproliferative Disorders
The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Myeloproliferative Disorders
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Myeloproliferative Disorders
The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review.
Myeloproliferative Disorders
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
Myeloproliferative Disorders
The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Myeloproliferative Disorders
Thrombopoietin in normal and neoplastic stem cell development.
Myeloproliferative Disorders
Transcriptional targets of Drosophila JAK/STAT pathway signalling as effectors of haematopoietic tumour formation.
Myeloproliferative Disorders
Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Myeloproliferative Disorders
Trisomy 13 in a Philadelphia negative chromosome and BCR-ABL negative myeloproliferative disorder.
Myeloproliferative Disorders
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
Myeloproliferative Disorders
Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
Myeloproliferative Disorders
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications.
Myeloproliferative Disorders
Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Myeloproliferative Disorders
Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome.
Myeloproliferative Disorders
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Myeloproliferative Disorders
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]
Myeloproliferative Disorders
[Experimental advance of targeted medicines for chronic myeloid leukemia--review]
Myeloproliferative Disorders
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]
Myeloproliferative Disorders
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
Myeloproliferative Disorders
[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]
Myeloproliferative Disorders
[Monitoring the chronic myeloid leukemia patients between 2008 and 2018; the experience of the Hematology and Bone Marrow Transplantation Unit Târgu-Mure?].
Myeloproliferative Disorders
[Utility of the bone marrow biopsy in the diagnosis of essential thrombocytemia.]
Myocardial Infarction
c-Src Kinase Inhibition Reduces Arrhythmia Inducibility and Connexin43 Dysregulation After Myocardial Infarction.
Myocardial Infarction
Cardiac-Specific Deletion of SOCS-3 Prevents Development of Left Ventricular Remodeling After Acute Myocardial Infarction.
Myocardial Infarction
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Myocardial Infarction
Quercetin protects against experimentally-induced myocardial infarction in rats by an antioxidant potential and concomitant activation of signal transducer and activator of transcription 3.
Myocardial Infarction
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
Myocardial Infarction
Tyrosine phosphorylation of eNOS regulates myocardial survival after an ischaemic insult: role of PYK2.
Myocardial Infarction
Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium.
Myocardial Infarction
Wnt11 Gene Therapy with Adeno-associated Virus 9 Improves Recovery from Myocardial Infarction by Modulating the Inflammatory Response.
Myocardial Ischemia
Characterization of novel lncRNAs in upper thoracic spinal cords of rats with myocardial ischemia-reperfusion injuries.
Myocardial Ischemia
MiR-27 alleviates myocardial cell damage induced by hypoxia/reoxygenation via targeting TGFBR1 and inhibiting NF-?B pathway.
Myocardial Ischemia
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
Myocarditis
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Myocarditis
Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis.
Myocarditis
lncRNA AK085865 Promotes Macrophage M2 Polarization in CVB3-Induced VM by Regulating ILF2-ILF3 Complex-Mediated miRNA-192 Biogenesis.
Myocarditis
The role of transgenic knockout models in defining the pathogenesis of viral heart disease.
Myocarditis
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Myocarditis
Wnt11 gene therapy with adeno-associated virus 9 improves the survival of mice with myocarditis induced by coxsackievirus B3 through the suppression of the inflammatory reaction.
Myocarditis
[Tanshinone attenuates myocardial injury via activating JAK2/STAT1 pathway in a murine model of viral myocarditis].
Myopathies, Structural, Congenital
Differential Muscle Hypertrophy Is Associated with Satellite Cell Numbers and Akt Pathway Activation Following Activin Type IIB Receptor Inhibition in Mtm1 p.R69C Mice.
Myopia
Association of Myopia and Genetic Variants of TGFB2-AS1 and TGFBR1 in the TGF-? Signaling Pathway: A Longitudinal Study in Chinese School-Aged Children.
Myositis
Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
Myositis Ossificans
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Myxoma
Myxoma virus induces extensive CD4 downregulation and dissociation of p56lck in infected rabbit CD4+ T lymphocytes.
Myxoma
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Myxoma
Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.
Nasal Polyps
[The profile of expression of transforming growth factor beta1 and TGFbetaRI, TGFbetaRII and TGFbetaRIII genes in nasal polyps]
Nasopharyngeal Carcinoma
5-aza-CdR induces the demethylation of Syk promoter in nasopharyngeal carcinoma cell.
Nasopharyngeal Carcinoma
Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Nasopharyngeal Carcinoma
Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis.
Nasopharyngeal Carcinoma
Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation.
Nasopharyngitis
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Necrobiosis Lipoidica
Successful treatment of ulcerative necrobiosis lipoidica with janus kinase inhibitor.
Necrobiosis Lipoidica
Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid.
Neoplasm Metastasis
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Neoplasm Metastasis
?-elemene inhibits non-small cell lung cancer cell migration and invasion by inactivating the FAK-Src pathway.
Neoplasm Metastasis
A BALB/c 3T3-transformed cell line suitable for transfection assay of metastasis-inducing genes.
Neoplasm Metastasis
A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Neoplasm Metastasis
A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis.
Neoplasm Metastasis
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
Neoplasm Metastasis
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Neoplasm Metastasis
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.
Neoplasm Metastasis
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
Neoplasm Metastasis
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Neoplasm Metastasis
A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing.
Neoplasm Metastasis
A radiation-induced murine ovarian granulosa cell tumor line: introduction of v-ras gene potentiates a high metastatic ability.
Neoplasm Metastasis
Abnormal expression of FAK and paxillin correlates with oral cancer invasion and metastasis.
Neoplasm Metastasis
Activated Cdc42 kinase regulates Dock localization in male germ cells during Drosophila spermatogenesis.
Neoplasm Metastasis
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Neoplasm Metastasis
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Neoplasm Metastasis
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
Neoplasm Metastasis
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
Neoplasm Metastasis
AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.
Neoplasm Metastasis
Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase.
Neoplasm Metastasis
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.
Neoplasm Metastasis
An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1.
Neoplasm Metastasis
Analysis of multiple physical parameters for mechanical phenotyping of living cells.
Neoplasm Metastasis
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Neoplasm Metastasis
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Neoplasm Metastasis
Ascending the PEAK1 toward targeting TGF? during cancer progression: Recent advances and future perspectives.
Neoplasm Metastasis
Ascochlorin Suppresses MMP-2-Mediated Migration and Invasion by Targeting FAK and JAK-STAT Signaling Cascades.
Neoplasm Metastasis
Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study.
Neoplasm Metastasis
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Neoplasm Metastasis
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
Neoplasm Metastasis
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
Neoplasm Metastasis
Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib.
Neoplasm Metastasis
Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells.
Neoplasm Metastasis
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
Neoplasm Metastasis
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer.
Neoplasm Metastasis
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
Neoplasm Metastasis
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
Neoplasm Metastasis
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Neoplasm Metastasis
Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.
Neoplasm Metastasis
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Neoplasm Metastasis
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.
Neoplasm Metastasis
CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase.
Neoplasm Metastasis
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity.
Neoplasm Metastasis
Cdc42-interacting protein 4 is a Src substrate that regulates invadopodia and invasiveness of breast tumors by promoting MT1-MMP endocytosis.
Neoplasm Metastasis
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
Neoplasm Metastasis
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Neoplasm Metastasis
Circular RNA circ_0000372 contributes to the proliferation, migration and invasion of colorectal cancer by elevating IL6 expression via sponging miR-495.
Neoplasm Metastasis
Clinical significance of focal adhesion kinase (FAK) in cervical cancer progression and metastasis.
Neoplasm Metastasis
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Neoplasm Metastasis
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Neoplasm Metastasis
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Neoplasm Metastasis
Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.
Neoplasm Metastasis
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Neoplasm Metastasis
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.
Neoplasm Metastasis
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Neoplasm Metastasis
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Neoplasm Metastasis
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Neoplasm Metastasis
Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Neoplasm Metastasis
Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer.
Neoplasm Metastasis
Cyclin G2 Inhibits Oral Squamous Cell Carcinoma Growth and Metastasis by Binding to IGFBP3 and Regulating the FAK-SRC-STAT Signaling Pathway.
Neoplasm Metastasis
Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion.
Neoplasm Metastasis
Cytotoxic effects of the anthraquinone derivatives 1'-deoxyrhodoptilometrin and (S)-(-)-rhodoptilometrin isolated from the marine echinoderm Comanthus sp.
Neoplasm Metastasis
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation.
Neoplasm Metastasis
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
Neoplasm Metastasis
Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK).
Neoplasm Metastasis
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.
Neoplasm Metastasis
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Neoplasm Metastasis
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Neoplasm Metastasis
Dependency of colorectal cancer on a TGF-?-driven program in stromal cells for metastasis initiation.
Neoplasm Metastasis
Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis.
Neoplasm Metastasis
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Neoplasm Metastasis
Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR.
Neoplasm Metastasis
Development of a High-Throughput Fluorescence Polarization Assay to Detect Inhibitors of the FAK-Paxillin Interaction.
Neoplasm Metastasis
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Neoplasm Metastasis
Diallyl trisulfide inhibits cell migration and invasion of human melanoma a375 cells via inhibiting integrin/facal adhesion kinase pathway.
Neoplasm Metastasis
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Neoplasm Metastasis
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Neoplasm Metastasis
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.
Neoplasm Metastasis
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Neoplasm Metastasis
Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking.
Neoplasm Metastasis
Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Neoplasm Metastasis
Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.
Neoplasm Metastasis
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Neoplasm Metastasis
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Neoplasm Metastasis
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Neoplasm Metastasis
Downregulation of microRNA-4324 promotes the EMT of esophageal squamous-cell carcinoma cells via upregulating FAK.
Neoplasm Metastasis
DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer.
Neoplasm Metastasis
Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis.
Neoplasm Metastasis
Dynamics of p14ARF and Focal Adhesion Kinase-Mediated Autophagy in Cancer.
Neoplasm Metastasis
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Neoplasm Metastasis
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Neoplasm Metastasis
EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2.
Neoplasm Metastasis
Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis.
Neoplasm Metastasis
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development.
Neoplasm Metastasis
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Neoplasm Metastasis
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
Neoplasm Metastasis
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Neoplasm Metastasis
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Neoplasm Metastasis
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Neoplasm Metastasis
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Neoplasm Metastasis
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Neoplasm Metastasis
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Neoplasm Metastasis
Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Neoplasm Metastasis
Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis.
Neoplasm Metastasis
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Neoplasm Metastasis
Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
Neoplasm Metastasis
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
Neoplasm Metastasis
Evaluation of FAK and Src Expression in Human Benign and Malignant Thyroid Lesions.
Neoplasm Metastasis
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma.
Neoplasm Metastasis
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Neoplasm Metastasis
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Neoplasm Metastasis
Expression of focal adhesion kinase (p125 FAK) and proline-rich tyrosine kinase 2 (PYK2/CAKb) in cerebral metastases, correlation with VEGF-R-, ecNOS III-labelling and morphometric data.
Neoplasm Metastasis
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Neoplasm Metastasis
Expression of pY397 FAK promotes the development of non-small cell lung cancer.
Neoplasm Metastasis
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Neoplasm Metastasis
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Neoplasm Metastasis
FAK alternative splice mRNA variants expression pattern in colorectal cancer.
Neoplasm Metastasis
FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR?/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.
Neoplasm Metastasis
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication.
Neoplasm Metastasis
FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer.
Neoplasm Metastasis
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Neoplasm Metastasis
Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Neoplasm Metastasis
Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4.
Neoplasm Metastasis
Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues.
Neoplasm Metastasis
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
Neoplasm Metastasis
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Neoplasm Metastasis
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
Neoplasm Metastasis
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Neoplasm Metastasis
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Neoplasm Metastasis
Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.
Neoplasm Metastasis
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Neoplasm Metastasis
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Neoplasm Metastasis
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Neoplasm Metastasis
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Neoplasm Metastasis
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Neoplasm Metastasis
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Neoplasm Metastasis
Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.
Neoplasm Metastasis
Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasis.
Neoplasm Metastasis
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Neoplasm Metastasis
Function and mechanism of neurotensin (NTS) and its receptor 1 (NTSR1) in occurrence and development of tumors.
Neoplasm Metastasis
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Neoplasm Metastasis
Fyn Requires HnRNPA2B1 and Sam68 to Synergistically Regulate Apoptosis in Pancreatic Cancer.
Neoplasm Metastasis
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Neoplasm Metastasis
Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.
Neoplasm Metastasis
Genomic characterization of liver metastases from colorectal cancer patients.
Neoplasm Metastasis
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.
Neoplasm Metastasis
Heparan Sulfate-Instructed Self-Assembly Selectively Inhibits Cancer Cell Migration.
Neoplasm Metastasis
HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.
Neoplasm Metastasis
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Neoplasm Metastasis
High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
Neoplasm Metastasis
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
Neoplasm Metastasis
Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
Neoplasm Metastasis
Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Neoplasm Metastasis
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation.
Neoplasm Metastasis
Identification of potential small-molecule protein-protein inhibitors of cancer metastasis by 3D epitope-based computational screening.
Neoplasm Metastasis
Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.
Neoplasm Metastasis
IGF-I Induces Epithelial-to-Mesenchymal Transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin Pathway in Nasopharyngeal Carcinoma Cells.
Neoplasm Metastasis
IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.
Neoplasm Metastasis
IL?6 plays a crucial role in epithelial?mesenchymal transition and pro?metastasis induced by sorafenib in liver cancer.
Neoplasm Metastasis
In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Neoplasm Metastasis
In Vitro Phosphorylation of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase by Src Kinase.
Neoplasm Metastasis
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Neoplasm Metastasis
Induction of membrane ruffling by growth factors in morphologically TPA-resistant Balb/c3T3 TR4 cells.
Neoplasm Metastasis
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.
Neoplasm Metastasis
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Neoplasm Metastasis
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Neoplasm Metastasis
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Neoplasm Metastasis
Inhibitory effect of aloe-emodin on metastasis potential in HO-8910PM cell line.
Neoplasm Metastasis
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Neoplasm Metastasis
Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
Neoplasm Metastasis
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
Neoplasm Metastasis
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Neoplasm Metastasis
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Neoplasm Metastasis
Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells.
Neoplasm Metastasis
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Neoplasm Metastasis
JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma.
Neoplasm Metastasis
Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Neoplasm Metastasis
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Neoplasm Metastasis
Knockdown of FAK inhibits the invasion and metastasis of Tca?8113 cells in vitro.
Neoplasm Metastasis
Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells.
Neoplasm Metastasis
LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Neoplasm Metastasis
Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Neoplasm Metastasis
Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia.
Neoplasm Metastasis
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases.
Neoplasm Metastasis
Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells.
Neoplasm Metastasis
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Neoplasm Metastasis
Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.
Neoplasm Metastasis
Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src.
Neoplasm Metastasis
Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
Neoplasm Metastasis
Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo.
Neoplasm Metastasis
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
Neoplasm Metastasis
MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer.
Neoplasm Metastasis
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
Neoplasm Metastasis
MiR-199a-5p Inhibits the Growth and Metastasis of Colorectal Cancer Cells by Targeting ROCK1.
Neoplasm Metastasis
MiR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITG?8- JAK2/STAT3 axis.
Neoplasm Metastasis
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Neoplasm Metastasis
Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain.
Neoplasm Metastasis
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Neoplasm Metastasis
Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer.
Neoplasm Metastasis
Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling.
Neoplasm Metastasis
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Neoplasm Metastasis
Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis.
Neoplasm Metastasis
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Neoplasm Metastasis
Nanomechanical Property Maps of Breast Cancer Cells As Determined by Multiharmonic Atomic Force Microscopy Reveal Syk-Dependent Changes in Microtubule Stability Mediated by MAP1B.
Neoplasm Metastasis
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Neoplasm Metastasis
Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis.
Neoplasm Metastasis
Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.
Neoplasm Metastasis
Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner.
Neoplasm Metastasis
Novel long non-coding RNA LINC02323 promotes epithelial-mesenchymal transition and metastasis via sponging miR-1343-3p in lung adenocarcinoma.
Neoplasm Metastasis
Osthole suppresses the migratory ability of human glioblastoma multiforme cells via inhibition of focal adhesion kinase-mediated matrix metalloproteinase-13 expression.
Neoplasm Metastasis
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Neoplasm Metastasis
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Neoplasm Metastasis
Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.
Neoplasm Metastasis
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Neoplasm Metastasis
Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation.
Neoplasm Metastasis
Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.
Neoplasm Metastasis
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Neoplasm Metastasis
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Neoplasm Metastasis
Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential.
Neoplasm Metastasis
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.
Neoplasm Metastasis
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Neoplasm Metastasis
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
Neoplasm Metastasis
pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Neoplasm Metastasis
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Neoplasm Metastasis
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Neoplasm Metastasis
Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes.
Neoplasm Metastasis
Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-releasing peptide's morphogenic properties.
Neoplasm Metastasis
Possible involvement of bone morphogenetic protein 2 in heterotopic ossification in metastatic lesion from urothelial carcinoma of bladder.
Neoplasm Metastasis
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Neoplasm Metastasis
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Neoplasm Metastasis
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis.
Neoplasm Metastasis
Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Neoplasm Metastasis
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Neoplasm Metastasis
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Neoplasm Metastasis
Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
Neoplasm Metastasis
Recognition of LD motifs by the focal adhesion targeting domains of focal adhesion kinase and proline-rich tyrosine kinase 2-beta: Insights from molecular dynamics simulations.
Neoplasm Metastasis
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
Neoplasm Metastasis
Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells.
Neoplasm Metastasis
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Neoplasm Metastasis
Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.
Neoplasm Metastasis
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
Neoplasm Metastasis
Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis.
Neoplasm Metastasis
Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
Neoplasm Metastasis
Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
Neoplasm Metastasis
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Neoplasm Metastasis
Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
Neoplasm Metastasis
Sequence variation in the src gene product affects metastasis formation: the central, but not exclusive, role of the tumor immune response.
Neoplasm Metastasis
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Neoplasm Metastasis
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.
Neoplasm Metastasis
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer.
Neoplasm Metastasis
Specific induction of pp125 focal adhesion kinase in human breast cancer.
Neoplasm Metastasis
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Neoplasm Metastasis
Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation.
Neoplasm Metastasis
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Neoplasm Metastasis
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.
Neoplasm Metastasis
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Neoplasm Metastasis
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Neoplasm Metastasis
Src kinase activation by nitric oxide promotes resistance to anoikis in tumour cell lines.
Neoplasm Metastasis
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Neoplasm Metastasis
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Neoplasm Metastasis
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Neoplasm Metastasis
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Neoplasm Metastasis
Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Neoplasm Metastasis
Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds.
Neoplasm Metastasis
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
Neoplasm Metastasis
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Neoplasm Metastasis
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Neoplasm Metastasis
Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Neoplasm Metastasis
Suppression of MMP-9 and FAK expression by pomolic acid via blocking of NF-?B/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells.
Neoplasm Metastasis
SYK allelic loss and the role of Syk-regulated genes in breast cancer survival.
Neoplasm Metastasis
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Neoplasm Metastasis
Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.
Neoplasm Metastasis
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
Neoplasm Metastasis
Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Neoplasm Metastasis
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Neoplasm Metastasis
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Neoplasm Metastasis
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
Neoplasm Metastasis
Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling.
Neoplasm Metastasis
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Neoplasm Metastasis
TGF-Beta Suppresses VEGFA-Mediated Angiogenesis in Colon Cancer Metastasis.
Neoplasm Metastasis
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
Neoplasm Metastasis
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
Neoplasm Metastasis
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Neoplasm Metastasis
The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Neoplasm Metastasis
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance.
Neoplasm Metastasis
The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337.
Neoplasm Metastasis
The Src Family Kinase Inhibitors PP2 and PP1 block TGF-beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-beta Receptors.
Neoplasm Metastasis
The TGF-? Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.
Neoplasm Metastasis
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Neoplasm Metastasis
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Neoplasm Metastasis
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Neoplasm Metastasis
Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box.
Neoplasm Metastasis
Transcriptional and Post-Translational Control Mechanisms for EphB4 Expression in Physiology and Cancer Disease.
Neoplasm Metastasis
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Neoplasm Metastasis
TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.
Neoplasm Metastasis
Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-?B transactivation in LNCaP cells.
Neoplasm Metastasis
Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels.
Neoplasm Metastasis
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Neoplasm Metastasis
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Neoplasm Metastasis
Upregulation of TCTP is associated with cholangiocarcinoma progression and metastasis.
Neoplasm Metastasis
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
Neoplasm Metastasis
Visualizing and manipulating focal adhesion kinase regulation in live cells.
Neoplasm Metastasis
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
Neoplasm Metastasis
Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.
Neoplasm Metastasis
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Neoplasm Metastasis
ZAP-70 tyrosine kinase is required for LFA-1-dependent T cell migration.
Neoplasm Metastasis
[Effect of Janus kinase inhibitor AG490 on invasion and metastasis of human breast cancer cells]
Neoplasm Metastasis
[Effect of SRC Kinase on Adriamycin Resistance and Invasion and Metastasis in Human Breast Cancer Cells].
Neoplasm Metastasis
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
Neoplasm Metastasis
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Neoplasm Metastasis
[Expression of focal adhesion kinase in lymphatic endothelial cells of metastasis]
Neoplasm Metastasis
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
Neoplasm Metastasis
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]
Neoplasm Metastasis
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
Neoplasm Metastasis
[Influence of Pyk2 on hepatic metastasis and ultrastructure of human colonic cancer cells].
Neoplasm Metastasis
[Inhibitory effect of full-length spleen tyrosine kinase on invasion and metastasis of human laryngeal squamous cells].
Neoplasm Metastasis
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
Neoplasm Metastasis
[Novel non-tumorigenic cell variants showing potentially different susceptibility to v-src induced metastasis]
Neoplasm Metastasis
[SRC kinase inhibitor PP2 inhibits invasion and metastasis of lung cancer A549 cells by upregulating connexin43 expression].
Neoplasm Micrometastasis
TGF-? stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
Neoplasm, Residual
A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
Neoplasm, Residual
Acute Myeloid Leukemia with Philadelphia Chromosome, Near-tetraploidy, and 5q Deletion.
Neoplasm, Residual
An assessment of chimeric transcript detection in CML patients after bone marrow transplantation.
Neoplasm, Residual
Association of cytogenetic abnormalities with detection of BCR-ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL).
Neoplasm, Residual
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Neoplasm, Residual
Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Neoplasm, Residual
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Neoplasm, Residual
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Neoplasm, Residual
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Neoplasm, Residual
Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
Neoplasm, Residual
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Neoplasm, Residual
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
Neoplasm, Residual
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Neoplasm, Residual
Detection and quantification of the abelson tyrosine kinase domains of the BCR-ABL gene translocation in chronic myeloid leukaemia using genomic quantitative real-time polymerase chain reaction.
Neoplasm, Residual
Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation.
Neoplasm, Residual
Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph?+?ALL with minimal residual disease.
Neoplasm, Residual
Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML.
Neoplasm, Residual
Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
Neoplasm, Residual
Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).
Neoplasm, Residual
Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion.
Neoplasm, Residual
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Neoplasm, Residual
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Neoplasm, Residual
Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
Neoplasm, Residual
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Neoplasm, Residual
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Neoplasm, Residual
Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients.
Neoplasm, Residual
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
Neoplasm, Residual
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse.
Neoplasm, Residual
Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.
Neoplasm, Residual
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Neoplasm, Residual
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Neoplasm, Residual
Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Neoplasm, Residual
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Neoplasm, Residual
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.
Neoplasm, Residual
Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Neoplasm, Residual
Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation.
Neoplasm, Residual
Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Neoplasm, Residual
Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy.
Neoplasm, Residual
Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: The threats and challenges in monitoring minimal residual disease (MRD).
Neoplasm, Residual
Retreatment with purine analogs in patients with chronic lymphocytic leukemia.
Neoplasm, Residual
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Neoplasm, Residual
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Neoplasm, Residual
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Neoplasm, Residual
Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review.
Neoplasm, Residual
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Neoplasm, Residual
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
Neoplasm, Residual
WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.
Neoplasm, Residual
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction]
Neoplasm, Residual
[Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction]
Neoplasm, Residual
[Expression of the Wilms' Tumor Gene WT1 and Detection of Minimal Residual Disease in Acute Leukemia]
Neoplasm, Residual
[Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification]
Neoplasms
(+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min/+ mouse.
Neoplasms
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Neoplasms
1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
Neoplasms
17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Neoplasms
3-Deoxy-2?,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells.
Neoplasms
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Neoplasms
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Neoplasms
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
Neoplasms
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
Neoplasms
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Neoplasms
?-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer.
Neoplasms
?3?1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.
Neoplasms
A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.
Neoplasms
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Neoplasms
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Neoplasms
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
Neoplasms
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Neoplasms
A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.
Neoplasms
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia.
Neoplasms
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
Neoplasms
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
Neoplasms
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation.
Neoplasms
A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells.
Neoplasms
A constitutively active Lck kinase promotes cell proliferation and resistance to apoptosis through signal transducer and activator of transcription 5b activation.
Neoplasms
A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Neoplasms
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
Neoplasms
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Neoplasms
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients.
Neoplasms
A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F-positive polycythemia vera in vitro.
Neoplasms
A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Neoplasms
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Neoplasms
A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk.
Neoplasms
A genetic screen for modifiers of the lats tumor suppressor gene identifies C-terminal Src kinase as a regulator of cell proliferation in Drosophila.
Neoplasms
A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.
Neoplasms
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Neoplasms
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Neoplasms
A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden.
Neoplasms
A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis.
Neoplasms
A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.
Neoplasms
A New Class of Orthosteric uPARuPA Small-Molecule Antagonists Are Allosteric Inhibitors of the uPARVitronectin Interaction.
Neoplasms
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Neoplasms
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor.
Neoplasms
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
Neoplasms
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.
Neoplasms
A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling.
Neoplasms
A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma.
Neoplasms
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.
Neoplasms
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
Neoplasms
A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis.
Neoplasms
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.
Neoplasms
A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathways.
Neoplasms
A novel quantitative kinase assay using bacterial surface display and flow cytometry.
Neoplasms
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Neoplasms
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Neoplasms
A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration.
Neoplasms
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.
Neoplasms
A Patient With BCR-ABL and JAK2 V617F Double-Positive Myeloproliferative Neoplasm With Overlapping Clinical Phenotypes.
Neoplasms
A Peptide-Based Biosensor Assay To Detect Intracellular Syk Kinase Activation and Inhibition.
Neoplasms
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Neoplasms
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Neoplasms
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Neoplasms
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Neoplasms
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Neoplasms
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
Neoplasms
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Neoplasms
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Neoplasms
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
Neoplasms
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Neoplasms
A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.
Neoplasms
A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase.
Neoplasms
A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing.
Neoplasms
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
Neoplasms
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Neoplasms
A rapid and sensitive method for EphB4 identification as a diagnostic and therapeutic biomarker in invasive breast cancer.
Neoplasms
A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
Neoplasms
A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells.
Neoplasms
A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants.
Neoplasms
A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer.
Neoplasms
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).
Neoplasms
A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1.
Neoplasms
A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis.
Neoplasms
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Neoplasms
A small molecule Focal Adhesion Kinase (FAK) inhibitor, targeting Y397 site: 1-(2-Hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
Neoplasms
A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
Neoplasms
A Small-Molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK And Mdm-2 Interaction, And Blocks Breast And Colon Tumorigenesis In Vivo.
Neoplasms
A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
Neoplasms
A Swiss 3T3 variant cell line resistant to the effects of tumor promoters cannot be transformed by src.
Neoplasms
A Synthetic Curcuminoid Analog, (2E,6E)-2,6-bis(2-(trifluoromethyl)benzylidene)cyclohexanone, Ameliorates Impaired Wound Healing in Streptozotocin-Induced Diabetic Mice by Increasing miR-146a.
Neoplasms
A transformation-competent recombinant between v-src and Rous-associated virus RAV-1.
Neoplasms
A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma.
Neoplasms
A Virtual Screening approach for the Identificationof High affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of Chronic Myeloid Leukemia.
Neoplasms
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Neoplasms
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.
Neoplasms
A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.
Neoplasms
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Neoplasms
Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
Neoplasms
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Neoplasms
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Neoplasms
Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.
Neoplasms
Aberrant Methylation of Suppressor of Cytokine Signaling 1 (SOCS1) Gene as a Biomarker for Early Prediction and Diagnosis of Bladder Cancer.
Neoplasms
Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors.
Neoplasms
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Neoplasms
Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity.
Neoplasms
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Neoplasms
ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Neoplasms
Abl kinases are required for invadopodia formation and chemokine-induced invasion.
Neoplasms
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Neoplasms
Abl2/Abl-related Gene Stabilizes Actin Filaments, Stimulates Actin Branching by Actin-related Protein 2/3 Complex, and Promotes Actin Filament Severing by Cofilin.
Neoplasms
Abnormal expression of FAK and paxillin correlates with oral cancer invasion and metastasis.
Neoplasms
Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia.
Neoplasms
Abnormal Uterine Bleeding Is Associated With Increased BMP7 Expression in Human Endometrium.
Neoplasms
Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in human pituitary adenomas.
Neoplasms
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Neoplasms
Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients.
Neoplasms
Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy.
Neoplasms
Absence of progesterone receptor membrane component 1 reduces migration and metastasis of breast cancer.
Neoplasms
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Neoplasms
Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia.
Neoplasms
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.
Neoplasms
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
Neoplasms
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Neoplasms
Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.
Neoplasms
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
Neoplasms
Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas.
Neoplasms
Ack promotes tissue growth via phosphorylation and suppression of the Hippo pathway component Expanded.
Neoplasms
ACK1 is dispensable for development, skin tumor formation, and breast cancer cell proliferation.
Neoplasms
Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and ?1-integrin signaling pathway in tumor cells.
Neoplasms
Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors.
Neoplasms
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Neoplasms
Activated Cdc42 kinase regulates Dock localization in male germ cells during Drosophila spermatogenesis.
Neoplasms
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Neoplasms
Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
Neoplasms
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Neoplasms
Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects.
Neoplasms
Activation of bcr-abl fusion gene and ras oncogenes in chronic myelogenous leukemia.
Neoplasms
Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src.
Neoplasms
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Neoplasms
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Neoplasms
Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor ? induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Neoplasms
Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.
Neoplasms
Activation of Focal Adhesion Kinase in Detached Human Epidermal Cancer Cells and Their Long-term Survival Might be Associated with Cell Surface Expression of Laminin-5.
Neoplasms
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells.
Neoplasms
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
Neoplasms
Activation of NF-kappaB by fluid shear stress, but not TNF-alpha, requires focal adhesion kinase in osteoblasts.
Neoplasms
Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium.
Neoplasms
Activation of spleen tyrosine kinase is required for TNF-?-induced endothelin-1 upregulation in human aortic endothelial cells.
Neoplasms
Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Neoplasms
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Neoplasms
Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56lck.
Neoplasms
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice.
Neoplasms
Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype.
Neoplasms
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
Neoplasms
Activation of the Lutropin/Choriogonadotropin Receptor in MA-10 Cells Leads to the Tyrosine Phosphorylation of the Focal Adhesion Kinase by a Pathway that Involves Src Family Kinases.
Neoplasms
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Neoplasms
Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis.
Neoplasms
Activators of protein kinase C induce dissociation of CD4, but not CD8, from p56lck.
Neoplasms
Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition.
Neoplasms
Active recombinant human tyrosine kinase c-Yes: expression in baculovirus system, purification, comparison to c-Src, and inhibition by a c-Src inhibitor.
Neoplasms
Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
Neoplasms
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Neoplasms
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Neoplasms
Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
Neoplasms
ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
Neoplasms
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Neoplasms
ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance.
Neoplasms
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Neoplasms
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Neoplasms
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.
Neoplasms
Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Neoplasms
Adenovirus-mediated transfer of FRNK augments drug-induced cytotoxicity in cultured SCCHN cells.
Neoplasms
Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase.
Neoplasms
Administration of a plasmid that expresses SDF-1? affects the oncogenic potential of mouse bcr-abl-transformed cells.
Neoplasms
Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.
Neoplasms
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.
Neoplasms
Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
Neoplasms
Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction in Cholesterol Efflux-Related Gene Expression in Macrophages.
Neoplasms
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.
Neoplasms
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
Neoplasms
Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl.
Neoplasms
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Neoplasms
Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
Neoplasms
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
Neoplasms
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Neoplasms
Alantolactone Inhibits Cell Proliferation by Interrupting the Interaction between Cripto-1 and Activin Receptor Type II A in Activin Signaling Pathway.
Neoplasms
Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
Neoplasms
Allo-skin graft rejection, tumor rejection and natural killer activity in mice lacking p56lck.
Neoplasms
alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo.
Neoplasms
Alterations in expression of p56lck during myeloid differentiation of LSTRA cells.
Neoplasms
Alterations in focal adhesion kinase activity and associated proteins during malignant conversion of mouse keratinocytes.
Neoplasms
Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Neoplasms
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Neoplasms
Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase.
Neoplasms
Altered p-JAK1 expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma.
Neoplasms
Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells.
Neoplasms
Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
Neoplasms
Alternagin-C binding to ?2?1 integrin controls matrix metalloprotease-9 and matrix metalloprotease-2 in breast tumor cells and endothelial cells.
Neoplasms
Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
Neoplasms
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.
Neoplasms
Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.
Neoplasms
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Neoplasms
Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein.
Neoplasms
Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms.
Neoplasms
Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma.
Neoplasms
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Neoplasms
An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase.
Neoplasms
An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma.
Neoplasms
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Neoplasms
An Association Study of Polymorphisms in JAK3 Gene with Lung Cancer in the Korean Population.
Neoplasms
An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion.
Neoplasms
An EGFR/Src-dependent ?4 integrin/FAK complex contributes to malignancy of breast cancer.
Neoplasms
An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer.
Neoplasms
An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.
Neoplasms
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.
Neoplasms
An overview of translocation-related oncogenesis in the chronic myeloid leukaemias.
Neoplasms
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Neoplasms
Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.
Neoplasms
Analysis of loss of heterozygosity in lymphoma and leukaemia arising in F1 hybrid mice locates a common region of chromosome 4 loss.
Neoplasms
Analysis of microsatellite instability, TGF-beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction-associated biliary tract tumors.
Neoplasms
Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues.
Neoplasms
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Neoplasms
Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Neoplasms
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Neoplasms
Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Neoplasms
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Neoplasms
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
Neoplasms
Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy.
Neoplasms
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Neoplasms
Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.
Neoplasms
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Neoplasms
Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach.
Neoplasms
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Neoplasms
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
Neoplasms
Anti-neoplastic effect of ?-hydroxyisovalerylshikonin on a human choriocarcinoma cell line.
Neoplasms
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Neoplasms
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Neoplasms
Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.
Neoplasms
Antibody neutralization of cell-surface gC1qR/HABP1/SF2-p32 prevents lamellipodia formation and tumorigenesis.
Neoplasms
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Neoplasms
Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line.
Neoplasms
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.
Neoplasms
Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte-specific protein tyrosine kinase.
Neoplasms
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
Neoplasms
Antitumor activity of NPB001-05, an orally active inhibitor of Bcr-Abl tyrosine kinase.
Neoplasms
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Neoplasms
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.
Neoplasms
Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.
Neoplasms
Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1?.
Neoplasms
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Neoplasms
Antroquinonol Targets FAK-Signaling Pathway Suppressed Cell Migration, Invasion, and Tumor Growth of C6 Glioma.
Neoplasms
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
Neoplasms
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Neoplasms
Aphidicolin-induced proliferative arrest of murine mast cells: morphological and biochemical changes are not accompanied by alterations in cytokine gene induction.
Neoplasms
Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms.
Neoplasms
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Neoplasms
Artocarpin Targets Focal Adhesion Kinase-Dependent Epithelial to Mesenchymal Transition and Suppresses Migratory-Associated Integrins in Lung Cancer Cells.
Neoplasms
Ascending the PEAK1 toward targeting TGF? during cancer progression: Recent advances and future perspectives.
Neoplasms
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Neoplasms
Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
Neoplasms
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Neoplasms
Association between Int7G24A rs334354 polymorphism and cancer risk: a meta-analysis of case-control studies.
Neoplasms
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Neoplasms
Association between TGFBR1 Polymorphisms and Cancer Risk: A Meta-Analysis of 35 Case-Control Studies.
Neoplasms
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Neoplasms
Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Neoplasms
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Neoplasms
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Neoplasms
Association of herpesvirus saimiri tip with lipid raft is essential for downregulation of T-cell receptor and CD4 coreceptor.
Neoplasms
Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
Neoplasms
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
Neoplasms
Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence.
Neoplasms
Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.
Neoplasms
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Neoplasms
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Neoplasms
Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands.
Neoplasms
Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
Neoplasms
Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells.
Neoplasms
Automated tracking of tumor-stroma morphology in microtissues identifies functional targets within the tumor microenvironment for therapeutic intervention.
Neoplasms
Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.
Neoplasms
Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis.
Neoplasms
Autophagy-independent induction of LC3B through oxidative stress reveals its non-canonical role in anoikis of ovarian cancer cells.
Neoplasms
Autophosphorylation-independent and dependent functions of Focal Adhesion Kinase during development.
Neoplasms
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
Neoplasms
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Neoplasms
B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.
Neoplasms
Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice.
Neoplasms
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Neoplasms
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Neoplasms
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Neoplasms
BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro.
Neoplasms
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.
Neoplasms
BCL6 regulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
Neoplasms
Bcr (breakpoint cluster region) protein binds to PDZ-domains of scaffold protein PDZK1 and vesicle coat protein Mint3.
Neoplasms
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Neoplasms
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Neoplasms
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Neoplasms
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
Neoplasms
BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Neoplasms
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Neoplasms
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Neoplasms
BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Neoplasms
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Neoplasms
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Neoplasms
Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
Neoplasms
Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor.
Neoplasms
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
Neoplasms
Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway.
Neoplasms
Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Neoplasms
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
Neoplasms
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
Neoplasms
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Neoplasms
BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Neoplasms
Beta-arrestins operate an on/off control switch for focal adhesion kinase activity.
Neoplasms
Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
Neoplasms
Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells.
Neoplasms
Beta2 integrin-dependent phosphorylation of protein-tyrosine kinase Pyk2 stimulated by tumor necrosis factor alpha and fMLP in human neutrophils adherent to fibrinogen.
Neoplasms
Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage.
Neoplasms
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
Neoplasms
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.
Neoplasms
Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.
Neoplasms
Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Neoplasms
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Neoplasms
Bioinformatics-based study to detect chemical compounds that show potential as treatments for pulmonary thromboembolism.
Neoplasms
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Neoplasms
Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature.
Neoplasms
Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.
Neoplasms
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.
Neoplasms
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Neoplasms
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Neoplasms
Blockade of Lyn kinase upregulates both canonical and non-canonical TLR-3 pathways in THP-1 monocytes exposed to human cytomegalovirus.
Neoplasms
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Neoplasms
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T cell activity and promotes regression.
Neoplasms
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Neoplasms
Bombesin stimulation of p125 focal adhesion kinase tyrosine phosphorylation. Role of protein kinase C, Ca2+ mobilization, and the actin cytoskeleton.
Neoplasms
Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Neoplasms
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Neoplasms
Bone sialoprotein-?v?3 integrin axis promotes breast cancer metastasis to the bone.
Neoplasms
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Neoplasms
Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.
Neoplasms
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
Neoplasms
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Neoplasms
Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.
Neoplasms
Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Neoplasms
Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer.
Neoplasms
Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.
Neoplasms
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Neoplasms
Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm.
Neoplasms
Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Neoplasms
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Neoplasms
Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Neoplasms
Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Neoplasms
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Neoplasms
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Neoplasms
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Neoplasms
Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)?-Suppressed Migration and Invasion of Prostate Cancer.
Neoplasms
Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells.
Neoplasms
Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Neoplasms
Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells.
Neoplasms
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
Neoplasms
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.
Neoplasms
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.
Neoplasms
Bruton's Tyrosine Kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
Neoplasms
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
Neoplasms
Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Neoplasms
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Neoplasms
BTK inhibitors synergize with 5-FU to treat drug-resistant TP53-null colon cancers.
Neoplasms
BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis.
Neoplasms
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer.
Neoplasms
c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Neoplasms
C-Abl inhibitor imatinib enhances insulin production by ? cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
Neoplasms
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.
Neoplasms
c-Abl Kinase Is a Regulator of ?v?3 Integrin Mediated Melanoma A375 Cell Migration.
Neoplasms
c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.
Neoplasms
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
Neoplasms
c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Neoplasms
c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors.
Neoplasms
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Neoplasms
c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
Neoplasms
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
Neoplasms
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
Neoplasms
C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance.
Neoplasms
c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
Neoplasms
c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.
Neoplasms
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
Neoplasms
c-Src Antisense Complexed with PAMAM Denderimes Decreases of c-Src Expression and EGFR-Dependent Downstream Genes in the Human HT-29 Colon Cancer Cell Line.
Neoplasms
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
Neoplasms
c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer.
Neoplasms
c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
Neoplasms
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK.
Neoplasms
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
Neoplasms
c-Src-induced activation of ceramide metabolism impairs membrane microdomains and promotes malignant progression by facilitating the translocation of c-Src to focal adhesions.
Neoplasms
c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.
Neoplasms
C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor.
Neoplasms
C-terminal Src kinase controls development and maintenance of mouse squamous epithelia.
Neoplasms
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Neoplasms
c-Yes Tyrosine Kinase Is a Potent Suppressor of ES Cell Differentiation and Antagonizes the Actions of Its Closest Phylogenetic Relative, c-Src.
Neoplasms
CADM1 enhances intestinal barrier function in a rat model of mild inflammatory bowel disease by inhibiting the STAT3 signaling pathway.
Neoplasms
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation.
Neoplasms
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Neoplasms
Calpain activity is generally elevated during transformation but has oncogene-specific biological functions.
Neoplasms
CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
Neoplasms
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.
Neoplasms
Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations.
Neoplasms
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Neoplasms
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Neoplasms
Cancer cells escape from oncogene addiction: Understanding the mechanisms behind treatment failure for more effective targeting.
Neoplasms
Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.
Neoplasms
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Neoplasms
Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Neoplasms
Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK)
Neoplasms
Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK).
Neoplasms
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Neoplasms
Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Neoplasms
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Neoplasms
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Neoplasms
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Neoplasms
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Neoplasms
CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia.
Neoplasms
CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase.
Neoplasms
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Neoplasms
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
Neoplasms
CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.
Neoplasms
CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.
Neoplasms
CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma.
Neoplasms
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity.
Neoplasms
Cdc42-interacting protein 4 is a Src substrate that regulates invadopodia and invasiveness of breast tumors by promoting MT1-MMP endocytosis.
Neoplasms
Cell budding from pre-invasive tumors: Intrinsic precursor of invasive breast lesions?
Neoplasms
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Neoplasms
Cell Invasion of Highly Metastatic MTLn3 Cancer Cells Is Dependent on Phospholipase D2 (PLD2) and Janus Kinase 3 (JAK3).
Neoplasms
Cell type-specific tumor induction in neural transplants by retrovirus-mediated oncogene transfer.
Neoplasms
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
Neoplasms
Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.
Neoplasms
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Neoplasms
Centrosomal targeting of Syk kinase is controlled by its catalytic activity and depends on microtubules and the dynein motor.
Neoplasms
Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors.
Neoplasms
Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.
Neoplasms
Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
Neoplasms
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Neoplasms
Characterization of in vitro metabolism of focal adhesion kinase inhibitors by LC/MS/MS.
Neoplasms
Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance.
Neoplasms
Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.
Neoplasms
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Neoplasms
Characterization of the avian GLUT1 glucose transporter: differential regulation of GLUT1 and GLUT3 in chicken embryo fibroblasts.
Neoplasms
Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies.
Neoplasms
Characterization of transforming viruses rescued from a hamster tumour cell line harbouring the v-src gene flanked by long terminal repeats.
Neoplasms
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Neoplasms
Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors.
Neoplasms
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Neoplasms
Chemoproteomic profiling of an Ibrutinib analogue reveals its unexpected role in DNA damage repair.
Neoplasms
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
Neoplasms
Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.
Neoplasms
Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Neoplasms
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Neoplasms
Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Neoplasms
Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.
Neoplasms
Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
Neoplasms
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Neoplasms
Circular RNA circMTO1 acts as an antitumor factor in rectal cancer cell lines by downregulation of miR-19b-3p.
Neoplasms
CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling.
Neoplasms
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
Neoplasms
CKAP2 Promotes Ovarian Cancer Proliferation and Tumorigenesis Through the FAK-ERK Pathway.
Neoplasms
Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.
Neoplasms
Cleavage of focal adhesion kinase by different proteases during SRC-regulated transformation and apoptosis. Distinct roles for calpain and caspases.
Neoplasms
CLEC4M overexpression inhibits progression and is associated with a favorable prognosis in hepatocellular carcinoma.
Neoplasms
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Neoplasms
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Neoplasms
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Neoplasms
Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase.
Neoplasms
Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Neoplasms
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Neoplasms
Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma.
Neoplasms
Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.
Neoplasms
Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer.
Neoplasms
Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells.
Neoplasms
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Neoplasms
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Neoplasms
Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.
Neoplasms
Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNF?-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.
Neoplasms
Clinicopathologic Characterization of Breast Carcinomas in Patients with Non-BRCA Germline Mutations: Results from a Single Institution's High Risk Population.
Neoplasms
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Neoplasms
Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene.
Neoplasms
Cloning, molecular characterization, and expression analysis of the signal transducer and activator of transcription 3 (STAT3) gene from grass carp (Ctenopharyngodon idellus).
Neoplasms
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Neoplasms
Co-operative effect of c-Src and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells.
Neoplasms
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Neoplasms
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Neoplasms
Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells.
Neoplasms
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Neoplasms
Coelomic Fluid of Lumbricus rubellus Synergistically Enhances Cytotoxic Effect of 5-Fluorouracil through Modulation of Focal Adhesion Kinase and p21 in HT-29 Cancer Cell Line.
Neoplasms
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Neoplasms
Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.
Neoplasms
Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.
Neoplasms
Coexpression of an unusual form of the EWS-WT1 fusion transcript and interleukin 2/15 receptor betamRNA in a desmoplastic small round cell tumour.
Neoplasms
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Neoplasms
Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.
Neoplasms
Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway.
Neoplasms
Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
Neoplasms
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Neoplasms
Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia.
Neoplasms
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Neoplasms
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Neoplasms
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Neoplasms
Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Neoplasms
Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
Neoplasms
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Neoplasms
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Neoplasms
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Neoplasms
Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.
Neoplasms
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Neoplasms
Combining a QSAR Approach and Structural Analysis to Derive an SAR Map of Lyn Kinase Inhibition.
Neoplasms
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Neoplasms
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Neoplasms
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Neoplasms
Commentary on Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT McKenzie S, Sakamoto S, Kyprianou N, Division of Urology, Department of Surgery, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY.
Neoplasms
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Neoplasms
Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis.
Neoplasms
Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Neoplasms
Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.
Neoplasms
Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
Neoplasms
Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour.
Neoplasms
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Neoplasms
Comparison of tyrosine phosphorylation of proteins by membrane fractions from mouse liver, Ehrlich ascites tumor and MH134 hepatoma.
Neoplasms
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Neoplasms
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
Neoplasms
Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.
Neoplasms
Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer.
Neoplasms
Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma.
Neoplasms
Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.
Neoplasms
Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Neoplasms
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.
Neoplasms
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Neoplasms
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Neoplasms
Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma.
Neoplasms
Conservation of structure and expression of the c-yes and fyn genes in lower vertebrates.
Neoplasms
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Neoplasms
Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.
Neoplasms
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
Neoplasms
Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis.
Neoplasms
Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Neoplasms
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Neoplasms
Constitutively active transforming growth factor ? receptor 1 in the mouse ovary promotes tumorigenesis.
Neoplasms
Construction and expression of a recombinant DNA gene encoding a polyomavirus middle-size tumor antigen with the carboxyl terminus of the vesicular stomatitis virus glycoprotein G.
Neoplasms
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Neoplasms
Cool-1 functions as an essential regulatory node for EGFreceptor- and Src-mediated cell growth.
Neoplasms
Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.
Neoplasms
Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.
Neoplasms
Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.
Neoplasms
Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.
Neoplasms
Cordycepin Suppresses Endothelial Cell Proliferation, Migration, Angiogenesis, and Tumor Growth by Regulating Focal Adhesion Kinase and p53.
Neoplasms
Core Element Cloning, Cis-Element Mapping and Serum Regulation of the Human EphB4 Promoter: A Novel TATA-Less Inr/MTE/DPE-Like Regulated Gene.
Neoplasms
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Neoplasms
Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437.
Neoplasms
Correction: deletion of the endothelial bmx tyrosine kinase decreases tumor angiogenesis and growth.
Neoplasms
Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines.
Neoplasms
Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.
Neoplasms
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Neoplasms
Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Neoplasms
Correlation of V-src gene amplification with the tumorigenic phenotype in a Syrian hamster embryo cell line.
Neoplasms
Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Neoplasms
Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125FAK, in tumor and nontransformed cells.
Neoplasms
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy.
Neoplasms
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with premalignant oral epithelial lesions.
Neoplasms
Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer.
Neoplasms
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Neoplasms
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Neoplasms
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology.
Neoplasms
CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Neoplasms
Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
Neoplasms
Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Neoplasms
Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice.
Neoplasms
Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Neoplasms
CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
Neoplasms
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell.
Neoplasms
Cross Talk Between TGF-? and JAK Expressions and Nepherotoxicity Induced by Tetrachloromethane: Role of Phytotherapy.
Neoplasms
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.
Neoplasms
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Neoplasms
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
Neoplasms
Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.
Neoplasms
CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling.
Neoplasms
CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway.
Neoplasms
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Neoplasms
Cx43 and Associated Cell Signaling Pathways Regulate Tunneling Nanotubes in Breast Cancer Cells.
Neoplasms
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone.
Neoplasms
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Neoplasms
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Neoplasms
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Neoplasms
Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.
Neoplasms
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
Neoplasms
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.
Neoplasms
Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells.
Neoplasms
DAPT suppresses proliferation and migration of hepatocellular carcinoma by regulating the extracellular matrix and inhibiting the Hes1/PTEN/AKT/mTOR signaling pathway.
Neoplasms
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Neoplasms
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Neoplasms
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Neoplasms
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Neoplasms
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Neoplasms
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Neoplasms
Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Neoplasms
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Neoplasms
Dasatinib?+?Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Neoplasms
Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization.
Neoplasms
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.
Neoplasms
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
Neoplasms
De Novo proteome analysis of genetically modified tumor cells by a metabolic labeling/azide-alkyne cycloaddition approach.
Neoplasms
Deciphering Mode of Action of Functionally Important Regions in the Intrinsically Disordered Paxillin (Residues 1-313) Using Its Interaction with FAT (Focal Adhesion Targeting Domain of Focal Adhesion Kinase).
Neoplasms
Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells overexpressing the early growth response-1 protein.
Neoplasms
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Neoplasms
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Neoplasms
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Neoplasms
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Neoplasms
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Neoplasms
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.
Neoplasms
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Neoplasms
Degradation of endothelial cell matrix collagen is correlated with induction of stromelysin by an activated ras oncogene.
Neoplasms
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Neoplasms
Deletion of Adipose Triglyceride Lipase Links Triacylglycerol Accumulation to a More-Aggressive Phenotype in A549 Lung Carcinoma Cells.
Neoplasms
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Neoplasms
Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth.
Neoplasms
Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers.
Neoplasms
Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Neoplasms
Depletion of Csk preferentially reduces the protein level of LynA in a Cbl-dependent manner in cancer cells.
Neoplasms
Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway.
Neoplasms
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Neoplasms
Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis.
Neoplasms
Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor.
Neoplasms
Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation.
Neoplasms
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Neoplasms
Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
Neoplasms
Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Neoplasms
Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.
Neoplasms
Design, synthesis, and biological evaluation of F-18-labelled 2, 4-diaminopyrimidine-type FAK-targeted inhibitors as potential tumour imaging agents.
Neoplasms
Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
Neoplasms
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Neoplasms
Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
Neoplasms
Design, Synthesis, Biological Evaluation, and Molecular Docking of 2,4-Diaminopyrimidine Derivatives Targeting Focal Adhesion Kinase as Tumor Radiotracers.
Neoplasms
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Neoplasms
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
Neoplasms
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Neoplasms
Detection of multiple tumor suppressor genes for Syrian hamster fibrosarcomas by somatic cell hybridization.
Neoplasms
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Neoplasms
Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Neoplasms
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Neoplasms
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Neoplasms
Development of a Bifunctional Andrographolide-Based Chemical Probe for Pharmacological Study.
Neoplasms
Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR.
Neoplasms
Development of a High-Throughput Fluorescence Polarization Assay to Detect Inhibitors of the FAK-Paxillin Interaction.
Neoplasms
Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells.
Neoplasms
Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells.
Neoplasms
Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
Neoplasms
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Neoplasms
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Neoplasms
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Neoplasms
Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report.
Neoplasms
Diallyl trisulfide inhibits cell migration and invasion of human melanoma a375 cells via inhibiting integrin/facal adhesion kinase pathway.
Neoplasms
Dietary choline deficiency and excess induced intestinal inflammation and alteration of intestinal tight junction protein transcription potentially by modulating NF-?B, STAT and p38 MAPK signaling molecules in juvenile Jian carp.
Neoplasms
Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
Neoplasms
Differences and similarities in ibrutinib and acalabrutinib effects on platelet functions.
Neoplasms
Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
Neoplasms
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Neoplasms
Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Neoplasms
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Neoplasms
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Neoplasms
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Neoplasms
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Neoplasms
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Neoplasms
Differential response to retinoic acid of Syrian hamster embryo fibroblasts expressing v-src or v-Ha-ras oncogenes.
Neoplasms
Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Neoplasms
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Neoplasms
Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus.
Neoplasms
Diminished in vitro tyrosine kinase activity of the EGF receptor of senescent human fibroblasts.
Neoplasms
Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway.
Neoplasms
Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor.
Neoplasms
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Neoplasms
Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.
Neoplasms
Direct Interactions with the Integrin ?1 Cytoplasmic Tail Activate the Abl2/Arg Kinase.
Neoplasms
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Neoplasms
Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Neoplasms
Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.
Neoplasms
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Neoplasms
Discovery of 14-3-3 Protein-Protein Interaction Inhibitors that Sensitize Multidrug-Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693.
Neoplasms
Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Neoplasms
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Neoplasms
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.
Neoplasms
Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
Neoplasms
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Neoplasms
Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton.
Neoplasms
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Neoplasms
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.
Neoplasms
Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and N-Substituted Benzamides as Potential FAK Inhibitors and Anticancer Agents.
Neoplasms
Discovery of Novel Bruton's Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking.
Neoplasms
Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.
Neoplasms
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Neoplasms
Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Neoplasms
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Neoplasms
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Neoplasms
Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Neoplasms
Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
Neoplasms
Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Neoplasms
Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.
Neoplasms
Disruption of Ca2+-dependent cell-matrix adhesion enhances c-Src kinase activity, but causes dissociation of the c-Src/FAK complex and dephosphorylation of tyrosine-577 of FAK in carcinoma cells.
Neoplasms
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Neoplasms
Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
Neoplasms
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study.
Neoplasms
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
Neoplasms
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Neoplasms
Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation.
Neoplasms
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Neoplasms
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Neoplasms
Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.
Neoplasms
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Neoplasms
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Neoplasms
Distinct roles of cellular Lck and p80 proteins in herpesvirus saimiri Tip function on lipid rafts.
Neoplasms
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Neoplasms
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Neoplasms
Diterpenoids and Triterpenoids From Frankincense Are Excellent Anti-psoriatic Agents: An in silico Approach.
Neoplasms
Diversity of Long-Lived Intermediates along the Binding Pathway of Imatinib to Abl Kinase Revealed by MD Simulations.
Neoplasms
DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway.
Neoplasms
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Neoplasms
Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
Neoplasms
Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models.
Neoplasms
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Neoplasms
Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.
Neoplasms
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Neoplasms
Down-regulation of focal adhesion kinase, pp125FAK, in endothelial cell retraction during tumor cell invasion.
Neoplasms
Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.
Neoplasms
Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
Neoplasms
Downregulation of drs mRNA expression is associated with the progression of adult T-cell leukemia/lymphoma.
Neoplasms
Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Neoplasms
Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer.
Neoplasms
Downregulation of microRNA-4324 promotes the EMT of esophageal squamous-cell carcinoma cells via upregulating FAK.
Neoplasms
Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas.
Neoplasms
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Neoplasms
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Neoplasms
Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.
Neoplasms
Drosophila linker histone H1 coordinates STAT-dependent organization of heterochromatin and suppresses tumorigenesis caused by hyperactive JAK-STAT signaling.
Neoplasms
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Neoplasms
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Neoplasms
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Neoplasms
Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Neoplasms
Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Neoplasms
Dsi-1, a region with frequent proviral insertions in Moloney murine leukemia virus-induced rat thymomas.
Neoplasms
Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases.
Neoplasms
Dual Inhibiton of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110? as a Therapeutic Approach to Treat non-Hodgkin's B cell Malignancies.
Neoplasms
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Neoplasms
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Neoplasms
Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Neoplasms
Dual-Modality Micro-Positron Emission Tomography/Computed Tomography and Near-Infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models.
Neoplasms
Dynamic changes in the gene expression profile during rat oral carcinogenesis induced by 4?nitroquinoline 1?oxide.
Neoplasms
Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by Mammalian Target of Rapamycin Complex 2 in Bladder Cancer Cells.
Neoplasms
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Neoplasms
Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression.
Neoplasms
Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion.
Neoplasms
Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.
Neoplasms
E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin ?v?6 and maintained through TGF? signalling.
Neoplasms
ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D-DIGE Proteomics.
Neoplasms
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Neoplasms
Edaravone mitigates hemorrhagic cystitis by modulating Nrf2, TLR-4/NF-?B, and JAK1/STAT3 signaling in cyclophosphamide-intoxicated rats.
Neoplasms
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Neoplasms
Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells.
Neoplasms
Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.
Neoplasms
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Neoplasms
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Neoplasms
Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
Neoplasms
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
Neoplasms
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Neoplasms
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Neoplasms
Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Neoplasms
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Neoplasms
Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen.
Neoplasms
Effective Photothermal Chemotherapy Using Doxorubicin-Loaded Gold Nanospheres That Target EphB4 Receptors in Tumors.
Neoplasms
Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Neoplasms
Effectiveness of Scutellaria barbata water extract on inhibiting colon tumor growth and metastasis in tumor-bearing mice.
Neoplasms
Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.
Neoplasms
Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium.
Neoplasms
Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.
Neoplasms
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Neoplasms
Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines.
Neoplasms
Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
Neoplasms
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Neoplasms
Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway.
Neoplasms
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Neoplasms
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Neoplasms
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Neoplasms
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.
Neoplasms
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Neoplasms
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.
Neoplasms
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
Neoplasms
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Neoplasms
EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5.
Neoplasms
EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2.
Neoplasms
EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
Neoplasms
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Neoplasms
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Neoplasms
Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue.
Neoplasms
Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
Neoplasms
Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Neoplasms
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Neoplasms
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.
Neoplasms
Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone.
Neoplasms
Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis.
Neoplasms
Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.
Neoplasms
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Neoplasms
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development.
Neoplasms
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.
Neoplasms
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.
Neoplasms
Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction.
Neoplasms
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Neoplasms
Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Neoplasms
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Neoplasms
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
Neoplasms
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Neoplasms
Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.
Neoplasms
Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens.
Neoplasms
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Neoplasms
EphB4 cellular kinase activity assayed using an enzymatic protein interaction system.
Neoplasms
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.
Neoplasms
EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Neoplasms
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Neoplasms
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Neoplasms
EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Neoplasms
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Neoplasms
EphB4 Promotes Site-Specific Metastatic Tumor Cell Dissemination by Interacting with Endothelial Cell-Expressed EphrinB2.
Neoplasms
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Neoplasms
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Neoplasms
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.
Neoplasms
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Neoplasms
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Neoplasms
Ephrin type-B receptor 4 affinity chromatography: An effective and rapid method studying the active compounds targeting Ephrin type-B receptor 4.
Neoplasms
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Neoplasms
Ephrin?B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis?free survival in breast cancer.
Neoplasms
Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers.
Neoplasms
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Neoplasms
Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Neoplasms
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation.
Neoplasms
Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma.
Neoplasms
Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis.
Neoplasms
Epithelial BMP signaling is required for proper specification of epithelial cell lineages and gastric endocrine cells.
Neoplasms
Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
Neoplasms
Epithelial Membrane Protein-2 (EMP2) Activates Src and is a Novel Therapeutic Target for GBM.
Neoplasms
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Neoplasms
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells.
Neoplasms
Erb?B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53?responsive microRNA?3184?5p in cervical cancer cells.
Neoplasms
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Neoplasms
ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.
Neoplasms
ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
Neoplasms
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Neoplasms
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Neoplasms
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Neoplasms
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Neoplasms
Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis.
Neoplasms
Establishment and characterization of seven human renal cell carcinoma cell lines.
Neoplasms
Establishment of a lymphoblastoid cell line, SD-1, expressing the p190 bcr-abl chimaeric protein.
Neoplasms
Establishment of PI3K inhibitor-resistant cancer cell lines and the therapeutic strategies for overcoming the resistance.
Neoplasms
Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors.
Neoplasms
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Neoplasms
Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis.
Neoplasms
Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway.
Neoplasms
Evaluation of BAT-26 as an indicator of microsatellite instability in gallbladder carcinomas.
Neoplasms
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Neoplasms
Evaluation of FAK and Src Expression in Human Benign and Malignant Thyroid Lesions.
Neoplasms
Evaluation of the Clinical Significance of Focal Adhesion Kinase and Src Expression in Human Pancreatic Ductal Adenocarcinoma.
Neoplasms
Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis.
Neoplasms
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Neoplasms
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Neoplasms
Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Neoplasms
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
Neoplasms
Evidence for interaction of the NLRP3 inflammasome and Bruton's tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta.
Neoplasms
Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).
Neoplasms
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
Neoplasms
Evidence that there exist four classes of RNA tumor viruses which encode proteins with associated tyrosine protein kinase activities.
Neoplasms
Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Neoplasms
Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Neoplasms
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.
Neoplasms
Exosomes of Mesenchymal Stem Cells as a Proper Vehicle for Transfecting miR-145 into the Breast Cancer Cell Line and Its Effect on Metastasis.
Neoplasms
Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Neoplasms
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Neoplasms
Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
Neoplasms
Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.
Neoplasms
Exposure-Response Analysis of Acalabrutinib and its Active Metabolite, ACP-5862, in Patients With B-Cell Malignancies.
Neoplasms
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma.
Neoplasms
Expression and mutation of SMAD4 in poorly differentiated carcinoma and signet-ring cell carcinoma of the colorectum.
Neoplasms
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Neoplasms
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Neoplasms
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Neoplasms
Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.
Neoplasms
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Neoplasms
Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry.
Neoplasms
Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.
Neoplasms
Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative.
Neoplasms
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Neoplasms
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Neoplasms
Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.
Neoplasms
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Neoplasms
Expression of c-yes oncogene product in various animal tissues and spontaneous canine tumours.
Neoplasms
Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.
Neoplasms
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Neoplasms
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival.
Neoplasms
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Neoplasms
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Neoplasms
Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
Neoplasms
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Neoplasms
Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors.
Neoplasms
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Neoplasms
Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.
Neoplasms
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Neoplasms
Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling.
Neoplasms
Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness.
Neoplasms
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Neoplasms
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Neoplasms
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Neoplasms
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Neoplasms
Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system.
Neoplasms
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Neoplasms
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Neoplasms
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Neoplasms
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Neoplasms
Expression, purification, and bioactivity of GST-fused v-Src from a bacterial expression system.
Neoplasms
Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma.
Neoplasms
Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment.
Neoplasms
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
Neoplasms
Fak and Has Inhibtion Synergistically Decrease Colon Cancer Cell Viability and Affect Expression Of Critical Genes.
Neoplasms
FAK auto-phosphorylation site tyrosine 397 is required for development but dispensable for normal skin homeostasis.
Neoplasms
FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.
Neoplasms
FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis.
Neoplasms
FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy.
Neoplasms
FAK Inhibition Abrogates the Malignant Phenotype in Aggressive Pediatric Renal Tumors.
Neoplasms
FAK Inhibition Induces Glioblastoma Cell Senescence-Like State through p62 and p27.
Neoplasms
FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
Neoplasms
FAK overexpression and p53 mutations are highly correlated in human breast cancer.
Neoplasms
FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR?/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.
Neoplasms
FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs.
Neoplasms
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Neoplasms
FAK signaling in neoplastic disorders: a linkage between inflammation and cancer.
Neoplasms
FAK signalling controls insulin sensitivity through regulation of adipocyte survival.
Neoplasms
FAK tyrosine phosphorylation is regulated by AMPK and controls metabolism in human skeletal muscle.
Neoplasms
FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
Neoplasms
Fc epsilon RI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells.
Neoplasms
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Neoplasms
FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer.
Neoplasms
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Neoplasms
Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression.
Neoplasms
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
Neoplasms
FES kinase promotes mast cell recruitment to mammary tumors via the stem cell factor/KIT receptor signaling axis.
Neoplasms
Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Neoplasms
Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth.
Neoplasms
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.
Neoplasms
First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Neoplasms
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Neoplasms
Fish Oil Alleviates Activation of Hypothalamic-Pituitary-Adrenal Axis Associated with Inhibition of TLR4 and NOD Signaling Pathways in Weaned Piglets after a Lipopolysaccharide Challenge.
Neoplasms
Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function.
Neoplasms
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Neoplasms
Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Neoplasms
Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues.
Neoplasms
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
Neoplasms
Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
Neoplasms
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling.
Neoplasms
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Neoplasms
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Neoplasms
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Neoplasms
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Neoplasms
Focal Adhesion Kinase Activity and Localization is Critical for TNF-?-Induced Nuclear Factor-?B Activation.
Neoplasms
Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.
Neoplasms
Focal Adhesion Kinase and ?-Catenin Cooperate to Induce Hepatocellular Carcinoma.
Neoplasms
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Neoplasms
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.
Neoplasms
Focal adhesion kinase and protein kinase B cooperate to suppress Doxorubicin-induced apoptosis of breast tumor cells.
Neoplasms
Focal adhesion kinase as a regulator of cell tension in the progression of cancer.
Neoplasms
Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Neoplasms
Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
Neoplasms
Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
Neoplasms
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.
Neoplasms
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Neoplasms
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Neoplasms
Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Neoplasms
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Neoplasms
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Neoplasms
Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells.
Neoplasms
Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker.
Neoplasms
Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis.
Neoplasms
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Neoplasms
Focal adhesion kinase promotes progression and predicts poor clinical outcomes in patients with osteosarcoma.
Neoplasms
Focal Adhesion Kinase Regulates Expression of Thioredoxin-interacting Protein (TXNIP) in Cancer Cells.
Neoplasms
Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids.
Neoplasms
Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
Neoplasms
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Neoplasms
Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered wnt signaling.
Neoplasms
Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein.
Neoplasms
Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
Neoplasms
Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.
Neoplasms
Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis.
Neoplasms
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Neoplasms
Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer.
Neoplasms
Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
Neoplasms
Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FR?/c-SRC/ERK1/2/NF?B/TP53 pathway: in vitro and in vivo studies.
Neoplasms
Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
Neoplasms
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Neoplasms
Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.
Neoplasms
Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability.
Neoplasms
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.
Neoplasms
Frequent development of murine T-cell lymphomas with TcR alpha/beta+, CD4-/8- phenotype after implantation of human inflammatory breast cancer cells in BALB/c nude mice.
Neoplasms
Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers.
Neoplasms
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
Neoplasms
FRK Inhibits Migration and Invasion of Human Glioma Cells by Promoting N-cadherin/?-catenin Complex Formation.
Neoplasms
FRK plays an oncogenic role in non-small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.
Neoplasms
FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation.
Neoplasms
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
Neoplasms
From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management.
Neoplasms
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Neoplasms
Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Neoplasms
Function and mechanism of neurotensin (NTS) and its receptor 1 (NTSR1) in occurrence and development of tumors.
Neoplasms
Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo.
Neoplasms
Function-dependent cooperation between oncogene activation and nonrandom chromosome change during tumorigenic conversion of Syrian hamster cells.
Neoplasms
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
Neoplasms
Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas.
Neoplasms
Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.
Neoplasms
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Neoplasms
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Neoplasms
Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy.
Neoplasms
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Neoplasms
Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting.
Neoplasms
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Neoplasms
Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha.
Neoplasms
Fyn Requires HnRNPA2B1 and Sam68 to Synergistically Regulate Apoptosis in Pancreatic Cancer.
Neoplasms
Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity.
Neoplasms
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.
Neoplasms
Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.
Neoplasms
Gamma linolenic acid inhibits tyrosine phosphorylation of focal adhesion kinase and paxillin and tumour cell matrix interaction.
Neoplasms
Gastrin-stimulated G?13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells.
Neoplasms
GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
Neoplasms
Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
Neoplasms
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
Neoplasms
Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triplenegative breast cancers.
Neoplasms
Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.
Neoplasms
Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms.
Neoplasms
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
Neoplasms
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC? subversion induces an upregulation of PKC?II expression in B lymphocytes.
Neoplasms
Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.
Neoplasms
Genetic alterations are frequent in APC but rare in the TGF-beta type II receptor gene in cancer in adenomas of the colon.
Neoplasms
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Neoplasms
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Neoplasms
Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability.
Neoplasms
Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity.
Neoplasms
Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma.
Neoplasms
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Neoplasms
Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.
Neoplasms
Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study.
Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Neoplasms
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
Neoplasms
Genome-wide association study identifies new loci associated with noise-induced tinnitus in Chinese populations.
Neoplasms
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Neoplasms
Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53.
Neoplasms
Geranylgeraniol Suppresses the Expression of IRAK1 and TRAF6 to Inhibit NF?B Activation in Lipopolysaccharide-Induced Inflammatory Responses in Human Macrophage-Like Cells.
Neoplasms
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.
Neoplasms
Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.
Neoplasms
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes.
Neoplasms
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Neoplasms
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
Neoplasms
Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in k562 human chronic myeloid leukemia cells.
Neoplasms
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Neoplasms
Glycine-extended gastrin activates two independent tyrosine-kinases in upstream of p85/p110 phosphatidylinositol 3-kinase in human colonic tumour cells.
Neoplasms
GM1 controlled lateral segregation of tyrosine kinase Lck predispose T-cells to cell-derived galectin-1-induced apoptosis.
Neoplasms
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Neoplasms
Grb7 and Hax1 may colocalize partially to mitochondria in EGF-treated SKBR3 cells and their interaction can affect Caspase3 cleavage of Hax1.
Neoplasms
Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation.
Neoplasms
GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.
Neoplasms
GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity.
Neoplasms
Guar gum fiber increases suppressor of cytokine signaling-1 expression via toll-like receptor 2 and dectin-1 pathways, regulating inflammatory response in small intestinal epithelial cells.
Neoplasms
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Neoplasms
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.
Neoplasms
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
Neoplasms
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Neoplasms
Heat Shock Protein 27 Phosphorylation Regulates Tumor Cell Migration under Shear Stress.
Neoplasms
Heat shock protein 90? stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells.
Neoplasms
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Neoplasms
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Neoplasms
Heme oxygenase-1 protects rat liver against warm ischemia/reperfusion injury via TLR2/TLR4-triggered signaling pathways.
Neoplasms
Hepatocyte growth factor induces tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and enhances cell-matrix interactions.
Neoplasms
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Neoplasms
Herpes simplex virus type 1 VP22-mediated intercellular delivery of PTEN increases the antitumor activity of PTEN in esophageal squamous cell carcinoma cells in vitro and in vivo.
Neoplasms
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Neoplasms
Heterogeneous addiction to TGF? signalling in recessive dystrophic epidermolysis bullosa associated cutaneous squamous cell carcinoma.
Neoplasms
Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.
Neoplasms
HIF-1?-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.
Neoplasms
High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs.
Neoplasms
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Neoplasms
High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
Neoplasms
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
Neoplasms
High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease.
Neoplasms
High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients.
Neoplasms
High rate of morphological reversion in tumor cell line H-19 associated with permanent transcriptional suppression of the LTR, v-src, LTR provirus.
Neoplasms
High resolution crystal structure of the FAK FERM domain reveals new insights on the Druggability of tyrosine 397 and the Src SH3 binding site.
Neoplasms
High tumor grade in salivary gland mucoepidermoid carcinomas and loss of expression of transforming growth factor beta receptor type II.
Neoplasms
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
Neoplasms
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Neoplasms
Highly specific characterization of tyrosine phosphoproteins in tumor cells based on monoclonal antibodies defined by conjugated phosphotyramine.
Neoplasms
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Neoplasms
HLX affects cell cycle and proliferation in AML cells via the JAK/STAT signaling pathway.
Neoplasms
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.
Neoplasms
HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.
Neoplasms
hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress.
Neoplasms
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Neoplasms
Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated ?-catenin loss in hepatocellular carcinoma.
Neoplasms
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Neoplasms
How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Neoplasms
How the Discovery of the CD4/CD8-p56lck Complexes Changed Immunology and Immunotherapy.
Neoplasms
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Neoplasms
Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Neoplasms
Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Neoplasms
Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
Neoplasms
Human homologue of the Drosophila discs large tumor suppressor binds to p56lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes.
Neoplasms
Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK.
Neoplasms
Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain.
Neoplasms
Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases.
Neoplasms
Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?
Neoplasms
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Neoplasms
Hypoxia-Induced Caveolin-1 Expression Promotes Migration and Invasion of Tumor Cells.
Neoplasms
I-FISH control of CGH-detected gain of DNA sequence copy number in oral squamous cell carcinomas (OSCC).
Neoplasms
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Neoplasms
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Neoplasms
Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
Neoplasms
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Neoplasms
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Neoplasms
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Neoplasms
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Neoplasms
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Neoplasms
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Neoplasms
Ibrutinib inhibits B-cell receptor and NF-?B signaling and reduces tumor proliferation in tissue-resident cells of patients with chronic lymphocytic leukemia.
Neoplasms
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Neoplasms
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.
Neoplasms
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Neoplasms
Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients.
Neoplasms
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Neoplasms
Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
Neoplasms
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Neoplasms
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Neoplasms
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Neoplasms
Icariin enhance mild hypothermia-induced neuroprotection via inhibiting the activation of NF-?B in experimental ischemic stroke.
Neoplasms
ICV vs. VMH injection of leptin: comparative effects on hypothalamic gene expression.
Neoplasms
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.
Neoplasms
Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Neoplasms
Identification and characterization of tyrosine kinase activity associated with mitochondrial outer membrane in sarcoma 180 cells.
Neoplasms
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Neoplasms
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Neoplasms
Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value.
Neoplasms
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Neoplasms
Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.
Neoplasms
Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma.
Neoplasms
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
Neoplasms
Identification of Avian leukosis virus subgroup J associated acutely transforming viruses carrying the v-src oncogene in layer chickens.
Neoplasms
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Neoplasms
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Neoplasms
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Neoplasms
Identification of cis-acting promoter elements that support expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) in v-src transformed Madin-Darby canine kidney cells.
Neoplasms
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Neoplasms
Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data.
Neoplasms
Identification of FAK substrate peptides via colorimetric screening of a one-bead one-peptide combinatorial library.
Neoplasms
Identification of immune-activating metabolite for enhancing T cell therapy of cancer.
Neoplasms
Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Neoplasms
Identification of key genes implicated in the suppressive function of human FOXP3+CD25+CD4+ regulatory T cells through the analysis of time?series data.
Neoplasms
Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions.
Neoplasms
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation.
Neoplasms
Identification of methyl violet 2B as a novel blocker of focal adhesion kinase signaling pathway in cancer cells.
Neoplasms
Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR.
Neoplasms
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Neoplasms
Identification of potential small-molecule protein-protein inhibitors of cancer metastasis by 3D epitope-based computational screening.
Neoplasms
Identification of potential therapeutic target genes, key miRNAs and mechanisms in acute myeloid leukemia based on bioinformatics analysis.
Neoplasms
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Neoplasms
Identification of pY654-?-catenin as a critical co-factor in hypoxia-inducible factor-1? signaling and tumor responses to hypoxia.
Neoplasms
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.
Neoplasms
Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
Neoplasms
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN? That Induce PD-L1 Expression in Head and Neck Cancer.
Neoplasms
Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments.
Neoplasms
Identification of the JAK-STAT pathway in canine splenic hemangiosarcoma, thyroid carcinoma, mast cell tumor, and anal sac adenocarcinoma.
Neoplasms
Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.
Neoplasms
Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties.
Neoplasms
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Neoplasms
IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.
Neoplasms
IL-6 attenuates trimethyltin-induced cognitive dysfunction via activation of JAK2/STAT3, M1 mAChR and ERK signaling network.
Neoplasms
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Neoplasms
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Neoplasms
Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells.
Neoplasms
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Neoplasms
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Neoplasms
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Neoplasms
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Neoplasms
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Neoplasms
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
Neoplasms
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Neoplasms
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Neoplasms
Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
Neoplasms
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Neoplasms
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Neoplasms
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Neoplasms
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Neoplasms
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Neoplasms
Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Neoplasms
Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
Neoplasms
Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Neoplasms
Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.
Neoplasms
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Neoplasms
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Neoplasms
Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors.
Neoplasms
Immunohistochemical Analysis of PDGFR-?, PDGFR-? and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
Neoplasms
Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.
Neoplasms
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Neoplasms
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Neoplasms
Immunohistochemical Expression of Cortactin and Focal Adhesion Kinase Predicts Recurrence Risk and Laryngeal Cancer Risk Beyond Histologic Grading.
Neoplasms
Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea.
Neoplasms
Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Neoplasms
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Neoplasms
Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Neoplasms
Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Neoplasms
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Neoplasms
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Neoplasms
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Neoplasms
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Neoplasms
Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation.
Neoplasms
In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Neoplasms
In situ photoactivation of a caged phosphotyrosine peptide derived from focal adhesion kinase temporarily halts lamellar extension of single migrating tumor cells.
Neoplasms
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
Neoplasms
In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
Neoplasms
In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae.
Neoplasms
In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-Family Kinase C-Helix-out Inhibitor Resistance.
Neoplasms
In vitro metabolism of ibrutinib in rat, dog and human hepatocytes by using liquid chromatography combined with diode array detector and Q-Exactive Orbitrap tandem mass spectrometry.
Neoplasms
In Vitro Phosphorylation of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase by Src Kinase.
Neoplasms
In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Neoplasms
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
Neoplasms
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
Neoplasms
In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).
Neoplasms
In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.
Neoplasms
In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives.
Neoplasms
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
Neoplasms
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Neoplasms
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Neoplasms
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Neoplasms
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Neoplasms
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Neoplasms
Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.
Neoplasms
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Neoplasms
Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer.
Neoplasms
Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury.
Neoplasms
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma.
Neoplasms
Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas.
Neoplasms
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Neoplasms
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Neoplasms
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Neoplasms
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Neoplasms
Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA.
Neoplasms
Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced With Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC).
Neoplasms
Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides.
Neoplasms
Induction of growth alterations in factor-dependent hematopoietic progenitor cell lines by cocultivation with irradiated bone marrow stromal cell lines.
Neoplasms
Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene.
Neoplasms
Induction of WNT11 by hypoxia and hypoxia-inducible factor-1? regulates cell proliferation, migration and invasion.
Neoplasms
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Neoplasms
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.
Neoplasms
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Neoplasms
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Neoplasms
Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.
Neoplasms
Influence of controlled release of resveratrol from electrospun fibers in combination with siRNA on leukemia cells.
Neoplasms
Influence of the transduced 3'UTR of the c-src oncogene on tumour growth induced by the v-src gene of avian sarcoma virus PR2257.
Neoplasms
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Neoplasms
Inhibiting FAK-Paxillin Interaction Reduces Migration and Invadopodia-Mediated Matrix Degradation in Metastatic Melanoma Cells.
Neoplasms
Inhibiting focal adhesion kinase (FAK) blocks IL-4 induced VCAM-1 expression and eosinophil recruitment in vitro and in vivo.
Neoplasms
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Neoplasms
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.
Neoplasms
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Neoplasms
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Neoplasms
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Neoplasms
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI.
Neoplasms
Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Neoplasms
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
Neoplasms
Inhibition of c-Yes induces differentiation of HT-29 human colon cancer stem cells through midbody elongation.
Neoplasms
Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells.
Neoplasms
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.
Neoplasms
Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.
Neoplasms
Inhibition of FAK Signaling Elicits Lamin A/C-Associated Nuclear Deformity and Cellular Senescence.
Neoplasms
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Neoplasms
Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
Neoplasms
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Neoplasms
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Neoplasms
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Neoplasms
Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.
Neoplasms
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Neoplasms
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
Neoplasms
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Neoplasms
Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall.
Neoplasms
Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.
Neoplasms
Inhibition of p21 and Akt Potentiates SU6656-Induced Caspase-Independent Cell Death in FRO Anaplastic Thyroid Carcinoma Cells.
Neoplasms
Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.
Neoplasms
Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
Neoplasms
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Neoplasms
INHIBITION OF SRC WITH AZD0530 REVEALS THE SRC-FOCAL ADHESION KINASE COMPLEX AS A NOVEL THERAPEUTIC TARGET IN PAPILLARY AND ANAPLASTIC THYROID CANCERS.
Neoplasms
Inhibition of TGF-? signaling in tumor cells by small molecule Src family kinase inhibitors.
Neoplasms
Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
Neoplasms
Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Neoplasms
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.
Neoplasms
Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice.
Neoplasms
Inhibition of Transforming Growth Factor-? (TGF-?) Signaling by Scutellaria baicalensis and Fritillaria cirrhosa Extracts in Endometrial Cancer.
Neoplasms
Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
Neoplasms
Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Neoplasms
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Neoplasms
Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces.
Neoplasms
Inhibitors of Bruton's Tyrosine Kinase (Btk) May Treat Inflammation, Immunological Disorders, and Cancer.
Neoplasms
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Neoplasms
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
Neoplasms
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.
Neoplasms
Inhibitory effect of isomorellin on cholangiocarcinoma cells via suppression of NF-?B translocation, the phosphorylated p38 MAPK pathway and MMP-2 and uPA expression.
Neoplasms
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
Neoplasms
Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies.
Neoplasms
Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Neoplasms
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.
Neoplasms
Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer.
Neoplasms
Integrin-linked kinase: a multi-functional regulator modulating extracellular pressure-stimulated cancer cell adhesion through focal adhesion kinase and AKT.
Neoplasms
Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1.
Neoplasms
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth.
Neoplasms
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
Neoplasms
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
Neoplasms
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Neoplasms
Interplay between epidermal growth factor receptor and Janus kinase 3 regulates polychlorinated biphenyl-induced matrix metalloproteinase-3 expression and transendothelial migration of tumor cells.
Neoplasms
Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs.
Neoplasms
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Neoplasms
Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth.
Neoplasms
Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway.
Neoplasms
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.
Neoplasms
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Neoplasms
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
Neoplasms
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Neoplasms
Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression.
Neoplasms
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
Neoplasms
Investigations of FAK inhibitors: a combination of 3D-QSAR, docking, and molecular dynamics simulations studies.
Neoplasms
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Neoplasms
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Neoplasms
Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.
Neoplasms
Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.
Neoplasms
Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin.
Neoplasms
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Neoplasms
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Neoplasms
Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Neoplasms
Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?: Multi-Institutional Study.
Neoplasms
Ischaemic conditioning strategies reduce ischaemia/reperfusion-induced organ injury.
Neoplasms
Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Neoplasms
Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras.
Neoplasms
Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.
Neoplasms
Isolation and properties of gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors.
Neoplasms
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Neoplasms
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Neoplasms
JAK2
V617F
-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure.
Neoplasms
JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Neoplasms
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Neoplasms
JAK2 in the Diagnosis and Treatment of Lymphoid Malignancies: A Review of the Literature.
Neoplasms
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Neoplasms
JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Neoplasms
JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms.
Neoplasms
JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East.
Neoplasms
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Neoplasms
JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.
Neoplasms
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
Neoplasms
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN?.
Neoplasms
JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
Neoplasms
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
Neoplasms
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.
Neoplasms
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Neoplasms
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Neoplasms
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Neoplasms
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Neoplasms
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Neoplasms
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Neoplasms
Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Neoplasms
Jieduquyuziyin Prescription Suppresses Inflammatory Activity of MRL/lpr Mice and Their Bone Marrow-Derived Macrophages via Inhibiting Expression of IRAK1-NF-?B Signaling Pathway.
Neoplasms
JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.
Neoplasms
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Neoplasms
Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.
Neoplasms
Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Neoplasms
Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Neoplasms
Kinome profiling in pediatric brain tumors as a new approach for target discovery.
Neoplasms
Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Neoplasms
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Neoplasms
Knockdown of FAK inhibits the invasion and metastasis of Tca?8113 cells in vitro.
Neoplasms
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Neoplasms
l-Amino acid oxidase isolated from Calloselasma rhodostoma snake venom induces cytotoxicity and apoptosis in JAK2V617F-positive cell lines.
Neoplasms
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
Neoplasms
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Neoplasms
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.
Neoplasms
Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients-Characteristics along with a validation of 2016 WHO criteria.
Neoplasms
LCK as a Potential Therapeutic Target for Acute Rejection after Kidney Transplantation: A Bioinformatics Clue.
Neoplasms
LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme.
Neoplasms
Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML.
Neoplasms
Licochalcone D directly targets JAK2 to induced apoptosis in human oral squamous cell carcinoma.
Neoplasms
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.
Neoplasms
Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Neoplasms
Ligand-independent anti-oncogenic activity of the alpha subunit of the type I interferon receptor.
Neoplasms
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Neoplasms
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Neoplasms
Lineage-specific control of superantigen-induced cell death by the protein tyrosine kinase p56(lck).
Neoplasms
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
Neoplasms
Liver Protects Metastatic Prostate Cancer From Induced Death by Activating E-cadherin Signaling.
Neoplasms
Long non-coding RNA ABHD11-AS1 promotes colorectal cancer progression and invasion through targeting the integrin subunit alpha 5/focal adhesion kinase/phosphoinositide 3 kinase/Akt signaling pathway.
Neoplasms
Long noncoding RNA ABHD11-AS1 promote cells proliferation and invasion of colorectal cancer via regulating the miR-1254-WNT11 pathway.
Neoplasms
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
Neoplasms
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Neoplasms
Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Neoplasms
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Neoplasms
Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.
Neoplasms
Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor.
Neoplasms
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Neoplasms
Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma.
Neoplasms
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases.
Neoplasms
Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth.
Neoplasms
Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells.
Neoplasms
Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype.
Neoplasms
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice.
Neoplasms
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.
Neoplasms
Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Neoplasms
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
Neoplasms
LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation.
Neoplasms
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.
Neoplasms
Lymphocyte activation provokes modification of a lymphocyte-specific protein tyrosine kinase (p56lck).
Neoplasms
Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation.
Neoplasms
Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase.
Neoplasms
Lyn deficiency leads to increased microbiota-dependent intestinal inflammation and susceptibility to enteric pathogens.
Neoplasms
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
Neoplasms
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Neoplasms
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Neoplasms
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Neoplasms
Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer.
Neoplasms
Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors.
Neoplasms
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Neoplasms
Macrophage Syk-PI3K? Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Neoplasms
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Neoplasms
Major histocompatibility (B) complex control of the growth pattern of v-src DNA-induced primary tumors.
Neoplasms
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Neoplasms
Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3.
Neoplasms
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Neoplasms
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Neoplasms
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression.
Neoplasms
Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
Neoplasms
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Neoplasms
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Neoplasms
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.
Neoplasms
Mangiferin ameliorates Porphyromonas gingivalis-induced experimental periodontitis by inhibiting phosphorylation of nuclear factor-?B and Janus kinase 1-signal transducer and activator of transcription signaling pathways.
Neoplasms
Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
Neoplasms
Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT.
Neoplasms
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm.
Neoplasms
mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB.
Neoplasms
Measles virus P protein suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying enzyme A20.
Neoplasms
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Neoplasms
Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations.
Neoplasms
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Neoplasms
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Neoplasms
Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression.
Neoplasms
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Neoplasms
Meeting the Challenge of Identifying New Treatments for Type 2-low Neutrophilic Asthma.
Neoplasms
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Neoplasms
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Neoplasms
Melatonin attenuates apoptotic liver damage in fulminant hepatic failure induced by the rabbit hemorrhagic disease virus.
Neoplasms
Membranal tyrosine protein kinase activity (but not cAMP-dependent protein kinase activity) is associated with growth of rat mammary tumors.
Neoplasms
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Neoplasms
Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.
Neoplasms
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Neoplasms
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Neoplasms
Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes.
Neoplasms
Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review).
Neoplasms
Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, Osteoblastogenesis, Cardiovascular disease, Malignancies.
Neoplasms
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Neoplasms
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms.
Neoplasms
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Neoplasms
Microarray analysis reveals distinct immune signatures in BCR-ABL positive and negative myeloproliferative neoplasms.
Neoplasms
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.
Neoplasms
microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia.
Neoplasms
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Neoplasms
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
Neoplasms
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
Neoplasms
MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-? RII.
Neoplasms
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
Neoplasms
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
Neoplasms
MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
Neoplasms
MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression.
Neoplasms
MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.
Neoplasms
Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea.
Neoplasms
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Neoplasms
MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
Neoplasms
MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells.
Neoplasms
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
Neoplasms
miR-146a Polymorphism Influences Levels of miR-146a, IRAK-1, and TRAF-6 in Young Patients with Coronary Artery Disease.
Neoplasms
miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis.
Neoplasms
MiR-199a-5p Inhibits the Growth and Metastasis of Colorectal Cancer Cells by Targeting ROCK1.
Neoplasms
miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC.
Neoplasms
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.
Neoplasms
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.
Neoplasms
MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Neoplasms
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Neoplasms
miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX.
Neoplasms
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Neoplasms
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.
Neoplasms
Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.
Neoplasms
Mitochondrial dysfunction as an early event in the process of apoptosis induced by woodfordin I in human leukemia K562 cells.
Neoplasms
Mitogen-stimulated tyrosine phosphorylation of a 42-kD cellular protein: evidence for a protein kinase-C requirement.
Neoplasms
Mitoxantrone Targets The ATP-Binding Site Of FAK, Binds The FAK Kinase Domain And Decreases FAK, Pyk-2, C-Src, And IGF-1R, Pyk-2 In Vitro Kinase Activities.
Neoplasms
Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
Neoplasms
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Neoplasms
Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain.
Neoplasms
Molecular and biological properties of hamster tumor cell lines transformed with B77 virus: expression of v-src does not correlate with metastatic potential.
Neoplasms
Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2.
Neoplasms
Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.
Neoplasms
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Neoplasms
Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.
Neoplasms
Molecular cloning and characterization of a cDNA clone for a protein specifically expressed in embryo as well as in a chemically induced pancreatic B cell tumor of rat.
Neoplasms
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.
Neoplasms
Molecular mechanisms of cell proliferation induced by low power laser irradiation.
Neoplasms
Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.
Neoplasms
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
Neoplasms
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
Neoplasms
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Neoplasms
Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Neoplasms
Monosodium Urate and Tumor Necrosis Factor-? Increase Apoptosis in Human Chondrocyte Cultures.
Neoplasms
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
Neoplasms
MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma.
Neoplasms
MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.
Neoplasms
MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix.
Neoplasms
mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion.
Neoplasms
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
Neoplasms
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.
Neoplasms
Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling.
Neoplasms
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Neoplasms
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Neoplasms
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Neoplasms
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Neoplasms
Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells.
Neoplasms
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.
Neoplasms
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Neoplasms
Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate.
Neoplasms
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer.
Neoplasms
Muscle-bone interactions: From experimental models to the clinic? A critical update.
Neoplasms
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Neoplasms
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Neoplasms
Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors.
Neoplasms
Mutational Profiles Reveal an Aberrant TGF-?-CEA Regulated Pathway in Colon Adenomas.
Neoplasms
Mutations in G protein ? subunits promote transformation and kinase inhibitor resistance.
Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Neoplasms
Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells.
Neoplasms
Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment.
Neoplasms
Myoferlin Depletion Elevates Focal Adhesion Kinase and Paxillin Phosphorylation and Enhances Cell-Matrix Adhesion in Breast Cancer Cells.
Neoplasms
Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix.
Neoplasms
Myristoylation of Src kinase mediates Src induced and high fat diet accelerated prostate tumor progression in mice.
Neoplasms
N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Neoplasms
Na/K-ATPase Y260 Phosphorylation-mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth.
Neoplasms
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
Neoplasms
Nanomechanical Property Maps of Breast Cancer Cells As Determined by Multiharmonic Atomic Force Microscopy Reveal Syk-Dependent Changes in Microtubule Stability Mediated by MAP1B.
Neoplasms
Near infrared light mediated photochemotherapy for efficiently treating deep orthotopic tumors guided by ultrasound imaging.
Neoplasms
Negative regulation of PYK2/related adhesion focal tyrosine kinase signal transduction by hematopoietic tyrosine phosphatase SHPTP1.
Neoplasms
Neoplastic transformation of normal and carcinogen-induced preneoplastic Syrian hamster embryo cells by the v-src oncogene.
Neoplasms
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Neoplasms
Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
Neoplasms
Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1.
Neoplasms
New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.
Neoplasms
New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
Neoplasms
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Neoplasms
New insights into the role of dietary spermine on inflammation, immune function and related-signalling molecules in the thymus and spleen of piglets.
Neoplasms
New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies.
Neoplasms
New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.
Neoplasms
New roles for B cell receptor associated kinases: when the B cell is not the target.
Neoplasms
New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway.
Neoplasms
Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines.
Neoplasms
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Neoplasms
Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3/NF-?B signaling, oxidative stress and inflammation.
Neoplasms
Nilotinib significantly induces apoptosis in imatinib resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.
Neoplasms
No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
Neoplasms
Nobiletin Inhibits Angiogenesis by Regulating Src/FAK/STAT3-Mediated Signaling through PXN in ER? Breast Cancer Cells.
Neoplasms
Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.
Neoplasms
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes I?B? mediated p53 nuclear exclusion.
Neoplasms
Noncanonical TGF? Pathway Relieves the Blockade of IL1?/TGF?-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
Neoplasms
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Neoplasms
Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.
Neoplasms
Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.
Neoplasms
Notch signaling promotes serrated neoplasia pathway in colorectal cancer through epigenetic modification of EPHB2 and EPHB4.
Neoplasms
Novel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice.
Neoplasms
Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.
Neoplasms
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Neoplasms
Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner.
Neoplasms
Novel FRET-Based Src Biosensor Reveals Mechanisms of Src Activation and Its Dynamics in Focal Adhesions.
Neoplasms
Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms.
Neoplasms
Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.
Neoplasms
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.
Neoplasms
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.
Neoplasms
Novel SYK gene variations and changes in binding sites of miRs in breast cancer patients.
Neoplasms
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Neoplasms
NOX5-L can stimulate proliferation and apoptosis depending on its levels and cellular context, determining cancer cell susceptibility to cisplatin.
Neoplasms
NPV-BSK805, an Antineoplastic Jak2 Inhibitor Effective in Myeloproliferative Disorders, Causes Adiposity in Mice by Interfering With the Action of Leptin.
Neoplasms
Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Neoplasms
Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.
Neoplasms
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Neoplasms
Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression.
Neoplasms
Nucleotide sequence analysis of c-raf-1 cDNA and promoter from a radiation-resistant human squamous carcinoma cell line: deletion within exon 17.
Neoplasms
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Neoplasms
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Neoplasms
Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.
Neoplasms
Oncogene withdrawal engages the immune system to induce sustained cancer regression.
Neoplasms
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Neoplasms
Oncogene-dependent survival of highly transformed cancer cells under conditions of extreme centrifugal force - implications for studies on extracellular vesicles.
Neoplasms
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Neoplasms
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.
Neoplasms
Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-kinase Inhibitors.
Neoplasms
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Neoplasms
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Neoplasms
Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation.
Neoplasms
Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways.
Neoplasms
Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies.
Neoplasms
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.
Neoplasms
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
Neoplasms
Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Neoplasms
Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Neoplasms
Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
Neoplasms
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Neoplasms
Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Neoplasms
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Neoplasms
Osthole suppresses the migratory ability of human glioblastoma multiforme cells via inhibition of focal adhesion kinase-mediated matrix metalloproteinase-13 expression.
Neoplasms
Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
Neoplasms
Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
Neoplasms
Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.
Neoplasms
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Neoplasms
Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database.
Neoplasms
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Neoplasms
Overexpression of a constitutively active form of c-src in skin epidermis increases sensitivity to tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Neoplasms
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Neoplasms
Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis.
Neoplasms
Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.
Neoplasms
Overexpression of EphB4 in the mammary epithelium shifts the differentiation pathway of progenitor cells and promotes branching activity and vascularization.
Neoplasms
Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
Neoplasms
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Neoplasms
Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Neoplasms
Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.
Neoplasms
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Neoplasms
Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
Neoplasms
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.
Neoplasms
Overlap of juvenile polyposis syndrome and cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: implications for treatment and surveillance.
Neoplasms
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Neoplasms
Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson's Disease.
Neoplasms
Oxidized LDL induces vimentin secretion by macrophages and contributes to atherosclerotic inflammation.
Neoplasms
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
Neoplasms
p110? inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma.
Neoplasms
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.
Neoplasms
p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation.
Neoplasms
p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity.
Neoplasms
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
Neoplasms
p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.
Neoplasms
P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
Neoplasms
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
Neoplasms
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Neoplasms
Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression.
Neoplasms
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Neoplasms
Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Neoplasms
Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Neoplasms
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Neoplasms
Parsaclisib, a potent and highly selective PI3K? inhibitor, in patients with relapsed or refractory B-cell malignancies.
Neoplasms
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Neoplasms
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Neoplasms
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Neoplasms
Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.
Neoplasms
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Neoplasms
PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Neoplasms
PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma.
Neoplasms
PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells.
Neoplasms
PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
Neoplasms
Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Neoplasms
Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts.
Neoplasms
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
Neoplasms
Perfusion bioreactor enabled fluid-derived shear stress conditions for novel bone metastatic prostate cancer testbed.
Neoplasms
Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth.
Neoplasms
Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.
Neoplasms
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Neoplasms
Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine.
Neoplasms
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Neoplasms
PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation.
Neoplasms
pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Neoplasms
Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.
Neoplasms
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Neoplasms
Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development.
Neoplasms
Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Neoplasms
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Neoplasms
Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Neoplasms
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Neoplasms
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Neoplasms
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
Neoplasms
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors.
Neoplasms
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies.
Neoplasms
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Neoplasms
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.
Neoplasms
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Neoplasms
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
Neoplasms
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Neoplasms
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
Neoplasms
PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer.
Neoplasms
Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.
Neoplasms
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant.
Neoplasms
Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa bcr-abl protein.
Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Neoplasms
Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes.
Neoplasms
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Neoplasms
Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion.
Neoplasms
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Neoplasms
Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion.
Neoplasms
Phosphorylation impact on Spleen Tyrosine kinase conformation by Surface Enhanced Raman Spectroscopy.
Neoplasms
Phosphorylation of connexin43 induced by Src: regulation of gap junctional communication between transformed cells.
Neoplasms
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Neoplasms
Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for Ras transformation of fibroblasts.
Neoplasms
Phosphorylation of FOXP3 by LCK downregulates MMP9 expression and represses cell invasion.
Neoplasms
Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression.
Neoplasms
Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for IGF-I-mediated regulation of focal adhesion kinase (FAK).
Neoplasms
Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation.
Neoplasms
Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Neoplasms
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.
Neoplasms
Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.
Neoplasms
PI3K? inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K? and BTK inhibitors.
Neoplasms
Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
Neoplasms
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Neoplasms
Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
Neoplasms
Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents.
Neoplasms
Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
Neoplasms
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Neoplasms
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Neoplasms
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy.
Neoplasms
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Neoplasms
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Neoplasms
Polyethylenimine-coated SPION exhibits potential intrinsic anti-metastatic properties inhibiting migration and invasion of pancreatic tumor cells.
Neoplasms
Polyethylenimine-complexed Plasmid Particles Targeting Focal Adhesion Kinase Function as Melanoma Tumor Therapeutics.
Neoplasms
Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression.
Neoplasms
Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis.
Neoplasms
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Neoplasms
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Neoplasms
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Neoplasms
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
Neoplasms
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Neoplasms
Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development.
Neoplasms
Potential anti-osteoporotic activity of low-molecular weight hyaluronan by attenuation of osteoclast cell differentiation and function in vitro.
Neoplasms
Potential applications of RNA interference technology in the treatment of cancer.
Neoplasms
Potential role of the src gene product in inhibition of gap-junctional communication in NIH/3T3 cells.
Neoplasms
Potential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth.
Neoplasms
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL
Neoplasms
PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
Neoplasms
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Neoplasms
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Neoplasms
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Neoplasms
Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Neoplasms
Predicting Kinase Inhibitor Resistance: Physics-Based and Data-Driven Approaches.
Neoplasms
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Neoplasms
Preponderance of cells with stem cell characteristics in metastasising mouse mammary tumours induced by deregulated EphB4 and ephrin-B2 expression.
Neoplasms
Preservation of NADH ubiquinone-oxidoreductase activity by Src kinase-mediated phosphorylation of NDUFB10.
Neoplasms
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
Neoplasms
Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran.
Neoplasms
Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Neoplasms
Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.
Neoplasms
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Neoplasms
Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine.
Neoplasms
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Neoplasms
Prognostic significance of c-Met, ?-catenin and FAK in patients with hepatocellular carcinoma following surgery.
Neoplasms
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Neoplasms
Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine.
Neoplasms
Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
Neoplasms
Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy.
Neoplasms
Prognostic values and clinical relationship of TYK2 in laryngeal squamous cell cancer.
Neoplasms
Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Neoplasms
Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Neoplasms
Progressive cardiac fibrosis and myocyte injury in v-fps transgenic mice. A model for primary disorders of connective tissue in the heart?
Neoplasms
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway.
Neoplasms
Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.
Neoplasms
Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells.
Neoplasms
Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Neoplasms
Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.
Neoplasms
Prostaglandins Isolated from the Octocoral Plexaura homomalla: In Silico and In Vitro Studies Against Different Enzymes of Cancer.
Neoplasms
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Neoplasms
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase as a Therapeutic Strategy for Cancer.
Neoplasms
PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis.
Neoplasms
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Neoplasms
Protective effects of type I and type II interferons toward Rous sarcoma virus-induced tumors in chickens.
Neoplasms
Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.
Neoplasms
Protein kinase B/AKT and focal adhesion kinase: two close signaling partners in cancer.
Neoplasms
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Neoplasms
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Neoplasms
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Neoplasms
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Neoplasms
Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT.
Neoplasms
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Neoplasms
Protein tyrosine kinase p56lck is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-kappa B, AP-1, JNK, and apoptosis.
Neoplasms
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells.
Neoplasms
Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors.
Neoplasms
Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors.
Neoplasms
Proteomic analysis of p38alpha mitogen-activated protein kinase-regulated changes in membrane fractions of RAS-transformed fibroblasts.
Neoplasms
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.
Neoplasms
Proviruses selected for high and stable expression of transduced genes accumulate in broadly transcribed genome areas.
Neoplasms
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
Neoplasms
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Neoplasms
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.
Neoplasms
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Neoplasms
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Neoplasms
PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Neoplasms
PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling.
Neoplasms
PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.
Neoplasms
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Neoplasms
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Neoplasms
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
Neoplasms
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.
Neoplasms
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Neoplasms
Purification and assay of kinase-active EGF receptor from mammalian cells by immunoaffinity chromatography.
Neoplasms
Purification of a tyrosine-specific protein kinase from Rous sarcoma virus-induced rat tumor.
Neoplasms
Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src.
Neoplasms
Putrescine enhances intestinal immune function and regulates intestinal bacteria in weaning piglets.
Neoplasms
Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells.
Neoplasms
Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation.
Neoplasms
Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor.
Neoplasms
Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Neoplasms
Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells.
Neoplasms
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Neoplasms
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Neoplasms
Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology.
Neoplasms
Quantitative In vivo Imaging of the Effects of Inhibiting Integrin Signaling via Src and FAK on Cancer Cell Movement: Effects on E-cadherin Dynamics.
Neoplasms
Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Neoplasms
Rabaptin-5 and Rabex-5 are neoplastic tumour suppressor genes that interact to modulate Rab5 dynamics in Drosophila melanogaster.
Neoplasms
Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation.
Neoplasms
RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Neoplasms
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Neoplasms
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Neoplasms
Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Neoplasms
Rapid and nonisotopic SSCP-based analysis of the BAT-26 mononucleotide repeat for identification of the replication error phenotype in human cancers.
Neoplasms
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Neoplasms
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Neoplasms
Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma.
Neoplasms
RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients.
Neoplasms
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Neoplasms
Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase.
Neoplasms
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Neoplasms
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Neoplasms
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Neoplasms
Recognition of LD motifs by the focal adhesion targeting domains of focal adhesion kinase and proline-rich tyrosine kinase 2-beta: Insights from molecular dynamics simulations.
Neoplasms
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
Neoplasms
Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo.
Neoplasms
Recombinant tumor necrosis factor alpha and interleukin 1 alpha increase expression of c-abl protooncogene mRNA in cultured human marrow stromal cells.
Neoplasms
Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP ?1/SHP-2 signaling system.
Neoplasms
Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation.
Neoplasms
Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
Neoplasms
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Neoplasms
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Neoplasms
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Neoplasms
Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein.
Neoplasms
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Neoplasms
Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
Neoplasms
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Neoplasms
Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase.
Neoplasms
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Neoplasms
Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines.
Neoplasms
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
Neoplasms
Regulation of inflammatory responses in tumor necrosis factor - activated and rheumatoid arthritis synovial macrophages by Janus kinase inhibitors.
Neoplasms
Regulation of Large Conductance Voltage-and Ca2+-Activated K+ Channels by the Janus Kinase JAK3.
Neoplasms
Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells.
Neoplasms
Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition.
Neoplasms
Regulatory effects of miR-146a/b on the function of endothelial progenitor cells in acute ischemic stroke in mice.
Neoplasms
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
Neoplasms
Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Neoplasms
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Neoplasms
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Neoplasms
Repression of interferon ?-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Neoplasms
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Neoplasms
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
Neoplasms
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
Neoplasms
Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis.
Neoplasms
Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation.
Neoplasms
Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis.
Neoplasms
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Neoplasms
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Neoplasms
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia".
Neoplasms
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Neoplasms
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Neoplasms
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line.
Neoplasms
Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent TGF-? pathway.
Neoplasms
Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Neoplasms
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ?-tubulin explains KXO1's low clinical toxicity.
Neoplasms
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.
Neoplasms
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Neoplasms
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Neoplasms
Role of EFNB2/EPHB4 signaling in spiral artery development during pregnancy: An appraisal.
Neoplasms
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Neoplasms
Role of focal adhesion kinase in human cancer: a potential target for drug discovery.
Neoplasms
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Neoplasms
Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria.
Neoplasms
Role of tumor necrosis factor-alpha, interleukin-8, and dexamethasone in the focal adhesion kinase expression by human nucleus pulposus cells.
Neoplasms
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Neoplasms
Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Neoplasms
Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells.
Neoplasms
Rounding up the Usual Suspects: Assessing Yorkie, AP-1, and Stat Coactivation in Tumorigenesis.
Neoplasms
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Neoplasms
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.
Neoplasms
S100A9 promotes prostate cancer cell invasion by activating TLR4/NF-?B/integrin ?1/FAK signaling.
Neoplasms
S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH.
Neoplasms
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Neoplasms
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Neoplasms
Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma.
Neoplasms
Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1? pathways in breast cancer.
Neoplasms
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Neoplasms
Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Neoplasms
Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm.
Neoplasms
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Neoplasms
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Neoplasms
Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells.
Neoplasms
Seleno-L-Methionine Suppresses Immunoglobulin E-Mediated Allergic Response in RBL-2H3 Cells.
Neoplasms
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.
Neoplasms
Sensitive Detection and Quantification of the JAK2V617F Allele by Real-Time PCR Blocking Wild-Type Amplification by Using a Peptide Nucleic Acid Oligonucleotide.
Neoplasms
Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates.
Neoplasms
Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes.
Neoplasms
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?
Neoplasms
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Neoplasms
Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival.
Neoplasms
Sex hormone-induced mammary carcinogenesis in female Noble rats: expression of TGF-beta1 and its receptors, TGF-alpha, and EGF-R in mammary carcinogenesis.
Neoplasms
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
Neoplasms
Short-Chain Fatty Acids Suppress Inflammatory Reactions in Caco-2 Cells and Mouse Colons.
Neoplasms
Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Neoplasms
Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation?
Neoplasms
Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Neoplasms
SHP2 mediates the localized activation of Fyn downstream of the ?6?4 integrin to promote carcinoma invasion.
Neoplasms
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells.
Neoplasms
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Neoplasms
Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity.
Neoplasms
Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.
Neoplasms
Signal transduction pathways in liver and the influence of hepatitis C virus infection on their activities.
Neoplasms
Signaling pathway of globo-series glycosphingolipids and ?1,3-galactosyltransferase V (?3GalT5) in breast cancer.
Neoplasms
Silencing of focal adhesion kinase by tumor direct injection of small interfering RNA decreases in vivo tumor growth.
Neoplasms
Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3?/Wnt/?-catenin signaling.
Neoplasms
Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.
Neoplasms
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Neoplasms
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer.
Neoplasms
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Neoplasms
Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models.
Neoplasms
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
Neoplasms
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
Neoplasms
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Neoplasms
Site-specific metastasis formation: Chemokines as regulators of tumor cell adhesion, motility and invasion.
Neoplasms
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Neoplasms
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Neoplasms
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Neoplasms
Small G protein signalling modulator 2 (SGSM2) is involved in oestrogen receptor-positive breast cancer metastasis through enhancement of migratory cell adhesion via interaction with E-cadherin.
Neoplasms
Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells.
Neoplasms
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
Neoplasms
Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Neoplasms
Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
Neoplasms
Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
Neoplasms
Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.
Neoplasms
Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia.
Neoplasms
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Neoplasms
Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide.
Neoplasms
Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs.
Neoplasms
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Neoplasms
Soyasaponins reduce inflammation by downregulating MyD88 expression and suppressing the recruitments of TLR4 and MyD88 into lipid rafts.
Neoplasms
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Neoplasms
Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression.
Neoplasms
Specific down-regulation of annexin II expression in human cells interferes with cell proliferation.
Neoplasms
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.
Neoplasms
Specific tumor delivery of paclitaxel using glycolipid-like polymer micelles containing gold nanospheres.
Neoplasms
Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Neoplasms
Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Neoplasms
Spleen tyrosine kinase (Syk) dependent calcium signals mediate efficient CpG-induced exocytosis of tumor necrosis factor alpha (TNF?) in innate immune cells.
Neoplasms
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
Neoplasms
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Neoplasms
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Neoplasms
Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization.
Neoplasms
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Neoplasms
Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells.
Neoplasms
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Neoplasms
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Neoplasms
Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation.
Neoplasms
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
Neoplasms
Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells.
Neoplasms
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.
Neoplasms
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Neoplasms
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Neoplasms
Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes.
Neoplasms
Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson's Disease Models.
Neoplasms
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Neoplasms
Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Neoplasms
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Neoplasms
Src kinase activation by nitric oxide promotes resistance to anoikis in tumour cell lines.
Neoplasms
Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappaB.
Neoplasms
Src kinase activity coordinates cell adhesion and spreading with activation of mTOR in pancreatic endocrine tumor cells.
Neoplasms
Src kinase function controls progenitor cell pools during regeneration and tumor onset in the Drosophila intestine.
Neoplasms
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Neoplasms
Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C ? Pathway in a Subset of Triple-Negative Breast Cancers.
Neoplasms
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Neoplasms
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
Neoplasms
Src Plays a Key Role in ADAM28 Expression in v-src-Transformed Epithelial Cells and Human Carcinoma Cells.
Neoplasms
Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition.
Neoplasms
Src signaling links mediators of inflammation to Cx43 gap junction channels in primary and transformed CFTR-expressing airway cells.
Neoplasms
Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background.
Neoplasms
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Neoplasms
Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
Neoplasms
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Neoplasms
Src tyrosine kinase mediates stimulation of Raf-1 and mitogen-activated protein kinase by the tumor promoter thapsigargin.
Neoplasms
Src tyrosine kinase phosphorylation of nuclear receptor HNF4? correlates with isoform-specific loss of HNF4? in human colon cancer.
Neoplasms
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Neoplasms
Src-mediated morphology transition of lung cancer cells in three-dimensional organotypic culture.
Neoplasms
Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter.
Neoplasms
Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention.
Neoplasms
src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors.
Neoplasms
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Neoplasms
STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms.
Neoplasms
Stealthy nanoparticles protect endothelial barrier from leakiness by resisting the absorption of VE-cadherin.
Neoplasms
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Neoplasms
STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.
Neoplasms
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
Neoplasms
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Neoplasms
STING-mediated Syk Signaling Attenuates Tumorigenesis of Colitis?associated Colorectal Cancer Through Enhancing Intestinal Epithelium Pyroptosis.
Neoplasms
Store-operated Ca 2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation.
Neoplasms
Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds.
Neoplasms
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.
Neoplasms
Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.
Neoplasms
Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase.
Neoplasms
Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
Neoplasms
Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Neoplasms
Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
Neoplasms
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
Neoplasms
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Neoplasms
Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells.
Neoplasms
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Neoplasms
Subcellular and Dynamic Coordination between Src Activity and Cell Protrusion in Microenvironment.
Neoplasms
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Neoplasms
Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Neoplasms
Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl.
Neoplasms
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
Neoplasms
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Neoplasms
Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Neoplasms
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1.
Neoplasms
Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma.
Neoplasms
Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells.
Neoplasms
Suppression of human MDA-MB-435S tumor by U6 promoter-driven short hairpin RNAs targeting focal adhesion kinase.
Neoplasms
Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Neoplasms
Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Neoplasms
Suppression of MMP-9 and FAK expression by pomolic acid via blocking of NF-?B/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells.
Neoplasms
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway.
Neoplasms
Suppression of Rous sarcoma virus-induced tumor formation by preinfection with viruses encoding src protein with novel N termini.
Neoplasms
Suppression of Spleen Tyrosine Kinase (Syk) by Histone Deacetylation Promotes, Whereas BAY61-3606, a Synthetic Syk Inhibitor Abrogates Colonocyte Apoptosis by ERK Activation.
Neoplasms
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.
Neoplasms
Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
Neoplasms
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Neoplasms
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Neoplasms
Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.
Neoplasms
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Neoplasms
Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.
Neoplasms
SWAP-70 is required for oncogenic transformation by v-Src in mouse embryo fibroblasts.
Neoplasms
SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.
Neoplasms
SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
Neoplasms
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro.
Neoplasms
Syk Inhibits the Activity of Protein Kinase A by Phosphorylating Tyrosine 330 of the Catalytic Subunit.
Neoplasms
SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells.
Neoplasms
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients.
Neoplasms
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Neoplasms
Synergistic effect of focal adhesion kinase overexpression and hepatocyte growth factor stimulation on cell transformation.
Neoplasms
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Neoplasms
Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
Neoplasms
Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
Neoplasms
Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
Neoplasms
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
Neoplasms
Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
Neoplasms
Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.
Neoplasms
Synthesis, radiolabelling and initial biological characterisation of 18F-labelled xanthine derivatives for PET imaging of Eph receptors.
Neoplasms
Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.
Neoplasms
Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer.
Neoplasms
T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity.
Neoplasms
T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor.
Neoplasms
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
Neoplasms
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Neoplasms
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Neoplasms
TANK-binding kinase 1 and Janus kinase 2 play important roles in the regulation of mitogen-activated protein kinase phosphatase-1 expression after toll-like receptor 4 activation.
Neoplasms
Target fishing and docking studies of the novel derivatives of aryl-aminopyridines with potential anticancer activity.
Neoplasms
Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Neoplasms
Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1.
Neoplasms
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Neoplasms
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Neoplasms
Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Neoplasms
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
Neoplasms
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Neoplasms
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Neoplasms
Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
Neoplasms
Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.
Neoplasms
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Neoplasms
Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
Neoplasms
Targeting cell signaling pathways for drug discovery: an old lock needs a new key.
Neoplasms
Targeting chronic myeloid leukemia stem cells: can transcriptional program be a druggable target for cancers?
Neoplasms
Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions.
Neoplasms
Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Neoplasms
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Neoplasms
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Neoplasms
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.
Neoplasms
Targeting heat shock protein 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Neoplasms
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Neoplasms
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Neoplasms
Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Neoplasms
Targeting Kinases in Fasciola hepatica: Anthelminthic Effects and Tissue Distribution of Selected Kinase Inhibitors.
Neoplasms
Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
Neoplasms
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
Neoplasms
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Neoplasms
Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
Neoplasms
Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells Following DNA Damage.
Neoplasms
Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.
Neoplasms
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Neoplasms
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Neoplasms
Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Neoplasms
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Neoplasms
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Neoplasms
Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions.
Neoplasms
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Neoplasms
Targeting thioredoxin reductase by ibrutinib promotes apoptosis of SMMC-7721 cells.
Neoplasms
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Neoplasms
Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation.
Neoplasms
Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.
Neoplasms
Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset.
Neoplasms
TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition.
Neoplasms
TGF-? activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Neoplasms
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Neoplasms
TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.
Neoplasms
TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system.
Neoplasms
TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Neoplasms
TGF? isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications.
Neoplasms
TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Neoplasms
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Neoplasms
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Neoplasms
The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation.
Neoplasms
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Neoplasms
The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase.
Neoplasms
The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase.
Neoplasms
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
Neoplasms
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
Neoplasms
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Neoplasms
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Neoplasms
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae.
Neoplasms
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway.
Neoplasms
The c-Fes protein tyrosine kinase as a potential anti-angiogenic target in cancer.
Neoplasms
The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines.
Neoplasms
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
Neoplasms
The Cardenolide Glycoside Acovenoside A Interferes with Epidermal Growth Factor Receptor Trafficking in Non-Small Cell Lung Cancer Cells.
Neoplasms
The cardioprotective effects of urocortin are mediated via activation of the Src tyrosine kinase-STAT3 pathway.
Neoplasms
The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells.
Neoplasms
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.
Neoplasms
The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression.
Neoplasms
The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells.
Neoplasms
The cooperative complex of Argonaute-2 and microRNA-146a regulates hepatitis B virus replication through flap endonuclease 1.
Neoplasms
The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication.
Neoplasms
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
Neoplasms
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Neoplasms
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Neoplasms
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Neoplasms
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
Neoplasms
The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein.
Neoplasms
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers.
Neoplasms
The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.
Neoplasms
The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
Neoplasms
The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.
Neoplasms
The effects of focal adhesion kinase on the motility, proliferation and apoptosis of Caco2 and SMMC-7721 cells.
Neoplasms
The effects of inducible overexpression of FAK-related non-kinase (FRNK) on a transformed epithelial cell line.
Neoplasms
The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia.
Neoplasms
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Neoplasms
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Neoplasms
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Neoplasms
The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
Neoplasms
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
Neoplasms
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Neoplasms
The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation.
Neoplasms
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
Neoplasms
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Neoplasms
The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Neoplasms
The Fer tyrosine kinase is important for platelet-derived growth factor-BB-induced signal transducer and activator of transcription 3 (STAT3) protein phosphorylation, colony formation in soft agar, and tumor growth in vivo.
Neoplasms
The fingerprints of the host innate immunity on the cells of primary virus-induced tumors.
Neoplasms
The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation.
Neoplasms
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways.
Neoplasms
The function of FAK/CCDC80/E-cadherin pathway in the regulation of B16F10 cell migration.
Neoplasms
The gene expression patterns of BMPR2, EP300, TGF?2, and TNFAIP3 in B-Lymphoma cells.
Neoplasms
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Neoplasms
The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Neoplasms
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.
Neoplasms
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Neoplasms
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Neoplasms
The human splice variant ?16HER2 induces rapid tumor onset in a reporter transgenic mouse.
Neoplasms
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Neoplasms
The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives.
Neoplasms
The impact of oncogenic mutations of the viral Src kinase on the structure and stability of the SH3 domain.
Neoplasms
The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms.
Neoplasms
The Inhibition of Spinal Astrocytic JAK2-STAT3 Pathway Activation Correlates with the Analgesic Effects of Triptolide in the Rat Neuropathic Pain Model.
Neoplasms
The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer.
Neoplasms
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
Neoplasms
The Interaction between Cancer Stem Cell Marker CD133 and Src Protein Promotes Focal Adhesion Kinase (FAK) Phosphorylation and Cell Migration.
Neoplasms
The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer.
Neoplasms
The interplay between glioblastoma and microglia cells leads to endothelial cell monolayer dysfunction via the interleukin-6-induced JAK2/STAT3 pathway.
Neoplasms
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Neoplasms
The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/?-catenin signaling in human multiple myeloma.
Neoplasms
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
Neoplasms
The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness.
Neoplasms
The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src.
Neoplasms
The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337.
Neoplasms
The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma.
Neoplasms
The LTR, v-src, LTR provirus in H-19 hamster tumor cell line is integrated adjacent to the negative regulatory region.
Neoplasms
The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts.
Neoplasms
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
Neoplasms
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Neoplasms
The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
Neoplasms
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
Neoplasms
The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
Neoplasms
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
Neoplasms
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
Neoplasms
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.
Neoplasms
The non-receptor tyrosine kinase ACK: regulatory mechanisms, signalling pathways and opportunities for attACKing cancer.
Neoplasms
The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51.
Neoplasms
The Novel Src Kinase Inhibitor M475271 Inhibits VEGF-Induced Vascular Endothelial-Cadherin and beta-Catenin Phosphorylation but Increases Their Association.
Neoplasms
The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions.
Neoplasms
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Neoplasms
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Neoplasms
The PEAK1-PPP1R12B axis inhibits tumor growth and metastasis by regulating Grb2/PI3K/Akt signalling in colorectal cancer.
Neoplasms
The Pharmacogenomics "Side-Effect" of TP53/EGFR in Non-Small Cell Lung Cancer Companied with Atorvastatin Therapy: A Functional Network Analysis.
Neoplasms
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Neoplasms
The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.
Neoplasms
The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.
Neoplasms
The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies.
Neoplasms
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
Neoplasms
The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts.
Neoplasms
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Neoplasms
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Neoplasms
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
Neoplasms
The regulation of Neuropilin 1 expression by miR-338-3p promotes non-small cell lung cancer via changes in EGFR signaling.
Neoplasms
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Neoplasms
The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.
Neoplasms
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Neoplasms
The role of exogenous Fibrinogen in cardiac surgery: stop bleeding or induce cardiovascular disease.
Neoplasms
The role of FAK catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Neoplasms
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Neoplasms
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Neoplasms
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: Therapeutic implications.
Neoplasms
The role of miR-146a on NF-?B expression level in human umbilical vein endothelial cells under hyperglycemic condition.
Neoplasms
The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome.
Neoplasms
The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
Neoplasms
The role of RIP3 in cardiomyocyte necrosis induced by mitochondrial damage of myocardial ischemia-reperfusion.
Neoplasms
The role of Src family kinases in the normal and neoplastic gastrointestinal tract.
Neoplasms
The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors.
Neoplasms
The Roles of Tissue Rigidity and Its Underlying Mechanisms in Promoting Tumor Growth.
Neoplasms
The root bark of Morus alba L. regulates tumor-associated macrophages by blocking recruitment and M2 polarization of macrophages.
Neoplasms
The secretome of non-tumorigenic mammary cells MCF-10A elicits DNA damage in MCF-7 and MDA-MB-231 breast cancer cells.
Neoplasms
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Neoplasms
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Neoplasms
The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence.
Neoplasms
The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
Neoplasms
The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway.
Neoplasms
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Neoplasms
The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
Neoplasms
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
Neoplasms
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Neoplasms
The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.
Neoplasms
The Src signaling pathway: a potential target in melanoma and other malignancies.
Neoplasms
The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.
Neoplasms
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Neoplasms
The TCR Vbeta repertoire usage of T-cells from cord blood induced by chronic myelogenous leukemia associated antigen.
Neoplasms
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Neoplasms
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Neoplasms
The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer.
Neoplasms
The therapeutic effect of artesunate on rosacea through the inhibition of the JAK/STAT signaling pathway.
Neoplasms
The therapeutic effects of Periploca forrestii Schltr. Stem extracts on collagen-induced arthritis by inhibiting the activation of Src/NF-?B signaling pathway in rats.
Neoplasms
The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Neoplasms
The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.
Neoplasms
The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Neoplasms
The tumor suppressor DAPK is reciprocally regulated by tyrosine kinase Src and phosphatase LAR.
Neoplasms
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-?8 in prostate cancer cells.
Neoplasms
The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
Neoplasms
The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
Neoplasms
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
Neoplasms
The tyrosine kinase v-Src modifies cytotoxicities of anticancer drugs targeting cell division.
Neoplasms
The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity.
Neoplasms
The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases.
Neoplasms
The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
Neoplasms
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
Neoplasms
The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line.
Neoplasms
The v-Src and c-Src tyrosine kinases immunoprecipitated from Rous sarcoma virus-transformed cells display different peptide substrate specificities.
Neoplasms
The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.
Neoplasms
Theoretical studies of the role of C-terminal cysteines in the process of S-nitrosylation of human Src kinases.
Neoplasms
Therapeutic Advances in Myeloproliferative Neoplasms: The Role of New-Small Molecule Inhibitors.
Neoplasms
Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.
Neoplasms
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Neoplasms
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
Neoplasms
Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Neoplasms
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Neoplasms
Therapeutic Potential of TNF? and IL1? Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.
Neoplasms
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Neoplasms
Three-dimensional genome architecture influences partner selection for chromosomal translocations in human disease.
Neoplasms
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Neoplasms
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Neoplasms
Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
Neoplasms
Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.
Neoplasms
Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis.
Neoplasms
TNF? contributes for attenuating both Y397 FAK and Y416 Src phosphorylations in osteoblasts.
Neoplasms
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
Neoplasms
To C or not to C: direct and indirect redox regulation of Src protein tyrosine kinase.
Neoplasms
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Neoplasms
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Neoplasms
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
Neoplasms
Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells.
Neoplasms
Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box.
Neoplasms
Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression.
Neoplasms
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Neoplasms
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Neoplasms
Transcriptional and Post-Translational Control Mechanisms for EphB4 Expression in Physiology and Cancer Disease.
Neoplasms
Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
Neoplasms
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Neoplasms
Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules.
Neoplasms
Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin.
Neoplasms
Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness.
Neoplasms
Transformation suppressor activity of a Jun transcription factor lacking its activation domain.
Neoplasms
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Neoplasms
Transforming growth factor beta depletion is the primary determinant of Smad signaling kinetics.
Neoplasms
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Neoplasms
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
Neoplasms
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Neoplasms
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Neoplasms
Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
Neoplasms
Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes.
Neoplasms
Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase.
Neoplasms
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice.
Neoplasms
Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death.
Neoplasms
Transplantation resistance to a Rous sarcoma virus-induced tumor in mice immunized with v-src protein.
Neoplasms
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Neoplasms
Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population.
Neoplasms
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Neoplasms
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model.
Neoplasms
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Neoplasms
TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Neoplasms
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
Neoplasms
Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861.
Neoplasms
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.
Neoplasms
Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4.
Neoplasms
Tumor cells induced by the v-src oncogene are heterogeneous for expression of markers of mesenchyme differentiation.
Neoplasms
Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
Neoplasms
Tumor growth suppression by adenovirus-mediated introduction of a cell growth suppressing gene tob in a pancreatic cancer model.
Neoplasms
Tumor induction by the LTR, v-src, LTR DNA in four B (MHC) congenic lines of chickens.
Neoplasms
Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation.
Neoplasms
Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity.
Neoplasms
Tumor Necrosis Factor-? (TNF?)-induced Ceramide Generation via Ceramide Synthases Regulates Loss of Focal Adhesion Kinase (FAK) and Programmed Cell Death.
Neoplasms
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Neoplasms
Tumor necrosis factor-alpha inhibits osteogenic differentiation of pre-osteoblasts by downregulation of EphB4 signaling via activated nuclear factor-kappaB signaling pathway.
Neoplasms
Tumor necrosis factor-alpha mediates pancreatitis responses in acinar cells via protein kinase C and proline-rich tyrosine kinase 2.
Neoplasms
Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression.
Neoplasms
Tumor promoters cause changes in the state of phosphorylation and apparent molecular weight of a tyrosine protein kinase in T lymphocytes.
Neoplasms
Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-?B transactivation in LNCaP cells.
Neoplasms
Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing's sarcoma cells.
Neoplasms
Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity.
Neoplasms
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas.
Neoplasms
Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
Neoplasms
Tumor-associated intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferation.
Neoplasms
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Neoplasms
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Neoplasms
Tumour induction in fetal brain transplants exposed to the viral oncogenes polyoma middle T and v-src.
Neoplasms
Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.
Neoplasms
Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case.
Neoplasms
Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase.
Neoplasms
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Neoplasms
Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy.
Neoplasms
Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse.
Neoplasms
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Neoplasms
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Neoplasms
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Neoplasms
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Neoplasms
Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.
Neoplasms
Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors.
Neoplasms
Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia.
Neoplasms
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
Neoplasms
Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin.
Neoplasms
Tyrosine-phosphorylated low density lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC in SRC-transformed cells.
Neoplasms
Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Neoplasms
Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Neoplasms
Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Neoplasms
Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway.
Neoplasms
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Neoplasms
Upregulation of Focal Adhesion Kinase by 14-3-3? via NF?B Activation in Hepatocellular Carcinoma.
Neoplasms
Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration.
Neoplasms
Uptake of a cell permeable G7-18NATE construct into cells and binding with the Grb7-SH2 domain.
Neoplasms
Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
Neoplasms
Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinaseAbl transcript in the treatment of chronic myeloid leukaemia.
Neoplasms
Use of QSAR Global Models and Molecular Docking for Developing New Inhibitors of c-src Tyrosine Kinase.
Neoplasms
Use of various immunotherapies for refractory ulcerative colitis in a person living with HIV: a case report.
Neoplasms
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Neoplasms
Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study.
Neoplasms
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.
Neoplasms
v-fps protein-tyrosine kinase coordinately enhances the malignancy and growth factor responsiveness of pre-neoplastic lung fibroblasts.
Neoplasms
v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.
Neoplasms
v-src activation of the collagenase-1 (matrix metalloproteinase-1) promoter through PEA3 and STAT: requirement of extracellular signal-regulated kinases and inhibition by retinoic acid receptors.
Neoplasms
v-Src causes delocalization of Mklp1, Aurora B, and INCENP from the spindle midzone during cytokinesis failure.
Neoplasms
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
Neoplasms
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.
Neoplasms
v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element.
Neoplasms
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.
Neoplasms
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
Neoplasms
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Neoplasms
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Neoplasms
Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples.
Neoplasms
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Neoplasms
Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
Neoplasms
Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
Neoplasms
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.
Neoplasms
Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.
Neoplasms
Water-pipe smoking promotes epithelial-mesenchymal transition and invasion of human breast cancer cells via ERK1/ERK2 pathways.
Neoplasms
Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome.
Neoplasms
What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Neoplasms
What Is the Role of JAK2V617F Mutation in Leukemic Transformation of Myeloproliferative Neoplasms?
Neoplasms
Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression.
Neoplasms
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Neoplasms
Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.
Neoplasms
Wnt/?-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
Neoplasms
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Neoplasms
WNT11 Expression Is Induced by Estrogen-Related Receptor {alpha} and {beta}-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration.
Neoplasms
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Neoplasms
Xiaoyaosan exerts anxiolytic-like effects by down-regulating the TNF-?/JAK2-STAT3 pathway in the rat hippocampus.
Neoplasms
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Neoplasms
Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase.
Neoplasms
Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
Neoplasms
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Neoplasms
ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases.
Neoplasms
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Neoplasms
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
Neoplasms
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Neoplasms
Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
Neoplasms
ZINC4085554 inhibits cancer cell adhesion by interfering with the interaction of Akt1 and FAK.
Neoplasms
Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
Neoplasms
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Neoplasms
[Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]
Neoplasms
[Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Neoplasms
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
Neoplasms
[Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].
Neoplasms
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
Neoplasms
[Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow].
Neoplasms
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
Neoplasms
[Changes of serum miR-375 and blood target genes in patients with allergic rhinitis before and after treatment and its significance].
Neoplasms
[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Neoplasms
[Characteristics of the epidermal growth factor receptors in the epithelium of the gastrointestinal tract of rats and in intestinal tumors induced by 1,2-dimethylhydrazine]
Neoplasms
[Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Neoplasms
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
Neoplasms
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Neoplasms
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
Neoplasms
[Detection of fps tumor antigen with mono-specific anti-fps serum in tumors induced by acute transforming ALV].
Neoplasms
[Differential gene expression in nasopharyngeal carcinoma cell with reduced and normal expression of 6A8 alpha-mannosidase]
Neoplasms
[Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
Neoplasms
[Establishment of mouse SP2/0 cell line stably expressing bcr-abl fusion gene fragment]
Neoplasms
[Expression of focal adhesion kinase in lymphatic endothelial cells of metastasis]
Neoplasms
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
Neoplasms
[FAK related non-kinase (FRNK) inhibits migration of a human breast carcinoma cell line MDA-MB-435]
Neoplasms
[Functions of spleen tyrosine kinase (Syk) gene and its correlation to neoplasms]
Neoplasms
[Induction of unstable mutations in Drosophila melanogaster by microinjection of oncogenic virus DNA into polar embryonic plasm. Malignant effect of oncoviral DNA]
Neoplasms
[Influences of bcr-abl Gene Vaccine on Inoculated SP2/0/bcr-abl Tumor Cells in Mice.]
Neoplasms
[Inhibitory effect of full-length spleen tyrosine kinase on invasion and metastasis of human laryngeal squamous cells].
Neoplasms
[Investigation of the influence of mechanical signals on the structure of CD44/FERM complex via molecular dynamics simulation].
Neoplasms
[Involvement of Src kinase in the down-regulation of ultra-rapid delayed rectifier K(+)current induced by tumor necrosis factor-? in cardiomyocytes].
Neoplasms
[JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
Neoplasms
[JAK2V617F mutation and BCR-ABL fusion gene positive myeloproliferative neoplasm: two case report].
Neoplasms
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
Neoplasms
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
Neoplasms
[Mullerian inhibiting substance type II receptor as a potential target for antineoplastic therapy].
Neoplasms
[Personalized medicine based on genomic information: the present status in terms of clinical application]
Neoplasms
[Polymerase chain reaction (PCR)--a novel tool for the molecular diagnosis of neoplasms]
Neoplasms
[Protective effect of Shenfu injection on the endothelium of severe sepsis by inhibiting CD11b+ cell paralysis induced by high mobility group protein B1].
Neoplasms
[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
Neoplasms
[Research progress on aurora kinase inhibitor MK-0457 in therapy for some hematological malignancies -- review]
Neoplasms
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
Neoplasms
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Neoplasms
[Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)]
Neoplasms
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
Neoplasms
[The distribution of various type of oncogenes products in the tumor tissue of malignant mesothelioma]
Neoplasms
[The effect of transfected microRNA-146a on expression of interleukin-1 receptor-associated kinase 1 and tumor necrosis factor receptor-associated factor 6 in alveolar macrophages].
Neoplasms
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
Neoplasms
[The involvement of c-Abl and D40 (AF15q14/CASC5) proteins in the regulation of cell proliferation and cancer]
Neoplasms
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Neoplasms
[Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
Neoplasms
[Tumor antigens presented to T helper lymphocytes--critical components of the cancer vaccine]
Neoplasms
{beta}1 integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their phosphorylation.
Neoplasms, Germ Cell and Embryonal
A novel SMAD4 gene mutation in seminoma germ cell tumors.
Neoplasms, Germ Cell and Embryonal
The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors.
Neoplasms, Squamous Cell
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Neoplasms, Squamous Cell
Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
Neoplasms, Squamous Cell
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
Neoplastic Cells, Circulating
Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Neoplastic Cells, Circulating
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Nephritis
BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Nephritis
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Nephritis
Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis.
Nephritis, Hereditary
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Nephritis, Interstitial
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Nephrolithiasis
The Wnt11 Signaling Pathway in Potential Cellular EMT and Osteochondral Differentiation Progression in Nephrolithiasis Formation.
Nephrosis, Lipoid
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Nephrotic Syndrome
Enhanced expression of the cytoskeletal-associated protein, paxillin, in experimental nephrotic syndrome.
Nerve Sheath Neoplasms
Intraosseous intraneural perineurioma derived from the inferior alveolar nerve with an abnormality of chromosome 22 and expression of the BCR-ABL fusion gene: report of a case and review of recent literature.
Nervous System Diseases
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Neuralgia
A Src family kinase maintains latent sensitization in rats, a model of inflammatory and neuropathic pain.
Neuralgia
Activation of EphB receptors contributes to primary sensory neuron excitability by facilitating Ca2+ influx directly or through Src kinase-mediated NMDA receptor phosphorylation.
Neuralgia
Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain.
Neuralgia
Aspirin-triggered Lipoxin A4 attenuates mechanical allodynia in association with inhibiting spinal JAK2/STAT3 signaling in neuropathic pain in rats.
Neuralgia
BDNF released during neuropathic pain potentiates NMDA receptors in primary afferent terminals.
Neuralgia
Corrigendum: Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain.
Neuralgia
Curcumin ameliorates neuropathic pain by down-regulating spinal IL-1? via suppressing astroglial NALP1 inflammasome and JAK2-STAT3 signalling.
Neuralgia
Electroacupuncture ameliorates mechanical hypersensitivity by down-regulating spinal Janus kinase 2/signal transducer and activation of transcription 3 and interleukin 6 in rats with spared nerve injury.
Neuralgia
Electroacupuncture treatment upregulates ?7nAChR and inhibits JAK2/STAT3 in dorsal root ganglion of rat with spared nerve injury.
Neuralgia
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Neuralgia
Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain.
Neuralgia
IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain.
Neuralgia
Ligustrazine attenuates neuropathic pain by inhibition of JAK/STAT3 pathway in a rat model of chronic constriction injury.
Neuralgia
Lyn tyrosine kinase is required for P2X(4) receptor upregulation and neuropathic pain after peripheral nerve injury.
Neurilemmoma
Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.
Neuroacanthocytosis
Defective mitochondrial and lysosomal trafficking in chorea-acanthocytosis is independent of Src-kinase signaling.
Neuroacanthocytosis
Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity.
Neuroacanthocytosis
Neuronal Dysfunction in iPSC-Derived Medium Spiny Neurons from Chorea-Acanthocytosis Patients Is Reversed by Src Kinase Inhibition and F-Actin Stabilization.
Neuroacanthocytosis
Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease.
Neurobehavioral Manifestations
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Neuroblastoma
A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis.
Neuroblastoma
Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Neuroblastoma
Acrylamide-induced peripheral neuropathy: manifestations, mechanisms, and potential treatment modalities.
Neuroblastoma
An inward rectifier K+ current modulates in neuroblastoma cells the tyrosine phosphorylation of the pp125FAK and associated proteins: role in neuritogenesis.
Neuroblastoma
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells.
Neuroblastoma
Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.
Neuroblastoma
Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
Neuroblastoma
Cadmium blocks receptor-mediated Jak/STAT signaling in neurons by oxidative stress.
Neuroblastoma
CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase.
Neuroblastoma
Degradation and dephosphorylation of focal adhesion kinase during okadaic acid-induced apoptosis in human neuroblastoma cells.
Neuroblastoma
Direct interaction of beta-amyloid with Na,K-ATPase as a putative regulator of the enzyme function.
Neuroblastoma
Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death.
Neuroblastoma
Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen.
Neuroblastoma
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Neuroblastoma
Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Neuroblastoma
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
Neuroblastoma
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.
Neuroblastoma
Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses.
Neuroblastoma
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Neuroblastoma
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Neuroblastoma
Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
Neuroblastoma
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Neuroblastoma
Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Neuroblastoma
Inhibitors of protein kinases induce differentiation in human neuroblastoma cell lines.
Neuroblastoma
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Neuroblastoma
Interaction of integrin beta1 with cytokeratin 1 in neuroblastoma NMB7 cells.
Neuroblastoma
Interferon-? induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway.
Neuroblastoma
Iron depletion results in Src kinase inhibition with associated cell cycle arrest in neuroblastoma cells.
Neuroblastoma
K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
LIMK2 Mediates Resistance to Chemotherapeutic Drugs in Neuroblastoma Cells through Regulation of Drug-Induced Cell Cycle Arrest.
Neuroblastoma
Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.
Neuroblastoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Neuroblastoma
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Neuroblastoma
Src kinase family inhibitor PP2 induces aggregation and detachment of neuroblastoma cells and inhibits cell growth in a PI3 kinase/Akt pathway-independent manner.
Neuroblastoma
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro.
Neuroblastoma
TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Neuroblastoma
The human ion channel TRPM2 modulates neuroblastoma cell survival and mitochondrial function through Pyk2, CREB, and MCU activation.
Neuroblastoma
The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-?1 and focal adhesion kinase activation.
Neuroblastoma
The spin trapping agent PBN stimulates H2 O2 -induced Erk and Src kinase activity in human neuroblastoma cells.
Neuroblastoma
Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth.
Neuroblastoma
Tyrosine phosphorylation of measles virus P-phosphoprotein in persistently infected neuroblastoma cells.
Neuroblastoma
[Inhibition of Non-Receptor Tyrosine Kinase JAK2 Reduces Neuroblastoma Cell Growth and Enhances the Action of Doxorubicin].
Neurodegenerative Diseases
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
Neurodegenerative Diseases
c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder.
Neurodegenerative Diseases
Canonical JAK-STAT signaling is pivotal for long-term depression at adult hippocampal temporoammonic-CA1 synapses.
Neurodegenerative Diseases
Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
Neurodegenerative Diseases
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Neurodegenerative Diseases
Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease.
Neurodegenerative Diseases
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
Neurodegenerative Diseases
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Neurodegenerative Diseases
Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.
Neurodegenerative Diseases
STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis.
Neuroectodermal Tumors, Primitive, Peripheral
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Neuroendocrine Tumors
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Neurofibroma
Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Neurofibromatoses
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Neurofibromatoses
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibromatoses
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Neurofibromatoses
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Neurofibromatosis 1
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Neurofibromatosis 1
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibromatosis 2
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Neurofibrosarcoma
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Neurofibrosarcoma
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Neurofibrosarcoma
Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression.
Neurofibrosarcoma
Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components.
Neurofibrosarcoma
Neuregulin-1beta and neuregulin-1alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.
Neurofibrosarcoma
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.
Neuroinflammatory Diseases
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
Neuroinflammatory Diseases
A c-Src Inhibitor Peptide Based on Connexin43 Exerts Neuroprotective Effects through the Inhibition of Glial Hemichannel Activity.
Neuroinflammatory Diseases
A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation.
Neuroinflammatory Diseases
Aspirin-triggered Lipoxin A4 attenuates mechanical allodynia in association with inhibiting spinal JAK2/STAT3 signaling in neuropathic pain in rats.
Neuroinflammatory Diseases
c-Abl-p38? signaling pathway mediates dopamine neuron loss in trigeminal neuralgia.
Neuroinflammatory Diseases
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Neuroinflammatory Diseases
Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Neuroinflammatory Diseases
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
Neuroinflammatory Diseases
Mechanism of Non-receptor Tyrosine Kinase Src Regulating Neuroinflammation Through Phosphatase and Tensin Homology Protein in Microglia.
Neuroinflammatory Diseases
Neuronal c-Abl activation leads to induction of cell cycle and interferon signaling pathways.
Neuroinflammatory Diseases
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Neuroinflammatory Diseases
Overexpression of EphB4 promotes neurogenesis, but inhibits neuroinflammation in mice with acute ischemic stroke.
Neuroinflammatory Diseases
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
Neuroinflammatory Diseases
Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.
Neuroinflammatory Diseases
Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson's Disease Models.
Neuroinflammatory Diseases
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Neuroinflammatory Diseases
Tyrosine kinase Fyn promotes apoptosis after intracerebral hemorrhage in rats by activating Drp1 signaling.
Neutropenia
Association of src-kinase Lyn and non-src-kinase Syk with the granulocyte colony-stimulating factor receptor (G-CSFR) is not abrogated in neutrophils from severe congenital neutropenia patients with point mutations in the G-CSFR mRNA.
Neutropenia
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Nevus
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
Niemann-Pick Disease, Type C
c-Abl links APP-BACE1 interaction promoting APP amyloidogenic processing in Niemann-Pick type C disease.
Nijmegen Breakage Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Nijmegen Breakage Syndrome
Reduced expression of SRC family kinases decreases PI3K activity in NBS1-/- lymphoblasts.
Non-alcoholic Fatty Liver Disease
Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout.
Non-alcoholic Fatty Liver Disease
Function of inhibitor of Bruton's tyrosine kinase isoform ? (IBTK?) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.
Non-Radiographic Axial Spondyloarthritis
Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy.
non-specific protein-tyrosine kinase deficiency
A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.
non-specific protein-tyrosine kinase deficiency
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
non-specific protein-tyrosine kinase deficiency
A positive role for c-Abl in Atm and Atr activation in DNA damage response.
non-specific protein-tyrosine kinase deficiency
An infant with ZAP-70 deficiency with disseminated mycobacterial disease.
non-specific protein-tyrosine kinase deficiency
BMP type II receptor deficiency confers resistance to growth inhibition by TGF-? in pulmonary artery smooth muscle cells: role of proinflammatory cytokines.
non-specific protein-tyrosine kinase deficiency
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1?-mediated colitis.
non-specific protein-tyrosine kinase deficiency
Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction.
non-specific protein-tyrosine kinase deficiency
Bruton's tyrosine kinase deficiency inhibits autoimmune arthritis but fails to block immune complex-mediated inflammatory arthritis.
non-specific protein-tyrosine kinase deficiency
c-Abl Deficiency Provides Synaptic Resiliency Against A?-Oligomers.
non-specific protein-tyrosine kinase deficiency
c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression.
non-specific protein-tyrosine kinase deficiency
c-Abl-Mediated Tyrosine Phosphorylation of the T-bet DNA-Binding Domain Regulates CD4+ T-Cell Differentiation and Allergic Lung Inflammation.
non-specific protein-tyrosine kinase deficiency
Clinical and Mutation Description of the First Iranian Cohort of Infantile Inflammatory Bowel Disease: The Iranian Primary Immunodeficiency Registry (IPIDR).
non-specific protein-tyrosine kinase deficiency
Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.
non-specific protein-tyrosine kinase deficiency
Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility.
non-specific protein-tyrosine kinase deficiency
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
non-specific protein-tyrosine kinase deficiency
Critical role of Bmpr1a in mandibular condyle growth.
non-specific protein-tyrosine kinase deficiency
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency.
non-specific protein-tyrosine kinase deficiency
Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.
non-specific protein-tyrosine kinase deficiency
Effects of p56lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line.
non-specific protein-tyrosine kinase deficiency
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
non-specific protein-tyrosine kinase deficiency
Fatal Progressive Meningoencephalitis Diagnosed in Two Members of a Family With X-Linked Agammaglobulinemia.
non-specific protein-tyrosine kinase deficiency
Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
non-specific protein-tyrosine kinase deficiency
Functions of Fyn kinase in the completion of meiosis in mouse oocytes.
non-specific protein-tyrosine kinase deficiency
Genotype-phenotype correlation in Bruton's tyrosine kinase deficiency.
non-specific protein-tyrosine kinase deficiency
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.
non-specific protein-tyrosine kinase deficiency
Herpesvirus saimiri replaces ZAP-70 for CD3- and CD2-mediated T cell activation.
non-specific protein-tyrosine kinase deficiency
Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.
non-specific protein-tyrosine kinase deficiency
Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency.
non-specific protein-tyrosine kinase deficiency
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
non-specific protein-tyrosine kinase deficiency
IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
non-specific protein-tyrosine kinase deficiency
Immunological reconstitution in a patient with ZAP-70 deficiency following transfusion of blood lymphocytes from a previously transplanted sibling without conditioning.
non-specific protein-tyrosine kinase deficiency
Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice.
non-specific protein-tyrosine kinase deficiency
Impairment of Wnt11 function leads to kidney tubular abnormalities and secondary glomerular cystogenesis.
non-specific protein-tyrosine kinase deficiency
Increased sensitivity to apoptotic stimuli in c-abl-deficient progenitor B-cell lines.
non-specific protein-tyrosine kinase deficiency
Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling.
non-specific protein-tyrosine kinase deficiency
Loss of BMP signaling through BMPR1A in osteoblasts leads to greater collagen cross-link maturation and material-level mechanical properties in mouse femoral trabecular compartments.
non-specific protein-tyrosine kinase deficiency
Molecular characterization of Bruton's tyrosine kinase deficiency in 12 Iranian patients with presumed X-linked agammaglobulinemia.
non-specific protein-tyrosine kinase deficiency
Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.
non-specific protein-tyrosine kinase deficiency
Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.
non-specific protein-tyrosine kinase deficiency
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.
non-specific protein-tyrosine kinase deficiency
Novel Mutation of ZAP-70-related Combined Immunodeficiency: First Case from the National Iranian Registry and Review of the Literature.
non-specific protein-tyrosine kinase deficiency
Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia.
non-specific protein-tyrosine kinase deficiency
Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses.
non-specific protein-tyrosine kinase deficiency
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
non-specific protein-tyrosine kinase deficiency
RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.
non-specific protein-tyrosine kinase deficiency
Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells.
non-specific protein-tyrosine kinase deficiency
Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy.
non-specific protein-tyrosine kinase deficiency
Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency.
non-specific protein-tyrosine kinase deficiency
Smooth muscle cell-specific Tgfbr1 deficiency attenuates neointimal hyperplasia but promotes an undesired vascular phenotype for injured arteries.
non-specific protein-tyrosine kinase deficiency
Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.
non-specific protein-tyrosine kinase deficiency
Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling.
non-specific protein-tyrosine kinase deficiency
Studies of patients' thymi aid in the discovery and characterization of immunodeficiency in humans.
non-specific protein-tyrosine kinase deficiency
Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.
non-specific protein-tyrosine kinase deficiency
TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis.
non-specific protein-tyrosine kinase deficiency
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
non-specific protein-tyrosine kinase deficiency
The Abl-1 Kinase is Dispensable for NK Cell Inhibitory Signalling and is not Involved in Murine NK Cell Education.
non-specific protein-tyrosine kinase deficiency
Time-dependent decline of T-cell receptor excision circle levels in ZAP-70 deficiency.
non-specific protein-tyrosine kinase deficiency
ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
non-specific protein-tyrosine kinase deficiency
ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency.
non-specific protein-tyrosine kinase deficiency
ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis.
non-specific protein-tyrosine kinase deficiency
[Primary immunodeficiency secondary to ZAP-70 deficiency]
Obesity
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Obesity
Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity.
Obesity
Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Obesity
c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice.
Obesity
Combined parental obesity augments single-parent obesity effects on hypothalamus inflammation, leptin signaling (JAK/STAT), hyperphagia, and obesity in the adult mice offspring.
Obesity
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Obesity
Fgr kinase is required for proinflammatory macrophage activation during diet-induced obesity.
Obesity
Inhibition of Bruton's TK regulates macrophage NF-?B and NLRP3 inflammasome activation in metabolic inflammation.
Obesity
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Obesity
Leptin enhances the potency of circulating angiogenic cells via src kinase and integrin (alpha)vbeta5: implications for angiogenesis in human obesity.
Obesity
Leptin Resistance in the Ovary of Obese Mice is Associated with Profound Changes in the Transcriptome of Cumulus Cells.
Obesity
Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity.
Obstetric Labor, Premature
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Obstetric Labor, Premature
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
Obstetric Labor, Premature
High levels of fetal membrane activin beta A and activin receptor IIB mRNAs and augmented concentration of amniotic fluid activin A in women in term or preterm labor.
Ocular Hypertension
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Ocular Hypertension
Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma.
Ocular Hypertension
Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma.
Odontogenic Tumors
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Oligodendroglioma
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Oncogene Addiction
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Oncogene Addiction
From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.
Oncogene Addiction
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Oncogene Addiction
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Oncogene Addiction
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Oncogene Addiction
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
Oncogene Addiction
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Opportunistic Infections
A Case of Disseminated Cutaneous Mycobacterium chelonae Infection During Treatment With Tofacitinib.
Opportunistic Infections
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Opportunistic Infections
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Opportunistic Infections
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Opportunistic Infections
Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib.
Optic Nerve Injuries
MMP Inhibition Preserves Integrin Ligation and FAK Activation to Induce Survival and Regeneration in RGCs Following Optic Nerve Damage.
Osteitis
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Osteoarthritis
Cerebrospinal fluid of chronic osteoarthritic patients induced interleukin-6 release in human glial cell-line T98G.
Osteoarthritis
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis.
Osteoarthritis
FAK inhibition protects condylar cartilage under excessive mechanical stress.
Osteoarthritis
Functional analysis of discoidin domain receptor 2 in synovial fibroblasts in rheumatoid arthritis.
Osteoarthritis
Impact of extracellular matrix derived from osteoarthritis subchondral bone osteoblasts on osteocytes: role of integrin?1 and focal adhesion kinase signaling cues.
Osteoarthritis
In vivo bone-specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis.
Osteoarthritis
Ingenuity pathway analysis of human facet joint tissues: Insight into facet joint osteoarthritis.
Osteoarthritis
LncRNA HOTTIP leads to osteoarthritis progression via regulating miR-663a/ Fyn-related kinase axis.
Osteoarthritis
Mechanical Loading Disrupts Focal Adhesion Kinase Activation in Mandibular Fibrochondrocytes During Murine Temporomandibular Joint Osteoarthritis.
Osteoarthritis
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Osteoarthritis
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype.
Osteoarthritis
Tyrosine kinase Fyn promotes osteoarthritis by activating the ?-catenin pathway.
Osteoarthritis, Knee
[Phosphorylated Focal Adhesion Kinase, Phosphinositides 3 Kinase and Aggrecan Genes and Proteins in Cartilage Cells Are Probably Involved in Needle Knife Intervention Induced Improvement of Knee Osteoarthritis in Rabbits].
Osteogenesis Imperfecta
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Osteogenesis Imperfecta
Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.
Osteolysis
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone.
Osteolysis
Inhibitory Effect of Adenovirus-Mediated siRNA-Targeting BMPR-IB on UHMWPE-Induced Bone Destruction in the Murine Air Pouch Model.
Osteomyelitis
The nonreceptor tyrosine kinase SYK drives caspase-8/NLRP3 inflammasome-mediated autoinflammatory osteomyelitis.
Osteonecrosis
PPARgamma-2 and BMPR2 genes were differentially expressed in peripheral blood of SLE patients with osteonecrosis.
Osteonecrosis
PPARgamma-2 and BMPR2 Genes Were Significantly Differentially Expressed in Peripheral Blood of SLE Patients with Osteonecrosis.
Osteopetrosis
Characterization of unique functionalities in c-Src domains required for osteoclast podosome belt formation.
Osteopetrosis
In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene.
Osteopetrosis
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Osteopetrosis
The protein tyrosine kinase p60c-Src is not implicated in the pathogenesis of the human autosomal recessive form of osteopetrosis: a study of 13 children.
Osteoporosis
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys.
Osteoporosis
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Osteoporosis
Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral bone.
Osteoporosis
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand.
Osteoporosis
Genetic studies of bone diseases: evidence for involvement of DNA damage response proteins in bone remodeling.
Osteoporosis
Muscle-bone interactions: From experimental models to the clinic? A critical update.
Osteoporosis
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
Osteoporosis
Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.
Osteoporosis
Specific inhibition of FAK signaling attenuates subchondral bone deterioration and articular cartilage degeneration during osteoarthritis pathogenesis.
Osteoporosis
Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds.
Osteoporosis
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Osteoporosis
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.
Osteosarcoma
2-Hydroxypropyl-?-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Osteosarcoma
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Osteosarcoma
Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells.
Osteosarcoma
Analyzing time-series microarray data reveals key genes in spinal cord injury.
Osteosarcoma
Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells.
Osteosarcoma
Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.
Osteosarcoma
Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: The pivotal role of focal adhesion kinase signalling.
Osteosarcoma
BMPR1A is necessary for chondrogenesis and osteogenesis, whereas BMPR1B prevents hypertrophic differentiation.
Osteosarcoma
BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.
Osteosarcoma
Depression of Focal Adhesion Kinase Induces Apoptosis in Rat Osteosarcoma OSR-6 Cells in a Caspase-Dependent Pathway.
Osteosarcoma
Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.
Osteosarcoma
Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Osteosarcoma
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Osteosarcoma
Downregulation of miR-19a inhibits the proliferation and promotes the apoptosis of osteosarcoma cells by regulating the JAK2/STAT3 pathway.
Osteosarcoma
Erratum: Focal adhesion kinase is involved in the migration of human osteosarcoma cells.
Osteosarcoma
Focal adhesion kinase is involved in the migration of human osteosarcoma cells.
Osteosarcoma
Focal adhesion kinase promotes progression and predicts poor clinical outcomes in patients with osteosarcoma.
Osteosarcoma
Glycogen synthase kinase 3? promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
Osteosarcoma
Inhibition of autophagy attenuated curcumol-induced apoptosis in MG-63 human osteosarcoma cells via Janus kinase signaling pathway.
Osteosarcoma
Inhibition of focal adhesion kinase induces apoptosis in human osteosarcoma SAOS-2 cells.
Osteosarcoma
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Osteosarcoma
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Osteosarcoma
miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.
Osteosarcoma
Potential Antimetastatic Effect of Timosaponin AIII against Human Osteosarcoma Cells through Regulating the Integrin/FAK/Cofilin Axis.
Osteosarcoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Osteosarcoma
Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells.
Osteosarcoma
Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.
Osteosarcoma
Tanshinone IIA Inhibits Osteosarcoma Growth through a Src Kinase-Dependent Mechanism.
Osteosarcoma
Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
Osteosarcoma
The ?5/focal adhesion kinase/glycogen synthase kinase 3? integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
Osteosarcoma
The effect of bone morphogenetic protein-7 on the expression of type I inositol 1,4,5-trisphosphate receptor in G-292 osteosarcoma cells and primary osteoblast cultures.
Osteosarcoma
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
Osteosarcoma
WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.
Osteosarcoma
[Expression analysis of protein tyrosine kinases of the FAK (focal adhesion kinase) family in osteosarcoma]
Osteosclerosis
Genetic studies of bone diseases: evidence for involvement of DNA damage response proteins in bone remodeling.
Otosclerosis
Signaling by way of type IB and II bone morphogenetic protein receptors regulates bone formation in otospongiosis.
Ovarian Diseases
Expression of TGFBR1, TGFBR2, TGFBR3, ACVR1B and ACVR2B is altered in ovaries of cows with cystic ovarian disease.
Ovarian Hyperstimulation Syndrome
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Ovarian Neoplasms
8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic Acid (SD-1008), a Novel Janus Kinase 2 Inhibitor, Increases Chemotherapy Sensitivity in Human Ovarian Cancer Cells.
Ovarian Neoplasms
A heterodimeric nuclear protein complex binds two palindromic sequences in the proximal enhancer of the human erbB-2 gene.
Ovarian Neoplasms
A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-?, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.
Ovarian Neoplasms
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Ovarian Neoplasms
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Ovarian Neoplasms
Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.
Ovarian Neoplasms
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.
Ovarian Neoplasms
Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Ovarian Neoplasms
Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase.
Ovarian Neoplasms
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
Ovarian Neoplasms
Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells.
Ovarian Neoplasms
Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.
Ovarian Neoplasms
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.
Ovarian Neoplasms
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Ovarian Neoplasms
CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.
Ovarian Neoplasms
CD166 Promotes the Cancer Stem-like Properties of Primary Epithelial Ovarian Cancer Cells.
Ovarian Neoplasms
CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.
Ovarian Neoplasms
CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
Ovarian Neoplasms
Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Ovarian Neoplasms
Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Ovarian Neoplasms
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Ovarian Neoplasms
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Ovarian Neoplasms
Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE).
Ovarian Neoplasms
Differential molecular regulation of processing and membrane expression of Type-I BMP receptors: implications for signaling.
Ovarian Neoplasms
Differential Wnt11 Expression Related to Wnt5a in High- and Low-grade Serous Ovarian Cancer: Implications for Migration, Adhesion and Survival.
Ovarian Neoplasms
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
Ovarian Neoplasms
FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.
Ovarian Neoplasms
Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway.
Ovarian Neoplasms
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Ovarian Neoplasms
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Ovarian Neoplasms
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
Ovarian Neoplasms
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Ovarian Neoplasms
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Ovarian Neoplasms
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Ovarian Neoplasms
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Ovarian Neoplasms
HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.
Ovarian Neoplasms
Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer.
Ovarian Neoplasms
Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
Ovarian Neoplasms
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Ovarian Neoplasms
Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer.
Ovarian Neoplasms
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Ovarian Neoplasms
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Ovarian Neoplasms
Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.
Ovarian Neoplasms
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Ovarian Neoplasms
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.
Ovarian Neoplasms
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.
Ovarian Neoplasms
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
Ovarian Neoplasms
Leptin receptor signaling via Janus kinase 2/Signal transducer and activator of transcription 3 impacts on ovarian cancer cell phenotypes.
Ovarian Neoplasms
Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin.
Ovarian Neoplasms
Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via G?i2, Src, and HIF1? signaling nexus.
Ovarian Neoplasms
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Ovarian Neoplasms
Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Ovarian Neoplasms
MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.
Ovarian Neoplasms
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Ovarian Neoplasms
Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.
Ovarian Neoplasms
Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation.
Ovarian Neoplasms
Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors.
Ovarian Neoplasms
Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors.
Ovarian Neoplasms
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Ovarian Neoplasms
Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression.
Ovarian Neoplasms
Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer.
Ovarian Neoplasms
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Ovarian Neoplasms
Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK.
Ovarian Neoplasms
SOX2 enhances the migration and invasion of ovarian cancer cells via Src kinase.
Ovarian Neoplasms
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Ovarian Neoplasms
Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.
Ovarian Neoplasms
SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
Ovarian Neoplasms
Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.
Ovarian Neoplasms
Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells.
Ovarian Neoplasms
Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation.
Ovarian Neoplasms
Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways.
Ovarian Neoplasms
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Ovarian Neoplasms
Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Ovarian Neoplasms
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Ovarian Neoplasms
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
Ovarian Neoplasms
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
Ovarian Neoplasms
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Ovarian Neoplasms
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Overweight
Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity.
Paget Disease, Extramammary
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Pancreatic Neoplasms
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Pancreatic Neoplasms
Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.
Pancreatic Neoplasms
Allergen?removed Rhus verniciflua Stokes suppresses invasion and migration of pancreatic cancer cells through downregulation of the JAK/STAT and Src/FAK signaling pathways.
Pancreatic Neoplasms
Apigenin Inhibits NNK-Induced Focal Adhesion Kinase Activation in Pancreatic Cancer Cells.
Pancreatic Neoplasms
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
Pancreatic Neoplasms
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
Pancreatic Neoplasms
CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion.
Pancreatic Neoplasms
Clinical implications of EphB4 receptor expression in pancreatic cancer.
Pancreatic Neoplasms
Clinical significance of focal adhesion kinase in resectable pancreatic cancer.
Pancreatic Neoplasms
Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreatic Cancer.
Pancreatic Neoplasms
Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437.
Pancreatic Neoplasms
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Pancreatic Neoplasms
Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer.
Pancreatic Neoplasms
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Pancreatic Neoplasms
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Pancreatic Neoplasms
Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Pancreatic Neoplasms
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Pancreatic Neoplasms
Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Pancreatic Neoplasms
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Pancreatic Neoplasms
Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
Pancreatic Neoplasms
Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor.
Pancreatic Neoplasms
Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data.
Pancreatic Neoplasms
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Pancreatic Neoplasms
Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma.
Pancreatic Neoplasms
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Pancreatic Neoplasms
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
Pancreatic Neoplasms
Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
Pancreatic Neoplasms
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Pancreatic Neoplasms
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Pancreatic Neoplasms
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness.
Pancreatic Neoplasms
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
Pancreatic Neoplasms
Lysophosphatidic Acid Stimulates Activation of Focal Adhesion Kinase and Paxillin and Promotes Cell Motility, via LPA1-3, in Human Pancreatic Cancer.
Pancreatic Neoplasms
Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Pancreatic Neoplasms
Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pancreatic Neoplasms
MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2.
Pancreatic Neoplasms
miR-202 Diminishes TGFbeta Receptors and Attenuates TGFbeta1-induced EMT in Pancreatic Cancer.
Pancreatic Neoplasms
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.
Pancreatic Neoplasms
MUC4-induced nuclear translocation of ?-catenin: A novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer.
Pancreatic Neoplasms
New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma.
Pancreatic Neoplasms
Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.
Pancreatic Neoplasms
Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling.
Pancreatic Neoplasms
PAUF promotes adhesiveness of pancreatic cancer cells by modulating focal adhesion kinase.
Pancreatic Neoplasms
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.
Pancreatic Neoplasms
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
Pancreatic Neoplasms
Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Pancreatic Neoplasms
PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Pancreatic Neoplasms
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Pancreatic Neoplasms
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Pancreatic Neoplasms
Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Pancreatic Neoplasms
Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2.
Pancreatic Neoplasms
Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
Pancreatic Neoplasms
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
Pancreatic Neoplasms
S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.
Pancreatic Neoplasms
Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells.
Pancreatic Neoplasms
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Pancreatic Neoplasms
Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.
Pancreatic Neoplasms
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Pancreatic Neoplasms
Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer.
Pancreatic Neoplasms
The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
Pancreatic Neoplasms
The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells.
Pancreatitis
c-Abl kinase regulates neutrophil extracellular trap formation, inflammation, and tissue damage in severe acute pancreatitis.
Pancreatitis
Da-Cheng-Qi Decoction Alleviates Intestinal Injury in Rats with Severe Acute Pancreatitis by Inhibiting the JAK2-STAT3 Signaling Pathway.
Pancreatitis
Da-Huang-Fu-Zi-Tang attenuates liver injury in rats with severe acute pancreatitis.
Pancreatitis
Effect of SOCS3 on lung injury in rats with severe acute pancreatitis through regulating JAK2/STAT3 signaling pathway.
Pancreatitis
Effects of Tec Tyrosine Kinase Inhibition on the Inflammatory Response of Severe Acute Pancreatitis-Associated Acute Lung Injury in Mice.
Pancreatitis
Protective Effect of Alprostadil on Acute Pancreatitis in Rats via Inhibiting Janus Kinase 2 (JAK2)/STAT3 Signal Transduction Pathway.
Pancreatitis
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Pancreatitis
Tumor necrosis factor-alpha mediates pancreatitis responses in acinar cells via protein kinase C and proline-rich tyrosine kinase 2.
Pancytopenia
[CD22 signal abnormalities in the pathogenesis of immune related pancytopenia].
Panniculitis
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Panniculitis
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Papilledema
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.
Papilloma
Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells.
Papilloma
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Papilloma
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
Papilloma
Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis.
Papilloma
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Papilloma
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Papilloma
p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling.
Papilloma
Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes.
Papilloma
Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene.
Papilloma
The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells.
Papilloma
Variable transduction efficiency of murine leukemia retroviral vector on mammalian cells: role of cellular glycosylation.
Paralysis
A novel type 3 secretion system effector, YspI of Yersinia enterocolitica, induces cell paralysis by reducing total focal adhesion kinase.
Paraparesis, Spastic
Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
Paraproteinemias
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
Paraproteinemias
Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia.
Parasitemia
Syk inhibitors interfere with erythrocyte membrane modification during P falciparum growth and suppress parasite egress.
Parasitemia
Testosterone-induced persistent susceptibility to Plasmodium chabaudi malaria: long-term changes of lincRNA and mRNA expression in the spleen.
Paratuberculosis
ZAP-70, CTLA-4 and proximal T cell receptor signaling in cows infected with Mycobacterium avium subsp. paratuberculosis.
Parkinson Disease
?-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism.
Parkinson Disease
?-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment.
Parkinson Disease
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Parkinson Disease
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.
Parkinson Disease
c-Abl phosphorylates ?-synuclein and regulates its degradation: implication for ?-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Parkinson Disease
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Parkinson Disease
Effect of kaempferol on IgE-mediated anaphylaxis in C57BL/6 mice and LAD2 cells.
Parkinson Disease
Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research.
Parkinson Disease
Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
Parkinson Disease
Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
Parkinson Disease
Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Parkinson Disease
Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Parkinson Disease
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Parkinson Disease
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Parkinson Disease
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Parkinsonian Disorders
c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism.
Pemphigoid, Bullous
Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib.
Pemphigus
A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
Pemphigus
Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.
Pemphigus
Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus.
Pemphigus
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Pemphigus
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
Pemphigus
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus.
Pemphigus
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Pemphigus
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Periapical Granuloma
JAK2/STAT3 is associated with the inflammatory process in periapical granuloma.
Periapical Periodontitis
The potential effect of Bruton's tyrosine kinase in refractory periapical periodontitis.
Periapical Periodontitis
[Effects of Bruton's tyrosine kinase on the proliferation and differentiation of osteoclasts].
Periodontitis
CD24 activates the NLRP3 inflammasome through c-Src kinase activity in a model of the lining epithelium of inflamed periodontal tissues.
Periodontitis
Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports.
Periodontitis
Mangiferin ameliorates Porphyromonas gingivalis-induced experimental periodontitis by inhibiting phosphorylation of nuclear factor-?B and Janus kinase 1-signal transducer and activator of transcription signaling pathways.
Periodontitis
Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Peripheral Nerve Injuries
Lyn tyrosine kinase is required for P2X(4) receptor upregulation and neuropathic pain after peripheral nerve injury.
Peripheral Nerve Injuries
Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics.
Peripheral Nervous System Diseases
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.
Peritoneal Fibrosis
Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the TGF-?1/Smad3 Signaling Pathway.
Peritoneal Fibrosis
The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Persistent Infection
Cortactin: A Major Cellular Target of the Gastric Carcinogen Helicobacter pylori.
Persistent Infection
The Structural Basis for Activation and Inhibition of ZAP-70 Kinase Domain.
Peutz-Jeghers Syndrome
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Pheochromocytoma
Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor.
Pheochromocytoma
HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells.
Pheochromocytoma
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Pheochromocytoma
Neurite extension and protein tyrosine phosphorylation elicited by inducible expression of the v-src oncogene in a PC12 cell line.
Pheochromocytoma
Tyrosine 402 phosphorylation of pyk2 is involved in ionomycin-induced neurotransmitter release.
Pheochromocytoma
v-src genes stimulate neurite outgrowth in pheochromocytoma (PC12) variants unresponsive to neurotrophic factors.
Pituitary Neoplasms
The expression of integrinbeta1 and FAK in pituitary adenomas and their correlation with invasiveness.
Pituitary Neoplasms
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Pityriasis
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Pityriasis Rubra Pilaris
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Plasmablastic Lymphoma
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Plasmacytoma
BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis.
Plasmacytoma
Constitutive NF-{kappa}B Activation Confers Interleukin 6 (IL6) Independence and Resistance to Dexamethasone and Janus Kinase Inhibitor INCB018424 in Murine Plasmacytoma Cells.
Plasmacytoma
Genomic instability in B-cells and diversity of recombinations that activate c-myc.
Plasmacytoma
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Pleural Effusion
Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report.
Pleural Effusion
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.
Pleural Effusion
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Pneumonia
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Pneumonia
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Pneumonia
c-Abl-Mediated Tyrosine Phosphorylation of PARP1 Is Crucial for Expression of Proinflammatory Genes.
Pneumonia
Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response.
Pneumonia
Deletion of Src family kinase Lyn aggravates endotoxin-induced lung inflammation.
Pneumonia
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family.
Pneumonia
Genetic ablation of the src kinase p59fynT exacerbates pulmonary inflammation in an allergic mouse model.
Pneumonia
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Pneumonia
Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Pneumonia
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Pneumonia
The effect of siRNA-mediated lymphocyte-specific protein tyrosine kinase (Lck) inhibition on pulmonary inflammation in a mouse model of asthma.
Pneumonia
TLR4 activation of TRPC6-dependent calcium signaling mediates endotoxin-induced lung vascular permeability and inflammation.
Pneumonia, Bacterial
ABL kinase inhibition promotes lung regeneration through expansion of an SCGB1A1+ SPC+ cell population following bacterial pneumonia.
Polycystic Kidney Diseases
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Polycystic Kidney, Autosomal Dominant
Apico-basal polarity in polycystic kidney disease epithelia.
Polycystic Kidney, Autosomal Dominant
Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.
Polycystic Ovary Syndrome
Dysregulated miR-142, -33b, and -423 in granulosa cells target TGFBR1 and SMAD7: a possible role in polycystic ovary syndrome.
Polycythemia
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Polycythemia
Erythroblast transformation by the friend spleen focus-forming virus is associated with a block in erythropoietin-induced STAT1 phosphorylation and DNA binding and correlates with high expression of the hematopoietic phosphatase SHP-1.
Polycythemia
Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly.
Polycythemia
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Polycythemia
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Polycythemia
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
Polycythemia
The small molecule inhibitor g6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of jak2-mediated myelofibrosis.
Polycythemia Vera
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Polycythemia Vera
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Polycythemia Vera
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Polycythemia Vera
A rare case of large aortopulmonary window with Eisenmenger syndrome and adult survival.
Polycythemia Vera
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
Polycythemia Vera
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Polycythemia Vera
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Polycythemia Vera
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Polycythemia Vera
Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera.
Polycythemia Vera
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
Polycythemia Vera
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Polycythemia Vera
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Polycythemia Vera
Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Polycythemia Vera
Chromosomal abnormalities and molecular markers in myeloproliferative disorders.
Polycythemia Vera
Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.
Polycythemia Vera
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Polycythemia Vera
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Polycythemia Vera
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Polycythemia Vera
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Polycythemia Vera
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Polycythemia Vera
Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.
Polycythemia Vera
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Polycythemia Vera
Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Polycythemia Vera
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Polycythemia Vera
Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.
Polycythemia Vera
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Polycythemia Vera
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Polycythemia Vera
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
Polycythemia Vera
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Polycythemia Vera
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Polycythemia Vera
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
Polycythemia Vera
Hereditary gene mutations in Korean patients with isolated erythrocytosis.
Polycythemia Vera
How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey.
Polycythemia Vera
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Polycythemia Vera
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Polycythemia Vera
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Polycythemia Vera
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Polycythemia Vera
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Polycythemia Vera
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Polycythemia Vera
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Polycythemia Vera
JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
Polycythemia Vera
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
Polycythemia Vera
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Polycythemia Vera
JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
Polycythemia Vera
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Polycythemia Vera
Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor.
Polycythemia Vera
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Polycythemia Vera
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Polycythemia Vera
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Polycythemia Vera
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Polycythemia Vera
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Polycythemia Vera
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Polycythemia Vera
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Polycythemia Vera
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Polycythemia Vera
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Polycythemia Vera
Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.
Polycythemia Vera
Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.
Polycythemia Vera
New advances in the pathogenesis and therapy of essential thrombocythemia.
Polycythemia Vera
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Polycythemia Vera
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Polycythemia Vera
Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations
Polycythemia Vera
Polycythemia vera as a presentation of renal angiomyolipoma: a case report.
Polycythemia Vera
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Polycythemia Vera
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Polycythemia Vera
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Polycythemia Vera
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Polycythemia Vera
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.
Polycythemia Vera
Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera.
Polycythemia Vera
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Polycythemia Vera
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Polycythemia Vera
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Polycythemia Vera
Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Polycythemia Vera
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Polycythemia Vera
Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
Polycythemia Vera
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Polycythemia Vera
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Polycythemia Vera
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
Polycythemia Vera
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Polycythemia Vera
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Polycythemia Vera
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Polycythemia Vera
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
Polycythemia Vera
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Polycythemia Vera
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Polycythemia Vera
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Polycythemia Vera
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Polycythemia Vera
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Polycythemia Vera
Typical essential thrombocythaemia does not express bcr-abelson fusion transcript.
Polycythemia Vera
Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
Polycythemia Vera
Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.
Polycythemia Vera
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
Polycythemia Vera
[Molecular mechanisms of myeloproliferative diseases and myelodysplastic syndromes]
Polycythemia Vera
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Polycythemia Vera
[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
Polycythemia Vera
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Polycythemia Vera
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Polyneuropathies
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Polyneuropathies
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Pre-Eclampsia
Association study of interleukin-1 receptor associated kinase 1 rs3027898 A/C gene polymorphism and preeclampsia in Pakistani population.
Pre-Eclampsia
EPHB4 Regulates Human Trophoblast Cell Line HTR-8/SVneo Function: Implications for the Role of EPHB4 in Preeclampsia.
Pre-Eclampsia
EPHB4, a down stream target of IFN-?/STAT1 signal pathway, regulates endothelial activation possibly contributing to the development of preeclampsia.
Pre-Eclampsia
HOXA9 transcriptionally regulates the EPHB4 receptor to modulate trophoblast migration and invasion.
Pre-Eclampsia
Induction of TGF-? receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia.
Pre-Eclampsia
PP039. ETK/BMX and renin-angiotensin system (RAS) components are differentially expressed in renal tissue in both normal and preeclamptic pregnancy.
Pre-Eclampsia
Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A late-appearing Philadelphia chromosome in acute lymphoblastic leukemia confirmed by expression of BCR-ABL mRNA.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABL deletion without associated BCR-ABL in precursor B-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute bilateral retina hemorrhages beneath internal limiting membrane: An unusual ophthalmological case report of acute leukemia during complete clinical remission.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia Expressing b3a2 (p210), e1a2 (p190), and Variant e1a2 BCR-ABL Transcripts: A Case Report and Review of the Literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Amplification of BCR-ABL rearrangement in atypical Philadelphia chromosome: a new variant detected by fluorescence in situ hybridization in one case of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL fusion protein detection in peripheral blood and bone marrow samples of adult precursor B-cell acute lymphoblastic leukemia patients using the flow cytometric immunobead assay.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL rearrangement in adult T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
bcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL translocation as a favorable prognostic factor in elderly acute lymphoblastic leukemia patients in potent tyrosine kinase era.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL Translocation in Pediatric Acute Lymphoblastic Leukemia in Southern India.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Can clues to the molecular defects in chronic myelogenous leukemia come from genetic studies on the Abelson tyrosine kinase in fruit flies?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ all resolution after decitabine therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparison of a pediatric-inspired treatment protocol versusstandard-intensity chemotherapy for young adults with standard-riskBCR-ABL negative acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Constitutive 53BP1/?H2AX foci are increased in cells of ALL patients dependent on BCR-ABL and TEL-AML1 preleukemic gene fusions.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics and molecular genetics of childhood leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib: An Anti-Tumour Agent via Src Inhibition.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection and Clinical Relevance of BCR-ABL Fusion Gene in Childhood T-lineage Acute Lymphoblastic Leukemia: A Report on 4 Cases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of BCR-ABL transcripts in acute lymphoblastic leukemia in Indian patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Development of BCR-ABL positive acute lymphoblastic leukemia in donor cells after allogeneic hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Diagnostic utility of oncogenes and their products in human cancer.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Electrochemical detection of leukemia oncogenes using enzyme-loaded carbon nanotube labels.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Focal adhesion kinase comes into focus for B-cell acute lymphoblastic leukemia treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Frequency and clinical impact of ETV6/RUNX1, AF4-MLL, and BCR/ABL fusion genes on features of acute lymphoblastic leukemia at presentation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genetic evaluation of childhood acute lymphoblastic leukemia in Iraq using FTA cards.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Imatinib treatment alone in Philadelphia-positive acute lymphoblastic leukemia: is it enough?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunologic characterization of the tumor-specific bcr-abl junction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R? mutations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Keeping PACE with Ph Positive to Ph-Like Detection in B-Lineage Acute Lymphoblastic Leukemia: A Practical and Cost Effective (PACE) Approach in a Resource Constrained Setting.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular cytogenetics in childhood acute lymphoblastic leukemia: a hospital-based observational study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular diagnostics in the treatment of childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular diagnostics in the treatment of leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular mechanisms of Bcr-Abl-induced oncogenesis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multiplex PCR of bcr-abl fusion transcripts in Philadelphia positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
New approved dasatinib regimen available for clinical use.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel antibody-based therapies for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel conventional therapies in onco-hemathology.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NUP214-ABL1 mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pepsi® or Coke®? Influence of acid on dasatinib absorption.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Separated into Two Subgroups Associated with Survival by BCR-ABL Fluorescence in situ Hybridization of Segmented Cell Nuclei: Report from a Single Institution.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ponatinib-induced neutrophilic panniculitis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Practical management of dasatinib for maximum patient benefit.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Quinacrine Depletes BCR-ABL and Suppresses Ph-Positive Leukemia Cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Role of Vitamins A and D in BCR-ABL Arf-/- Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Specific inhibition of bcr-abl gene expression by small interfering RNA.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Src, Akt, NF-?B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The BCR-ABL/NF-?B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The existence of lymphoid lineage restricted Philadelphia chromosome-positive acute lymphoblastic leukemia with heterogeneous bcr-abl rearrangement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant Related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tumor classification ranking from microarray data.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Undifferentiated immunophenotypes and not expression of BCR-ABL can be associated in adult Mestizo Mexican patients with ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
VE-cadherin Regulates Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Sensitivity to Apoptosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[A Modified Protocol for Rapid Establishing Mouse Model with Ph+ Positive Acute Lymphoblastic Leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Adult acute lymphoblastic leukemia with atypical BCR-ABL transcript e1a3: a case report and literature review].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Effects of PCI-32765 and Dasatinib on the Acute Lymphoblastic Leukemic Cells and Their Mechanisms].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Frequently ABL kinase domain G:C?A:T mutation and uracil DNA glycosylase abnormal expression in TKI-resistant acute lymphoblastic leukemia of Chinese population].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Molecular genetics of acute lymphoblastic leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[PCR detection of relevant translocations in pediatric acute lymphoblastic leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Prognostic significance of Ph-positive acute lymphoblastic leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Risk Factors of Leukemia-free Survival in Ph
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Acute leukemia: subtype discovery and prediction of outcome by gene expression profiling.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Multidisciplinary analysis of pediatric T-ALL: 9q34 gene fusions.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Mutations Encountered in Acute Lymphoblastic Leukemia: A Retrospective Study in a Teaching Hospital in Jeddah, Saudi Arabia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Persistence of TEL-AML1 transcript in acute lymphoblastic leukemia in long-term remission.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
VLA-4 Induces Chemoresistance of T Cell Acute Lymphoblastic Leukemia Cells via PYK2-Mediated Drug Efflux.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
Prediabetic State
Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.
Pregnancy, Tubal
Networks of E-cadherin, ?1 integrin, and focal adhesion kinase in the pathogenesis of tubal pregnancy.
Primary Immunodeficiency Diseases
A novel deletion mutation and structural abnormality in the Bruton's tyrosine kinase gene identified in a Chinese patient with X-linked agammaglobulinemia.
Primary Immunodeficiency Diseases
Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy.
Primary Immunodeficiency Diseases
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Primary Immunodeficiency Diseases
Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.
Primary Immunodeficiency Diseases
Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.
Primary Immunodeficiency Diseases
Debilitating progressive encephalitis in a patient with BTK deficiency.
Primary Immunodeficiency Diseases
Delayed diagnosis of X-linked agammaglobulinaemia in a boy with recurrent meningitis.
Primary Immunodeficiency Diseases
Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.
Primary Immunodeficiency Diseases
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Primary Immunodeficiency Diseases
IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
Primary Immunodeficiency Diseases
Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report.
Primary Immunodeficiency Diseases
Multiple colorectal neoplasms in X-linked agammaglobulinemia.
Primary Immunodeficiency Diseases
Novel deletion mutation in Bruton's tyrosine kinase results in X-linked agammaglobulinemia: A case report.
Primary Immunodeficiency Diseases
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.
Primary Immunodeficiency Diseases
Splice-correction strategies for treatment of x-linked agammaglobulinemia.
Primary Immunodeficiency Diseases
X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis.
Primary Immunodeficiency Diseases
X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.
Primary Immunodeficiency Diseases
X-Linked Agammaglobulinemia With Chronic Meningoencephalitis: A Diagnostic Challenge.
Primary Myelofibrosis
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Primary Myelofibrosis
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Primary Myelofibrosis
A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Primary Myelofibrosis
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
Primary Myelofibrosis
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Primary Myelofibrosis
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Primary Myelofibrosis
A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.
Primary Myelofibrosis
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Primary Myelofibrosis
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Primary Myelofibrosis
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Primary Myelofibrosis
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Primary Myelofibrosis
A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers.
Primary Myelofibrosis
A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.
Primary Myelofibrosis
Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis.
Primary Myelofibrosis
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
Primary Myelofibrosis
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Primary Myelofibrosis
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Primary Myelofibrosis
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
Primary Myelofibrosis
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Primary Myelofibrosis
Allogeneic Hematopoietic Stem-Cell Transplantation in Myelofibrosis: Key Messages for Clinical Practice in the Era of Janus Kinase 1/2 Inhibitors.
Primary Myelofibrosis
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Primary Myelofibrosis
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Primary Myelofibrosis
An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.
Primary Myelofibrosis
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Primary Myelofibrosis
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
Primary Myelofibrosis
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Primary Myelofibrosis
Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Primary Myelofibrosis
Chromosomal abnormalities and molecular markers in myeloproliferative disorders.
Primary Myelofibrosis
Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.
Primary Myelofibrosis
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
Primary Myelofibrosis
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Primary Myelofibrosis
Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Primary Myelofibrosis
Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
Primary Myelofibrosis
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Primary Myelofibrosis
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Primary Myelofibrosis
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Primary Myelofibrosis
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Primary Myelofibrosis
Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report.
Primary Myelofibrosis
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Primary Myelofibrosis
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Primary Myelofibrosis
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
Primary Myelofibrosis
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.
Primary Myelofibrosis
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Primary Myelofibrosis
Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Primary Myelofibrosis
De novo variant in tyrosine kinase SRC causes thrombocytopenia: case report of a second family.
Primary Myelofibrosis
Definition and management of ruxolitinib treatment failure in myelofibrosis.
Primary Myelofibrosis
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Primary Myelofibrosis
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Primary Myelofibrosis
Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.
Primary Myelofibrosis
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
Primary Myelofibrosis
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Primary Myelofibrosis
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Primary Myelofibrosis
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Primary Myelofibrosis
Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
Primary Myelofibrosis
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
Primary Myelofibrosis
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
Primary Myelofibrosis
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Primary Myelofibrosis
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I.
Primary Myelofibrosis
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Primary Myelofibrosis
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Primary Myelofibrosis
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Primary Myelofibrosis
Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Primary Myelofibrosis
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Primary Myelofibrosis
Essential thrombocythaemia: challenges and evidence-based management.
Primary Myelofibrosis
Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects.
Primary Myelofibrosis
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Primary Myelofibrosis
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Primary Myelofibrosis
Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-?1 Signaling Pathway.
Primary Myelofibrosis
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.
Primary Myelofibrosis
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
Primary Myelofibrosis
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.
Primary Myelofibrosis
Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
Primary Myelofibrosis
Idiopathic myelofibrosis causing inflammatory central retinal vein occlusion mimicking frosted branch angiitis.
Primary Myelofibrosis
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Primary Myelofibrosis
Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Primary Myelofibrosis
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Primary Myelofibrosis
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.
Primary Myelofibrosis
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Primary Myelofibrosis
Investigational Janus kinase inhibitors in development for myelofibrosis.
Primary Myelofibrosis
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.
Primary Myelofibrosis
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Primary Myelofibrosis
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Primary Myelofibrosis
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Primary Myelofibrosis
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Primary Myelofibrosis
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.
Primary Myelofibrosis
JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
Primary Myelofibrosis
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Primary Myelofibrosis
JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling.
Primary Myelofibrosis
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Primary Myelofibrosis
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Primary Myelofibrosis
Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis.
Primary Myelofibrosis
Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
Primary Myelofibrosis
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Primary Myelofibrosis
Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis.
Primary Myelofibrosis
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Primary Myelofibrosis
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Primary Myelofibrosis
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Primary Myelofibrosis
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Primary Myelofibrosis
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Primary Myelofibrosis
Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors.
Primary Myelofibrosis
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Primary Myelofibrosis
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Primary Myelofibrosis
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Primary Myelofibrosis
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Primary Myelofibrosis
Molecular genetics of myelofibrosis and its associated disease phenotypes.
Primary Myelofibrosis
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Primary Myelofibrosis
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Primary Myelofibrosis
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Primary Myelofibrosis
Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.
Primary Myelofibrosis
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Primary Myelofibrosis
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
Primary Myelofibrosis
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Primary Myelofibrosis
Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Primary Myelofibrosis
Myelofibrosis: clinicopathologic features, prognosis, and management.
Primary Myelofibrosis
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Primary Myelofibrosis
Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.
Primary Myelofibrosis
New advances in the pathogenesis and therapy of essential thrombocythemia.
Primary Myelofibrosis
New insights into the pathogenesis and drug treatment of myelofibrosis.
Primary Myelofibrosis
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Primary Myelofibrosis
Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Primary Myelofibrosis
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Primary Myelofibrosis
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Primary Myelofibrosis
Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
Primary Myelofibrosis
Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Primary Myelofibrosis
Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Primary Myelofibrosis
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
Primary Myelofibrosis
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
Primary Myelofibrosis
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Primary Myelofibrosis
Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
Primary Myelofibrosis
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Primary Myelofibrosis
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
Primary Myelofibrosis
Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Primary Myelofibrosis
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Primary Myelofibrosis
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Primary Myelofibrosis
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment.
Primary Myelofibrosis
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Primary Myelofibrosis
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
Primary Myelofibrosis
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Primary Myelofibrosis
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
Primary Myelofibrosis
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Primary Myelofibrosis
Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
Primary Myelofibrosis
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Primary Myelofibrosis
Ruxolitinib photodegradation mechanisms by theoretical and experimental chemistry.
Primary Myelofibrosis
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
Primary Myelofibrosis
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Primary Myelofibrosis
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Primary Myelofibrosis
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Primary Myelofibrosis
Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Primary Myelofibrosis
SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Primary Myelofibrosis
Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?
Primary Myelofibrosis
Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
Primary Myelofibrosis
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Primary Myelofibrosis
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Primary Myelofibrosis
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Primary Myelofibrosis
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Primary Myelofibrosis
The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Primary Myelofibrosis
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
Primary Myelofibrosis
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Primary Myelofibrosis
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
Primary Myelofibrosis
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Primary Myelofibrosis
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
Primary Myelofibrosis
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Primary Myelofibrosis
The Mutation Profile Of Calreticulin In Patients With Myeloproliferative Neoplasms And Acute Leukemia.
Primary Myelofibrosis
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Primary Myelofibrosis
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Primary Myelofibrosis
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Primary Myelofibrosis
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
Primary Myelofibrosis
Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
Primary Myelofibrosis
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Primary Myelofibrosis
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2.
Primary Myelofibrosis
Transforming growth factor ?-mediated micromechanics modulates disease progression in primary myelofibrosis.
Primary Myelofibrosis
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
Primary Myelofibrosis
Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.
Primary Myelofibrosis
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Primary Myelofibrosis
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
Primary Myelofibrosis
[Molecular mechanisms of myeloproliferative diseases and myelodysplastic syndromes]
Primary Myelofibrosis
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
Primary Myelofibrosis
[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
Primary Myelofibrosis
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Primary Myelofibrosis
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Primary Myelofibrosis
[Treatment options and limitations in the management of myelofibrosis].
Primary Ovarian Insufficiency
Association study of anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms with idiopathic primary ovarian insufficiency.
Primary Ovarian Insufficiency
BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency.
Prion Diseases
c-Abl Tyrosine Kinase Mediates Neurotoxic Prion Peptide-Induced Neuronal Apoptosis via Regulating Mitochondrial Homeostasis.
Prion Diseases
Differential expression of transforming growth factor-beta isoforms in human prion diseases.
Prion Diseases
Increased Src kinase level results in increased protein tyrosine phosphorylation in scrapie-infected neuronal cell lines.
Proctocolitis
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Prostatic Intraepithelial Neoplasia
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Prostatic Intraepithelial Neoplasia
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Prostatic Intraepithelial Neoplasia
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-?8 in prostate cancer cells.
Prostatic Neoplasms
?3?1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.
Prostatic Neoplasms
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Prostatic Neoplasms
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Prostatic Neoplasms
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Prostatic Neoplasms
Activation of intracellular calcium by multiple Wnt ligands and translocation of ?-catenin into the nucleus: a convergent model of Wnt/Ca2+ and Wnt/?-catenin pathways.
Prostatic Neoplasms
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
Prostatic Neoplasms
Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.
Prostatic Neoplasms
Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
Prostatic Neoplasms
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
Prostatic Neoplasms
Androgen deprivation modulates gene expression profile along prostate cancer progression.
Prostatic Neoplasms
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
Prostatic Neoplasms
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Prostatic Neoplasms
Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.
Prostatic Neoplasms
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.
Prostatic Neoplasms
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.
Prostatic Neoplasms
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Prostatic Neoplasms
Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
Prostatic Neoplasms
Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)?-Suppressed Migration and Invasion of Prostate Cancer.
Prostatic Neoplasms
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
Prostatic Neoplasms
c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.
Prostatic Neoplasms
C-Src-mediated phosphorylation of ?-catenin increases its protein stability and the ability of inducing nuclear distribution of ?-catenin.
Prostatic Neoplasms
Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners.
Prostatic Neoplasms
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.
Prostatic Neoplasms
Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Prostatic Neoplasms
Clinical Targeting of Mutated and Wild-type Protein Tyrosine Kinases in Cancer.
Prostatic Neoplasms
Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs.
Prostatic Neoplasms
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
Prostatic Neoplasms
Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer.
Prostatic Neoplasms
CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors.
Prostatic Neoplasms
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone.
Prostatic Neoplasms
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation.
Prostatic Neoplasms
Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells overexpressing the early growth response-1 protein.
Prostatic Neoplasms
Determination of the membrane topology of lemur tyrosine kinase 2 (LMTK2) by fluorescence protease protection.
Prostatic Neoplasms
Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
Prostatic Neoplasms
Differential transformation capacity of Src family kinases during the initiation of prostate cancer.
Prostatic Neoplasms
Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.
Prostatic Neoplasms
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Prostatic Neoplasms
Editor's Note: Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer.
Prostatic Neoplasms
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Prostatic Neoplasms
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Prostatic Neoplasms
Effects of lysophosphatidic acid on calpain-mediated proteolysis of focal adhesion kinase in human prostate cancer cells.
Prostatic Neoplasms
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.
Prostatic Neoplasms
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Prostatic Neoplasms
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Prostatic Neoplasms
Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Prostatic Neoplasms
Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
Prostatic Neoplasms
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Prostatic Neoplasms
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Prostatic Neoplasms
Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
Prostatic Neoplasms
Focal Adhesion Kinase Controls Prostate Cancer Progression via Intrinsic Kinase and Scaffolding Functions.
Prostatic Neoplasms
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Prostatic Neoplasms
Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion.
Prostatic Neoplasms
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Prostatic Neoplasms
Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity.
Prostatic Neoplasms
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
Prostatic Neoplasms
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
Prostatic Neoplasms
Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells.
Prostatic Neoplasms
Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Prostatic Neoplasms
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Prostatic Neoplasms
High intracellular Zn2+ ions modulate the VHR, ZAP-70 and ERK activities of LNCaP prostate cancer cells.
Prostatic Neoplasms
Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Prostatic Neoplasms
Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis.
Prostatic Neoplasms
In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
Prostatic Neoplasms
Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
Prostatic Neoplasms
Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase.
Prostatic Neoplasms
Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.
Prostatic Neoplasms
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Prostatic Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Prostatic Neoplasms
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Prostatic Neoplasms
Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Prostatic Neoplasms
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Prostatic Neoplasms
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
Prostatic Neoplasms
LCoR acts as a novel androgen receptor corepressor, inhibits prostate cancer growth and is functionally inactivated by the Src kinase.
Prostatic Neoplasms
Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
Prostatic Neoplasms
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells.
Prostatic Neoplasms
Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth.
Prostatic Neoplasms
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.
Prostatic Neoplasms
MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells.
Prostatic Neoplasms
MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells.
Prostatic Neoplasms
MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases.
Prostatic Neoplasms
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.
Prostatic Neoplasms
miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells.
Prostatic Neoplasms
Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization.
Prostatic Neoplasms
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Prostatic Neoplasms
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer.
Prostatic Neoplasms
Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Prostatic Neoplasms
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.
Prostatic Neoplasms
Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
Prostatic Neoplasms
New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration.
Prostatic Neoplasms
Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database.
Prostatic Neoplasms
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Prostatic Neoplasms
Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts.
Prostatic Neoplasms
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Prostatic Neoplasms
Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Prostatic Neoplasms
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects.
Prostatic Neoplasms
Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth.
Prostatic Neoplasms
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Prostatic Neoplasms
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Prostatic Neoplasms
Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells.
Prostatic Neoplasms
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Prostatic Neoplasms
Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein.
Prostatic Neoplasms
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Prostatic Neoplasms
Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells.
Prostatic Neoplasms
Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.
Prostatic Neoplasms
Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
Prostatic Neoplasms
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Prostatic Neoplasms
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Prostatic Neoplasms
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Prostatic Neoplasms
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Prostatic Neoplasms
Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Prostatic Neoplasms
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Prostatic Neoplasms
STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells.
Prostatic Neoplasms
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Prostatic Neoplasms
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Prostatic Neoplasms
SYK is a candidate kinase target for the treatment of advanced prostate cancer.
Prostatic Neoplasms
Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells.
Prostatic Neoplasms
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Prostatic Neoplasms
The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.
Prostatic Neoplasms
The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
Prostatic Neoplasms
The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer.
Prostatic Neoplasms
The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
Prostatic Neoplasms
The TGF-? Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.
Prostatic Neoplasms
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-?8 in prostate cancer cells.
Prostatic Neoplasms
Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse.
Prostatic Neoplasms
Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.
Prostatic Neoplasms
Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity.
Prostatic Neoplasms
ZNF507 affects TGF-? signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state.
Protein Deficiency
Early-onset colorectal cancer: A distinct entity with unique genetic features.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase 1B Deficiency Ameliorates Murine Experimental Colitis via the Expansion of Myeloid-Derived Suppressor Cells.
protein-tyrosine-phosphatase deficiency
SHP-1 deficiency in B-lineage cells is associated with heightened lyn protein expression and increased lyn kinase activity.
Proteinuria
Angiotensin II down-regulates nephrin-Akt signaling and induces podocyte injury: roleof c-Abl.
Proteinuria
BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Proteinuria
Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Proteinuria
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis.
Proteinuria
Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril.
Pruritus
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Pruritus
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Pruritus
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Pruritus
Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Pruritus
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Pruritus
Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
Pruritus
Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Pruritus
The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Pseudarthrosis
Mechanical microenvironments and protein expression associated with formation of different skeletal tissues during bone healing.
Pseudomonas Infections
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
Psoriasis
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
Psoriasis
A randomised Phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Psoriasis
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
Psoriasis
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Psoriasis
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Psoriasis
Assessment of the role of spleen tyrosine kinase and zeta-chain-associated 70-kDa protein (tyrosine) kinase in the pathogenesis of psoriasis.
Psoriasis
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Psoriasis
Conformational insights into the inhibitory mechanism of phyto-compounds against Src kinase family members implicated in psoriasis.
Psoriasis
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Psoriasis
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Psoriasis
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Psoriasis
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Psoriasis
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Psoriasis
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
Psoriasis
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
Psoriasis
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Psoriasis
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Psoriasis
Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, on Clinical Signs of Moderate-to-Severe Plaque Psoriasis in Different Body Regions.
Psoriasis
Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Psoriasis
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Psoriasis
Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study.
Psoriasis
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Psoriasis
Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris.
Psoriasis
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
Psoriasis
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Psoriasis
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Psoriasis
JAK/STAT and VEGF/PAK1 signaling as emerging targets for topical treatment of psoriasis: a pilot study.
Psoriasis
Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives.
Psoriasis
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Psoriasis
Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis.
Psoriasis
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Psoriasis
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Psoriasis
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Psoriasis
Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Psoriasis
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Psoriasis
Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis.
Psoriasis
Phase 2a Randomised, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study to Evaluate the Efficacy and Safety of ASP015K, a Novel Janus Kinase (JAK) Inhibitor, in Patients with Moderate to Severe Psoriasis.
Psoriasis
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Psoriasis
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
Psoriasis
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Psoriasis
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Psoriasis
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Psoriasis
The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Psoriasis
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Psoriasis
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Psoriasis
Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.
Psoriasis
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Psoriasis
Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Psoriasis
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Psoriasis
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Psoriasis
Tofacitinib withdrawal and re-treatment in moderate-to-severe chronic plaque psoriasis: a randomised controlled trial.
Psoriasis
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Psoriasis
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Psoriasis
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Psoriasis
Tyrosine kinase 2 and Janus kinase?signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Puberty, Delayed
BMPR1A is a candidate gene for congenital heart defects associated with the recurrent 10q22q23 deletion syndrome.
Pulmonary Alveolar Proteinosis
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Pulmonary Arterial Hypertension
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
Pulmonary Arterial Hypertension
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Pulmonary Arterial Hypertension
Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.
Pulmonary Arterial Hypertension
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Pulmonary Arterial Hypertension
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Pulmonary Arterial Hypertension
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Pulmonary Arterial Hypertension
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.
Pulmonary Arterial Hypertension
Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Erratum to: BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Genetics of pulmonary arterial hypertension: current and future implications.
Pulmonary Arterial Hypertension
miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Pulmonary Arterial Hypertension
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.
Pulmonary Arterial Hypertension
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Pulmonary Arterial Hypertension
Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
Pulmonary Arterial Hypertension
The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Pulmonary Arterial Hypertension
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
[NF-?B inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
Pulmonary Atelectasis
BMP signaling is essential in neonatal surfactant production during respiratory adaptation.
Pulmonary Disease, Chronic Obstructive
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
Pulmonary Disease, Chronic Obstructive
Decreased expression of TGF-beta type II receptor in bronchial glands of smokers with COPD.
Pulmonary Disease, Chronic Obstructive
Effect of Liuweibuqi capsule, a Chinese patent medicine, on the JAK1/STAT3 pathway and MMP9/TIMP1 in a chronic obstructive pulmonary disease rat model.
Pulmonary Disease, Chronic Obstructive
Hematopoietic cell kinase gene polymorphisms and the risk of chronic obstructive pulmonary disease in a Chinese population.
Pulmonary Disease, Chronic Obstructive
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Pulmonary Disease, Chronic Obstructive
Lyn regulates epithelial-mesenchymal transition in CS-exposed model through Smad2/3 signaling.
Pulmonary Disease, Chronic Obstructive
Src Regulates Cigarette Smoke-induced Ceramide Generation via nSMase2 in the Airway Epithelium.
Pulmonary Disease, Chronic Obstructive
[The Involvement of Src in Airway Inflammation Induced by Repeated Exposure to Lipopolysaccharide in Mice].
Pulmonary Fibrosis
Abrogation of transforming growth factor-?-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Pulmonary Fibrosis
Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis.
Pulmonary Fibrosis
Antifibrotic Effects of Focal Adhesion Kinase Inhibitor in Bleomycin-Induced Pulmonary Fibrosis in Mice.
Pulmonary Fibrosis
Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGF? signaling through TGFBR1 stabilization.
Pulmonary Fibrosis
miR-770-5p inhibits the activation of pulmonary fibroblasts and silica-induced pulmonary fibrosis through targeting TGFBR1.
Pulmonary Fibrosis
Non-canonical Wnt Signaling Promotes Myofibroblast Differentiation in Pulmonary Fibrosis.
Pulmonary Fibrosis
Overexpression of Inhibitor of DNA-Binding 2 Attenuates Pulmonary Fibrosis through Regulation of c-Abl and Twist.
Pulmonary Fibrosis
Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis.
Pulmonary Fibrosis
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Pulmonary Fibrosis
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Pulmonary Fibrosis
Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis.
Purpura, Thrombocytopenic, Idiopathic
A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.
Purpura, Thrombocytopenic, Idiopathic
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.
Purpura, Thrombocytopenic, Idiopathic
Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats.
Purpura, Thrombocytopenic, Idiopathic
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib for the treatment of chronic immune thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib for the treatment of immune thrombocytopenia in adults.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Purpura, Thrombocytopenic, Idiopathic
Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Purpura, Thrombocytopenic, Idiopathic
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Purpura, Thrombocytopenic, Idiopathic
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Purpura, Thrombocytopenic, Idiopathic
Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series.
Pyoderma Gangrenosum
Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
Pyoderma Gangrenosum
Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation.
Rabies
Focal adhesion kinase is involved in rabies virus infection through its interaction with viral phosphoprotein P.
Radiation Pneumonitis
Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Rectal Neoplasms
Circular RNA circMTO1 acts as an antitumor factor in rectal cancer cell lines by downregulation of miR-19b-3p.
Rectal Neoplasms
Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
Rectal Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Rectal Neoplasms
The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.
Red-Cell Aplasia, Pure
Philadelphia negative, Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia.
Renal Insufficiency
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Renal Insufficiency
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Renal Insufficiency
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Renal Insufficiency
Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
Renal Insufficiency
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Renal Insufficiency, Chronic
Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?
Renal Insufficiency, Chronic
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Renal Insufficiency, Chronic
Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
Renal Insufficiency, Chronic
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Renal Insufficiency, Chronic
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Reperfusion Injury
Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the Janus Kinase 2 and Signal Transducer and Activator of Transcription 3 Signaling Pathway.
Reperfusion Injury
Basal and Src kinase-mediated activation of the EphA2 promoter requires a cAMP-responsive element but is CREB-independent.
Reperfusion Injury
Commentary on 'protective effect of focal adhesion kinase against skeletal muscle reperfusion injury after acute limb ischemia'.
Reperfusion Injury
Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway in rats.
Reperfusion Injury
Effect of sevoflurane on hepatic ischemia-reperfusion injury in rats via JAK2-STAT3 pathway.
Reperfusion Injury
Granulocyte colony-stimulating factor prevents reperfusion injury after heart preservation.
Reperfusion Injury
Imatinib Is Protective Against Ischemia-Reperfusion Injury in an Ex Vivo Rabbit Model of Lung Injury.
Reperfusion Injury
Increased Bioavailable Berberine Protects Against Myocardial Ischemia Reperfusion Injury Through Attenuation of NF?B and JNK Signaling Pathways.
Reperfusion Injury
Intratubular epithelial-mesenchymal transition and tubular atrophy after kidney injury in mice.
Reperfusion Injury
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation.
Reperfusion Injury
Ouabain protects rat hearts against ischemia-reperfusion injury via pathway involving src kinase, mitoKATP, and ROS.
Reperfusion Injury
Protective Effect of Focal Adhesion Kinase against Skeletal Muscle Reperfusion Injury after Acute Limb Ischemia.
Reperfusion Injury
Proteomics study of oxidative stress and Src kinase inhibition in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment.
Reperfusion Injury
Re: 'Protective Effect of Focal Adhesion Kinase against Skeletal Muscle Reperfusion Injury after Acute Limb Ischemia'.
Reperfusion Injury
Re: 'Protective Effect of Focal Adhesion Kinase against Skeletal Muscle Reperfusion Injury after Acute Limb Ischemia': Exciting Questions about Ischemia Reperfusion Injury.
Reperfusion Injury
Role of the Janus kinase 2/signal transducers and activators of transcription 3 pathway in the protective effect of remote ischemia preconditioning against cerebral ischemia-reperfusion injury in rats.
Reperfusion Injury
Transcriptional modulation of the T helper 17/interleukin 17 axis ameliorates renal ischemia-reperfusion injury.
Reperfusion Injury
[Activation of JAK2/STAT3 pathway by CPU0213 alleviates myocardial ischemia-reperfusion and oxidative stress injury in rats].
Respiratory Distress Syndrome
Keratinocyte growth factor expression is suppressed in early acute lung injury/acute respiratory distress syndrome by smad and c-Abl pathways.
Respiratory Distress Syndrome
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
Respiratory Distress Syndrome
Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for SARS-CoV-2 patients.
Respiratory Tract Infections
Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.
Reticuloendotheliosis, Avian
Feed?back loops integrating RELA, SOX18 and FAK mediate the break?down of the lymph?endothelial barrier that is triggered by 12(S)?HETE.
Retinal Degeneration
LIF-dependent JAK3 activation is not essential for retinal degeneration.
Retinal Neovascularization
c-abl is required for the development of hyperoxia-induced retinopathy.
Retinal Neovascularization
Proline-rich tyrosine kinase 2 via enhancing signal transducer and activator of transcription 3-dependent cJun expression mediates retinal neovascularization.
Retinal Neovascularization
Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.
Retinal Neovascularization
Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularization.
Retinal Neovascularization
[Variation of expression of Pyk2 in oxygen-induced retinal neovascularization mice model].
Retinoblastoma
A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle.
Retinoblastoma
Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms.
Retinoblastoma
c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors.
Retinoblastoma
Cell-cell contact promotes specific activity of pp60c-src protein kinase in human retinoblastoma cells.
Retinoblastoma
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Retinoblastoma
Erb-B2 receptor tyrosine kinase 2 knockdown inhibits retinoblastoma progression via Wnt/?-catenin signaling pathway in vitro.
Retinoblastoma
Hepatoprotective Effects of Traditional Chinese Medicine on Liver Fibrosis from Ethanol Administration following Partial Hepatectomy.
Retinoblastoma
Immunohistochemical Analysis of PDGFR-?, PDGFR-? and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
Retinoblastoma
Induction of protein-tyrosine-phosphatase activity by interleukin 6 in M1 myeloblastic cells and analysis of possible counteractions by the BCR-ABL oncogene.
Retinoblastoma
Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines.
Retinoblastoma
Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Retinoblastoma
Overexpression of Inhibitor of DNA-Binding 2 Attenuates Pulmonary Fibrosis through Regulation of c-Abl and Twist.
Retinoblastoma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Retinoblastoma
Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma.
Retinoblastoma
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Retinoblastoma
Spleen tyrosine kinase expression and its correlation with necrosis and high-risk histopathologic features in retinoblastoma.
Retinoblastoma
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Retinoblastoma
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Retinoblastoma
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
Retinoblastoma
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
Retinoblastoma
Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.
Retinoblastoma
v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.
Retinoblastoma
[Effect of AG490 on JAK2/STAT3 signaling pathway in human retinoblastoma HXO-RB44 cell lines].
Retinopathy of Prematurity
c-abl is required for the development of hyperoxia-induced retinopathy.
Retinopathy of Prematurity
Expression of ephrinB2 and its receptors on fibroproliferative membranes in ocular angiogenic diseases.
Retroviridae Infections
Cooperative transforming activities of ras, myc, and src viral oncogenes in nonestablished rat adrenocortical cells.
Rett Syndrome
Unraveling Molecular Pathways Altered in MeCP2-Related Syndromes, in the Search for New Potential Avenues for Therapy.
Rhabdoid Tumor
The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
Rhabdomyosarcoma
An E2F-dependent late-serum-response promoter in a gene that controls glycolysis.
Rhabdomyosarcoma
Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
Rhabdomyosarcoma
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Rhabdomyosarcoma
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.
Rhabdomyosarcoma
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
Rhabdomyosarcoma
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Rhabdomyosarcoma
SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Rhabdomyosarcoma
Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.
Rhabdomyosarcoma
Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.
Rheumatic Diseases
Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR).
Rheumatic Diseases
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.
Rheumatic Diseases
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Rheumatic Diseases
Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Rheumatic Diseases
Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series.
Rhinitis, Allergic
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Rhinitis, Allergic
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Rhinitis, Allergic
MicroRNA-let-7e regulates the progression and development of allergic rhinitis by targeting suppressor of cytokine signaling 4 and activating Janus kinase 1/signal transducer and activator of transcription 3 pathway.
Rhinitis, Allergic
Src-type tyrosine kinase p56lck is critical for thymic stromal lymphopoietin-induced allergic rhinitis.
Rhinitis, Allergic
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Root Resorption
Intermittent parathyroid hormone promotes cementogenesis via ephrinB2-EPHB4 forward signaling.
Rosacea
Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea.
Salmonella Infections
CARD9 negatively regulates NLRP3-induced IL-1? production on Salmonella infection of macrophages.
Sarcoidosis
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.
Sarcoidosis
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Sarcoidosis
Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera.
Sarcoidosis
Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.
Sarcoidosis
Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis.
Sarcoidosis, Pulmonary
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.
Sarcoidosis, Pulmonary
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
Sarcoma
A common cellular pathway for v-mos and v-Ki-ras is not required for v-Ki-ras-induced tumorigenicity in a nonmalignant, v-mos-expressing revertant cell.
Sarcoma
A guanine nucleotide-dependent phosphatidylinositol 4,5-diphosphate phospholipase C in cells transformed by the v-fms and v-fes oncogenes.
Sarcoma
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
Sarcoma
A lysine in the ATP-binding site of P130gag-fps is essential for protein-tyrosine kinase activity.
Sarcoma
A major site of tyrosine phosphorylation within the SH2 domain of Fujinami sarcoma virus P130gag-fps is not required for protein-tyrosine kinase activity or transforming potential.
Sarcoma
A new acute transforming feline retrovirus with fms homology specifies a C-terminally truncated version of the c-fms protein that is different from SM-feline sarcoma virus v-fms protein.
Sarcoma
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.
Sarcoma
A recessive cellular mutation in v-fes-transformed mink cells restores contact inhibition and anchorage-dependent growth.
Sarcoma
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Sarcoma
Activation of SRC kinase and phosphorylation of signal transducer and activator of transcription-5 are required for decidual transformation of human endometrial stromal cells.
Sarcoma
Analysis of functional domains of the v-fms-encoded protein of Susan McDonough strain feline sarcoma virus by linker insertion mutagenesis.
Sarcoma
Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O.
Sarcoma
Appropriate glycosylation of the fms gene product is a prerequisite for its transforming potency.
Sarcoma
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Sarcoma
c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms.
Sarcoma
Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.
Sarcoma
Catalytic and non-catalytic domains of the Fujinami sarcoma virus P130gag-fps protein-tyrosine kinase distinguished by the expression of v-fps polypeptides in Escherichia coli.
Sarcoma
Cell surface expression of the McDonough strain of feline sarcoma virus fms gene product (gp 140fms).
Sarcoma
Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage.
Sarcoma
Chromosomal assignment of the human homologues of feline sarcoma virus and avian myeloblastosis virus onc genes.
Sarcoma
Correlation between CSF-1 responsiveness and expression of (CSF-1 receptor) c-fms in purified murine granulocyte-macrophage progenitor cells (CFU-GM).
Sarcoma
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Sarcoma
Cytoplasmic localization of the transforming protein of Fujinami sarcoma virus: salt-sensitive association with subcellular components.
Sarcoma
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Sarcoma
Delineation of functional determinants in the transforming protein of Fujinami sarcoma virus.
Sarcoma
Detection of fms-oncogene-specific tyrosine kinase activity in human leukemia cells.
Sarcoma
Differences in mechanisms of transformation by independent feline sarcoma virus isolates.
Sarcoma
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Sarcoma
Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation.
Sarcoma
Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.
Sarcoma
Electrochemical investigations into kinase-catalyzed transformations of tau protein.
Sarcoma
Elevated expression of IRS2 in the progression from neurofibroma to malignant peripheral nerve sheath tumor.
Sarcoma
Enzymatic activation of Fujinami sarcoma virus gag-fps transforming proteins by autophosphorylation at tyrosine.
Sarcoma
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Sarcoma
Epidermal growth factor (EGF) modulation of feline sarcoma virus fms tyrosine kinase activity, internalization, degradation, and transforming potential in an EGF receptor/v-fms chimera.
Sarcoma
Epidermal growth factor receptor metabolism and protein kinase activity in human A431 cells infected with Snyder-Theilen feline sarcoma virus or harvey or Kirsten murine sarcoma virus.
Sarcoma
Escherichia coli virulence protein NleH1 interaction with the v-Crk sarcoma virus CT10 oncogene-like protein (CRKL) governs NleH1 inhibition of the ribosomal protein S3 (RPS3)/nuclear factor ?B (NF-?B) pathway.
Sarcoma
Evidence that there exist four classes of RNA tumor viruses which encode proteins with associated tyrosine protein kinase activities.
Sarcoma
Expression of a translocated c-abl gene in hybrids of mouse fibroblasts and chronic myelogenous leukaemia cells.
Sarcoma
Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation.
Sarcoma
Expression of proto-oncogenes and cytoskeletal actin gene in foreign body-induced murine sarcomas.
Sarcoma
Expression of the human monocyte membrane antigen gp55 by murine fibroblasts after DNA-mediated gene transfer.
Sarcoma
Expression of V-SRC and chromosome analysis of a newly established cell line from rat sarcoma induced by an avian retroviral strain.
Sarcoma
Extracellular pressure stimulates adhesion of sarcoma cells via activation of focal adhesion kinase and Akt.
Sarcoma
Fer kinase/FerT and adherens junction dynamics in the testis: an in vitro and in vivo study.
Sarcoma
Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src/PI3K/Akt pathway.
Sarcoma
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Sarcoma
Identification of SRC as a Potent Drug Target for Asthma, Using an Integrative Approach of Protein Interactome Analysis and In Silico Drug Discovery.
Sarcoma
Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase.
Sarcoma
In vitro transformation of osteoblasts: putative formation of osteosarcoma in vitro.
Sarcoma
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Sarcoma
Influence of tyrosine residues Y705 and Y807 on the transforming potency of the v-fms oncogene product of feline sarcoma virus.
Sarcoma
Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells.
Sarcoma
INNO-406 inhibits the growth of chronic myeloid leukemia and promotes its apoptosis via targeting PTEN.
Sarcoma
Investigation of the role of P130gag-fps in transformation: generation and use of a temperature-sensitive mutant P130gag-fps.
Sarcoma
Isolation and characterization of a human locus homologous to the transforming gene (v-fes) of feline sarcoma virus.
Sarcoma
Localization and characterization of phosphorylation sites of the Fujinami avian sarcoma virus and PRCII virus transforming proteins.
Sarcoma
Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase.
Sarcoma
Malignant transformation of a human fibroblast cell strain by transfection of a v-fes oncogene but not by transfection of a gag-human c-fes construct.
Sarcoma
Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes.
Sarcoma
Methylselenol, a selenium metabolite, plays common and different roles in cancerous colon HCT116 cell and noncancerous NCM460 colon cell proliferation.
Sarcoma
Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
Sarcoma
Molecular Analysis of a Mutated FSH Receptor Detected in a Patient with Spontaneous Ovarian Hyperstimulation Syndrome.
Sarcoma
Molecular and cellular mechanisms for differentiation and regeneration of the uterine endometrium.
Sarcoma
Molecular cloning and characterization of feline cellular genetic sequences homologous to the oncogene of the McDonough strain of feline sarcoma virus.
Sarcoma
Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene.
Sarcoma
Monoclonal antibodies specific to transforming polyproteins encoded by independent isolates of feline sarcoma virus.
Sarcoma
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
Sarcoma
Mutagenesis of Fujinami sarcoma virus: evidence that tyrosine phosphorylation of P130gag-fps modulates its biological activity.
Sarcoma
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Sarcoma
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Sarcoma
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Sarcoma
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
Sarcoma
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
Sarcoma
Preparation of rat monoclonal antibodies to epitopes encoded by the viral oncogene (v-fms) of McDonough feline sarcoma virus.
Sarcoma
Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.
Sarcoma
Protein kinase C delta-mediated cytoskeleton remodeling is involved in aloe-emodin-induced photokilling of human lung cancer cells.
Sarcoma
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Sarcoma
Reassessment of the v-fms sequence: threonine phosphorylation of the COOH-terminal domain.
Sarcoma
Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries.
Sarcoma
Relationship between c-src tyrosine kinase activity and the control of glucose transporter gene expression.
Sarcoma
Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.
Sarcoma
Rous sarcoma virus does not induce sarcoma in early chick embryos by lack of the v-src gene expression.
Sarcoma
Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins.
Sarcoma
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Sarcoma
Single amino acid substitution, from Glu1025 to Asp, of the fps oncogenic protein causes temperature sensitivity in transformation and kinase activity.
Sarcoma
Snyder-Theilen feline sarcoma virus P85 contains a single phosphotyrosine acceptor site recognized by its associated protein kinase.
Sarcoma
Specificity of disease induced by M-MuLV chimeric retroviruses containing v-myc or v-src is not determined by the LTR.
Sarcoma
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus.
Sarcoma
Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential.
Sarcoma
Suppression of Rous sarcoma virus-induced tumor formation by preinfection with viruses encoding src protein with novel N termini.
Sarcoma
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Sarcoma
Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
Sarcoma
The amino-terminal domain of the v-fms oncogene product includes a functional signal peptide that directs synthesis of a transforming glycoprotein in the absence of feline leukemia virus gag sequences.
Sarcoma
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.
Sarcoma
The myristylation signal of p60v-src functionally complements the N-terminal fps-specific region of P130gag-fps.
Sarcoma
The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts.
Sarcoma
The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts.
Sarcoma
The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal Cancer.
Sarcoma
The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes.
Sarcoma
The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.
Sarcoma
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.
Sarcoma
Three-dimensional contact with type I collagen mediates tyrosine phosphorylation in primary human fibroblasts.
Sarcoma
Transformation by the v-fms oncogene product: role of glycosylational processing and cell surface expression.
Sarcoma
Transformation-defective mutants of Snyder-Theilen feline sarcoma virus lack tyrosine-specific protein kinase activity.
Sarcoma
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Sarcoma
Transforming genes of avian (v-fps) and mammalian (v-fes) retroviruses correspond to a common cellular locus.
Sarcoma
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Sarcoma
Tyrosine 807 of the v-Fms oncogene product controls cell morphology and association with p120RasGAP.
Sarcoma
Tyrosine protein kinase activity of the HZ4-feline sarcoma virus P80gag-kit-transforming protein.
Sarcoma
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
Sarcoma
Wing web or intravenous inoculation of chickens with v-src DNA induces visceral sarcomas.
Sarcoma
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Sarcoma 180
Identification and characterization of tyrosine kinase activity associated with mitochondrial outer membrane in sarcoma 180 cells.
Sarcoma, Avian
A cis-acting element in Rous sarcoma virus long terminal repeat required for promoter repression by HeLa nuclear protein p21.
Sarcoma, Avian
A human c-src gene resides on the proximal long arm of chromosome 20 (cen----q131).
Sarcoma, Avian
A mutation in v-src that removes a single conserved residue in the SH-2 domain of pp60v-src restricts transformation in a host-dependent manner.
Sarcoma, Avian
A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps.
Sarcoma, Avian
A novel group IIA phospholipase A2 interacts with v-Src oncoprotein from RSV-transformed hamster cells.
Sarcoma, Avian
A tyrosine kinase related to pp60c-src is associated with membranes of Electrophorus electricus electric organ.
Sarcoma, Avian
Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients.
Sarcoma, Avian
Activation of the pp60c-src kinase during differentiation of monomyelocytic cells in vitro.
Sarcoma, Avian
Amino acid alterations within a highly conserved region of the Rous sarcoma virus src gene product pp60src inactivate tyrosine protein kinase activity.
Sarcoma, Avian
An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins.
Sarcoma, Avian
Analysis of cDNAs of the proto-oncogene c-src: heterogeneity in 5' exons and possible mechanism for the genesis of the 3' end of v-src.
Sarcoma, Avian
Autocrine factor-independent growth of mammalian fibroblasts established in fully synthetic medium: no v-onc requirement in establishment.
Sarcoma, Avian
Band 3 tyrosine kinase in avian erythrocyte plasma membrane is immunologically related to pp60c-src.
Sarcoma, Avian
Binding of pp60v-src to membranes: evidence for multiple membrane interactions.
Sarcoma, Avian
C-terminal end of v-src protein interacts with peptide coded by gadd7/adapt15-like RNA in two-hybrid system.
Sarcoma, Avian
Calcium-dependent conformational changes in the 36-kDa subunit of intestinal protein I related to the cellular 36-kDa target of Rous sarcoma virus tyrosine kinase.
Sarcoma, Avian
Cellular homologue (c-src) of the transforming gene of Rous sarcoma virus: isolation, mapping, and transcriptional analysis of c-src and flanking regions.
Sarcoma, Avian
Cellular src gene product detected in the freshwater sponge Spongilla lacustris.
Sarcoma, Avian
Changes in protein phosphorylation in Rous sarcoma virus-transformed chicken embryo cells.
Sarcoma, Avian
Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease.
Sarcoma, Avian
cis-Acting RNA packaging locus in the 115-nucleotide direct repeat of Rous sarcoma virus.
Sarcoma, Avian
Comparison of protein phosphorylations in variant A431 cells with different growth responses to epidermal growth factor.
Sarcoma, Avian
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Sarcoma, Avian
Creation and characterization of temperature-sensitive mutants of the lck tyrosine protein kinase.
Sarcoma, Avian
Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
Sarcoma, Avian
Cytokinesis Failure Leading to Chromosome Instability in v-Src-Induced Oncogenesis.
Sarcoma, Avian
Decrease in coupling of Gs in v-src-transformed NIH-3T3 fibroblasts: possible involvement of tyrosine phosphorylation of Gs by pp60v-src.
Sarcoma, Avian
Down regulation by p60v-src of genes specifically expressed and developmentally regulated in postmitotic quail neuroretina cells.
Sarcoma, Avian
Effect of dimerization on signal transduction and biological function of oncogenic Ros, insulin, and insulin-like growth factor I receptors.
Sarcoma, Avian
Effect of tumor promoters on sarc gene expression in normal and transformed chick embryo fibroblasts.
Sarcoma, Avian
Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Sarcoma, Avian
Effects of herbimycin A derivatives on growth and differentiation of K562 human leukemic cells.
Sarcoma, Avian
Effects of v-src oncogene activation on radiation sensitivity in drug-sensitive and in multidrug-resistant rat fibroblasts.
Sarcoma, Avian
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.
Sarcoma, Avian
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon.
Sarcoma, Avian
Elevation of nerve growth factor synthesis by constitutive expression of v-src oncogene in cultured rat fibroblasts.
Sarcoma, Avian
Emerging Role for SRC family kinases in junction dynamics during spermatogenesis.
Sarcoma, Avian
Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates.
Sarcoma, Avian
Evidence that there exist four classes of RNA tumor viruses which encode proteins with associated tyrosine protein kinase activities.
Sarcoma, Avian
Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells.
Sarcoma, Avian
Expression of Rous sarcoma virus transforming protein pp60v-src in Saccharomyces cerevisiae cells.
Sarcoma, Avian
Expression of v-src in embryonic neural retina alters cell adhesion, inhibits histogenesis, and prevents induction of glutamine synthetase.
Sarcoma, Avian
Frameshift mutations in the v-src gene of avian sarcoma virus act in cis to specifically reduce v-src mRNA levels.
Sarcoma, Avian
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Sarcoma, Avian
Gene expression profiles analysis identifies key genes for acute lung injury in patients with sepsis.
Sarcoma, Avian
Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo.
Sarcoma, Avian
High-level expression of human c-jun gene causes cellular transformation of chicken embryo fibroblasts.
Sarcoma, Avian
Human cellular src gene: nucleotide sequence and derived amino acid sequence of the region coding for the carboxy-terminal two-thirds of pp60c-src.
Sarcoma, Avian
Identification of a ribosomal protein S6 kinase regulated by transformation and growth-promoting stimuli.
Sarcoma, Avian
Identification of an amino terminal domain required for the transforming activity of the Rous sarcoma virus src protein.
Sarcoma, Avian
Increased activity of c-Src and Csk in fibroblasts transformed by v-src oncogene.
Sarcoma, Avian
Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins.
Sarcoma, Avian
Influence of the transduced 3'UTR of the c-src oncogene on tumour growth induced by the v-src gene of avian sarcoma virus PR2257.
Sarcoma, Avian
Inhibition of the tyrosine kinase activity of v-src, v-fgr, and v-yes gene products by a monoclonal antibody which binds both amino and carboxy peptide fragments of pp60v-src.
Sarcoma, Avian
Intracellular localization and processing of pp60v-src proteins expressed by two distinct temperature-sensitive mutants of Rous sarcoma virus.
Sarcoma, Avian
Kinetics of v-src-induced epithelial-mesenchymal transition in developing glandular stomach.
Sarcoma, Avian
Localization and characterization of phosphorylation sites of the Fujinami avian sarcoma virus and PRCII virus transforming proteins.
Sarcoma, Avian
Localization of temperature-sensitive transformation mutations and back mutations in the Rous sarcoma virus src gene.
Sarcoma, Avian
Major histocompatibility (B) complex control of the growth pattern of v-src DNA-induced primary tumors.
Sarcoma, Avian
Membrane binding of myristylated peptides corresponding to the NH2 terminus of Src.
Sarcoma, Avian
miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1.
Sarcoma, Avian
Mitogenesis by v-Src: a need for active oncoprotein both in leaving G0 and in completing G1 phases of the cell cycle.
Sarcoma, Avian
Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ros: biological function and substrate interaction.
Sarcoma, Avian
Molecular cloning of the PRCII sarcoma viral genome and the chicken proto-oncogene c-fps.
Sarcoma, Avian
Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
Sarcoma, Avian
Mutations in v-Src SH3 and catalytic domains that jointly confer temperature-sensitive transformation with minimal temperature-dependent changes in cellular tyrosine phosphorylation.
Sarcoma, Avian
Myogenin expression is necessary for commitment to differentiation and is closely related to src tyrosine kinase activity in quail myoblasts transformed with Rous sarcoma virus.
Sarcoma, Avian
N-terminal deletion in the src gene of Rous sarcoma virus results in synthesis of a 45,000-Mr protein with mitogenic activity.
Sarcoma, Avian
Nature and specificity of lymphokine independence induced by a selectable retroviral vector expressing v-src.
Sarcoma, Avian
Neoplastic transformation of normal and carcinogen-induced preneoplastic Syrian hamster embryo cells by the v-src oncogene.
Sarcoma, Avian
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
Sarcoma, Avian
NSAID-induced apoptosis in Rous sarcoma virus-transformed chicken embryo fibroblasts is dependent on v-src and c-myc and is inhibited by bcl-2.
Sarcoma, Avian
Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family.
Sarcoma, Avian
Overexpression of avian or mouse c-jun in primary chick embryo fibroblasts confers a partially transformed phenotype.
Sarcoma, Avian
Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells.
Sarcoma, Avian
Partial purification and characterization of a pp60v-src-related tyrosine kinase from bovine brain.
Sarcoma, Avian
Partial reversion of conditional transformation correlates with a decrease in the sensitivity of rat cells to killing by the parvovirus minute virus of mice but not in their capacity for virus production: effect of a temperature-sensitive v-src oncogene.
Sarcoma, Avian
Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations.
Sarcoma, Avian
Phospholipids stimulate phosphorylation of of vinculin by the tyrosine-specific protein kinase of Rous sarcoma virus.
Sarcoma, Avian
Phospholipids stimulate phosphorylation of vinculin by the tyrosine-specific protein kinase of Rous sarcoma virus.
Sarcoma, Avian
Phosphopeptide occupancy and photoaffinity cross-linking of the v-Src SH2 domain attenuates tyrosine kinase activity.
Sarcoma, Avian
Phosphorylation of p125FAK and paxillin focal adhesion proteins in src-transformed cells with different metastatic capacity.
Sarcoma, Avian
Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro.
Sarcoma, Avian
Phosphorylation sites in enolase and lactate dehydrogenase utilized by tyrosine protein kinases in vivo and in vitro.
Sarcoma, Avian
Polypurine tract adjacent to the U3 region of the Rous sarcoma virus genome provides a cis-acting function.
Sarcoma, Avian
Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol.
Sarcoma, Avian
pp60c-src encoded by the proto-oncogene c-src is a product of sensory neurons.
Sarcoma, Avian
pp60src-dependent protein phosphorylation in membranes from Rous sarcoma virus-transformed chicken embryo fibroblasts.
Sarcoma, Avian
Properties of the src kinase purified from Rous sarcoma virus-induced rat tumors.
Sarcoma, Avian
Protein kinases and adherens junction dynamics in the seminiferous epithelium of the rat testis.
Sarcoma, Avian
Purification of a tyrosine-specific protein kinase from Rous sarcoma virus-induced rat tumor.
Sarcoma, Avian
Purification of the Rous sarcoma virus src kinase by casein-agarose and tyrosine-agarose affinity chromatography.
Sarcoma, Avian
Ras/MAP kinase pathway is associated with the control of myotube formation but not myofibril assembly in quail myoblasts transformed with Rous sarcoma virus.
Sarcoma, Avian
Reconstitution of interactions between the Src tyrosine kinases and Ras GTPase-activating protein using a baculovirus expression system.
Sarcoma, Avian
Role of gag sequence in the biochemical properties and transforming activity of the avian sarcoma virus UR2-encoded gag-ros fusion protein.
Sarcoma, Avian
Role of Gas1 down-regulation in mitogenic stimulation of quiescent NIH3T3 cells by v-Src.
Sarcoma, Avian
Role of replaced v-src and env genes in the duck-adapted variant of Rous sarcoma virus.
Sarcoma, Avian
Rous sarcoma virus does not induce sarcoma in early chick embryos by lack of the v-src gene expression.
Sarcoma, Avian
Rous sarcoma virus mutant dlPA105 induces different transformed phenotypes in quail embryonic fibroblasts and neuroretina cells.
Sarcoma, Avian
Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase.
Sarcoma, Avian
Slow time-dependent cellular transformation induced at restrictive temperature by ts-src mutants.
Sarcoma, Avian
Small deletion in v-src SH3 domain of a transformation defective mutant of Rous sarcoma virus restores wild type transforming properties.
Sarcoma, Avian
Splicing of intervening sequences introduced into an infectious retroviral vector.
Sarcoma, Avian
Src homology 2 domain deletion mutants of p60v-src do not phosphorylate cellular proteins of 120-150 kDa.
Sarcoma, Avian
src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors.
Sarcoma, Avian
STAT5 Phosphorylation in Malignant Melanoma Is Important for Survival and Is Mediated Through SRC and JAK1 Kinases.
Sarcoma, Avian
Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60.
Sarcoma, Avian
Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor.
Sarcoma, Avian
Structural Thermodynamics of myr-Src(2-19) Binding to Phospholipid Membranes.
Sarcoma, Avian
Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus.
Sarcoma, Avian
Substrate specificities of tyrosine-specific protein kinases toward cytoskeletal proteins in vitro.
Sarcoma, Avian
The avian sarcoma virus PRCII lacks 1020 nucleotides of the fps transforming gene.
Sarcoma, Avian
The expression in eukaryotes of a tyrosine kinase which is reactive with pp60v-src antibodies.
Sarcoma, Avian
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
Sarcoma, Avian
The location of v-src in a retrovirus vector determines whether the virus is toxic or transforming.
Sarcoma, Avian
The p60c-src family of protein-tyrosine kinases: structure, regulation, and function.
Sarcoma, Avian
The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor.
Sarcoma, Avian
The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts.
Sarcoma, Avian
The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.
Sarcoma, Avian
The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes.
Sarcoma, Avian
The transforming proteins of PRCII virus and Rous sarcoma virus form a complex with the same two cellular phosphoproteins.
Sarcoma, Avian
The tyrosine kinase v-Src causes mitotic slippage by phosphorylating an inhibitory tyrosine residue of Cdk1.
Sarcoma, Avian
The tyrosine phosphorylation substrate p36 is developmentally regulated in embryonic avian limb and is induced in cell culture.
Sarcoma, Avian
The v-Src and c-Src tyrosine kinases immunoprecipitated from Rous sarcoma virus-transformed cells display different peptide substrate specificities.
Sarcoma, Avian
Three Ca2+-binding proteins from porcine liver and intestine differ immunologically and physicochemically and are distinct in Ca2+ affinities.
Sarcoma, Avian
Transcriptional downregulation of the retina-specific QR1 gene by pp60v-src and identification of a novel v-src-responsive unit.
Sarcoma, Avian
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Sarcoma, Avian
Transformation by viral and cellular oncogenes of a mouse BALB/3T3 cell mutant resistant to transformation by chemical carcinogens.
Sarcoma, Avian
Transformation of chicken embryo fibroblasts and tumor induction by the middle T antigen of polyomavirus carried in an avian retroviral vector.
Sarcoma, Avian
Transforming potential and growth stimulating activity of the v-fos and c-fos genes carried by avian retrovirus vectors.
Sarcoma, Avian
Transforming protein of avian sarcoma virus UR2 is associated with phosphatidylinositol kinase activity: possible role in tumorigenesis.
Sarcoma, Avian
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Sarcoma, Avian
Transgene expression facilitated by the v-src splice acceptor can impair replication kinetics and lead to genomic instability of Rous sarcoma virus-based vectors.
Sarcoma, Avian
Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis.
Sarcoma, Avian
Transplantation resistance to a Rous sarcoma virus-induced tumor in mice immunized with v-src protein.
Sarcoma, Avian
tsLA23-NRK cells need pp60v-src protein-tyrosine kinase activity in G2 phase to initiate mitosis in serum-free medium.
Sarcoma, Avian
Tumor cells induced by the v-src oncogene are heterogeneous for expression of markers of mesenchyme differentiation.
Sarcoma, Avian
Tumor induction by the LTR, v-src, LTR DNA in four B (MHC) congenic lines of chickens.
Sarcoma, Avian
Two point mutations in the transmembrane domain of P68gag-ros inactive its transforming activity and cause a delay in membrane association.
Sarcoma, Avian
Tyrosine phosphorylation of a gap junction protein correlates with inhibition of cell-to-cell communication.
Sarcoma, Avian
Tyrosine-specific protein kinase activity associated with p105 of avian sarcoma virus PRCII.
Sarcoma, Avian
Tyrosyl and cyclic AMP-dependent protein kinase activities in BHK cells that express viral pp60src.
Sarcoma, Avian
Tyrosylprotein kinase and phosphatase activities in membrane vesicles from normal and Rous sarcoma virus-transformed rat cells.
Sarcoma, Avian
Unstable expression and amplification of a transfected oncogene in confluent and subconfluent cells.
Sarcoma, Avian
v-Src Causes Chromosome Bridges in a Caffeine-Sensitive Manner by Generating DNA Damage.
Sarcoma, Avian
v-Src causes delocalization of Mklp1, Aurora B, and INCENP from the spindle midzone during cytokinesis failure.
Sarcoma, Avian
v-Src enhances phosphorylation at Ser-282 of the Rous sarcoma virus integrase.
Sarcoma, Avian
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
Sarcoma, Avian
v-src mutations outside the carboxyl-coding region are not sufficient to fully activate transformation by pp60c-src in NIH 3T3 cells.
Sarcoma, Avian
v-src oncogene-specific carboxy-terminal peptide is immunoprotective against Rous sarcoma growth in chickens with MHC class I allele B-F12.
Sarcoma, Avian
VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.
Sarcoma, Avian
Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.
Sarcoma, Avian
[New molecular mechanisms of virus-mediated carcinogenesis: oncogenic transformation of cells by retroviral structural protein Envelope]
Sarcoma, Clear Cell
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.
Sarcoma, Ewing
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Sarcoma, Ewing
Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
Sarcoma, Ewing
Fusion FISH Imaging: Single-Molecule Detection of Gene Fusion Transcripts In Situ.
Sarcoma, Ewing
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
Sarcoma, Ewing
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Sarcoma, Ewing
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Sarcoma, Ewing
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Sarcoma, Ewing
Matrilin-3 as a putative effector of C-type natriuretic peptide signaling during TGF-? induced chondrogenic differentiation of mesenchymal stem cells.
Sarcoma, Ewing
Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines.
Sarcoma, Ewing
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules.
Sarcoma, Ewing
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Sarcoma, Ewing
SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
Sarcoma, Ewing
TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Sarcoma, Ewing
Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing's sarcoma cells.
Sarcoma, Ewing
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.
Sarcoma, Kaposi
Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.
Sarcoma, Kaposi
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Sarcoma, Kaposi
Vascular tumors produced by NIH/3T3 cells transfected with human AIDS Kaposi's sarcoma DNA.
Sarcoma, Myeloid
An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation.
Sarcoma, Myeloid
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
Sarcoma, Synovial
Clustered organization of Krüppel zinc-finger genes at Xp11.23, flanking a translocation breakpoint at OATL1: a physical map with locus assignments for ZNF21, ZNF41, ZNF81, and ELK1.
Sarcoma, Synovial
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Sarcopenia
Meeting Report: American Aging Association 40(th) Annual Meeting, Raleigh, North Carolina, June 3-6, 2011.
Sarcopenia
Muscle-bone interactions: From experimental models to the clinic? A critical update.
Schistosomiasis
Schistosoma mansoni FES Tyrosine Kinase Involvement in the Mammalian Schistosomiasis Outcome and Miracidia Infection Capability in Biomphalaria glabrata.
Scleroderma, Diffuse
Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Scleroderma, Localized
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.
Scleroderma, Systemic
Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
Scleroderma, Systemic
c-Abl silencing reduced the inhibitory effects of TGF-?1 on apoptosis in systemic sclerosis dermal fibroblasts.
Scleroderma, Systemic
Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
Scleroderma, Systemic
Imatinib and the treatment of fibrosis: recent trials and tribulations.
Scleroderma, Systemic
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Scleroderma, Systemic
Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Scleroderma, Systemic
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Seizures
Focal adhesion molecules regulate astrocyte morphology and glutamate transporters to suppress seizure-like behavior.
Seizures
Impairment of conditioned freezing to tone, but not to context, in Fyn-transgenic mice: relationship to NMDA receptor subunit 2B function.
Seizures
Role of the Fyn-PKC? signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy.
Seminoma
Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs.
Sepsis
Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Sepsis
Complement regulatory protein CD59 involves c-SRC related tyrosine phosphorylation of the creatine transporter in skeletal muscle during sepsis.
Sepsis
Functional polymorphism in exon 5 and variant haplotype of the interleukin-1 receptor-associated kinase 1 gene are associated with susceptibility to and severity of sepsis in the Chinese population.
Sepsis
In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.
Sepsis
miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling.
Sepsis
Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature.
Sepsis
Regulation of RelA/p65 and Endothelial Cell Inflammation by Proline-Rich Tyrosine Kinase 2.
Sepsis
Selective inhibition of interleukin-1 receptor-associated kinase 1 ameliorates lipopolysaccharide-induced sepsis in mice.
Sepsis
Sepsis-induced brain mitochondrial dysfunction is associated with altered mitochondrial Src and PTP1B levels.
Sepsis
Sepsis-Induced Cardiac Mitochondrial Dysfunction Involves Altered Mitochondrial-Localization of Tyrosine Kinase Src and Tyrosine Phosphatase SHP2.
Sepsis
Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis.
Sepsis
The potential value of plasma receptor interacting protein 3 in neonates with culture-positive late-onset sepsis.
Sepsis
Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival.
Sepsis
X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
Severe Acute Respiratory Syndrome
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
Severe Acute Respiratory Syndrome
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Severe Acute Respiratory Syndrome
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Severe Combined Immunodeficiency
A case of aberrant CD8 T cell-restricted IL-7 signaling with a Janus kinase 3 defect-associated atypical severe combined immunodeficiency.
Severe Combined Immunodeficiency
A novel mutation of intron 22 in Janus kinase 3-deficient severe combined immunodeficiency.
Severe Combined Immunodeficiency
Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes.
Severe Combined Immunodeficiency
Advances in the understanding and treatment of human severe combined immunodeficiency.
Severe Combined Immunodeficiency
Atypical immune phenotype in severe combined immunodeficiency patients with novel mutations in IL2RG and JAK3.
Severe Combined Immunodeficiency
Cutaneous granulomas with predominantly CD8(+) lymphocytic infiltrate in a child with severe combined immunodeficiency.
Severe Combined Immunodeficiency
Defective expression of p56lck in an infant with severe combined immunodeficiency.
Severe Combined Immunodeficiency
Dominant-negative zeta-associated protein 70 inhibits T cell antigen receptor signaling.
Severe Combined Immunodeficiency
Herpesvirus saimiri replaces ZAP-70 for CD3- and CD2-mediated T cell activation.
Severe Combined Immunodeficiency
Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase.
Severe Combined Immunodeficiency
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Severe Combined Immunodeficiency
Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.
Severe Combined Immunodeficiency
Identification of four highly conserved regions in DNA-PKcs.
Severe Combined Immunodeficiency
Immunodeficiencies caused by genetic defects in protein kinases.
Severe Combined Immunodeficiency
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.
Severe Combined Immunodeficiency
Insight into the therapeutic aspects of 'Zeta-Chain Associated Protein Kinase 70 kDa' inhibitors: a review.
Severe Combined Immunodeficiency
Intrathymic administration of hematopoietic progenitor cells enhances T cell reconstitution in ZAP-70 severe combined immunodeficiency.
Severe Combined Immunodeficiency
JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.
Severe Combined Immunodeficiency
Jak3 negatively regulates dendritic-cell cytokine production and survival.
Severe Combined Immunodeficiency
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.
Severe Combined Immunodeficiency
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Severe Combined Immunodeficiency
Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting.
Severe Combined Immunodeficiency
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.
Severe Combined Immunodeficiency
Persistence of natural killer cells with expansion of a hypofunctional CD56(-)CD16(+)KIR(+)NKG2C(+) subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency.
Severe Combined Immunodeficiency
Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells.
Severe Combined Immunodeficiency
Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.
Severe Combined Immunodeficiency
Severe combined immunodeficiency due to a defect in the tyrosine kinase ZAP-70.
Severe Combined Immunodeficiency
Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency.
Severe Combined Immunodeficiency
Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Severe Combined Immunodeficiency
Structural and functional basis for JAK3-deficient severe combined immunodeficiency.
Severe Combined Immunodeficiency
Unexpected and variable phenotypes in a family with JAK3 deficiency.
Severe Combined Immunodeficiency
Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.
Severe Combined Immunodeficiency
ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency.
Severe Combined Immunodeficiency
ZAP-70 restoration in mice by in vivo thymic electroporation.
Shock, Septic
Organ-specific and differential requirement of TYK2 and IFNAR1 for LPS-induced iNOS expression in vivo.
Sinus Thrombosis, Intracranial
Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis.
Sinusitis
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family.
Skin Diseases
A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib.
Skin Diseases
Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Skin Diseases
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Skin Diseases
Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
Skin Diseases
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Skin Diseases
Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Skin Diseases
Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report.
Skin Diseases
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Skin Diseases
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models.
Skin Diseases
SHP-1 (PTPN6) keeps the inflammation at bay: limiting IL-1?-mediated neutrophilic dermatoses by preventing Syk kinase activation.
Skin Diseases
The anti-inflammatory effect of topical tofacitinib on immediate and late-phase cutaneous allergic reactions in dogs: a placebo-controlled pilot study.
Skin Diseases
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Skin Neoplasms
Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation.
Skin Neoplasms
Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.
Skin Neoplasms
Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.
Skin Neoplasms
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Sleep Deprivation
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Small Cell Lung Carcinoma
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Small Cell Lung Carcinoma
Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Small Cell Lung Carcinoma
Cryptotanshinone inhibits lung tumor growth by increasing CD4(+) T cell cytotoxicity through activation of the JAK2/STAT4 pathway.
Small Cell Lung Carcinoma
Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells.
Small Cell Lung Carcinoma
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Small Cell Lung Carcinoma
Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Small Cell Lung Carcinoma
Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines.
Small Cell Lung Carcinoma
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.
Small Cell Lung Carcinoma
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Small Cell Lung Carcinoma
Syntenin increases the invasiveness of small cell lung cancer cells by activating p38, AKT, focal adhesion kinase and SP1.
Small Cell Lung Carcinoma
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Small Cell Lung Carcinoma
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Spinal Cord Compression
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Spinal Cord Compression
Src family kinase inhibitor PP1 reduces secondary damage after spinal cord compression in rats.
Spinal Cord Injuries
BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury.
Spinal Cord Injuries
Focal adhesion kinase signaling is decreased 56 days following spinal cord injury in rat gastrocnemius.
Spinal Cord Injuries
Lavendustin A enhances axon elongation in VHL gene-transfected neural stem cells.
Spinal Cord Injuries
Mechanisms of autophagy and apoptosis mediated by JAK2 signaling pathway after spinal cord injury of rats.
Spinal Cord Injuries
Src family kinase inhibitor PP1 improves motor function by reducing edema after spinal cord contusion in rats.
Spinal Cord Injuries
Tamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injury.
Spondylarthropathies
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Spondylarthropathies
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Spondylitis, Ankylosing
A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
Spondylitis, Ankylosing
Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey.
Spondylitis, Ankylosing
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Spondylitis, Ankylosing
Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Spondylitis, Ankylosing
Increased BMPR1A Expression Enhances the Adipogenic Differentiation of Mesenchymal Stem Cells in Patients with Ankylosing Spondylitis.
Spondylitis, Ankylosing
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Spondylitis, Ankylosing
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
Spondylitis, Ankylosing
Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials.
Spondylitis, Ankylosing
Nocebo effects of Janus kinase inhibitors in the treatment of active ankylosing spondylitis.
Spondylitis, Ankylosing
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Spondylitis, Ankylosing
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Squamous Cell Carcinoma of Head and Neck
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Squamous Cell Carcinoma of Head and Neck
Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.
Squamous Cell Carcinoma of Head and Neck
Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR/S6 signaling pathway in an ERK1/2-independent manner.
Squamous Cell Carcinoma of Head and Neck
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Squamous Cell Carcinoma of Head and Neck
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
c-Abl expression in oral squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Squamous Cell Carcinoma of Head and Neck
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Squamous Cell Carcinoma of Head and Neck
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Squamous Cell Carcinoma of Head and Neck
Current aspects of targeted therapy in head and neck tumors.
Squamous Cell Carcinoma of Head and Neck
DDR2 overexpression in oral squamous cell carcinoma is associated to lymph node metastasis.
Squamous Cell Carcinoma of Head and Neck
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Squamous Cell Carcinoma of Head and Neck
Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.
Squamous Cell Carcinoma of Head and Neck
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Squamous Cell Carcinoma of Head and Neck
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Squamous Cell Carcinoma of Head and Neck
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Squamous Cell Carcinoma of Head and Neck
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Squamous Cell Carcinoma of Head and Neck
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Squamous Cell Carcinoma of Head and Neck
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Squamous Cell Carcinoma of Head and Neck
Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.
Squamous Cell Carcinoma of Head and Neck
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of EphB4 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Squamous Cell Carcinoma of Head and Neck
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Squamous Cell Carcinoma of Head and Neck
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Squamous Cell Carcinoma of Head and Neck
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Squamous Cell Carcinoma of Head and Neck
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Fusobacteria modulate oral carcinogenesis and promote cancer progression.
Squamous Cell Carcinoma of Head and Neck
Genetic alterations in Wnt family of genes and their putative association with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Squamous Cell Carcinoma of Head and Neck
Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Squamous Cell Carcinoma of Head and Neck
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.
Squamous Cell Carcinoma of Head and Neck
Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G.
Squamous Cell Carcinoma of Head and Neck
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Squamous Cell Carcinoma of Head and Neck
Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Squamous Cell Carcinoma of Head and Neck
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Inhibitory Effect of 1,8-Cineol on ?-Catenin Regulation, WNT11 Expression, and Cellular Progression in HNSCC.
Squamous Cell Carcinoma of Head and Neck
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Squamous Cell Carcinoma of Head and Neck
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Squamous Cell Carcinoma of Head and Neck
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Squamous Cell Carcinoma of Head and Neck
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Squamous Cell Carcinoma of Head and Neck
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Squamous Cell Carcinoma of Head and Neck
Role of integrin ?1 as a biomarker of stemness in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Squamous Cell Carcinoma of Head and Neck
SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Squamous Cell Carcinoma of Head and Neck
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Squamous Cell Carcinoma of Head and Neck
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Taiwan cobra cardiotoxin III inhibits Src kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma Ca9-22 cells.
Squamous Cell Carcinoma of Head and Neck
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
[Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line].
Squamous Cell Carcinoma of Head and Neck
[Expression and clinical significance of focal adhesion kinase in oral squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
Starvation
Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence.
Starvation
Serum starvation regulates E-cadherin upregulation via activation of c-Src in non-small-cell lung cancer A549 cells.
Starvation
Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells.
Starvation
The yeast trimeric guanine nucleotide-binding protein alpha subunit, Gpa2p, controls the meiosis-specific kinase Ime2p activity in response to nutrients.
Starvation
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Starvation
Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Status Epilepticus
Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine.
Still's Disease, Adult-Onset
Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
Stomach Diseases
Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
Stomach Neoplasms
Aberrant JAK/STAT Signaling Suppresses TFF1 and TFF2 through Epigenetic Silencing of GATA6 in Gastric Cancer.
Stomach Neoplasms
ADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation.
Stomach Neoplasms
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Stomach Neoplasms
Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer.
Stomach Neoplasms
CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.
Stomach Neoplasms
Circular RNA CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and Regulating TGFBR1 Expression.
Stomach Neoplasms
Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer.
Stomach Neoplasms
Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report.
Stomach Neoplasms
Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Stomach Neoplasms
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Stomach Neoplasms
Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer.
Stomach Neoplasms
Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer.
Stomach Neoplasms
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
Stomach Neoplasms
Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways.
Stomach Neoplasms
Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Stomach Neoplasms
Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Stomach Neoplasms
Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells.
Stomach Neoplasms
Expression of ASAP1 and FAK in gastric cancer and its clinicopathological significance.
Stomach Neoplasms
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Stomach Neoplasms
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
Stomach Neoplasms
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Stomach Neoplasms
Formation of the IGF1R/CAV1/SRC tri-complex antagonizes TRAIL-induced apoptosis in gastric cancer cells.
Stomach Neoplasms
Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers.
Stomach Neoplasms
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.
Stomach Neoplasms
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.
Stomach Neoplasms
Genipin induces mitochondrial dysfunction and apoptosis via downregulation of Stat3/mcl-1 pathway in gastric cancer.
Stomach Neoplasms
High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome.
Stomach Neoplasms
Identification of protein-tyrosine kinase genes preferentially expressed in embryo stomach and gastric cancer.
Stomach Neoplasms
Identification of the prelinitis condition in gastric cancer and analysis of TGF-beta, TGF-beta RII and pS2 expression.
Stomach Neoplasms
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Stomach Neoplasms
Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.
Stomach Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Stomach Neoplasms
Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population.
Stomach Neoplasms
Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway.
Stomach Neoplasms
Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia.
Stomach Neoplasms
MicroRNA-150-5p and SRC kinase signaling inhibitor 1 involvement in the pathological development of gastric cancer.
Stomach Neoplasms
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer.
Stomach Neoplasms
miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway.
Stomach Neoplasms
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.
Stomach Neoplasms
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Stomach Neoplasms
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Stomach Neoplasms
Notch1 pathway-mediated microRNA-151-5p promotes gastric cancer progression.
Stomach Neoplasms
Over-Expression of Ephb4 Is Associated with Carcinogenesis of Gastric Cancer.
Stomach Neoplasms
Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
Stomach Neoplasms
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Stomach Neoplasms
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
Stomach Neoplasms
Polymorphisms of TGFBR1, TLR4 are associated with prognosis of gastric cancer in a Chinese population.
Stomach Neoplasms
Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development.
Stomach Neoplasms
Protein-tyrosine kinase and protein-serine/threonine kinase expression in human gastric cancer cell lines.
Stomach Neoplasms
PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression.
Stomach Neoplasms
Research of shRNAmir inhibitory effects towards focal adhesion kinase expression in the treatment of gastric cancer.
Stomach Neoplasms
Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.
Stomach Neoplasms
Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2.
Stomach Neoplasms
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Stomach Neoplasms
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells.
Stomach Neoplasms
TGFBR1 tagging SNPs and gastric cancer susceptibility: A two-stage case-control study in Chinese population.
Stomach Neoplasms
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Stomach Neoplasms
Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells.
Stomach Neoplasms
Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
Stomach Neoplasms
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
Stomach Neoplasms
[Effect of gastrin on tyrosine phosphorylation of focal adhesion kinase in human gastric cancer cell line SGC7901]
Stomach Neoplasms
[Effect of spleen tyrosine kinase expression re-activation by inhibition of DNA methylation on oncogenesis growth of gastric cancer]
Stomach Ulcer
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.
Strabismus
Combinatorial activity of Flamingo proteins directs convergence and extension within the early zebrafish embryo via the planar cell polarity pathway.
Stroke
EphrinB2 Activation Enhances Vascular Repair Mechanisms and Reduces Brain Swelling After Mild Cerebral Ischemia.
Stroke
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Stroke
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Stroke
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke.
Subarachnoid Hemorrhage
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Subarachnoid Hemorrhage
Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.
Superinfection
Differences in Activation of HIV-1 Replication by Superinfection With HIV-1 and HIV-2 in U1 Cells.
Superinfection
The effects of MAPK p38? on AZT resistance against reactivating HIV-1 replication in ACH2 cells.
Synovitis
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Synovitis
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Synovitis
SOCS3 participates in cholinergic pathway regulation of synovitis in rheumatoid arthritis.
Syringoma
Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Tachycardia, Ventricular
TGFBR1 Rare Variant Associated With Thoracic Aortic Aneurysm, Double Chamber Left Ventricle, Coronary Anomaly, and Inducible Ventricular Tachycardia.
Takayasu Arteritis
Genome-wide association study identifies susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu's arteritis.
Takayasu Arteritis
Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib.
Tauopathies
Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
Tauopathies
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.
Tauopathies
Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Tauopathies
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Tauopathies
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Tauopathies
Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in ?-Synucleinopathy.
Telangiectasia, Hereditary Hemorrhagic
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.
Telangiectasia, Hereditary Hemorrhagic
Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.
Telangiectasia, Hereditary Hemorrhagic
Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
Telangiectasis
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Telangiectasis
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.
Telangiectasis
Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.
Telangiectasis
Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
Telangiectasis
Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Testicular Neoplasms
Down-regulation of FAK and IAPs by laminin during cisplatin-induced apoptosis in testicular germ cell tumors.
Tetanus
Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells.
Tetanus
VEGF secretion during hypoxia depends on free radicals-induced Fyn kinase activity in mast cells.
Tetanus
[Synthesis, Cloning and Expression of a Multiple Epitope Antigen of BCR-ABL Fusion Gene]
Tetralogy of Fallot
Wnt11 regulates cardiac chamber development and disease during perinatal maturation.
Thalassemia
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Thalassemia
Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition.
Thrombasthenia
Clustering of integrin alphaIIb-beta3 differently regulates tyrosine phosphorylation of pp72syk, PLCgamma2 and pp125FAK in concanavalin A-stimulated platelets.
Thrombocythemia, Essential
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Thrombocythemia, Essential
A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
Thrombocythemia, Essential
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Thrombocythemia, Essential
A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia.
Thrombocythemia, Essential
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Thrombocythemia, Essential
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
Thrombocythemia, Essential
Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia.
Thrombocythemia, Essential
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Thrombocythemia, Essential
Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms.
Thrombocythemia, Essential
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
Thrombocythemia, Essential
bcr-abl hybrid messenger RNA in a patient with Philadelphia-negative essential thrombocythemia.
Thrombocythemia, Essential
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Thrombocythemia, Essential
BCR-ABL rearrangement is not detectable in essential thrombocythemia.
Thrombocythemia, Essential
BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance.
Thrombocythemia, Essential
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.
Thrombocythemia, Essential
Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.
Thrombocythemia, Essential
Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Thrombocythemia, Essential
Chromosomal abnormalities and molecular markers in myeloproliferative disorders.
Thrombocythemia, Essential
Chronic Myeloid Leukemia: Atypical Presentation and Diagnostic Pitfall in the Workup of Isolated Thrombocytosis.
Thrombocythemia, Essential
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Thrombocythemia, Essential
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Thrombocythemia, Essential
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Thrombocythemia, Essential
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Thrombocythemia, Essential
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Thrombocythemia, Essential
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Thrombocythemia, Essential
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Thrombocythemia, Essential
Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.
Thrombocythemia, Essential
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Thrombocythemia, Essential
Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients.
Thrombocythemia, Essential
Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Thrombocythemia, Essential
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Thrombocythemia, Essential
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Thrombocythemia, Essential
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Thrombocythemia, Essential
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Thrombocythemia, Essential
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Thrombocythemia, Essential
Essential Thrombocythemia Due to Janus Kinase 2 Mutation Unmasked After Splenectomy.
Thrombocythemia, Essential
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Thrombocythemia, Essential
Essential thrombocythemia: scientific advances and current practice.
Thrombocythemia, Essential
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Thrombocythemia, Essential
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Thrombocythemia, Essential
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Thrombocythemia, Essential
Genetic and epigenetic alterations of myeloproliferative disorders.
Thrombocythemia, Essential
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
Thrombocythemia, Essential
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.
Thrombocythemia, Essential
Identification of unipotent megakaryocyte progenitors in human hematopoiesis.
Thrombocythemia, Essential
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Thrombocythemia, Essential
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Thrombocythemia, Essential
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Thrombocythemia, Essential
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Thrombocythemia, Essential
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Thrombocythemia, Essential
JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
Thrombocythemia, Essential
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
Thrombocythemia, Essential
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Thrombocythemia, Essential
Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years.
Thrombocythemia, Essential
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Thrombocythemia, Essential
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Thrombocythemia, Essential
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.
Thrombocythemia, Essential
Molecular analysis of Philadelphia positive essential thrombocythemia.
Thrombocythemia, Essential
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Thrombocythemia, Essential
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Thrombocythemia, Essential
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.
Thrombocythemia, Essential
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Thrombocythemia, Essential
Novel strategies for patients with chronic myeloproliferative disorders.
Thrombocythemia, Essential
Patients with essential thrombocythemia do not express BCR-ABL transcripts.
Thrombocythemia, Essential
Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation.
Thrombocythemia, Essential
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Thrombocythemia, Essential
Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Thrombocythemia, Essential
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Thrombocythemia, Essential
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Thrombocythemia, Essential
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Thrombocythemia, Essential
Screening of Bcr-Abl transcripts in Philadelphia negative essential thrombocythemia.
Thrombocythemia, Essential
Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients.
Thrombocythemia, Essential
Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Thrombocythemia, Essential
Somatic mutations of calreticulin in myeloproliferative neoplasms.
Thrombocythemia, Essential
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Thrombocythemia, Essential
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
Thrombocythemia, Essential
The association of JAK2(V617F) mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Thrombocythemia, Essential
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Thrombocythemia, Essential
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Thrombocythemia, Essential
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Thrombocythemia, Essential
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
Thrombocythemia, Essential
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Thrombocythemia, Essential
The marrow stem cell niche in normal and malignant hematopoiesis.
Thrombocythemia, Essential
The Mutation Profile Of Calreticulin In Patients With Myeloproliferative Neoplasms And Acute Leukemia.
Thrombocythemia, Essential
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Thrombocythemia, Essential
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Thrombocythemia, Essential
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Thrombocythemia, Essential
Triple Negative Mutations in Essential Thrombocythemia With bcr-abl Rearrangement: Is There a Such Distinct Disease?
Thrombocythemia, Essential
Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.
Thrombocythemia, Essential
Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?
Thrombocythemia, Essential
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
Thrombocythemia, Essential
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Thrombocythemia, Essential
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Thrombocytopenia
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
Thrombocytopenia
Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia.
Thrombocytopenia
Acquired amegakaryocytic thrombocytopenia associated with proliferation of gamma/delta TCR T-lymphocytes and a BCR-ABL (p210) fusion transcript.
Thrombocytopenia
BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation.
Thrombocytopenia
Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
Thrombocytopenia
De novo variant in tyrosine kinase SRC causes thrombocytopenia: case report of a second family.
Thrombocytopenia
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Thrombocytopenia
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Thrombocytopenia
Identification of e6a2 bcr-abl fusion in a Philadelphia-positive cml with marked basophilia: implications for treatment strategy.
Thrombocytopenia
Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.
Thrombocytopenia
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Thrombocytopenia
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Thrombocytopenia
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Thrombocytopenia
The thrombopoietin receptor: revisiting the master regulator of platelet production.
Thrombocytopenia
Utility of laboratory tests in B-CLL patients in different clinical stages.
Thrombocytopenia
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
Thrombocytosis
An Unusual Cause of the Transient Osteoporosis of the Femoral Head: Essential Thrombocytosis.
Thrombocytosis
Back to biology: new insights on inheritance in myeloproliferative disorders.
Thrombocytosis
BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation.
Thrombocytosis
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Thrombocytosis
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Thrombocytosis
Chronic Myeloid Leukemia: Atypical Presentation and Diagnostic Pitfall in the Workup of Isolated Thrombocytosis.
Thrombocytosis
Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.
Thrombocytosis
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Thrombocytosis
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Thrombocytosis
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Thrombocytosis
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Thrombocytosis
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Thrombocytosis
Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis.
Thrombocytosis
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Thrombocytosis
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.
Thrombocytosis
Is Ciprofloxacin in Combination With Beta-lactam Antibiotics a Recipe for Thrombocytosis?: A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone.
Thrombocytosis
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.
Thrombocytosis
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Thrombocytosis
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Thrombocytosis
Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia.
Thrombocytosis
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Thrombocytosis
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Thrombocytosis
Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
Thrombocytosis
The small molecule inhibitor g6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of jak2-mediated myelofibrosis.
Thrombocytosis
[Exacerbation of acute leukemia bearing isolated i(17q) along with proliferation of blasts with high BMI-1 expression]
Thrombocytosis
[Report of 8 cases of bcr-abl gene positive thrombocytosis and review of the literature.]
Thrombocytosis
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Thromboembolism
Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease.
Thromboembolism
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Thromboembolism
The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Thromboembolism
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Thromboinflammation
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Thrombophilia
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Thrombophilia
Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia.
Thrombophilia
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Thrombosis
Acute ST-segment elevation myocardial infarction: A rare initial presentation of previously undiagnosed essential thrombocythemia.
Thrombosis
Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms.
Thrombosis
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Thrombosis
Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.
Thrombosis
Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.
Thrombosis
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Thrombosis
Dynamic interaction between Src and C-terminal Src kinase in integrin alphaIIbbeta3-mediated signaling to the cytoskeleton.
Thrombosis
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Thrombosis
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Thrombosis
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Thrombosis
Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study.
Thrombosis
Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca(2+)-dependent tyrosine kinase Pyk2.
Thrombosis
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Thrombosis
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
Thrombosis
NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
Thrombosis
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation.
Thrombosis
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Thrombosis
Platelet Activation and Thrombus Formation over IgG Immune Complexes Requires Integrin ?IIb?3 and Lyn Kinase.
Thrombosis
Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies.
Thrombosis
Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
Thrombosis
Refractory Arterial Insufficiency Associated with Janus Kinase 2 Positive Essential Thrombocythaemia.
Thrombosis
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Thrombosis
Resveratrol Improves Endothelial Progenitor Cell Function through miR-138 by Targeting Focal Adhesion Kinase (FAK) and Promotes Thrombus Resolution In Vivo.
Thrombosis
Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Thrombosis
The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis.
Thrombosis
The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer.
Thrombosis
The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation.
Thrombosis
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
Thrombosis
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Thrombosis
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Thymoma
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl.
Thymoma
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Thymoma
Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells.
Thymoma
Differential activation of multiple signalling pathways dictates eNOS upregulation by FGF2 but not VEGF in placental artery endothelial cells.
Thymoma
Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation.
Thymoma
Expression of a new tyrosine protein kinase is stimulated by retrovirus promoter insertion.
Thymoma
Expression of cellular oncogenes: unrearranged c-myc gene but altered promoter usage in radiation-induced thymoma.
Thymoma
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.
Thymoma
Generation and characterization of transforming variants of the lck tyrosine protein kinase.
Thymoma
Hematopoietic progenitor cells as possible origins of epithelial thymoma in a human T lymphocyte virus type I pX gene transgenic rat model.
Thymoma
Induction of hyperphosphorylation and activation of the p56lck protein tyrosine kinase by phenylarsine oxide, a phosphotyrosine phosphatase inhibitor.
Thymoma
LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Thymoma
Malignant transformation of thymoma in recipient rats by heterotopic thymus transplantation from HTLV-I transgenic rats.
Thymoma
Physical association of the cytoplasmic domain of CD2 with the tyrosine kinases p56lck and p59fyn.
Thymoma
Transcriptional activation of lck by retrovirus promoter insertion between two lymphoid-specific promoters.
Thymoma
Two lck transcripts containing different 5' untranslated regions are present in T cells.
Thymoma
Tyrosine phosphorylation of GAP and GAP-associated proteins in lymphoid and fibroblast cells expressing lck.
Thymus Neoplasms
Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms.
Thyroid Cancer, Papillary
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Thyroid Cancer, Papillary
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.
Thyroid Cancer, Papillary
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Thyroid Cancer, Papillary
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Thyroid Cancer, Papillary
Germline Bone Morphogenesis Protein Receptor 1A Mutation Causes Colorectal Tumorigenesis in Hereditary Mixed Polyposis Syndrome.
Thyroid Cancer, Papillary
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.
Thyroid Cancer, Papillary
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Thyroid Cancer, Papillary
Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.
Thyroid Cancer, Papillary
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
Thyroid Carcinoma, Anaplastic
Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Thyroid Diseases
Associations of secreted phosphoprotein 1 and B lymphocyte kinase gene polymorphisms with autoimmune thyroid disease.
Thyroid Neoplasms
Cytogenetic and fluorescence in situ hybridization studies in a case of anaplastic thyroid carcinoma.
Thyroid Neoplasms
Direct phosphorylation of proliferative and survival pathway proteins by RET.
Thyroid Neoplasms
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.
Thyroid Neoplasms
FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
Thyroid Neoplasms
Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.
Thyroid Neoplasms
Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study.
Thyroid Neoplasms
RET signals through focal adhesion kinase in medullary thyroid cancer cells.
Thyroid Neoplasms
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Thyroid Neoplasms
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Thyroid Neoplasms
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Thyroid Neoplasms
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Thyroid Neoplasms
Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration.
Thyroid Nodule
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Tongue Neoplasms
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Toxoplasmosis
Dysregulation of focal adhesion kinase upon Toxoplasma gondii infection facilitates parasite translocation across polarised primary brain endothelial cell monolayers.
Trauma, Nervous System
Long-term treatment with PP2 after spinal cord injury resulted in functional locomotor recovery and increased spared tissue.
Trigeminal Neuralgia
c-Abl-p38? signaling pathway mediates dopamine neuron loss in trigeminal neuralgia.
Triple Negative Breast Neoplasms
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Triple Negative Breast Neoplasms
Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy.
Triple Negative Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Triple Negative Breast Neoplasms
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Triple Negative Breast Neoplasms
Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.
Triple Negative Breast Neoplasms
Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase.
Triple Negative Breast Neoplasms
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Triple Negative Breast Neoplasms
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Triple Negative Breast Neoplasms
Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
Triple Negative Breast Neoplasms
Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Triple Negative Breast Neoplasms
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Triple Negative Breast Neoplasms
PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
Triple Negative Breast Neoplasms
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C ? Pathway in a Subset of Triple-Negative Breast Cancers.
Triple Negative Breast Neoplasms
Src: a potential target for the treatment of triple-negative breast cancer.
Triple Negative Breast Neoplasms
Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Triple Negative Breast Neoplasms
Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.
Triple Negative Breast Neoplasms
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Triple Negative Breast Neoplasms
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Triple Negative Breast Neoplasms
[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Trisomy 13 Syndrome
Trisomy 13 in a Philadelphia negative chromosome and BCR-ABL negative myeloproliferative disorder.
Truncus Arteriosus, Persistent
Outflow tract cushions perform a critical valve-like function in the early embryonic heart requiring BMPRIA-mediated signaling in cardiac neural crest.
Tuberculosis
A Case of Disseminated Cutaneous Mycobacterium chelonae Infection During Treatment With Tofacitinib.
Tuberculosis
Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages.
Tuberculosis
c-Abl-TWIST1 Epigenetically Dysregulate Inflammatory Responses during Mycobacterial Infection by Co-Regulating Bone Morphogenesis Protein and miR27a.
Tuberculosis
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Tuberculosis
Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling.
Tuberculosis
Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation.
Tuberculosis
Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology.
Tuberculosis
The role of Mycobacterium tuberculosis complex species on apoptosis and necroptosis state of macrophages derived from active pulmonary tuberculosis patients.
Tuberculosis, Pulmonary
Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment.
Tuberous Sclerosis
Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth.
Tuberous Sclerosis
Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.
Tumor Lysis Syndrome
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Tumor Lysis Syndrome
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Uremia
A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia.
Ureteral Obstruction
Activation of Wnt11 by transforming growth factor-? drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells.
Urinary Bladder Neoplasms
Bone marrow mesenchymal stem cells-derived exosomal microRNA-19b-1-5p reduces proliferation and raises apoptosis of bladder cancer cells via targeting ABL2.
Urinary Bladder Neoplasms
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF?R1/VEGF-D signaling.
Urinary Bladder Neoplasms
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
Urinary Bladder Neoplasms
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.
Urinary Bladder Neoplasms
Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Urinary Bladder Neoplasms
Focal adhesion kinases crucially regulate TGF?-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin.
Urinary Bladder Neoplasms
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Urinary Bladder Neoplasms
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Urinary Bladder Neoplasms
Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway.
Urinary Bladder Neoplasms
Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Urinary Bladder Neoplasms
Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Urinary Bladder Neoplasms
Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Urinary Bladder Neoplasms
Promoter analysis of epigenetically controlled genes in bladder cancer.
Urinary Bladder Neoplasms
TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
Urinary Bladder Neoplasms
The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer.
Urinary Bladder Neoplasms
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Urinary Bladder Neoplasms
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers.
Urinary Bladder Neoplasms
The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder.
Urinary Bladder Neoplasms
The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN.
Urinary Bladder Neoplasms
Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy.
Urticaria
?-Linolenic acid attenuates pseudo-allergic reactions by inhibiting Lyn kinase activity.
Urticaria
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Urticaria
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.
Urticaria
[Effect of electroacupuncture on expressions of Lyn and Syk in mast cells of subcutaneous loose connective tissue in rats with urticarial].
Urticaria
[Effect of pre-acupuncture intervention on serum IgE and cutaneous phosphorylated tyrosine-protein kinase expression in rats with urticaria].
Uterine Cervical Neoplasms
Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-?B/Survivin Expression in HeLa Cells.
Uterine Cervical Neoplasms
Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis.
Uterine Cervical Neoplasms
Clinical significance of focal adhesion kinase (FAK) in cervical cancer progression and metastasis.
Uterine Cervical Neoplasms
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Uterine Cervical Neoplasms
Differential gene expression in cervical cancer cell lines before and after ionizing radiation.
Uterine Cervical Neoplasms
Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells.
Uterine Cervical Neoplasms
Erb?B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53?responsive microRNA?3184?5p in cervical cancer cells.
Uterine Cervical Neoplasms
Fibronectin promotes cervical cancer tumorigenesis through activating FAK signaling pathway.
Uterine Cervical Neoplasms
Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa).
Uterine Cervical Neoplasms
Fyn-related kinase expression predicts favorable prognosis in patients with cervical cancer and suppresses malignant progression by regulating migration and invasion.
Uterine Cervical Neoplasms
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.
Uterine Cervical Neoplasms
MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer.
Uterine Cervical Neoplasms
MicroRNA?433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK.
Uterine Cervical Neoplasms
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Uterine Cervical Neoplasms
Redox Regulation of NOX Isoforms on FAK(Y397)/SRC(Y416) Phosphorylation Driven Epithelial-to-Mesenchymal Transition in Malignant Cervical Epithelial Cells.
Uterine Cervical Neoplasms
Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173.
Uterine Cervical Neoplasms
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
Uterine Cervical Neoplasms
Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study.
Uterine Cervical Neoplasms
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Uterine Cervical Neoplasms
Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome.
Uterine Cervical Neoplasms
[Effects of Src on cervical cancer cells proliferation and apoptosis through ERK signal transduction pathway].
Uterine Neoplasms
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
Uveitis
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Uveitis
Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis.
Uveitis, Anterior
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Vaccinia
CHK down-regulates SCF/KL-activated Lyn kinase activity in Mo7e megakaryocytic cells.
Vaccinia
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Vaccinia
Vaccinia virus growth factor stimulates tyrosine protein kinase activity of A431 cell epidermal growth factor receptors.
Vaccinia
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Varicose Ulcer
Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression.
Varicose Veins
Evaluation of transforming growth factor-beta signaling pathway in the wall of normal and varicose veins.
Vascular Calcification
Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?
Vascular Calcification
The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
Vascular Diseases
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Vascular Diseases
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Vascular Diseases
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
Vascular Diseases
Signalling through Src family kinase isoforms is not redundant in models of thrombo-inflammatory vascular disease.
Vascular Diseases
The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease.
Vascular Malformations
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
Vascular Malformations
EPHB4 Mutation Implicated in Capillary Malformation-Arteriovenous Malformation Syndrome: A Case Report.
Vascular Malformations
RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation.
Vascular System Injuries
Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.
Vascular System Injuries
The role of Rac1 in glycoprotein Ib-IX-mediated signal transduction and integrin activation.
Vasculitis
Levistilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats.
Vasculitis
Non-receptor type, proline-rich protein tyrosine kinase 2 (Pyk2) is a possible therapeutic target for Kawasaki disease.
Vasculitis
Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model.
Vasculitis
[The negative regulatory factor of CAWS (Candida albicans water-soluble fraction) -vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice].
Vasospasm, Intracranial
Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage.
Venous Thromboembolism
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Venous Thromboembolism
Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Venous Thromboembolism
Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.
Venous Thrombosis
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Venous Thrombosis
Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders.
Venous Thrombosis
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Venous Thrombosis
Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Venous Thrombosis
Prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.
Venous Thrombosis
Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Ventilator-Induced Lung Injury
Activation of c-Src tyrosine kinase mediated the degradation of occludin in ventilator-induced lung injury.
Ventilator-Induced Lung Injury
Activation of Src-dependent Smad3 signaling mediates the neutrophilic inflammation and oxidative stress in hyperoxia-augmented ventilator-induced lung injury.
Vesicular Stomatitis
Intracellular targeting of pp60src expression: localization of v-src to adhesion plaques is sufficient to transform chicken embryo fibroblasts.
Vesicular Stomatitis
Vesicular stomatitis virus produced from infected LSTRA lymphoma cells bear tyrosine protein kinase activity (p56).
Viremia
[Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].
Virus Diseases
An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense.
Virus Diseases
Blocking the PI3K/AKT pathway enhances mammalian reovirus replication by repressing IFN-stimulated genes.
Virus Diseases
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
Virus Diseases
Characterization of a novel non-receptor tyrosine kinase Src from Litopenaeus vannamei and its response to white spot syndrome virus infection.
Virus Diseases
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.
Virus Diseases
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Virus Diseases
Focal adhesion kinase is involved in rabies virus infection through its interaction with viral phosphoprotein P.
Virus Diseases
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Virus Diseases
Human immunodeficiency virus infection abolishes CD4-dependent activation of ZAP-70 by inhibition of p56lck.
Virus Diseases
Involvement of fish signal transducer and activator of transcription 3 (STAT3) in nodavirus infection induced cell death.
Virus Diseases
Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia.
Virus Diseases
Major histocompatibility (B) complex control of the growth pattern of v-src DNA-induced primary tumors.
Virus Diseases
Molecular cloning and functional analysis of three STAT isoforms in red swamp crayfish Procambarus clarkii.
Virus Diseases
Myxoma virus induces extensive CD4 downregulation and dissociation of p56lck in infected rabbit CD4+ T lymphocytes.
Virus Diseases
Positive regulatory role of c-Src-mediated TRIM25 tyrosine phosphorylation on RIG-I ubiquitination and RIG-I-mediated antiviral signaling pathway.
Virus Diseases
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Virus Diseases
Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages.
Virus Diseases
Role of Itk signaling in the interaction between influenza A virus and T cells.
Virus Diseases
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
Virus Diseases
Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection.
Virus Diseases
Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells.
Virus Diseases
The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection.
Virus Diseases
The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection.
Virus Diseases
Tumor necrosis factor-alpha production induced by viruses and by lipopolysaccharides in macrophages: similarities and differences.
Virus Diseases
Use of QSAR Global Models and Molecular Docking for Developing New Inhibitors of c-src Tyrosine Kinase.
Virus Diseases
Whole Transcriptome Analysis of Aedes albopictus Mosquito Head and Thorax Post-Chikungunya Virus Infection.
Vitamin D Deficiency
Role of Vitamins A and D in BCR-ABL Arf-/- Acute Lymphoblastic Leukemia.
Vitamin D Deficiency
Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.
Vitiligo
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Vitiligo
Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo.
Vitiligo
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Vitiligo
Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study.
Vitiligo
Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Vitiligo
Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata.
Vitiligo
Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
Vitiligo
Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis.
Vitiligo
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Vitiligo
Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo.
Vitiligo
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Vitiligo
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open label extension study with optional narrow-band ultraviolet B.
Vitiligo
Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib.
Vitreoretinopathy, Proliferative
Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
Vitreoretinopathy, Proliferative
Soluble EphB4 inhibits PDGF-induced RPE migration in vitro.
Waldenstrom Macroglobulinemia
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
Waldenstrom Macroglobulinemia
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Waldenstrom Macroglobulinemia
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
Waldenstrom Macroglobulinemia
A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.
Waldenstrom Macroglobulinemia
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Waldenstrom Macroglobulinemia
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Waldenstrom Macroglobulinemia
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Waldenstrom Macroglobulinemia
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Waldenstrom Macroglobulinemia
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Waldenstrom Macroglobulinemia
Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions.
Waldenstrom Macroglobulinemia
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Waldenstrom Macroglobulinemia
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Waldenstrom Macroglobulinemia
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Waldenstrom Macroglobulinemia
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Waldenstrom Macroglobulinemia
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
Waldenstrom Macroglobulinemia
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Waldenstrom Macroglobulinemia
Ibrutinib in the management of Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
Waldenstrom Macroglobulinemia
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Waldenstrom Macroglobulinemia
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Waldenstrom Macroglobulinemia
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Waldenstrom Macroglobulinemia
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Waldenstrom Macroglobulinemia
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Waldenstrom Macroglobulinemia
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Waldenstrom Macroglobulinemia
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Waldenstrom Macroglobulinemia
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Waldenstrom Macroglobulinemia
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Waldenstrom Macroglobulinemia
Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Waldenstrom Macroglobulinemia
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
Waldenstrom Macroglobulinemia
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
Waldenstrom Macroglobulinemia
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Waldenstrom Macroglobulinemia
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.
Warts
Expressionof langerhans cell and plasmacytoid dendritic cell markers, and toll-like receptor 7/9 signaling pathway proteins in verruca vulgaris lesions.
Warts
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Wasting Syndrome
Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Wasting Syndrome
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Werner Syndrome
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Wernicke Encephalopathy
Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters.
Wernicke Encephalopathy
Putamina involvement in Wernicke encephalopathy induced by Janus Kinase 2 inhibitor.
Wernicke Encephalopathy
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
West Nile Fever
Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells.
West Nile Fever
The Src family kinase c-Yes is required for maturation of West Nile virus particles.
West Nile Fever
Virus-induced Ca2+ influx extends survival of west nile virus-infected cells.
Whooping Cough
Activation of P2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C.
Whooping Cough
Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts.
Whooping Cough
Angiotensin II type 2 receptor-dependent increases in nitric oxide synthase expression in the pulmonary endothelium is mediated via a G alpha i3/Ras/Raf/MAPK pathway.
Whooping Cough
Antibody binding to cell surface amyloid precursor protein induces neuronal injury by deregulating the phosphorylation of focal adhesion signaling related proteins.
Whooping Cough
Bradykinin B2 receptors activate Na+/H+ exchange in mIMCD-3 cells via Janus kinase 2 and Ca2+/calmodulin.
Whooping Cough
Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in Helicobacter pylori-infected gastric epithelial AGS cells.
Whooping Cough
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Whooping Cough
Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells.
Whooping Cough
Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells.
Whooping Cough
G(i)-mediated Cas tyrosine phosphorylation in vascular endothelial cells stimulated with sphingosine 1-phosphate: possible involvement in cell motility enhancement in cooperation with Rho-mediated pathways.
Whooping Cough
GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain.
Whooping Cough
Induction of human neutrophil chemotaxis by Candida albicans-derived beta-1,6-long glycoside side-chain-branched beta-glucan.
Whooping Cough
Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Whooping Cough
Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B Streptococci and Staphylococcus aureus.
Whooping Cough
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Whooping Cough
Melanin-concentrating hormone receptor 1 activates extracellular signal-regulated kinase and synergizes with G(s)-coupled pathways.
Whooping Cough
P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism.
Whooping Cough
Pertussis toxin activates protein kinase C and a tyrosine protein kinase in the human T cell line Jurkat.
Whooping Cough
Platelet-activating factor stimulates calcium-dependent activation of protein-tyrosine kinase Syk in a human B cell line.
Whooping Cough
Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism.
Whooping Cough
Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes.
Whooping Cough
Regulation of endothelin-1- and lysophosphatidic acid-stimulated tyrosine phosphorylation of focal adhesion kinase (pp125fak) in Rat-1 fibroblasts.
Whooping Cough
Regulation of lysophosphatidic acid-stimulated tyrosine phosphorylation of mitogen-activated protein kinase by protein kinase C- and pertussis toxin-dependent pathways in the endothelial cell line EAhy 926.
Whooping Cough
Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of ?-opioid receptor.
Whooping Cough
Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases.
Whooping Cough
Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning.
Whooping Cough
Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
Whooping Cough
Src kinase mediates angiotensin II-dependent increase in pulmonary endothelial nitric oxide synthase.
Whooping Cough
Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
Whooping Cough
sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation.
Whooping Cough
The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor.
Whooping Cough
The upstream regulation of p38 mitogen-activated protein kinase phosphorylation by arachidonic acid in rat neutrophils.
Whooping Cough
Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2.
Whooping Cough
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.
Williams Syndrome
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Wilms Tumor
Bladder cancer-associated transcript 2 contributes to nephroblastoma progression.
Wilms Tumor
Germline Bone Morphogenesis Protein Receptor 1A Mutation Causes Colorectal Tumorigenesis in Hereditary Mixed Polyposis Syndrome.
Wilms Tumor
Identification of TCR V?11-2-D?1-J?1-1 T cell clone specific for WT1 peptides using high-throughput TCR? gene sequencing.
Wilms Tumor
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Wilms Tumor
Long Noncoding RNA DUXAP8 Promotes Pancreatic Carcinoma Cell Migration and Invasion Via Pathway by miR-448/WTAP/Fak Signaling Axis.
Wilms Tumor
Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression.
Wilms Tumor
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
Wilms Tumor
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules.
Wilms Tumor
The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.
Wilms Tumor
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Wilms Tumor
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
Wiskott-Aldrich Syndrome
An Evolutionarily Conserved Pathway Essential for Orsay Virus Infection of Caenorhabditis elegans.
Wiskott-Aldrich Syndrome
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
Wiskott-Aldrich Syndrome
c-Src and Neural Wiskott-Aldrich Syndrome Protein (N-WASP) Promote Low Oxygen-Induced Accelerated Brain Invasion by Gliomas.
Wiskott-Aldrich Syndrome
Distinctive roles of Abi1 in regulating actin-associated proteins during human smooth muscle cell migration.
Wiskott-Aldrich Syndrome
Effects of progesterone and medroxyprogesterone on actin remodeling and neuronal spine formation.
Wiskott-Aldrich Syndrome
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Wiskott-Aldrich Syndrome
Identification of host proteins involved in rickettsial invasion of tick cells.
Wiskott-Aldrich Syndrome
Identification of novel SH3 domain ligands for the Src family kinase Hck. Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1.
Wiskott-Aldrich Syndrome
Interaction between Wiskott-Aldrich Syndrome protein (WASP) and the Fyn protein-tyrosine kinase.
Wiskott-Aldrich Syndrome
Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP.
Wiskott-Aldrich Syndrome
Regulation of podosome dynamics by WASp phosphorylation: implication in matrix degradation and chemotaxis in macrophages.
Wiskott-Aldrich Syndrome
Role of the adapter protein Abi1 in actin-associated signaling and smooth muscle contraction.
Wiskott-Aldrich Syndrome
The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways.
X-Linked Combined Immunodeficiency Diseases
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family.
X-Linked Combined Immunodeficiency Diseases
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.
X-Linked Combined Immunodeficiency Diseases
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
X-Linked Combined Immunodeficiency Diseases
Role of Btk in B cell development and signaling.
X-Linked Combined Immunodeficiency Diseases
The transcription factor Bright associates with Bruton's tyrosine kinase, the defective protein in immunodeficiency disease.
X-Linked Combined Immunodeficiency Diseases
The transcription factor, Bright, and immunoglobulin heavy chain expression.
Xeroderma Pigmentosum
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.
Xeroderma Pigmentosum
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Zika Virus Infection
Integrin ?v?5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy.